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Radiotracers that target glutamate carboxypeptidase II, also known as the prostate specific 
membrane antigen (GCP(II)/PSMA), have shown exceptional promise for prostate cancer 
imaging and molecular radiotherapy. A number of bioconjugates have been developed to target 
GCP(II)/PSMA which utilise the simple and robust targeting motif (Lys-C(O)-Glu) (referred to as 
PSMA ligand), functionalised with a chelator for radiometal incorporation. This work utilised and 
evaluated the tris(hydroxypyridinone) (THP) chelator due to the simplicity, speed and selectivity 
of its radiolabelling with gallium radioisotopes, and its potential to be developed into one-step 
radiopharmaceutical kits. [68Ga]Ga-THP-PSMA was assessed as a PET imaging agent and 
[67Ga]Ga-THP-PSMA for molecular radiotherapy due to its Auger electron emissions.  
The first objective was to synthesise THP-PSMA and assess its radiolabelling with gallium-68. 
[68Ga]Ga-THP-PSMA with over 95% radiochemical purity was produced at room temperature, 
and pH 7 in just 5 minutes. A one-step kit was developed, suitable for use with gallium-68 directly 
from a generator. [68Ga]Ga-THP-PSMA exhibited specific uptake in GCP(II)/PSMA-expressing 
prostate cancer cells and 50% inhibition of binding at a concentration of 361 ± 60 nM. In vivo 
PET imaging showed speciﬁc uptake in GCP(II)/PSMA-expressing tumours, reaching 5.6 ± 1.2 
percentage injected dose per cubic centimetre. Overall, [68Ga]Ga-THP-PSMA had equivalent 
imaging properties but greatly simpliﬁed radiolabelling compared to other [68Ga]Ga-PSMA 
tracers. Clinical studies were then conducted by collaborators which found that [68Ga]Ga-THP-
PSMA could delineate prostate cancer in both initial staging and biochemical recurrence. 
The second objective was to assess [67Ga]Ga-THP-PSMA for molecular radiotherapy. Extremely 
high molar activity was achieved: 326 MBq/nmol (22% chelator occupancy). Despite this, the 
activity delivered to GCP(II)/PSMA expressing cells was low (max 0.1 Bq/cell) and the tracer 
showed rapid efflux. These findings were confirmed with in vivo studies showing poor retention 
of [67Ga]Ga-THP-PSMA in GCP(II)/PSMA-expressing prostate cancer tumours. These results 
suggest that the affinity and retention, but not the molar activity, limit the use of [67Ga]Ga-THP-
PSMA for molecular radiotherapy. 
The third objective was to determine whether replacing the urea with a thiourea in the 
GCP(II)/PSMA targeting motif resulted in higher affinity. This was studied using the inhibitors 
Glu-C(O)-Glu and Glu-C(S)-Glu, the syntheses of which are described. The in vitro inhibition 
assays showed that the affinity was made much weaker by the presence of the thiourea (135 
µM compared to 1.34 µM) and therefore this is not an effective strategy for improving affinity. 
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Overall the THP-PSMA bioconjugate shows excellent radiolabelling properties, with both 
gallium-68 and gallium-67. [68Ga]Ga-THP-PSMA is a good PET imaging agent for prostate cancer 
however, improved affinity for GCP(II)/PSMA and retention of the tracer may potentially 
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1 Imaging Prostate Cancer 
1.1 Prostate Cancer 
In 2015, 11,819 men died of prostate cancer in the UK, making it the third most common cause 
of cancer death (1). The number of people diagnosed with prostate cancer has increased over 
the last 15 years, due to advances in detection, but also an ageing population, with the majority 
of prostate cancer cases in men over 50 (average age at diagnosis 65-69) (2). Medical imaging is 
an extremely important tool for the detection and staging of prostate cancer and it is vital that 
it gives an accurate and comprehensive account of disease burden, as this informs the patient’s 
treatment plan, and inadequate data leads to over- or under-treatment. In this chapter, the 
current use of medical imaging in the diagnosis and staging of prostate cancer patients will be 
reviewed from a UK perspective and the clinical need for new imaging techniques within this 
pathway will be discussed. 
1.2 Diagnosis, Staging and Biochemical Reoccurrence 
If a patient presents with symptoms of prostate cancer, a prostate-specific antigen (PSA) blood 
test is carried out. PSA is excreted by the epithelial cells of the prostate and is elevated in cases 
of prostate cancer with blood serum levels increasing with tumour burden. Under 4 ng/mL is 
considered normal (3). The detected PSA level, a digital rectal examination, and the patient’s 
comorbidities, risk factors and wishes are all used to determine whether a patient proceeds to 
prostate biopsy (4). In some cases, this will also be supported by pre-biopsy multi-parametric 
magnetic resonance imaging (MRI). Normally a transrectal ultrasound-guided biopsy is 
performed, where ultrasound is used to locate the prostate, measure its size and shape, and 
guide the 12 biopsy locations. Samples are analysed with histological techniques to diagnose 
and grade prostate cancer, using the Gleason scoring system which measures the extent of gland 
uniformity and cell differentiation. Higher Gleason scores indicate more poorly differentiated 
and aggressive cancer types (5). The multiple core biopsies give information on the location and 
extent of cancer in the prostate. If the cancer is suspected to have spread outside the prostate 
then computed tomography (CT) or MRI are used to size pelvic lymph nodes (enlarged lymph 
nodes > 8 mm indicates possible prostate cancer (6)) and bone scintigraphy or single-photon 
emission computed tomography (SPECT) imaging with technetium-99m-
methylenediphosphonate ([99mTc]Tc-MDP), is used to detect osseous metastases. The normal 
course of disease progression for prostate cancer is from a primary tumour in the prostate to 
lymph nodes within the pelvis (pelvic, hypogastric, iliac, sacral), then distant lymph nodes (aortic, 
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common iliac, inguinal, supraclavicular, cervical) and then to the bone, with other organs (lung 
and liver) only involved at a very late stage (7). As shown in figure 1.1 the location and extent of 
prostate cancer determines the patient’s clinical stage as defined by the tumour, node and 
metastasis (TNM) system (7), and this, combined with the PSA level and Gleason score, gives the 
patient’s level of risk, which determines the treatments offered at the time of diagnosis. This is 
summarised in table 1.1. 
 
FIGURE 1.1: Clinical stages of prostate cancer: (A) Tumour (T) stages T1- T3. In stages T1 and T2 the tumour is 
contained within the prostate, in T3 the tumour extends outside of the prostate capsule; (B) Tumour stage T4, 
tumour has spread into adjacent organs; (C) Node (N) stage, cancerous lymph nodes present within the pelvis; 
(D) Metastasis (M) stage, cancer has spread beyond the pelvis, to distant lymph nodes, bone, or other organs. 




Level of risk PSA serum level  Gleason score  
Clinical stage 
(TNM system (7)) 
Low risk <10 ng/mL And ≤ 6 and T1-T2a 
Intermediate 
risk 
10-20 ng/mL Or 7 or T2b 
High risk >20 ng/mL Or 8- 10 or ≥ T2c 
 
TABLE 1.1: Summary of the different risk groups for patients diagnosed with prostate cancer and their 
dependence upon PSA serum level, Gleason score and clinical staging. Clinical stage 2a is defined as cancer 
detected in less than 50% of one lobe of the prostate gland, 2b as cancer detected in more than 50% of one lobe 
of the prostate gland and 2c as cancer detected in both lobes of the prostate gland. In stages 2a-2c the cancer is 
confined within the prostate. Table reproduced from (4) (open source document). 
Patients with low-risk prostate cancer are likely to begin active surveillance, which entails a 
multi-parametric MRI to define the disease burden within the prostate, regular measurement 
of PSA levels and digital rectal examinations, and a repeat biopsy at 12 months (4). Such 
surveillance aims to avoid over-treatment of clinically insignificant prostate cancer, whilst 
ensuring disease progression is detected. Patients with intermediate-risk or high-risk prostate 
cancer will be offered radical prostatectomy or radical radiotherapy, when this would offer long-
term disease control. If a patient has already progressed to having lymph node involvement or 
metastases, there is limited advantage in performing these radical treatments and they should 
instead start androgen therapy or chemotherapy. It is often difficult to correctly categorise these 
patients, because unless they have large enough lymph nodes to be detected by anatomical 
imaging (CT or MRI) or their bone scan indicates bone metastases, the spread of disease to 
lymph nodes cannot be detected with current imaging techniques and so risk tables are used to 
assess the likelihood of nodal involvement (7). Detection of such lymph nodes so that they can 
be removed during radical surgery, targeted with radiotherapy or categorise the patient as 
unsuitable for radical treatment, would be very beneficial. This creates a need to develop a 
suitable positron emission tomography (PET) scan that would allow detection of the primary 
tumour and involved lymph nodes throughout the whole body, providing a more accurate report 
of disease burden. There is precedence for the use of [18F]fluorodeoxyglucose ([18F]FDG) PET 
scans for staging in other cancers (breast cancer (9), lung cancer (10), and colorectal cancer (11)), 
however, studies evaluating the ability of [18F]FDG to stage prostate cancer showed limited value 
for clinical practice (12)(13)(14)(15). Therefore [18F]FDG scans are not recommended for the 
staging of prostate cancer by the UK’s National Institute for Health and Care Excellence (NICE) 
(4). The reasons why [18F]FDG is an unsuitable imaging agent for staging prostate cancer are 
explored in section 1.3.1. Alternative tracers are therefore required for imaging prostate cancer. 
Staging before radical treatment is the first of two scenarios where a PET scan specific for the 
detection of prostate cancer would serve a clinical need. 
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The second scenario where a PET scan suitable for prostate cancer would serve a clinical need 
is in patients with biochemical recurrence, indicated by a rising PSA after radical treatment (> 
0.2 ng/mL after radical prostatectomy, > 2 ng/mL after radical external-beam radiation therapy 
or brachytherapy (16)). This happens in approximately 20% of men diagnosed with 
intermediate-risk disease within 8 years of radical surgery and 35% of men within 8 years of 
radical radiotherapy (17). In cases of biochemical recurrence imaging with bone scintigraphy or 
CT has only been shown effective in determining the site of relapse when patients have a PSA 
over 20 ng/mL (16), therefore in the majority of cases where the PSA levels are lower than this 
threshold there is a clinical need to determine the site of recurrence in order to inform the 
treatment decision. By definition, if a patient has rising PSA after radical treatment then they 
have biochemical recurrence, even if this is a very small volume of disease, and consequently, 
current techniques are unable to visualise it (18). Available treatments in cases of biochemical 
recurrence include: salvage radiotherapy, salvage prostatectomy, cryotherapy, high intensity 
focused ultrasound, orchiectomy, androgen therapy or chemotherapy (4)(16), and the most 
suitable choice will depend on the extent and location of disease. 
In both scenarios, a PET scan would be an ideal imaging modality for detecting the presence of 
nodal and metastatic disease. It is a whole body scan with a high signal to noise ratio, which 
allows molecular rather than anatomical differences to be detected and quantified. An ideal 
tracer to detect these sites would have higher accumulation in prostate cancer than in normal 
prostate and other non-target organs, plus be suitable for the detection of well-differentiated 
through to undifferentiated prostate cancer, which would allow a primary tumour, lymph node 
involvement and soft tissue and bone metastases to all be identified, even if they are no longer 
androgen sensitive. Additionally, the choice of the positron-emitting radionuclide must be 
widely available and ensure high-quality images are produced within an acceptable patient dose, 
which favours the use of short half-life tracers with a high percentage of positron emission. 
A number of different radiotracers have already been proposed and assessed for imaging 
prostate cancer for both initial staging and detection of disease sites after biochemical 
recurrence and some are clinically approved (19)(20). The key clinical need these tracers should 
address is an accurate identification of involved lymph nodes and metastatic disease. The design 
of such tracers falls into three major classes: metabolic, androgen, and receptor-based imaging 




1.3 Metabolic Tracers for Prostate Cancer 
Metabolic PET tracers are radioactive analogues of small molecules vital for metabolism and cell 
proliferation. These tracers mimic sugars, amino acids, nutrients or small molecules that 
naturally occur in the body and they consequently localise in the same areas. Imaging with 
metabolic tracers therefore allows visualisation of this distribution. However, it is important that 
these radiotracers also have a trapping mechanism and are not fully metabolised by the same 
pathways, as this ensures that they accumulate intracellularly, providing enough signal to be 
detected on a PET scan and ensuring that the image shows only the distribution of the original 
tracer and rather than its radioactive metabolites. In cancer imaging, the changes in the 
metabolism of cancerous cells compared to normal cells, particularly when transporters are 
upregulated in order to aid proliferation, gives them different levels of tracer uptake to non-
cancerous cells allowing them to be identified on a PET scan. All metabolic tracers will have 
endogenous uptake, as they target vital metabolic pathways that exist in both healthy and 
disease states (even though the extent of the process varies). This background uptake is 
therefore always an important consideration when using metabolic tracers as it impacts on both 
the signal to noise ratio and dosimetry of the procedure. 
When using metabolic PET tracers in the context of prostate cancer it is also important to note 
that prostate cancer displays a wide range of proliferation rates (2 to 25 fold faster than matched 
normal tissue (21)), which will impact the extent of tracer uptake. In addition, the stage of the 
prostate cancer and therefore how well-differentiated it is, may also impact on its metabolism 
and therefore, on the uptake of the tracer (22). This is also likely to be influenced by any previous 
treatment the patient has received, in particular, androgen therapy (23), chemotherapy (23) and 
radiotherapy (24).  
In this section the following metabolic tracers will be described briefly in the context of prostate 
cancer: [18F]FDG, [11C]acetate, [11C]methionine, [11C]choline, [18F]fluoro-choline, and anti-1-
amino-3-[18F]fluorocyclobutane-1-carboxylic acid ([18F]FACBC). The structure of all of these are 
shown in figure 1.2. [11C]choline (20) and [18F]FACBC (19) have been approved for prostate 
cancer patients with suspected prostate cancer recurrence based on elevated PSA levels by the 
U.S. Food and Drug Administration (FDA). [18F]FDG, [11C]methionine and [11C]acetate are all FDA-
approved agents (25), and therefore widely available, but in this context, it is important to 
remember that their use in prostate cancer was not part of the evidence that gained them this 
approval (26). All of these tracers utilise the short-lived radionuclides carbon-11 or fluorine-18, 
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which are suitable for PET imaging, and are cyclotron-produced. See table 1.2 for more detail of 
the properties of these radionuclides. 
 
FIGURE 1.2: Structures of [18F]FDG, [11C]methionine, [11C]acetate, [11C]choline, [18F]fluoro-methyl-choline, 
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[18F]FDG is the most widely used PET tracer with over 100,000 scans performed every year in 
the UK alone (37). Many hospitals only provide PET scans with [18F]FDG. It is used for imaging a 
wide range of cancer types including breast cancer (9), lung cancer (10), and colorectal cancer 
(11) and the scans have become a vital tool in oncology. This has driven the large investment in 
PET scanners and production facilities seen over the last 20 years. [18F]FDG is an analogue of 
glucose and the mechanism for detection of cancer with [18F]FDG is through its increased glucose 
metabolism compared to normal tissue (the Warburg effect (12)). This is typically due to cancer 
cells upregulating the expression of glucose transporter 1 (GLUT1) on the cell membrane. Like 
glucose, [18F]FDG is phosphorylated once it enters the cell but, due to its structural modification 
with fluorine-18, cannot be metabolised further, causing intracellular accumulation (38). GLUT1 
is known to be upregulated in lung, stomach, thyroid, colon, oesophagus, bladder and breast 
cancer (22). However, the limited studies conducted on GLUT1 expression in prostate cancer 
suggest that the expression level is lower (39). It is known that the level of GLUT1 expression 
within prostate cancer cell lines varies between those that are well-differentiated and androgen-
sensitive, such as LNCaP (where the expression is low), and the poorly-differentiated and less 
androgen-sensitive cell lines DU145 and PC3 (where the expression level increases (22)). 
Similarly, in clinical studies metastases which are more [18F]FDG avid are considered indicative 
of more aggressive cancer (13)(40). 
There have been many clinical studies examining the use of [18F]FDG in prostate cancer, and 
overall they show it has limited value in clinical practice when compared to the utility of [18F]FDG 
in other cancer types (12)(13)(14)(15). Due to this evidence, the UK NICE guidelines do not 
support the use of this tracer in prostate cancer (4). [18F]FDG is particularly poor for primary 
tumour imaging as it cannot differentiate accurately between, normal tissue, prostatitis, and 
prostatic hyperplasia. Additionally, it is taken up in areas of inflammation or infection, making it 
prone to both false positive and false negative results (40)(41). Similar problems are seen when 
looking for reoccurrence in the prostate bed after radical prostatectomy, due to the uptake of 
[18F]FDG in scar tissue (13). However, [18F]FDG can be used for the detection of distant 
metastases particularly in biochemical recurrence, at PSA levels where bone scanning is 
unreliable (< 20 ng/mL (16)), in order to identify lymph node metastases or verify that enlarged 
lymph nodes detected by CT are malignant (40). A critical review summarising studies where 
patients with rising PSA after radical prostatectomy were imaged with [18F]FDG showed a 
detection rate of 19% for prostate cancer in any location and of 6% for distant lymph node 
25 
 
involvement (42). This is a particularly low detection rate, as by definition all patients with rising 
PSA after radical treatment have reoccurrence (18). 
Most of the alternative PET tracers for prostate cancer have been compared to [18F]FDG and 
have shown improved detection rates (42). In the remainder of this section, other metabolic PET 
tracers will be discussed and compared to the performance of [18F]FDG in prostate cancer. 
1.3.2 [11C]Acetate 
Acetate is a common anion within the body and as [11C]acetate has an identical chemical 
structure it will have identical behaviour. [11C]acetate is actively transported across cell 
membranes via monocarboxylate transporters. It is then converted to [11C]acetyl CoA in the 
mitochondria. From there it can either enter the tricarboxylic acid (TCA) cycle or be used in lipid 
or cholesterol synthesis (41)(43). The intracellular trapping of the radionuclide seen when 
[11C]acetate enters prostate cancer cells suggests that it is converted into lipids. This theory is 
supported by the known upregulation of fatty acid synthase in prostate cancer, with higher 
levels associated with more aggressive tumours (44). In healthy volunteers, the biodistribution 
of [11C]acetate showed uptake in the myocardium, pancreas, spleen, salivary glands and kidneys, 
but limited renal excretion, providing an advantage over [18F]FDG when looking for uptake in 
the prostate bed (45). However, studies into the use of [11C]acetate in the identification of 
primary prostate cancer showed no higher uptake in patients with cancer than in prostate 
hyperplasia or in healthy volunteers, making it unsuitable for this use (46). In metastatic prostate 
cancer, metastases were detected with [11C]acetate and the detection rate correlated with PSA 
levels (47)(48). In studies where [11C]acetate was compared to [18F]FDG PET in the same patient 
population (47)(48), both studies showed [11C]acetate was able to visualise local recurrences 
and regional lymph node metastases better than [18F]FDG, (figure 1.3) but the two studies 
showed conflicting results for detection rates in distant metastases (48). This tracer also suffers 
from false positives when used to detect prostate cancer due to uptake within inflamed tissue 




FIGURE 1.3 : Coronal images of the same patient scanned with (A) [18F]FDG and (B) [11C]acetate. This patient 
had histologically confirmed prostate cancer and biochemical recurrence after radical prostatectomy. [18F]FDG 
is unable to detect any disease, [11C]acetate shows uptake in the prostate bed (pr) and a pelvic lymph node (n). 
Reproduced with permission from (47). 
1.3.3 [11C] Methionine 
Methionine is an essential amino acid and as [11C]methionine has an identical chemical structure 
behaves identically in vivo. [11C]methionine accumulation in tumour cells is attributed to 
increased amino acid transport and metabolism. Methionine is transported into cells through 
sodium-dependent amino acid transporter systems, where it is metabolised and incorporated 
into proteins (50). The first 30 minutes of a [11C]methionine scan is believed to reflect 
methionine transport, with over 80% of [11C]methionine unmetabolised, but by 60 minutes a 
different distribution is observed due to production of metabolites and their incorporation into 
proteins (40% of the radionuclide is protein bound (50)(51)). Both the complex range of 
metabolites and the unspecific transport mechanism into cells are disadvantages for 
[11C]methionine as an imaging agent. [11C]methionine imaging (10-60 minutes post-injection) 
has been compared to [18F]FDG imaging and to conventional imaging, defined as a combination 
of CT, MRI and bone scans, in 12 patients with known metastatic prostate cancer and rising PSA 
levels (38). [11C]methionine showed the ability to delineate both soft tissue and bone metastases 
and identified more sites than [18F]FDG, but less than the combination of CT, MRI and bone scans 
that constituted the standard of care (72.1%). However, 37 additional metastatic sites were 
identified with [11C]methionine which were absent on bone scans. Figure 1.4 shows 
[11C]methionine and [18F]FDG PET scans in the same patient 2 hours apart and demonstrates a 
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higher number of detected lesions plus a higher uptake of [11C]methionine within them. Limited 
further studies into the effectiveness of [11C]methionine have been conducted in prostate cancer 
patients and also showed no advantage over conventional imaging techniques (52)(53). 
 
FIGURE 1.4: Imaging of patient who had presented with rising PSA levels (48.7 ng/mL). (A) [11C]methionine 
PET, (B) [18F]FDG PET. Reproduced with permission from (38). 
1.3.4 [11C]Choline, [18F]Fluoro-choline and [18F]FECH 
[11C]choline, [18F]fluoro-choline ([18F]fluoro-methyl choline) and [18F]FECH ([18F]fluoro-ethyl 
choline) are all radioactive analogues of the essential nutrient choline, and so accumulate in 
sites of high choline metabolism. Choline and its radioactive analogues are charged hydrophilic 
cations due to their quaternary amine and therefore need specific transporters to pass through 
cell membranes (54). Two key transporters are CHT1, a high-affinity Na+- and Cl--dependent 
choline transporter (55); and CLT1 a lower affinity Na+-independent choline transporter (23). 
Both of these transporters have been detected at higher expression levels in prostate cancer 
alongside a higher transport rate (54). The trapping mechanism of [11C]choline, [18F]fluoro-
choline and [18F]FECH in cells is the incorporation of these radiotracers into phosphatidylcholine. 
As phosphatidylcholine is a key component in cell membranes the increased uptake of choline 
in prostate cancer is indicative of cell proliferation (56). However, proliferation is unlikely to be 
the only factor increasing uptake, as prostate cancer cells are also known to have abnormal 
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choline phospholipid metabolism which is implicated in cell signalling (54). Physiologic uptake 
of radio-choline is similar between the carbon-11 and fluorine-18 analogues, with high uptake 
in the pancreas, spleen, liver, kidneys, and salivary glands and variable uptake in the intestines 
(57). However, the fluorine-18 versions also accumulate in the urine, a disadvantage for the 
detection of small volume disease in the prostate bed, due to potential overlap with the signal 
from the urine. This difference in renal excretion occurs because of structural modifications 
required to accommodate radio-fluorination cause incomplete tubular reabsorption (58). The 
ability of [11C]choline to localise cancer within the prostate in order to stage primary tumours 
(figure 1.5) was assessed in a study of 36 patients with known prostate cancer (59). The uptake 
of [11C]choline in the prostate was correlated with histopathology after radical prostatectomy 
and showed that [11C]choline identified the majority of sites containing prostate cancer 
(94/143), but failed to identify cancer in a third of regions (49/143). Uptake was also seen in 
areas without cancer, but with high-grade prostate intraepithelial neoplasm. These results show 
a high rate of false positives and false negatives and that [11C]choline imaging is not a suitable 
technique for primary tumour staging. However, [11C]choline/[18F]fluoro-choline PET imaging is 
more suitable, than anatomical imaging and bone scans for detection of involved lymph nodes 
before radical surgery or radical radiation therapy, as determined by over 9 prospective studies. 
These were summarised by a meta-analysis in 2013 (60) which showed a pooled sensitivity of 
49.2% (95% confidence interval (CI), 39.9–58.4%) and a pooled specificity of 95% (95% CI 92–
97.1). In such meta-analyses, sensitivity is defined as the probability of a person with prostate 
cancer having a positive test result, and specificity as the probability of a person without the 
disease having a negative test result and so it is ideal for both numbers to be as high as possible 
(61). These results therefore mean that [11C]choline/[18F]fluoro-choline PET imaging will miss 
around half of the involved lymph nodes that would have shown positive for prostate cancer by 
histological analysis after pelvic lymph node dissection (the gold standard), but that false 
positives would be much less frequent (~5%). In biochemical recurrence [11C]choline and 
[18F]fluoro-choline PET have been evaluated in a range of meta-analyses (62)(63)(64) and shows 
a much improved sensitivity (pooled sensitivity 84%-91%) compared to anatomical lymph node 
staging and bone scans, whilst maintaining good specificity (79%-93%). This may be due in part 
to a shift in the gold standard used to define true positive results towards lymph node sizing by 
MRI and CT and bone scans rather than histological analysis which can detect much smaller areas 
of disease but are more difficult to obtain in cases of biochemical recurrence. The main 
application of [11C]choline and [18F]fluoro-choline is therefore in the detection of biochemical 
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recurrence. The use of [11C]choline in this context has been approved by the FDA and therefore 
has become the benchmark for any novel tracers for prostate cancer. 
 
FIGURE 1.5: Imaging of a patient who has previously had a radical prostatectomy, and presented with rising 
PSA levels (6.2 ng/mL). (A) [11C]choline PET, (B) [18F]FDG PET (C) [99mTc]Tc-MDP bone scintigraphy. 
Reproduced with permission from (65). 
1.3.5 [18F]FACBC 
[18F]FACBC, also known as anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid, 
[18F]fluciclovine and by its trade name Axumin (56), is a fluorine-18 radiolabelled synthetic amino 
acid, which mimics the behaviour of glutamine in the body (figure 1.2). Glutamine can be 
transported into cells by a number of amino acid transporters, including alanine serine cysteine 
transporter 2 (ASTC2) (66) which is known to be upregulated in prostate cancer. Because of the 
differences in structure between glutamine and [18F]FACBC, after entering the cell, [18F]FACBC is 
not metabolised and intracellular accumulation occurs. Studies in healthy volunteers showed 
high physiological uptake in the liver (13.8 ± 3.3%), red bone marrow (11.1 ±  5.8%), lung (7.1 ± 
1.3%), and pancreas (4.2 ± 0.7%), with minimal (~4%) urinary excretion (67). Clinical imaging in 
patients with recently diagnosed prostate cancer (n=9) or biochemical recurrence (n=6) showed 
the ability to delineate intra-prostatic cancer and involved regional lymph nodes, with good 
concordance with histological findings (68). The results showed higher SUVs and tumour to 
muscle ratios when imaged at 4.5 minutes post-injection compared to at 20 or 65 minutes, this 
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optimal time point is surprisingly early and suggests that either the uptake is rapid followed by 
a rapid washout from tumours, or that this is a blood flow effect. One study comparing 
[11C]choline and [18F]FACBC in the same patients has been published and showed a slightly 
higher metastases detection rate in biochemical recurrence for [18F]FACBC (69), and example 
images are shown in figure 1.6. A meta-analysis (70) of clinical data for detection of biochemical 
recurrence with [18F]FACBC had pooled sensitivity values of 87% (95% CI, 80–92%) but a lower 
66% (95% CI, 56–75%) pooled specificity. The most recent studies of this tracer were not 
included in this meta-analysis but showed similar results (71)(72). This lower specificity indicates 
a larger number for false positive results compared to [11C]choline or [18F]fluoro-choline and was 
attributed to the uptake of [18F]FACBC in non-cancerous conditions including but not limited to 
prostatic hyperplasia and inflammation. Unfortunately, inflammation can be caused by 
treatments for prostate cancer and so is likely to be present in a significant number of patients 
undergoing PET imaging for recurrence, limiting the utility of [18F]FACBC. However, the strength 
of the evidence for the use [18F]FACBC in prostate cancer patients with suspected prostate 
cancer recurrence based on elevated PSA levels meant it was approved by the FDA in 2016 (19) 
and the European Medicines Agency (EMA) in 2017 (73). 
 
FIGURE 1.6: PET and PET/CT imaging in patients with biochemical recurrence with (A) [11C]choline, (B) 




1.4 Androgen Imaging  
The androgen receptor is a steroid hormone receptor, specific for testosterone and 
dihydrotestosterone, and is found in primary and metastatic prostate cancer of all grades and in 
androgen-independent cancers (74). Chemical or surgical castration can induce apoptosis of 
androgen-sensitive prostate cancer cells (74), leading to improved patient outcomes, as can the 
use of androgen deprivation therapy where anti-androgens are administered to block the 
androgen receptor and inhibit its function (16). The ability to image the distribution of the 
androgen receptor may provide information for prostate cancer staging but it also may have a 
more specific role in validating the ability of novel androgen therapy drugs to block the androgen 
receptor. 
1.4.1 16β-[18F]fluoro-5α-dihydrotestosterone  
 
FIGURE 1.7: Structures of testosterone and [18F]FDHT (16β-[18F]fluoro-5α-dihydrotestosterone) (75). 
The structure of 16β-[18F]fluoro-5α-dihydrotestosterone ([18F]FDHT) is very similar to that of 
testosterone as shown in figure 1.7 and so it behaves similarly in vivo. The first clinical study of 
[18F]FDHT compared its performance to [18F]FDG imaging in 7 patients with metastatic prostate 
cancer (76). A key finding was the rapid metabolism of the tracer with 80% conversion to more 
hydrophilic metabolites within 10 minutes of administration. Across the 12 patients studied the 
59 lesions were detectable by CT, MRI or bone scan. [18F]FDG was able to detect 97% of these 
metastatic sites, whereas [18F]FDHT imaging at 1 hour post-injection was only able to detect 
78%. A comparison of the two tracers’ performance in the same patient is shown in figure 1.8. 
Despite these findings which suggest it unsuitable for use in clinical practice, two clinical trials 
for androgen therapies have utilised [18F]FDHT to monitor response (77)(78). Although there is 
known rapid metabolism of [18F]FDHT, making it most appropriate to choose a very short 
imaging time point such as 5 minutes, the imaging time point chosen in these studies was 30 
minutes to 1 hour and these results were used to define the level of androgen receptor 
expression and binding capacity. In both studies the uptake of the tracer decreased after 4 
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weeks of androgen therapy in a dose dependent manner, suggesting the therapeutics bound to 
androgen receptors, blocking uptake of [18F]FDHT. 
 
FIGURE 1.8: (A) [18F]FDHT and (B) [18F]FDG PET images in a patient with metastatic prostate cancer which 
showing heterogeneity between the tracer uptake. Reproduced with permission from (76). 
1.5 Receptor-Based Imaging 
Cell surface receptors that are highly expressed in prostate cancer but poorly expressed or 
absent in healthy tissue provide a means of detecting disease sites by utilising radiotracers which 
selectively target these receptors. Upon binding the receptor, the tracer should remain intact 
and bound to the receptor, or be internalised, so that the concentration of the radiotracer 
increases substantially enough to provide a good signal to noise ratio, that allows detection of 
disease sites. Two key receptors implicated in prostate cancer are the gastrin-releasing peptide 
receptor and the prostate specific membrane antigen, both of which can be targeted with low 




1.5.1 Gastrin-Releasing Peptide Receptors 
 
FIGURE 1.9: The structure the GRPR antagonist DOTA-RM2 suitable for radiolabelling to produce [68Ga]Ga-
DOTA-RM2(79) and the structure of [18F]F-BAY 864367 with fluorine-18 in red (80). 
Gastrin-releasing peptide receptors (GRPRs) belong to the bombesin receptor family and can be 
targeted by the 14 amino acid peptide bombesin. GRPR expression is upregulated in prostate 
cancer compared to the normal prostate but its expression level is highest in lower grade 
prostate cancer rather than higher grade undifferentiated prostate cancer (Gleason scores over 
7 (81)). Radiotracers have been made from antagonists of these receptors and [68Ga]Ga-DOTA-
RM2 also known as BAY 867548 (79) as shown in  
figure 1.9, has been evaluated in the most clinical studies. In healthy volunteers [68Ga]Ga-DOTA-
RM2 showed extensive uptake in normal tissues, with the highest uptake seen in the pancreas, 
kidneys and bladder, and moderate uptake in the liver, spleen, gastrointestinal tract, and colon 
(80). Plasma studies showed 3 radioactive-metabolites within 10 minutes of administration, due 
to the cleavage of amide bonds, with the intact radiotracer dropping from 92% ± 9% at 1 minute 
post-injection to 15% ± 2% after 150 minutes (figure 1.10). Such rapid metabolism is a major 
concern and means imaging should be restricted to short time-points when the majority of the 
tracer is intact. Despite this, clinical evaluation in prostate cancer patients showed uptake in 
both the primary tumour and in involved lymph nodes when imaged at 60 minutes post-injection 
with SUVmax in the primary tumour of 6.6 ± 4.7 (81)(82). A fluorine-18 labelled analogue has also 
been produced called [18F]F-BAY 864367 and has been evaluated clinically, this showed the 
ability to delineate prostate cancer in the primary prostate and in lymph nodes, but the number 
of lymph nodes detected was lower than with [18F]fluoro-choline, and no metabolite studies 
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were completed. As the structure of [18F]F-BAY 864367 is very similar to that of [68Ga]Ga-DOTA-
RM2 ( 
figure 1.9), it is very probable that radioactive metabolites are also being produced so the PET 
images are not showing the distribution of just the desired tracer. Although the gastrin-releasing 
peptide receptors are interesting targets, the tracers that have been produced to image them 
in prostate cancer suffer from high background uptake and metabolic breakdown in vivo, 
suggesting that a new generation of tracers is required to observe the true distribution of this 
receptor in prostate cancer. However, even if this is achieved, the fact that the expression levels 
of this receptor decrease as the prostate cancer becomes more undifferentiated, will limit its 
ability to detect late-stage disease; a key requirement for clinical use. 
 
FIGURE 1.10: (A) Radio-HPLC of blood plasma 65 minutes after injection of [68Ga]Ga-DOTA-RM2 (BAY 867548) 
showing the presence of three metabolites. (B) Graph showing the ratios of intact tracer to the three metabolites 
in plasma samples from 1 minutes post-injection to 150 minutes post-injection of [68Ga]Ga-DOTA-RM2 (BAY 
867548). Reproduced with permissions from (80). 
1.5.2 The Prostate Specific Membrane Antigen/Glutamate Carboxypeptidase II 
Pathological studies have revealed the prostate specific membrane antigen (PSMA), also known 
as glutamate carboxypeptidase II (GCP(II)), as a suitable target for imaging prostate cancer 
(83)(84)(85). This is a transmembrane zinc metalloenzyme that catalyses the cleavage of a 
terminal glutamate from its natural substrates N-Acetyl-l-aspartyl-l-glutamate (NAAG) and poly-
γ-glutamated-folates (86) (figure 1.11). It is found naturally in prostate tissue, brain, kidneys, 
and intestinal tract but its expression is 100- 1000 times higher in prostate cancer cells (87)(88). 
A detailed description of the structure of GCP(II)/PSMA and its interaction with its natural 




FIGURE 1.11: Structures of the natural substrates (A, B) and inhibitors (C-G) of GCP(II)/PSMA, with the 
conserved terminal glutamate structure shown in blue. (A) Poly-γ-glutamated folate, (B) NAAG, (C) PMPA, (D) 
PBDA, (E) Glu- Glu, (F) Cys-Glu, (G) Lys-Glu.  
1.5.2.1 Imaging GCP(II)/PSMA with Antibodies 
GCP(II)/PSMA has been imaged previously with the indium-111 radiolabelled antibody 7E11.C5 
(ProstaScint). This targeted an internal epitope of GCP(II)/PSMA and so was suitable for the 
detection of GCP(II)/PSMA expressing non-viable or apoptotic cells, which only accumulate in 
quantities sufficient for imaging in larger solid tumours (89). Therefore the diagnostic 
performance of this radiolabelled antibody was limited. Monoclonal antibodies which recognise 
epitopes in the extracellular domain of GCP(II)/PSMA have also been identified and 
radiolabelled, most notably the monoclonal antibody J591 (89)(90). In addition, a number of 
smaller single chain fragments (91), and diabodies (92) of J591 have also been produced and 
used for imaging. A review of this work is outside the scope of this introduction and reviews are 
already available (89)(90). 
1.5.2.2 Imaging GCP(II)/PSMA with Small Molecule Inhibitors 
Generally, small molecule targeting agents offer comparable affinity to targeting with antibodies 
with a number of additional advantages. They typically accumulate quicker in tumours and have 
deeper penetration and faster blood clearance which results in shorter imaging time points and 
better signal to noise ratios (93). There are also fewer concerns about an immunogenic response 
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to small molecules (94), and they allow for the design of multiple analogues giving the 
opportunity to optimise properties such as binding affinity, pharmacokinetics and radiolabelling 
sites. Therefore, small molecule radiotracers have become the preferred approach for imaging 
GCP(II)/PSMA (95). 
The first small molecule inhibitors of GCP(II)/PSMA were designed as neuroprotection agents. 
GCP(II)/PSMA in the brain converts NAAG into glutamate and N-acetylaspartate (NAA) and 
excessive glutamate transmission is found in a range of neurological disorders including 
ischaemia and stroke, central nervous system trauma and amyotrophic lateral sclerosis (ALS) 
(86). Inhibitors for GCP(II)/PSMA in the brain were therefore developed using NAAG as a starting 
point rather than the other natural substrate, poly-γ-glutamated folate. Initially, phosphonate 
derivatives were designed with the most successful structures being 2-
(phosphonomethyl)pentane-1,5-dioic acid (PMPA) (96), and phosphonic bis-dicarboxylic acid 
(PBDA) (97)(98) (figure 1.11) which have low nM affinities (IC50 = 5.1 ± 0.6 nM (98), and EC50 6.9 
± 0.7 nM (97) respectively). These studies also highlighted the importance of conserving a 
terminal L- glutamate (L-glutamic acid)-like structure in order to achieve high affinity, and that 
dipeptides gave enhanced inhibition (86). PMPA is still the small molecule inhibitor of choice for 
GCP(II)/PSMA and has been used as a blocking agent in order to demonstrate specific binding in 
a number of studies (99)(100)(101)(102), as well as to provide nephroprotection for 
GCP(II)/PSMA targeted therapies (103). However, PMPA cannot be functionalised whilst 
maintaining its high affinity and so urea-based GCP(II)/PSMA inhibitors were developed by 
further rational design (98). These utilise a urea as an amide bond mimic, allowing the structure 
of the terminal L-glutamic acid to be conserved, but stopping its enzymatic cleavage by 
GCP(II)/PSMA. The urea also allows for the addition of a second amino acid with a terminal 
amide (L-lysine) or thiol group (L-cysteine) allowing functionalisation (figure 1.11). In fact, this 
structure is extremely robust to functionalisation of this second amino acid and maintains 
excellent affinity to GCP(II)/PSMA with a wide range of modifications. As a results this urea-
based motif has been chosen as the GCP(II)/PSMA targeting scaffold for many GCP(II)/PSMA 
targeting radiotracers, radiolabelled either covalently with 123/124/125/131I, 11C or 18F, or by means 
of an attached chelator allowing radiometals such as 68Ga, 64Cu, 99mTc, and 177Lu to be 
incorporated. The key PSMA tracers that use this targeting motif that have reached clinical 
evaluation will be discussed in the following sections and are summarised in table 1.3. The 
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1.5.2.3 Carbon-11-Based Tracers 
The first tracer to utilise the urea-based scaffold was [11C]MCG (99) figure 1.12. This tracer was 
only evaluated in healthy mice and baboon studies but paved the way for the development of 
all other PSMA radiotracers with the same scaffold (99). [11C]MCG has a low nanomolar affinity 
(Ki = 1.9 nM) for GCP(II)/PSMA and showed a bio-distribution which mirrored its known 
physiological expression, with the majority of uptake seen in the kidneys, which could be 
blocked by PMPA administration. There was minimal uptake in the brain, suggesting that the 
compound does not pass through the blood-brain barrier, probably due to its hydrophilicity, and 
so would not be suitable for imaging the distribution of GCP(II)/PSMA in the brain. 
 
FIGURE 1.12: The structure of the radiotracer [11C]MCG (99). The location of carbon-11 is shown in red and the 
conserved terminal glutamate is shown in blue. 
1.5.2.4 Iodine-123-Based Tracers 
Iodine-123-based PSMA tracers were the first to be developed for SPECT imaging of 
GCP(II)/PSMA. Iodine-123 has a half-life of 13.3 hours and major gamma emissions at 159 keV 
(34). Two analogues [123I]I-MIP-1072 and [123I]I-MIP-1095 figure 1.13 were synthesised, 
radiolabelled (95) and tested in vitro. They both showed specific uptake and internalisation in 
GCP(II)/PSMA expressing human prostate cancer cells (LNCaP) and affinity values (Ki values 4.6 
± 1.6 nM and 0.24 ± 0.14 nM respectively (114)). These compounds were then tested in a 
xenograft model of prostate cancer using the same cell line and had comparable tumour uptake 
values at 1 hour ([123I]I-MIP-1072 17.4 ± 6.3 %ID/g, [123I]I-MIP-1095 20.7 ± 5.8 %ID/g) however, 
[123I]I-MIP-1095 had higher background tissue uptake than [123I]I-MIP-1072 most likely due to its 
longer circulation time (114). These two tracers have also been assessed for safety, 
pharmacokinetics and ability to visualise prostate cancer. A phase 1 clinical study was conducted 
in which 6 patients were imaged with both tracers, with scans two weeks apart (104). The 
injected activity at each session was 370 MBq, and patients were imaged at time points up to 72 
hours. The safety study reported 4 cases of mild adverse events including, chills, constipation, 
insomnia, and mild injection site irritation. SPECT imaging at 1 hour detected tracer uptake in 
metastatic bone and lymph node lesions, which correlated with bone scans and lymph node 
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sizing from CT. Uptake was also seen in the liver, spleen, bowel, kidneys, salivary and lachrymal 
glands. The liver and spleen are not known to express GCP(II)/PSMA and so uptake in these 
organs is probably not GCP(II)/PSMA-mediated (115)(116). The tumour-to-background ratio 
from SPECT imaging was the highest for both tracers 24 hours post-injection with ratios above 
15:1. The calculated effective doses for [123I]I-MIP-1072 and [123I]I-MIP-1095 were 0.022 and 
0.032 mSv/MBq respectively. In both cases, the dose-limiting organs were the kidney, salivary 
glands and thyroid. The high thyroid values are due to radioiodine-containing metabolites and 
radio-iodide localising in the thyroid due to its natural iodine avidity, and should be controllable 
with a thyroid blockade. These promising results suggest that either of these agents could be 
used for SPECT imaging of GCP(II)/PSMA-expressing prostate cancer, but no further studies 
demonstrating their use in this manner have been published. Instead, the iodine-124 and iodine-
131 version of MIP-1095 have been explored for PET imaging and molecular radiotherapy 
(105)(117). 
 
FIGURE 1.13: The structure of the radiotracers [123I]I-MIP-1072 and [123I]I-MIP- 1095. The location of iodine-
123 is shown in red and the conserved terminal glutamate is shown in blue (95)(104). 
1.5.2.5 Technetium-99m-Based Tracers 
Technetium-99m tracers for SPECT imaging of GCP(II)/PSMA expressing prostate cancer were 
the first to demonstrate that the urea-based GCP(II)/PSMA targeting motif (Lys-C(O)-Glu) could 
be modified with a chelator and radiometal, whilst maintaining low nanomolar affinity 
(102)(118). The chelator choice and type of linker between the chelator and the GCP(II)/PSMA 
targeting motif were both found to influence affinity, and this knowledge was incorporated into 
future tracer design for a range of radiometals (119)(120)(121)(122). The two technetium-99m 
tracers that have progressed to clinical studies are [99mTc]Tc-MIP-1404 and [99mTc]Tc-MIP-1405, 
shown in figure 1.14, which incorporate [99mTc](Tc(CO)3)+ through their TIM and CIM chelators 
respectively (123). The tracers both have low nanomolar Kd values ([99mTc]Tc-MIP-1404 = 1.07 ± 
0.89 nM, [99mTc]Tc-MIP-1405 = 4.35 ± 0.35 nM) and were shown in preclinical studies to have 
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uptakes of 10.3 ± 2.5 %ID/g and 12.4 ± 2.3 %ID/g in LNCaP tumour xenografts at 1 hour post-
injection (123). The phase 1 clinical study for [99mTc]Tc-MIP-1404 and [99mTc]Tc-MIP-1405 utilised 
a 6 patient cross-over design, which meant that each patient was imaged with the first of 2 
tracers and then, 2 weeks later, imaged with the other tracer (106). All patients had evidence of 
metastatic prostate cancer by CT and the average administered activity during each imaging 
session was 784 ± 59 MBq (20 µg of cold tracer). This phase 1 study showed that both tracers 
identified soft-tissue prostate cancer lesions including lymph nodes less than 10 mm in size 
(greater than 8 mm suggests lymph node involvement using anatomical imaging (6)) and were 
also able to detect the majority of bone metastasis when compared to bone scans with [99mTc]Tc-
MDP. The two tracers showed different renal excretion patterns with a much higher percentage 
of [99mTc]Tc-MIP-1405 in the urine 24 hours after injection (25-30%) than [99mTc]Tc-MIP-1404 (5-
10%). Non-target tissue uptake was seen was seen in the salivary glands, liver, kidneys, and 
gastrointestinal tract for both tracers but uptake was higher for [99mTc]Tc-MIP-1404. 
 
FIGURE 1.14: The structures of MIP-1404 and MIP-1405 for radiolabelling with [99mTc](Tc(CO)3)+ to produce 
[99mTc]Tc-MIP-1404 and [99mTc]Tc-MIP-1405 respectively (106). The conserved terminal glutamate is shown in 
blue. 
[99mTc]Tc-MIP-1404 was selected for further study, due to its higher uptake in metastatic sites 
and minimal activity in the bladder, which allowed better visualisation of the prostate and 
surrounding lymph nodes during initial staging. It has completed a phase 2 study, under the 
name [99mTc]Trofolastat, evaluating its use in staging before radical surgery in 105 patients with 
histologically proven prostate cancer (124). Imaging was undertaken 3-6 hours post-injection. 
The tracer identified prostate cancer in 94% of patients and detected local lymph node 
involvement with a sensitivity of 50% and specificity of 87%. There are two published studies 
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that have assessed [99mTc]Tc-MIP-1404 in biochemical recurrence (125)(126). Both showed a 
high detection rate (≥ 90%) in patients with PSA levels above 2 ng/mL but lower detection rates 
below this threshold (54% (125) and 40% (126)). A phase 3 clinical trial (clinical trial registry 
number, NCT02615067 (127)) was conducted in over 500 patients across 45 sites in the US and 
Canada between December 2015 and December 2017. However, results have not yet been 
published. This trial focuses on using the SPECT imaging with [99mTc]Tc-MIP-1404 in low-grade 
prostate cancer as a tool for active surveillance and will be validated against histological samples 
from either biopsy or prostatectomy taken within 42 days of imaging. It aims to determine the 
sensitivity and specificity of the tracer for the detection of prostate cancer in this context. This 
will be the first phase 3 trial completed for a PSMA-based tracer and its results will be 
instrumental in defining how PSMA agents gain regulatory approval.  
1.5.2.6 Fluorine-18-Based Tracers 
[18F]DCFBC and [18F]DCFPyL shown in figure 1.15 are first and second generation radiotracers 
from the Pomper research group and have both been evaluated in vitro, in a mouse xenograft 
model of prostate cancer and in clinical trials (93)(107)(128)(129). These tracers incorporate 
fluorine-18 through a terminal aromatic group - either an [18F]fluorobenzyl or an 
[18F]fluoropyridy substituent. The reported affinity values are not directly comparable as they 
were obtained by different techniques but were both in the low nanomolar range ([18F]DCFBC, 
IC50 = 13.9 nM (128) and [18F]DCFPyL, Ki = 1.1 ± 0.1 nM (129)). Despite their similar structure and 
affinity values, they showed differences in biodistribution. Tumour uptake values at 1 hour post-
injection in a mouse xenograft model of GCP(II)/PSMA expressing prostate cancer (PC-3 PIP 
tumour) were 8.2 ± 2.5 %ID/g for [18F]DCFBC (128) and 44.2 ± 9.7 %ID/g for [18F]DCFPyL (129). 
The tracers had similar uptake in the kidney (41.6 ± 7.2, 42.3 ± 19.0 %ID/g) but [18F]DCFBC had 
higher uptake in the liver (5.1 ± 0.8 %ID/g, 2.87 ± 0.92 %ID/g) and some activity also associated 
with the bone (1.7 ± 0.8 %ID/g) which suggests the presence of free fluoride, and therefore some 




FIGURE 1.15: The structure of the radiotracers [18F]DCFBC (128), [18F]DCFPyL (107)(129), and [18F]F-PSMA-
1007 (108)(131). The location of fluorine-18 is shown in red and the conserved terminal glutamate is shown in 
blue.  
The phase 1 studies for both tracers used patients with histologically confirmed prostate cancer 
and evidence of disease progression using conventional imaging techniques (93)(107). In the 
[18F]DCFBC study patients were administered an average of 370 MBq and imaged up to 120 
minutes post-injection. A similar protocol was used in [18F]DCFPyL study with 320 MBq 
administered and imaging performed for 150 minutes. [18F]DCFBC allowed detection of involved 
lymph nodes (median lymph node SUVmax = 5.6, 2 hours post-injection) and bone metastases 
(median bone lesion SUVmax = 3.6, 2 hours post-injection) and was able to detect smaller involved 
lymph nodes than detected by anatomical imaging. As defluorination was suspected in 
preclinical studies this was investigated in humans by taking patient plasma samples over time 
and analysing the ratio of [18F]DCFBC to [18F]fluoride levels. This was seen to be over 95% at the 
end of the 2 hour scan which was comparable to the administered radiochemical purity. The 
[18F]DCFPyL study detected involved lymph nodes and bone metastases with improved 
visualisation due to higher SUVmax values (mean SUVmax = 45 bone lesions, and mean SUVmax = 25 
for lymph nodes at 2 hours post-injection) and therefore better tumour to background ratios 
(107). Further studies have also confirmed the ability of [18F]DCFBC to detect disease in primary 
prostate cancer (132) and shown that both tracers have superior detection of metastatic 
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prostate cancer compared to the conventional imaging modalities (133)(134). However, specific 
studies looking at the performance in detection rates in biochemical recurrence are not yet 
available.  
Another important fluorine-18-based PSMA tracer is [18F]F-PSMA-1007 which has a very similar 
structure to the DOTA-PSMA(617) tracer used for both [68Ga]Ga-PSMA PET imaging and 
[177Lu]Lu-PSMA beta therapy, discussed in detail later on and shown in figure 1.16. The 
GCP(II)/PSMA targeting scaffold (Lys-C(O)-Glu) is conserved between these tracers, as is the 
optimised lipophilic linker, however, in the fluorine-18 version the DOTA chelator is replaced by 
two glutamic acid residues and a [18F]fluoropyridyl substituent. The glutamic acid residues are 
included in order to conserve the hydrophilicity provided by carboxylic acids of the DOTA 
chelator not used in metal binding. This radiotracer has been designed to have very similar 
biodistribution and performance to [68Ga]Ga-DOTA-PSMA(617) so that it can act as replacement 
PET imaging agent. This is useful because fluorine-18 is a more amenable radionuclide than 
gallium-68 for the centralised production of radiotracers followed by shipping the tracer to a 
number of different hospitals for use, due to its longer half-life and the larger amounts of activity 
produced from one cyclotron run. 
The pre-clinical studies of [18F]F-PSMA-1007 showed high LNCaP cell internalisation ratios (67% 
± 13%) and 8.0 ± 2.4 %ID/g uptake in LNCaP xenografts at 1 hour post-injection (135). This tracer 
has been assessed as a clinical tool for primary staging and excellent alignment was found 
between it and histological GCP(II)/PSMA staining and, when available, multiparametric MRI 
(108)(136). A 12 patient study evaluating the performance of [18F]F-PSMA-1007 in biochemical 
recurrence detected metastases in 75% of patients, including metastases under 8 mm in size 
(137). The comparative performance of [18F]DCFPyL and [18F]F-PSMA-1007, in the same patient 
before undergoing radical prostatectomy has also recently been reported (138). The two tracers 
detected the same metastases with no statistical difference between their SUVmax values. 
However, differences were observed in non-target tissue, where [18F]DCFPyL showed greater 
renal excretion with associated higher kidney and bladder signal, whereas [18F]F-PSMA-1007 




1.5.2.7 Gallium-68-Based Tracers 
Gallium-68 is a radiometal with suitable positron (β+) emissions for PET imaging (89% positron 
emissions with an energy of 1.9 MeV (31)). Unlike the majority of PET radionuclides, gallium-68 
can be obtained from generators containing its parent isotope germanium-68 which has a half-
life of 270.95 days (139). The elution of a modern clinical grade generator provides 1-1.85 GBq 
of gallium-68 in 1.1 - 5 mL of 0.1 M HCl, which can be used to manufacture radiopharmaceuticals 
at doses which allow high-quality images to be obtained. Additionally, the 67.8 minute half-life 
(31) of gallium-68 makes it particularly suited to radiolabelling peptides and small molecules 
with fast pharmacokinetics, such as the GCP(II)/PSMA targeting motif (Lys-C(O)-Glu). 
The most widely studied PSMA radiotracer utilising gallium-68 is [68Ga]Ga-HBED-CC-PSMA. The 
urea-based GCP(II)/PSMA targeting scaffold (Lys-C(O)-Glu) is conserved and is joined by an 
amide-based linker to the acyclic chelator HBED-CC as shown in figure 1.16. This tracer was 
evaluated in vitro and found to have specific uptake in GCP(II)/PSMA expressing cells and a high 
internalisation rate (101). The biodistribution of this tracer in mice with LNCaP xenografts 
showed a tumour uptake of 7.70 ± 1.45% ID/g at 1 hour post-injection. This coincided with high 
kidney (139.4 ± 21.4% ID/g) and spleen (17.90 ± 2.87% ID/g)) uptake and renal excretion. These 
promising results led to the tracer being evaluated in patients with biochemical recurrence after 
treatment (109). This initial study showed the ability to delineate local relapse lymph node, soft 
tissue and bone metastases (figure 1.17), and was cross-validated with samples from biopsy or 
surgery in 6 out of 37 patients (109). Non-target tissue accumulation was seen most strongly for 
the kidneys and the salivary glands with less intense uptake seen for the lacrimal glands, liver, 
spleen and intestinal tract as shown in figure 1.17. The lung uptake seen in the mouse model 
was not seen in humans. The urinary excretion could have been a disadvantage for this tracer, 
however, if the bladder is voided before a scan and PET/CT is used rather than PET alone, it is 
possible to differentiate metastatic lymph nodes from urinary excretion particularly when axial 
slices are used. Dosimetry studies have found the effective dose of [68Ga]Ga-HBED-CC-PSMA to 
be 0.0236 ± 0.0036 mSv/MBq, with the highest dose delivered to the kidneys and bladder (110). 
Since these initial studies, the use of this tracer has become widespread across research centres, 
and large patient populations have been imaged. For staging before treatment, two major 
studies have shown that [68Ga]Ga-HBED-CC-PSMA is able to detect metastasis more accurately 
than morphological imaging (CT or MR) with postoperative histology used as the ground truth 
(140)(141). Both studies also reported high sensitivites and specificities (84%, 82% (141) and 
65.9%, 98.9% (140)) which, when compared to CT (42%, 82% (6)) and [11C]choline imaging 
45 
 
(49.2%, 95% (60)) show similar specificity but enhanced sensitivity, making it the best 
performing PET tracer for primary staging to date. 
 
 
FIGURE 1.16: Structures of HBED-CC-PSMA (101), DOTA-PSMA(617) (111), DOTAGA-FFK(Sub-KuE) (121), 




FIGURE 1.17: (A) A maximum intensity projection of a patient with a normal biodistribution of [68Ga]Ga-HBED-
CC-PSMA (B) A maximum intensity projection of a patient with disseminated lymph node and bone metastases 
imaged with [68Ga]Ga-HBED-CC-PSMA at 1 hour post-injection. Non-target uptake is seen in the kidney, salivary 
glands, lacrimal glands, liver, spleen and intestinal tract. Reproduced with permissions from (109). 
The majority of clinical studies of [68Ga]Ga-HBED-CC-PSMA have focused on its use in 
biochemical recurrence. A meta-analysis of these results has been conducted and concluded 
that it had 86% sensitivity and 86% specificity on a per-patient basis (143), and that there was a 
clear correlation between detection rate using [68Ga]Ga-HBED-CC-PSMA and PSA level as 
demonstrated in figure 1.18. It is important to note that the detection of metastases is possible 
at much lower PSA levels than the PSA level where evaluation with bone scans and CT become 
reliable (20 ng/mL (16)), thus providing much earlier detection of recurrence. A more recent 
study summarised the results of 1007 consecutive scans of patients with biochemical 
reoccurrence at Heidelberg University Hospital again confirmed this relationship, with detection 
rates increasing with PSA levels, but interestingly they did not find a significant correlation 
between detection rates and Gleason score, PSA doubling time or PSA velocity (144).  
It is important to note that despite the excitement around [68Ga]Ga-HBED-CC-PSMA imaging and 
its adoption into clinical decision making, evidence from prospective multicentre trials is not yet 
available. A number of clinical trials are ongoing (145) and although the majority of these are 
single centre trials, a multicentre phase 1 and 2 trial is ongoing in 11 sites across Germany, 
Switzerland and Austria (146). This study will evaluate [68Ga]Ga-HBED-CC-PSMA in staging 
before radical prostatectomy, and findings will be correlated with histology. This study will 
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therefore provide key evidence for the clinical use of PSMA imaging agents and move them 
closer towards regulatory approval.  
 
FIGURE 1.18: (A) Scatter plot of prostate specific antigen (PSA) level versus the detection rate for [68Ga]Ga-
HBED-CC-PSMA in each study. The orange line is the meta-regression prediction with the shading showing the 
95% confidence interval. The size of the circles is related to the inverse of the variance (B) Mean disease 
detection rate for [68Ga]Ga-HBED-CC-PSMA over the PSA levels (ng/mL) <0.2 (black), 0.2-0.99 (dark grey), 
1.00-1.99 (light grey), >2 (white), modified with permissions from (143). 
Another important gallium-68 tracer that has been studied clinically is the DOTA conjugate 
[68Ga]Ga-DOTA-PSMA(617) (111). Unlike HBED-CC the DOTA chelator allows a range of radio-
metals to be bound including those suitable for molecular radiotherapy such as lutetium-177 
(147), yttrium-90 (148), bismuth-213 (149), and actinium-225 (150), so this tracer was designed 
with the dual purpose of imaging and therapy. This was achieved by screening a large number 
of different linker groups for the following properties: Ki value, specific cell binding, specific 
internalisation, tumour uptake and tumour to background ratios (119). It is interesting to note 
that these features were not as well correlated to each other as may be expected by intuition, 
with some tracers with low Ki (and therefore high affinity for GCP(II)/PSMA) showing lower 
specific cell binding and internalisation values than some of those with higher Ki values (and 
therefore lower affinity for GCP(II)/PSMA), and tracers with the highest tumour uptake not 
having the highest tumour to background ratio in vivo. This demonstrates the complexity of the 
GCP(II)/PSMA binding and internalisation mechanisms and that a screening protocol which 
looked at Ki values alone would not provide the optimal tracer for use in vivo. However, there 
was a correlation between the degree of specific internalisation in vitro and the tumour to 
background ratio seen in vivo with the same tracer having the best performance for both of 
these properties. This tracer, utilising a 2-naphthyl-L-alanine linker followed by a cyclohexanoic 
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acid between the GCP(II)/PSMA targeting moiety (Lys-C(O)-Glu) and the DOTA chelator (figure 
1.16), was named DOTA-PSMA(617) and was selected for clinical translation (111)(119). This 
tracer showed a similar biodistrubution to [68Ga]Ga-HBED-CC-PSMA and could delineate 
involved lymph nodes at one hour post-injection, however, there are limited further studies 
demonstrating its potential as an imaging agent. 
A third important tracer for gallium-68 imaging is [68Ga]Ga-DOTAGA-(I-y)fk (Sub-KuE) also 
referred to as [68Ga]Ga-DOTAGA-PSMA(I&T) (142). With I&T standing for imaging and therapy. 
This is an optimised version of the previously developed DOTA-FFK(Sub-KuE) (121)(151)(152) 
shown in figure 1.16. The structures differ in their stereochemistry within the linker, the 
replacement of the final phenyl group with a 4-hydroxy-3-iodophenyl group and the 
replacement of the DOTA chelator by DOTAGA, creating one further pendant carboxylic acid 
available for metal chelation (142). However, there is no description of why these specific 
changes were selected. This tracer has been evaluated clinically and, in a limited number of 
patients, has shown similar results to [68Ga]Ga-HBED-CC-PSMA (113)(142)(153)(154). A key 
study focused on detection rates in patients with biochemical recurrence over a range of PSA 
levels and these were found not to be statistically different from published results for [68Ga]Ga-
HBED-CC-PSMA (154). 
[68Ga]Ga-DOTA-PSMA(617) and [68Ga]Ga-DOTAGA-PSMA(I&T) show similar results to [68Ga]Ga-
HBED-CC-PSMA for PET imaging of prostate cancer but no advantage over it. Therefore due to 
the larger body of evidence supporting the use of [68Ga]Ga-HBED-CC-PSMA, it is likely to remain 
the most prevalent PSMA PET agent. The advantage of both [68Ga]Ga-DOTA-PSMA(617) and 
[68Ga]Ga-PSMA(I&T) should be their dual use for both imaging and therapy, but as the 
radiometal is different between the two versions, the complexes are inequivalent and will have 
slightly different biodistributions. This has been demonstrated for the gallium-68 and lutetium-
177 versions of DOTAGA-PSMA(I&T) in mice bearing prostate cancer xenografts (142) as shown 
in figure 1.19. These results suggest there is no real advantage in using the same bioconjugate 
over using another that targets GCP(II)/PSMA with similar bio-distribution (i.e. [68Ga]Ga-HBED-
CC-PSMA or even [18F]F-PSMA-1007) for therapeutic planning if a different radioactive element 
is to be used. These tracers have not been used in many published studies for PET imaging with 
gallium-68, and even when planning for therapy with their lutetium-177 analogues [68Ga]Ga-
HBED-CC-PSMA is more often used. This is probably less to do with the quality of the images 
produced by these tracers and more to do with the fact that [68Ga]Ga-HBED-CC-PSMA was 
already established in many centres and had been shown suitable for planning for therapy so 




FIGURE 1.19: Tumour-to-organ ratios of dual-tracer biodistribution of [68Ga]Ga-DOTAGA-PSMA(I&T) and 
[177Lu]Lu-DOTAGA-PSMA(I&T) 1 hour after injection of 1 nmol tracer in CD-1 nu/nu mice with LNCaP 
xenografts (n = 4) Reproduced with permissions from (142). 
1.5.2.8 Summary of PSMA Tracers  
PET and SPECT GCP(II)/PSMA imaging are clearly promising techniques for more accurate staging 
of prostate cancer and detection of metastatic disease in biochemical recurrence, and the body 
of evidence supporting their use continues to grow. As the most widely used tracer, the most 
clinical evidence exists for [68Ga]Ga-HBED-CC-PSMA, however, to date, no PSMA tracer has been 
approved by the EMA or FDA and therefore all current use of PSMA tracers must be within a 
research study or under regulations for non-approved radiopharmaceuticals (155). Large 
multicentre clinical trials will be required to obtain such approval, and these are ongoing for 
[99mTc]Tc-MIP-1404 (127) and [68Ga]Ga-HBED-CC-PSMA (146). Further evidence will also be 
required before reimbursement is issued by health insurance companies or government bodies 
such as NICE or the Centres for Medicare and Medicaid Services, which would enable 
widespread use of PSMA tracers in clinical practice. 
1.6 Comparison of All Tracers in Imaging Biochemical Recurrence 
The performance of 5 different tracers in the detection of prostate cancer sites in cases of 
biochemical recurrence (rising PSA serum levels >0.1 ng/mL)) after radical surgery was 
compared in a critical analysis of published literature in 2014 (42). In order to ensure that 
different studies could be fairly compared, data were only used if it fitted with a pre-defined set 
of patient selection criteria and verification standards. The tracers included were: [18F]FDG, 
[11C]acetate, [11C]choline or [18F]fluoro-choline (the results for these two tracers were 
combined), [18F]FACBC, and [68Ga]Ga-HBED-CC-PSMA. This study found that [18F]FDG had the 
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lowest detection rate with a positive scan in only 12% of patients and concluded that it was 
unsuitable for clinical detection of biochemical recurrence. [11C]acetate, [11C]choline/[18F]fluoro-
choline and [18F]FACBC all had higher disease detection rates, (48%, 51%, and 40%, respectively) 
with no statistically significant differences in their performance. However, [68Ga]Ga-PSMA 
showed the greatest disease detection in biochemical recurrence after radical prostatectomy 
(84%), and the highest rates of detection for extra-prostatic disease (77%), involved lymph nodes 
(45%) and bone lesions (25%). Similar findings were seen in patients who had biochemical 
recurrence after radical radiotherapy, confirming [68Ga]Ga-HBED-CC-PSMA imaging as a very 
promising tool. In the last 4 years since that review, the field of prostate cancer PET imaging has 
evolved rapidly, especially with regards to GCP(II)/PSMA imaging, and there is now much more 
data available to use in such a comparison (the 2014 critical review only used two [68Ga]Ga-
HEBD-CC-PSMA papers (156)(157)). A 2018 review looked at results of meta-analyses and critical 
reviews published for the most promising tracers in the localisation of biochemical recurrence, 
[11C]choline/[18F]fluoro-choline, [68Ga]Ga-HBED-CC-PSMA, and [18F]FACBC and compared their 
sensitivity and specificity as well as their detection rates across a range of PSA levels (56). A 
summary of the meta-analysis is shown in table 1.4 with very similar sensitivity and specificity 
values for all three tracer types, except for [11C]choline/[18F]fluoro-choline showing an 
advantage in specificity. In contrast, when the detection rates were compared at different 
patient PSA levels, [68Ga]Ga-HBED-CC-PSMA imaging showed markedly higher detection rates at 
all PSA levels (56).  PSMA imaging therefore shows clear advantages over the other available 
tracers in both detection rates and sensitivity and specificity for primary staging, and detection 





































































TABLE 1.4: Summary of sensitivity and specificity of meta-analyses evaluating [68Ga]Ga-HBED-CC-PSMA, 
[11C]choline/[18F]fluoro-choline, and [18F]FACBC PET/CT. CI = confidence interval. Modified from (56) with 
permission.  
1.7 Impact on Management and Survival 
PET scanning should provide additional information to ensure patients are on the correct 
treatment pathway. A limited number of studies have been conducted into change in 
management for [11C]choline (158)(159) (retrospective studies), [68Ga]Ga-HEBD-CC-PSMA (160) 
(161) (one retrospective and one prospective) and [18F]FACBC (2 prospective studies  
(162)(163)). The [11C]choline and [18F]FACBC studies focused solely on the impact in patients 
presenting with biochemical relapse and showed the treatment approach was altered in 45-55% 
of the patients after receiving a [11C]choline scan and in 40-62% after [18F]FACBC (162). The 
retrospective study into [68Ga]Ga-HEBD-CC-PSMA showed a 39% impact on treatment in 
biochemical relapse and the prospective study showed a higher impact in biochemical relapse 
rather than initial staging (62% and 21% respectively). These are all encouraging results which 
highlight the utility of the information provided by a PET scan with any of these 3 tracers, and 
that clinicians trust the results and are adjusting treatment accordingly. It is therefore important 
to validate that there is a relationship between the extent of disease detectable by the PET scan, 
and survival. Such analysis has only been attempted for [11C]choline (164) and showed that 
patients with positive scans for prostate cancer had worse survival than those with negative 
scans as demonstrated in figure 1.20. After such analysis has been performed the next step is to 
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prove that having the information from a PET scan allowed patients to be put onto a different 
treatment which goes on to positively impacted survival rates. 
 
FIGURE 1.20: Kaplan–Meier survival probability curves in patients with negative [11C]choline PET/CT and in 
patients with positive [11C]choline PET/CT. reproduced with permission from (164). 
1.8 GCP(II)/PSMA Targeted Radionuclide Therapy 
Another key use for GCP(II)/PSMA imaging, for which the other tracers are not suitable, is 
planning for GCP(II)/PSMA targeted molecular radiotherapy, where the same targeting motif is 
used (Lys-C(O)-Glu), but a therapeutic radionuclide is incorporated instead of a radionuclide 
suitable for SPECT or PET imaging. Tracers currently under evaluation include [131I]I-MIP-1095 
(105), [177Lu]Lu-DOTA-PSMA(617) (165) and [177Lu]Lu-DOTAGA-PSMA(I&T) (142) for beta-based 
therapy, [225Ac]Ac-DOTA-PSMA(617) (150), (2S)-2-(3-(1-carboxy-5-(4-[211At]astatobenzamido) 
pentyl) ureido)-pentanedioic acid (166) and [213Bi]Bi-DOTA-PSMA(617) (149) for alpha-based 
therapy, and 2-[3-[1-carboxy-5-(4-[125I] iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid 
([125I]I-DCIBzL) (167) for therapy with Auger electrons. Of these the most studied clinically is 
[177Lu]Lu-DOTA-PSMA(617), which has shown promising therapeutic results in patients with 
advanced metastatic prostate cancer. A typical protocol for [177Lu]Lu-DOTA-PSMA(617) is 2 
cycles of 6 GBq, 10 weeks apart (168). In 2017 a meta-analysis reviewed 7 small single centre 
clinical studies on the effect of therapy with [177Lu]Lu-DOTA-PSMA(617) or [177Lu]Lu-DOTGA-
PSMA(I&T) on the PSA levels of patients with metastatic prostate cancer (169). Most patients in 
the studies used for this meta-analysis had disease progression after being treated with 
docetaxel and post-chemotherapy androgen deprivation therapy. The analysis showed that over 
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70% of patients had a reduction in PSA levels and 51% of patients showed at least a 50% 
reduction in PSA figure 1.21. These are very promising results, even though there was substantial 
heterogeneity across studies. The next step will be a focus on survival as the endpoint rather 
than PSA reduction and application for a phase 3 trial of [177Lu]Lu-DOTA-PSMA(617) has been 
announced by the company Endocyte (170). 
 
FIGURE 1.21: Forest plot for meta-analysis results of the proportion of patients with > 50% PSA decline after 
therapy with [177Lu]Lu-DOTA-PSMA(617) or [177Lu]Lu-DOTGA-PSMA(I&T). Reproduced from (169). 
It is possible for a PSMA PET or SPECT scan to be used not only to assess the suitability of a 
patient for GCP(II)/PSMA targeted therapy (ensuring their metastatic sites express 
GCP(II)/PSMA) but also to monitor the effect of treatment as demonstrated in figure 1.22. In this 





FIGURE 1.22: [68Ga]Ga-HBED-CC-PSMA PET/CT images at 1 hour post-injection (175-180 MBq) for the same 
patient before (A) and three months after (B) therapy with [177Lu]Lu-PSMA I&T therapy (8 GBq). Modified with 
permission from (142). 
1.9 Concluding Remarks 
There is a clear clinical need for improved imaging in prostate cancer. This need is not fulfilled 
by anatomical imaging, bone scans or [18F]FDG PET. [11C]choline and [18F]FACBC offer significant 
advantages over these standard imaging techniques in biochemical recurrence and have 
therefore become FDA approved agents, but they are unproven for initial staging, and therefore 
their use is still limited to research sites rather than becoming integrated into standard clinical 
practice. The data available for [68Ga]Ga-HBED-CC-PSMA imaging suggest that it provides 
improved performance for both initial staging and for disease detection in biochemical 
recurrence at low PSA levels, and that it therefore has the potential to become the standard of 
care for prostate cancer imaging. Other PSMA tracers have high potential but have not been 
evaluated as fully in clinical studies. The fact that PSMA agents can also be used for determining 
the suitability of patients for radionuclide therapy with [177Lu]Lu-PSMA and monitoring response 
to this therapy is a further advantage which is likely to expedite translation into the clinic. It is 
clear that GCP(II)/PSMA is an excellent receptor for imaging the distribution of prostate cancer, 
at all stages of the disease, and the surprisingly simple and yet robust targeting motif (Lys-C(O)-
Glu) allows for specific targeting of this receptor, however, it remains unclear which PSMA tracer 
will become the most used clinically. Aside from clinical performance, major factors which could 
affect the choice of PSMA tracer used include how easily and cost effectively hospitals can obtain 
these tracers, or the radionuclides required for their production, and how simply radiosynthesis 
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could be carried out within existing infrastructure. These issues, and the ability to overcome 
some of these barriers by designing radiopharmaceutical kits which provide ease of 
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2 Ideal Radiolabelling: Generator Produced Radionuclides Combined 
with a One-Step Radiopharmaceutical Kit 
2.1 The Prevalence of Technetium-99m 
The majority of radiopharmaceuticals used to image patients every year are based on 
technetium-99m, a radio-metal which emits gamma radiation and has a half-life of 6.01 hours 
(1). This prevalence can be attributed to a number of factors, some clinical, others due to 
infrastructure and economics. These include but are not limited to: 1) The wide availability of 
SPECT and gamma cameras in hospitals; 2) The 140 keV gamma emissions of technetium-99m 
which are optimal for SPECT imaging and its 6.01 hour half-life (1) which allows imaging within 
an acceptable patient dose and minimal waste handling issues (2); 3) The wide range of 
technetium-99m radiopharmaceuticals clinically approved and commercially available (2)(3); 4) 
The relatively low production costs of tracers due to the generator production of technetium-
99m and easy to label kit preparations (2)(3). This chapter will focus on the advantages of 
radiopharmaceutical production based on a generator-produced radionuclide incorporated into 
a radiopharmaceutical by reconstitution of a one-step kit, and how this technology could also 
be applied to gallium-68 PET radiopharmaceuticals. 
2.1.1 Molybdenum-99/Technetium-99m Generators and Their Advantages 
Molybdenum-99/technetium-99m generators provide a convenient way to produce high molar 
activity technetium-99m on demand in a radiopharmacy for the manufacture of 
radiopharmaceuticals (4). These generators consist of an aluminium oxide column onto which 
the parent isotope molybdenum-99 in the form [99Mo][Mo(VI)O42-] is adsorbed (2). The 
molybdenum-99 on the column decays to technetium-99m producing [99mTc][Tc(VII)O4-], which 
due to its lower charge has a lower affinity for the column. Saline can be used to elute the 
generator and separate the two radionuclides by removing [[99mTc]Tc(VII)O4-] from the column 
without displacing the [[99Mo]Mo(VI)O42-] (4). Clinical generators are commonly eluted with 
0.9% saline and produce 2-150 GBq of technetium-99m per elution (2). A clinical generator is a 
benchtop-sized piece of equipment that weighs around 20 kg due to the required shielding (5). 
Generators are normally stored within hospital radiopharmacies in a customised lead drawer on 
a reinforced bench or in an isolator. The 66.02 hour half-life of molybdenum-99 means that 
generators have a lifetime of 1-2 weeks, giving plenty of time for transport from the 
manufacturer to radiopharmacies. This provides a big advantage over the nuclear reactor or 
cyclotron production of short half-life radionuclides, which can only be transported short 
69 
 
distances, limiting the number of sites that can utilise them. Molybdenum-99/technetium-99m 
generators can be eluted multiple times a day, depending on demand; this provides flexibility 
for scheduling. Additionally, as hospitals are charged per generator rather than for each batch 
of technetium-99m, the more the generator is used the lower the cost of each batch becomes. 
Generally, there is also a consistent supply of generators and the infrastructure is in place for 
their weekly delivery to radiopharmacies. However, as this supply relies on a small number of 
reactors for the production of molybdenum-99, and as limited excess capacity currently exists, 
any shut-down at these sites can cause world-wide generator shortages (6)(7). 
2.1.2 Typical Radiolabelling Procedure for a Technetium-99m Single Vial Kit 
Radiopharmaceutical 
Within a radiopharmacy, a diverse range of technetium-99m pharmaceuticals can be produced 
by eluting the generator and using the eluent to reconstitute commercially available 
radiopharmaceutical kits. This is typically a high-throughput environment where speed, 
simplicity, volume, and reproducibility of radiolabelling are essential, and would not be 
sustainable if complex radiolabelling procedures were required. 
A radiopharmaceutical kit consists of a vial containing all the non-radioactive chemical 
components required for radiolabelling (4). The kit manufacturer is responsible for ensuring that 
kits meet the required standards in terms of good manufacturing practice (GMP), chemical 
purity and sterility. In most cases all that is required to prepare the radiopharmaceutical is the 
addition of technetium-99m pertechnetate in saline to the kit vial, inverting or shaking to ensure 
the contents have fully dissolved, and then leaving it at ambient temperature for the reaction 
to proceed (usually no more than a few minutes). In some cases, heating is also required to 
improve radiochemical yield and is done by heating the sealed kit vial on a hot plate, or in a 
water bath (3). As manipulation of radioactive substances is minimal, the process is quick 
(typically taking less than 10 minutes) and the radiation dose to the operator producing the 
tracer is minimised. A small sample can then be removed from the vial for quality control (QC), 
which typically involves analysis of pH, radiochemical purity (RCP) using instant thin layer 
chromatography (iTLC), and in some cases sterility testing. The methods will follow the 
monograph for the specific radiopharmaceutical defined within the pharmacopoeia for the 
relevant governed region or the methods described in the summary of product characteristics 
within the documentation provided for marketing authorisation. Simple kit-based radiolabelling 
procedures supported by well-defined QC procedures allow tracers to be produced consistently 
and reproducibly across all hospitals, with minimal extra training for staff members. 
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2.1.3 A Typical Technetium-99m Radiopharmaceutical Kit 
A kit for a technetium-99m radiopharmaceutical is typically a single vial, containing a lyophilised 
powder made up of all the non-radioactive components required for radiolabelling of the 
desired complex at high radiochemical purity. The kits will be sterile and septum-sealed under 
an inert atmosphere (4). Most kits have a shelf life of 1 year (3) meaning a radiopharmacy can 
have a stock of kits that are used in response to demand. Some kits have been designed for 
single patient doses and others are suitable for multiple doses. Each type of kit contains a unique 
active ingredient, which will form the final complex with technetium. In order for complexation 
to be possible technetium-99m pertechnetate ([99mTc][TcO4]-), the form in which technetium is 
eluted from the generator, must be reduced to a lower oxidation state (Tc(VI), Tc(V), Tc(IV), 
Tc(III), Tc(II) or Tc(I)) (2). This is achieved with a reducing agent, most commonly tin(II) chloride 
(SnCl2) and the quantity used and the pH and temperature affect the oxidation state achieved 
(2)(3). Kits may also include other components, such as antioxidants to minimise autoradiolysis, 
and weak chelating agents to create stable intermediates with technetium before it is chelated 
with the active ingredient, avoiding [99mTc]TcO2 colloid formation (2). Additionally, buffers are 
often used to create the optimal pH and ensure complexation of the desired species, as well as 
bulking agents to aid the lyophilisation process (4). Once radiolabelled, kits are usually stable for 
4-12 hours (3) and this combined with the 6.01 hour half-life of technetium-99m, gives a wide 
time period within which the tracer can be administered to a patient. 
An example of a one-step kit is the [99mTc]Tc-MDP kit (3). This tracer is used to image bone 
metastasis and is an important and widely used clinical tracer for prostate cancer staging as 
described in chapter 1. These lyophilised GMP kits contain 10 mg MDP (methylene diphosphonic 
acid), 1 mg tin chloride dihydrate and 2 mg ascorbic acid (3). Radiolabelling is carried out by the 
addition of 4 mL of technetium-99m pertechnetate to the kit, shaking for 1 minute and QC after 
5 minutes. The kit should then have a pH of 5-7, and a radiochemical purity (RCP) over 95% as 
measured by iTLC.  
2.1.4 Disadvantages of Existing Kits and Challenges in Developing New Ones 
Despite the extremely simple radiolabelling of [99mTc]Tc-MDP and its clinical utility, the chemical 
structure of this complex remains unknown (4)(8)(9)(10). Multiple species are formed upon 
radiolabelling which can be separated by high pressure liquid chromatography (HPLC) and the 
ratios formed are dependent upon the exact radiolabelling conditions (8)(9). These individual 
species have been shown to have different biodistributions in animal studies, in particular, 
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differences in bone-seeking ability were observed (8). This finding raises concerns about the 
tracer’s consistency in the detection of bone metastases in clinical practice. Poorly understood 
species formed upon binding technetium-99m is not a problem unique to [99mTc]Tc-MDP. Other 
technetium tracers produced with a one-step kit produce multiple species or distinct 
stereoisomers upon binding. These include: [99mTc]Tc-DMSA (11)(12)(13), [99mTc]Tc-DTPA 
(4)(14), and [99mTc]Tc-MAG3 (4)(15). When these radiotracers were granted regulatory approval 
in the 1970’s and 1980’s full understanding of the complexes produced was not a requirement, 
but the process to gain regulatory and marketing approval is now much more rigorous and 
evidence that only one species is formed upon radiolabelling is likely to be a requirement. This 
can only be achieved by taking into account the coordination chemistry of technetium and 
careful design of ligands which will bind this radiometal in just one configuration without 
producing any chiral centres or other isomerism (6). 
An additional challenge to producing one-step kits for novel radiopharmaceuticals is that, thus 
far, kits have only be developed for small molecule technetium-99m tracers. However, the field 
of nuclear medicine has moved on from functional to receptor-based imaging which often 
requires more complex bioconjugates, labelled at high molar activity. This presents further 
challenges for designing kit-based radiopharmaceuticals. At the moment bioconjugates utilising 
technetium-99m are mainly HYNIC (2)(4)(16) or tricarbonyl complexes (2)(3)(17), neither of 
which are currently amenable to one-step kit-based production. HYNIC is only a bidentate 
chelator and so requires a co-ligand to fully coordinate technetium; this leads to isomerism and 
it is difficult to characterise the complexes formed especially as these are sensitive the reaction 
conditions (6). In the case of tricarbonyl-based tracers, the radiolabelling process always 
requires two steps, one to generate the [[99mTc]Tc(CO)3(H2O)3]+ intermediate and the second to 
chelate it (3)(17). 
As an example, the radiolabelling procedure for the PSMA tracer [99mTc]Tc-MIP-1404 which is 
currently undergoing a phase 3 clinical trial in the USA (18), is a tricarbonyl complex. Compared 
to one-step kits the radiolabelling procedure for this tracer is more lengthy and complex. The 
structure of MIP-1404 consists of a GCP(II)/PSMA targeting Lys-C(O)-Glu motif attached by a 
linker to the TIM chelator as shown in figure 2.1. Radiolabelling is performed in two stages and 
takes over 90 minutes to complete (19). A summary of this process is shown in figure 2.2. The 
first stage is the generation of the tricarbonyl intermediate [[99mTc]Tc(CO)3(H2O)3]+, by adding 
generator eluate to a commercially available kit (IsoLink, Covidien) containing sodium tartrate, 
sodium tetraborate, sodium carbonate and sodium boranocarbonate and heating to 100°C for 
20-30 minutes (3)(17). These components ensure an alkaline pH, the reduction of Tc(VII) to Tc(I) 
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and the production of carbon monoxide ligands which stabilise technetium in this oxidation 
state. The second stage is to add the cold precursor MIP-1404 into this vial (100 µg in 100 µl) 
and heat at 100°C for 1 hour. Once complete the reaction mixture is neutralised and loaded onto 
a C18 column. The final radiolabelled complex is then eluted from the column with 1 mL ethanol, 
diluted with 9 mL saline and sterile filtered before QC and patient administration. Fortunately, 
multiple patient doses can be made with each synthesis, but the process is much longer, more 
labour intensive and therefore would require more training to perform than a one-step kit-based 
labelling procedure, and so is far from ideal. Clearly, the development of one-step technetium-
99m kits has not kept pace with the development of receptor-based molecular imaging. 
 





FIGURE 2.2: Radiolabelling steps for [99mTc]Tc-MDP (3) and [99mTc]Tc-MIP-1404 (19). 
74 
 
2.2 Applying One-Step Kits to PET Tracers 
The advantages of the generator and one-step kit model have led to widespread use of 
technetium-99m radiopharmaceuticals. However, a kit and generator model is not compatible 
for the majority of clinically approved PET tracers because of the focus on fluorine-18 and 
carbon-11 tracers (20)(21). These short-lived radionuclides are produced in a cyclotron, rather 
than a generator, limiting production of tracers to sites with these facilities and delivery to a 
small area around the production site. As non-metals, they require complex synthetic chemistry 
to be incorporated into a radiotracer (21) that is usually incompatible with a kit. However, 
radiometals with suitable emissions can also be used for PET imaging and these have the 
potential to be developed into one-step kits. This would allow extremely simple radiolabelling 
procedures to be combined with the advantages of PET imaging: higher sensitivity which leads 
better signal to noise ratio, more accurate quantification of images, and the possibility to 
perform dynamic scans (22). Gallium-68 is the PET radiometal that is currently most appropriate 
for designing one-step kits. It is generator-produced and well-suited for PET imaging as 90% of 
its emissions are positrons (β+) with an average energy of 1.9 MeV (23). The 67.8 minute half-
life of gallium-68 also makes it particularly well-matched to the short pharmacokinetics of 
peptides and small molecules, and even small proteins, and means high-quality imaging can be 
achieved with similar injected activity to fluorine-18 tracers, with similar radiation doses to 
patients. 
2.2.1 Germanium-68/Gallium-68 Generators 
Like molybdenum-99/technetium-99m generators, germanium-68/gallium-68 generators are 
bench top sized, produce gallium-68 within a radiopharmacy on demand, and can be eluted 
multiple times a day. Germanium-68/gallium-68 generators in clinical use that are manufactured 
to GMP compliant conditions and produce gallium-68 elute that reaches the standards for 
human injection (>99.9% gallium-68, <0.001% germanium-68 (24)) include the Galli-Eo (IRE, 
Fleurus, Belgium), the iThemba (IDB Holland BV, Netherlands), the ITG (Isotope Technologies 
Garching GmbH, Garching, Germany) and the Galliapharm (Eckert & Ziegler, Berlin, Germany). 
However, only the Galliapharm generator has been granted marketing authorisation in Europe 
(13 counties (25)) and is the only generator approved for the manufacture of [68Ga]Ga-DOTA-
TATE in the USA (26). Therefore it will be focused on here for the development of one-step kits. 
Most germanium-68/gallium-68 generators including the Galliapharm uses a titanium dioxide 
column onto which germanium-68 is adsorbed. When this decays [68Ga]Ga3+ is formed which 
has a lower affinity for the column and so can be eluted from it using hydrochloric acid (HCl). 
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The Galliapharm generator provides a maximum of 1.85 GBq of gallium-68 in 5 mL 0.1 M HCl, 
which can be used to manufacture radiopharmaceuticals. The generator has a 1 year lifetime; 
however, over this period the amount of activity produced in each elution drops considerably 
as shown in figure 2.3 (27). 
 
FIGURE 2.3: Change in the activity obtained over time from a 1.85 GBq Galliapharm germanium-68/gallium-68 
generator. Reproduced with permission from (27). 
Molybdenum-99/technetium-99m generators and germanium-68/gallium-68 generators can be 
compared in table 2.1. There are three big differences between a germanium-68/gallium-68 
generator and a molybdenum-99/technetium-99m generator: 1) The solution used to elute the 
generator: technetium-99m is eluted in saline at near-neutral pH, and can therefore be injected 
directly into patients (it is used for thyroid imaging due to its affinity for the sodium iodine 
symporter (28)) whereas gallium-68 is eluted in 0.1 M HCl and so the pH must be raised to both 
allow coordination of the ligand to a chelator and to produce a suitable pH for injection; 2) The 
generator’s lifetime is 2 weeks for a molybdenum-99/technetium-99m generator and 1 year for 
a germanium-68/gallium-68 generator. This is an advantage for germanium-68/gallium-68 
generators as radiopharmacies are not reliant on a weekly supply but introduces concerns about 
maintaining sterility and apyrogenicity over this timeframe; 3) The activity per elution is much 
lower for germanium-68/gallium-68 generators than molybdenum-99/technetium-99m 
generators - a maximum of 1.85 GBq compared to 703 GBq. The impact of this is that many 




 Tc-99m Gallium-68 
Name Ultra-Technekow™ V4 Galliapharm 
Supplier Mallinckrodt Pharmaceuticals Eckert & Zeigler 
Parent isotope Molybdenum-99 Germanium-68 
Half-life of parent 66.02 hours (29) 270.95 days (30) 
Lifetime of generator 2 weeks 1 year 
Elution solvent 0.9% saline 0.1 M HCl 
Eluted complex Tc(VII)O4- Ga(III)Cl3 
Elution volume 5-20 mL 5 mL 
Activity per elution max 703 GBq max 1.85 GBq 
Activity concentration max 35.15 GBq/mL max 0.37 GBq/mL 
Mininum time between 
elution 
1 hour 2 hours 
Maximum time between 
elution 
24 hours 24 hours 
Number of elutions per day 2 4 
Doses per elution > 100 1-4 
Column sorbent 
Aluminium oxide, ion 
exchange (Al2O3) 








Limits for contaminating 
radionuclides 
0.1% Mo-99 0.001% Ge-68 
GMP compliant Yes Yes 





Marketing approval Yes Yes 
 
TABLE 2.1: Properties of a molybdenum-99/technetium-99m (31) and a germanium-68/gallium-68 (32) 
generator.  
2.2.2 Ideal Kits for Gallium-68 
In this section, the ideal properties of a kit for radiolabelling gallium-68 will be defined and 
justified. Overall the simplicity of labelling will be the focus for optimisation here, but of course, 
this must not come at the expense of the clinical utility. Here we will assume that the tracer that 
will be radiolabelled is a bioconjugate with a small peptide or pharmacophore, attached to a 
chelator for gallium-68. The kit should be a single vial, and the radiolabelling process should 
simply be the addition of gallium-68 eluate directly from a generator into the kit. Radiolabelling 
then should reach completion (> 95%) quickly (< 5 minutes) at room temperature and, after 
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passing QC, should be suitable for administering directly to patients. In order for such a simple 
process to be possible, not only does the kit vial need to be designed carefully but the generator 
used also needs to be controlled. The Galliapharm generator has marketing authorisation and 
therefore is the most appropriate to design a kit for. It will be assumed that this generator has 
been well-maintained, is sterile and has been tested for contaminating radiometals (germanium-
68 <0.001%) before use with the kit.  
2.2.2.1 Kit Design 
It would be ideal to design a one-step kit to accommodate the whole elution volume from the 
generator (5 mL, 0.1 M HCl). This means the generator could be eluted directly into the kit, 
minimising the number of manipulations and any loss of activity from transferring between vials. 
This should also allow multiple patient doses to be produced at once, reducing the number of 
radiolabelling and QC procedures required per day, minimising cost. Once reconstituted, the kit 
should be at a pH and osmolality suitable for injection directly into patients, without any further 
dilution. The pH range for intravenous administration is pH 2-13 however, a physiological pH 
between 7.35-7.45 would be ideal as this is less likely to cause irritation at the site of injection 
(33). The acceptable osmolality limit is 1000 mOsm/kg, but again for patient comfort, it would 
be most preferable if the kit components were isotonic (300 mOsm/kg) (34). 
2.2.2.2 Excipients 
The only excipients vital to a gallium-68 kit should be a neutralising agent or buffer to modify 
the pH, as unlike technetium kits no reducing agent is required to change the oxidation state of 
the radiometal. There may also be the need for an antioxidant to reduce autoradiolysis and a 
bulking agent to improve lyophilisation or adjust osmolality. All components used should be 
pharmaceutical grade, already approved for human use and suitable for lyophilisation, as 
lyophilised kits typically have a much longer stability than solution-based ones. 
2.2.2.3 Active Ingredient/Bioconjugate Design 
The active ingredient design is the most important factor that will allow a one-step kit to be 
achieved. This active ingredient should be either a chelating agent which also provides a 
targeting mechanism (such as [67Ga]Ga-citrate for lymphoma staging), or a bioconjugate that 
combines a pharmacophore, which targets it to a disease site, and a chelator with excellent 
properties for labelling with gallium-68 as well as in vivo stability. When these two parts are 
combined the presence of the chelator should not compromise the targeting ability of the 
pharmacophore, nor should the presence of the pharmacophore compromise the radiolabelling. 
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An ideal chelator for use in such a bioconjugate would bind gallium-68 quantitatively, quickly (< 
5 minutes), at room temperature, and at low concentrations (< 10 µM). This allows the tracer to 
be produced at high molar activity, whilst ensuring that over 95% RCP is consistently achieved. 
The molar activity required for a high-quality image will depend on the target disease and the 
density of the transporter or receptor being imaged. If molar activity is not high enough, the 
excess cold tracer will act as an inhibitor and block uptake of the radiolabelled tracer in vivo, 
reducing signal (35). High molar activity is difficult to achieve for gallium-68 ratiotracers for a 
number of reasons including the high elution volume of generators, low activity concentration, 
and the presence of metal impurities in the generator eluate. Therefore the active ingredient 
should also utilise a chelator which is specific for gallium and does not bind to other metal 
impurities. Generator eluate does not only contain gallium-68, it also contains its decay product 
zinc-68 as well as a range of metals derived from the acid, the generator’s column, lead shielding 
and plastic tubing (36). Figure 2.4 and figure 2.5 shows a summary of the metals found in the 
eluate of a Galliapharm generator by inductively coupled plasma mass spectroscopy (ICP-MS). 
However, it should be noted that the generator was over 1 year old which may have affected 
leaching from the column (36). As these generators use a titanium dioxide on borosilicate 
column, titanium becomes the major contaminant from this source with levels at 2 µM. 
Additional metal ions present in high concentrations (0.1 µM to 5 µM) are Al, Fe, Zn, Ga and Pb 
(36). (Note that when detected by ICP-MS the oxidation state of each metal is unknown). By 
selecting or designing a chelator that is very specific to gallium and no other metal, and binds 
gallium quickly, competition for binding the chelator is minimised and higher molar activity 
should be achievable.  
The final requirement is that once the active ingredient binds the radio-metal a single, well-
characterised complex should be formed with no evidence of diastereomers, enantiomers, or 
geometric isomers. This is important as each isomer may have a different affinity for the target 
or a different biodistribution. The presence of multiple isomers is also likely to be a barrier to 
gaining regulatory approval and hence to widespread use for the tracer.  
2.2.2.4 Quality Control (QC) 
Due to the short half-life of gallium-68, it would be ideal for not only the radiolabelling but also 
the QC processes to be as fast as possible. When a batch of kits is manufactured, a sample of 
these kits are used to confirm sterility and apyrogenicity for the whole batch. This means the 
cold kit is guaranteed sterile and pyrogen free, which means once marketing authorisation has 
been granted for that kit, radiopharmacies do not need to carry out these tests on every kit. 
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Additionally, if it is only possible to form one complex upon radiolabelling, only an iTLC method 
that could differentiate between bound and unbound gallium-68 would be required to assess 
radiochemical purity, whereas HPLC would be needed if multiple complexes are possible, in 
order to ensure the ratio of these is known and remains consistent between batches. This is of 
particular importance if different complexes are expected or known to have different in vivo 
properties, and the ratio of complexes formed changes depending on labelling conditions.  
 
FIGURE 2.4: The concentrations of selected metals in each fraction of the Galliapharm germanium-68/gallium-
68 generator eluate, and in the HCl used to elute the generator as measured by ICP-MS. The elution analysed 





FIGURE 2.5: The concentrations of selected metals in each fraction of the Galliapharm germanium-68/gallium-
68 generator eluate, and in the HCl used to elute the generator as measured by ICP-MS. The elution analysed 
was obtained 5 hours after the previous elution. Reproduced with permission from the supplementary material 
for (36). 
2.2.2.5 Advantages of a Kit 
Kits that fulfil the criteria outlined above would have the following advantages over multistep 
radiolabelling. 1) Radiolabelling will take 5 minutes to perform. This would allow many labelling 
procedures to be done per day, with minimal extra staffing. The speed is particularly important 
for gallium-68-based radiopharmaceuticals due to the 67.8 minute half-life, the low activity 
produced by the generator and the drop off in activity from the generator over time. One-step 
kit-based preparations would therefore maximise the activity available for administration and 
should allow multiple patient doses to be produced per kit. 2) A generator and one-step kit 
method removes the need for multiple manual manipulations or complex automated equipment 
with multiple moving parts, controlled by software. This means radiolabelling is consistent, and 
the possibility of radiolabelling failures is minimised. A kit-based radiotracer can easily be 
produced in the same manner across a number of sites if the same generator and kit are used. 
This is vital when conducting clinical trials, for gaining regulatory approval, and when creating a 
commercial product. 3) The low number of manipulations also minimises dose for the staff 
reconstituting the kit. This is an important safety consideration, especially as PET isotopes 
produce higher energy gamma rays (511 keV (23)) compared to typically used SPECT isotopes 
81 
 
(technetium-99m has major emissions at 140 keV (1)). 4) Sterility is easier to control with a kit 
and therefore endotoxin testing does not need to be tested before the release of every batch. 
This means one-step kits not only reduce the radiolabelling time but also the time required for 
QC. 5) Costs are likely to be significantly lower with a generator and one-step kit-based 
production. This includes personnel costs, as well as lower infrastructure investment compared 
to manual or automated multiple step synthesis, or cyclotron produced radionuclides. 
2.2.3 Chelators for Gallium-68 
The ability to design a bioconjugate that can be radiolabelled in a one-step kit is dependent on 
the selection of an appropriate chelator. The ideal chelator for a one-step kit would be water 
soluble, able to incorporate gallium into the radiotracer rapidly, at room temperature, neutral 
pH and low concentration, forming a single (non-isomeric) well-characterised complex, with high 
stability in vivo. For bioconjugates it is also important that the chelator does not adversely affect 
the biodistribution. In this section, the most clinically relevant chelators for gallium-68 will be 
discussed alongside their suitability for use in a one-step kit. 
The design of chelators for gallium needs to reflect its chemistry. Gallium is a p-block element in 
group 13 of the periodic table, with the electronic configuration [Ar]3d10 4s2 4p1. Due to its full 
d orbitals, the chemistry of gallium is relatively simple compared to its neighbouring transition 
metals. It is a hard Lewis acid, with an ionic radius (Ga3+) of 0.62 Å. Gallium is predominantly 
trivalent and only stable as gallium(III) in aqueous solution, plus ligand-field effects play no role 
in its chemistry (6). As gallium(III) is a hard Lewis acid, it favours binding to hard Lewis bases such 
as nitrogen and oxygen. Its small radius means that gallium(III) is most stable as a six-coordinate 
(distorted) octahedron (6). It can also form four and five coordinate complexes but these are 
more sensitive to hydrolysis (6). Chelators for gallium that are to be used as radiopharmaceutical 
agents must form complexes with high kinetic inertness to ensure the stability of the complex 
in vivo. The chelator must also be able to rapidly complex gallium-68 at low concentration in 
aqueous solution, due to the constraints of radiopharmaceutical preparation. Another challenge 
is that chelators need to be able to compete with the formation of insoluble gallium colloid 
[Ga(OH)3] which is produced in aqueous solution when the pH is above 3 (37). Figure 2.6 shows 
the distribution of gallium-hydroxide species in aqueous solution as a function of pH. Often 
stabilising ligands such as citrate, acetate or oxalate are used to reduce [Ga(OH)3] formation; 
these are all weakly coordinating ligands and can therefore be easily exchanged for stronger 




FIGURE 2.6: Distribution of mononuclear Ga–hydroxide species as a function of temperature and pH at 
saturated water vapour pressure and infinite dilution. The species shown are: 0 = [Ga]3+; 1 = [Ga(OH)]2+; 2 = 
[Ga(OH)2]+; 3 = [Ga(OH)3 ] and 4 = [Ga(OH)4]- . Reproduced with permission from (37). 
2.2.3.1 DOTA 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) is a macrocyclic chelator with 
a 12-membered ring containing 4 amine nitrogen atoms and has 4 pendant carboxylic acids 
(Figure 2.7). DOTA is the most clinically-used chelator for radiometals, and can form stable 
complexes with a large range of metals in different oxidation states (e.g. Ac(III), Al(III), Bi(III), 
Cu(II), Co(II), Fe(II), Fe(III), Ga(III), In(III), Lu(III), Pb(II), Sc(III), Y(III) Zn(II) (39)(40)). This allows 
imaging and therapy to be performed using the same bioconjugate, bound to different 
radiometals. DOTA was designed for metals with larger ionic radii than gallium and a larger 
coordination number, but is still suitable for binding gallium, and does so as a N4O2 donor. 
However, this produces steric strain in the backbone of DOTA and leaves two of its pendant 
carboxylic acids uninvolved in coordinating the metal (6). These pendant carboxylic acids can be 
used to functionalise the chelator. Alternatively, the DOTAGA derivative can be used if it is 
necessary to preserve them both. See figure 2.7 for the structure DOTAGA. Radiolabelling of 
DOTA with gallium-68 is optimal at pH 3.5-4 (41) with heating to 90-95°C for 5 minutes 
(41)(42)(43). Under such conditions quantitative radiolabelling can occur at concentrations of 5-
70 µM (42)(44), however, post-labelling purification methods are commonly used to remove any 
remaining unchelated gallium-68 (42)(43). Because DOTA can bind a range of metals, it is very 
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sensitive to metal contaminants in gallium generator eluate and this restricts the molar activity 
that can be achieved. Figure 2.8 demonstrates how the radiolabelling of [68Ga]Ga-DOTA-TATE is 
affected by the presence of a range of contaminating metals (40). For this reason, a number of 
pre-labelling purification methods have been developed for use when labelling DOTA with 
gallium-68 (45)(46)(47)(48)(49). Both the requirement for a heating step at concentrations 
appropriate for radiolabelling and the sensitivity of DOTA to metal impurities, make it unsuitable 
for development into a one-step kit. 
 
FIGURE 2.7:The structures of DOTA and DOTAGA (39). 
 
FIGURE 2.8: Effect of metal ion addition to reaction solution on [68Ga]Ga-DOTA-TATE yield (pH 4, 95°C, 10 




Chelator Log KGaL 
DOTA (50) 21.3 
NOTA (51) 31.0 
TRAP (52) 26.24 
HBED (53) 38.5 
DFO (54) 28.65 
THP* 35.1 
DATAm (55) 21.7 
 
TABLE 2.2: Log KGaL values for a range of chelators. * = unpublished work courtesy of Cinzia Imberti, manuscript 
in preparation. 
2.2.3.2 NOTA 
NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) has a 9 membered ring containing 3 amine 
nitrogen and 3 pendant carboxylic acids, which matches the size, coordination number and 
geometry of gallium(III) and binds it as a N3O3 donor. Consequently, Ga-NOTA has a high stability 
constant with a log KGaL of 31.0 compared to 21.3 for Ga-DOTA (55) (see table 2.2 which shows 
a comparison of log KGaL values for all the chelators discussed). However, NOTA cannot retain 
this high-affinity binding for gallium if one of the pendant carboxylic acid arms is used for 
functionalisation with a targeting agent. Therefore the NODAGA bifunctional chelator was 
developed to preserve all pendant carboxylic acids. The structures of both chelators are shown 
in figure 2.10. Radiolabelling for NOTA or NODAGA with gallium-68 is optimal when carried out 
at pH 3.5 (56). Complex formation does not require heating, but complexation at 10 µM takes 
over 10 minutes to become quantitative at room temperature and at concentrations of 5 µM or 
below does not reach over 95% radiolabelling by 20 minutes (56). Therefore heating steps are 
often used to speed up the process or improve molar activity (55)(57). The stability of [67Ga]Ga-
NODAGA-TOC has been assessed through serum studies, mouse studies and metabolite analysis 
which all showed excellent stability for up to 4 hours (58). Particularly when radiolabelling is 
performed at high temperature, NOTA and NODAGA are sensitive to metal contaminants 
especially those with a smaller ionic radius such as Zn(II), Cu(II) and Fe(III) as shown in figure 2.9 
(59). The kinetics of NOTA and NODAGA and their sensitivity to metal contaminants mean that 
radiolabelling with unprocessed eluate is unlikely to be possible at high molar activity and 




FIGURE 2.9: Incorporation of gallium-68 (10–20 MBq, 95°C, pH 3) by NOPO, TRAP-Pr, TRAP-H, NOTA, and DOTA 
as functions of increasing concentrations (c) of metal ions (Zn2+, Cu2+, Fe3+). Vertical dashed lines indicate equal 





FIGURE 2.10: The structures of NOTA and NODAGA (55). 
2.2.3.3 TRAP, NOTP and NOPO 
TRAP, NOTP and NOPO are derivatives of NOTA where the carboxylic acid arms have been 
replaced with phosphinic or phosphonic acid groups, as shown in figure 2.11. They bind gallium 
as N3O3 donors and have higher stability constants than DOTA but lower than NOTA table 2.2. 
These modifications improve both molar activity and the ability to bind gallium-68 in the 
presence of metal impurities as shown in figure 2.9 (59). To date NOTP, has only been optimised 
with gallium-67 (60)(61) but gallium-68 labelling with modern generators has been optimised 
for TRAP and NOPO (62)(63). Radiolabelling for TRAP is optimal at a pH of 3-5 but possible over 
a broader range of pH 1-5. When radiolabelling is performed at room temperature (20°C), pH 
3.3 and with 90 µM chelator concentration, over 90% labelling is achieved within 10 minutes 
(52). Heating the reaction mixture increases the speed, molar activity and RCP of radiolabelling 
and is the published method used for most TRAP bioconjugates (62). Radiolabelling for NOPO 
has an optimal pH of 3-4 when performed at room temperature, and quantitative radiolabelling 
can be achieved within 5 minutes at a concentration of 30 µM (63). If a 95°C heating step is 
included the concentration required to obtain over 95% radiolabelling drops to 1 µM (63). The 
advantages of TRAP and NOPO over DOTA and NOTA in terms of molar activity are therefore 
most stark when radiolabelling is performed at low pH and high temperature, conditions 
incompatible with a one-step kit. When radiolabelling is performed at room temperature, 
relatively high concentrations of chelator (30-100 µM) are required to achieve quantitative 
radiolabelling (62)(63), and so it is unlikely that high enough molar activity could be achieved for 




FIGURE 2.11: The structures of TRAP (62), NOPO (63) and NOTP (60). 
2.2.3.4 HBED 
HBED (bis(2-hydroxybenzyl)ethylenediaminediacetic acid) binds gallium through its phenol, 
amine and carboxyl groups as an N2O4 donor, and has exceptionally high log KGaL value of 38.5 
(53). However, the drawback of this chelator is that the 3 different donor groups allow for the 
formation of multiple geometric isomers upon binding, as shown in figure 2.13. These are 
distinguishable by HPLC and nuclear magnetic resonance spectroscopy (NMR) (36)(64). The ratio 
of these geometric isomers can change depending on the temperature and pH of complexation 
(figure 2.15) (36)(64)(65). It has been proposed that the most thermodynamically stable of these 
is the RR conformation where the phenol groups are mutually trans, as this is the least sterically 
hindered. Therefore it is presumed that this is the geometric isomer formed in the highest 
quantity after heating the reaction mixture. It should also be noted that each geometric isomer 
will be a racemic mixture of its lambda and delta enantiomers, but these are likely to 
interconvert rapidly on the biological timescale, and so will not be considered further here. If 
the chelator HBED was to be functionalised using one of its carboxylic acids used to bind gallium 
this would impede binding and so the HBED-CC bifunctional chelator has been developed to 
avoid this, as shown in figure 2.12. At physiological pH, the pendant carboxylic acid not used for 
functionalisation will add an additional negative charge to this region of the molecule, not 
present in the Ga-HBED complex. The radiolabelling conditions for quantitative radiolabelling 
with HBED-CC are pH 4.2, room temperature 5-10 minutes at a concentration of 25 µM (57). 
When compared to NOTA, the kinetics of complexation are much faster as demonstrated in 
figure 2.14. However, due to the geometric isomers formed a heating step is often used to 
provide 90% RCP of the most thermodynamically favoured species. Such a heating step would 
make HBED and HBED-CC incompatible with a one-step kit. If radiolabelling was instead 
performed at room temperature the presence of multiple isomers means that HPLC QC is 
required before batch release, along with validation that both isomers have the same targeting 
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properties in vivo, and this still may not satisfy the requirements of the regulators. Therefore it 
would be prudent to avoid this chelator when designing novel bioconjugates for one-step kits.  
 
FIGURE 2.12: The structures of the HBED and HBED-CC chelators (36). 
 
FIGURE 2.13: Possible geometric isomers for hexadentate [Ga(HBED)]. Note that each isomer depicted here is 
one of a pair of enantiomers [Ga(HBED)]-1 is the RR conformation, [Ga(HBED)]-2 the SS conformation and 
[Ga(HBED)]-3 the SR/RS conformation. Reproduced with permission from (36). 
 
FIGURE 2.14: The difference in radiochemical yield for HBED-CC and NOTA conjugates at 25 µM bioconjugate, 




FIGURE 2.15: Reverse phase C18 HPLC radiochromatograms of [68Ga]Ga-HBED after radiolabelling at 25°C (top) 
and 90°C (middle). At 25°C at least three distinct signals can be distinguished but at 90°C, only two distinct 
signals are observed. The same species were observed when radiolabelling was performed at pH 3.5 and pH 6.5. 
UV chromatogram (bottom) of a solution of dissolved crystalline [Ga(HBED)(H2O)].CH3CN. Reproduced from the 
supplementary material section of (36). 
2.2.3.5 DFO 
Desferrioxamine B (DFO) is an acyclic chelator, originally derived from bacteria, which binds 
gallium as an O6 donor through its 3 hydroxamates (figure 2.16). However, its flexible structure 
means it has eight possible geometric isomers (66) as shown in figure 2.17. NMR studies of the 
Ga-DFO complex have shown that there are 2 major geometric isomers in solution, thought to 
be the N-cis, cis and C-trans, trans conformations (66). HPLC analysis of [68Ga]Ga-DFO also 
showed multiple peaks (36). Quantitative radiolabelling with processed eluate from a 
germanium-68/gallium-68 generator has been demonstrated with DFO-bioconjugates at 12 µM 
within 10 minutes at pH 5.2 (67). The production of multiple species upon binding gallium, 
despite its mild radiolabelling conditions, show that the DFO chelator is incompatible with the 




FIGURE 2.16: The structure of the DFO chelator (66). 
 
FIGURE 2.17: Structure of the eight possible Ga-DFO geometric isomers. The two geometric isomers believed 
to be present in solution are N-cis, cis and C- trans, trans (66). 
2.2.3.6 DATA 
The DATA (6-amino-1,4-diazepine triacetate) series of chelators form distorted octahedral 
complexes with gallium (III) as a N3O3 donor (68). The structures of a number of these variants 
are shown in figure 2.18. The 7 membered ring common to all of these chelators can form 
different conformations (chair, twist-chair, twist-boat, boat (69)) and so variants have been 
designed to favour only one of these conformations upon binding gallium. This has been 
achieved by the addition of sterically bulky substituents in the C6 position (Me or Ph group) 
which favours the equatorial positioning of this group and therefore the twist-chair 
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conformation (68). However, although the majority of DATA variants only produce one species 
upon binding gallium, the DATAM variant also produces a second minor species at a ratio of 9:1 
(70). The DATA series of chelators all show rapid (< 5 minutes), room temperature, quantitative 
labelling at pH 5 at concentrations of 5 µM (71). However, increases in pH to 7 or decreases to 
4 reduced the radiochemical yield significantly, demonstrating the importance of precise pH 
control for these chelators (71). However, the DATAPPh variant can still reach 95% RCP at 5 µM 
in 10 minutes at pH 7, whereas the RCP was < 85% for all other DATA variants tested under the 
same conditions. As these radiolabelling conditions were optimised with pre-processed eluate 
(acetone method) it is not known if these excellent radiolabelling properties could be achieved 
without such processing. However, it has been shown that a DATAM-TOC conjugate can achieve 
95% RCP after 1 minute at a concentration of 12 µM, pH 5, using fractionated eluate from a 
germanium-68/gallium-68 generator (72). The DATA chelators have also been shown to be 
sensitive to some metal contaminants, with radiochemical yields falling to under 95% at 4 
equivalents of iron(III) and 1.25 equivalents of copper(II) (71). These chelators therefore provide 
a number of qualities required for use in a one-step kit. 
 
FIGURE 2.18: Structures of the DATA chelators (71). 
2.2.3.7 THP 
The THP (tris(hydroxypyridinone) chelator is a hexadente O6 donor through its three 1,6-
dimethyl-3-hydroxypyridin-4-ones, with each acting as a bidentate ligand. When their hydroxyl 
groups are deprotonated these 3,4-hydroxypyridinone units are electron rich oxygen donors due 
to the delocalisation of electrons over the pyridinone ring and are therefore well suited for 
binding hard Lewis acids such as gallium. The lengths of the three arms of the chelator are well 
matched to the ionic radius and coordination sphere of gallium and upon binding an uncharged 
complex is formed, which has a high Log KGaL value (table 2.2). The tripodal design of THP with 
its three identical arms and C3 symmetry avoids the formation of geometric isomers upon 
chelating gallium. It would allow the formation of delta and lambda enantiomers associated with 
all hexadentate tripodal chelators, but these would be expected to rapidly interconvert on the 
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biological timescale. THP can be converted into a bifunctional derivative by functionalisation at 
the hub of the tripodal scaffold, which is distant from the 3,4-hydroxypyridinone units and so 
does not affect gallium binding. A number of bifunctional derivatives have been developed 
which are shown in figure 2.19. Gallium-68 radiolabelling with THP and its derivatives can be 
performed using unprocessed generator eluate at room temperature, pH 6.5 and is complete 
within 5 minutes at concentrations of 0.5-10 µM (36)(73)(74). RCP was determined to be over 
95% by iTLC and HPLC and showed a single species (73). Metal competition studies have shown 
that the THP chelator is very specific for gallium and radiolabelling is only affected by the 
presence of Fe, Al and Ti. These results are shown in figure 2.20. Additionally, its optimal 
radiolabelling conditions are near neutral pH which enables biological targeting agents that are 
sensitive to low pH, such as antibodies and single-chain fragments, to be radiolabelled with 
gallium-68 or gallium-67 (73)(75). [67Ga]Ga-THP has also been shown to be resistant to 
transchelation to transferrin and human serum proteins for up to 4 hours (73). The stability of 
this complex has also been assessed in mice with the bioconjugates, [68Ga]Ga-THP-mal-C2A (73), 
[68Ga]Ga-THP-Ph-NCS-RGD (76), [68Ga]Ga-THP-NCS-RGD (76), [68Ga]Ga-THP-TATE (74) and none 
showed evidence of the presence of non-chelated gallium up to 60 or 90 minutes in vivo, the 
expected timeframe for imaging with gallium-68. Therefore THP demonstrates near-ideal 
properties for a chelator to be formulated into a one-step kit. 
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FIGURE 2.20: Incorporation of gallium-68 (2-6 MBq, room temperature, pH 6-7) by THP in the presence of 
increasing concentrations of metal ions (Al, Fe, Ga, Ni, Pb, Ti, Zn). The vertical dashed line indicates equal 
concentrations of chelator and contaminant (5 µM), horizontal dashed line indicates 95% radiochemical purity. 
Figure courtesy of Ruslan Cusnir, manuscript in preparation. 
2.2.3.8 Comparative Studies 
It is almost impossible to compare fairly the performance of different chelators using literature 
data, tested by different groups, in different experiments with gallium-68 from different 
sources, before or after pre-processing steps. Therefore well-designed comparative studies are 
essential to assess the performance of different chelators. This has been addressed in two 
studies, one where a range of chelators (DOTA, NOTA, HBED, THP) were assessed with their own 
optimal radiolabelling conditions over a range of ligand concentrations (figure 2.21) (73), and 
the second where a range of chelators (DOTA, NOTA, NOTP, TRAP, HBED, DFO, THP) were 
assessed over a range of concentrations under specific conditions (figure 2.22) (36). The first 
experiment showed that the RCP of all chelators tested dropped off at ligand concentrations 
below 10 µM but that [68Ga]Ga-THP had the highest RCP of all chelators at 1 µM, even though it 
had the mildest radiolabelling conditions (pH 6.5, 5 minutes). In the second study, a broader 
range of ligands were studied (DOTA, NOTA, NOTP, TRAP, HBED, DFO, THP). Unfortunately, 
DATA chelators could not be included due to the lack of a commercial source. Radiolabelling was 
performed at pH 3.5 at 25°C, pH 6.5 at 25°C, pH 3.5 at 90°C and pH 6.5 at 90°C and the results 
are shown in figure 2.22. In assessing which chelators would be appropriate for one-step 
radiolabelling, the experiments performed at 25°C are the most informative. These 
investigations showed that all chelators performed poorly under 1 µM at a pH of 3.5, but that at 
pH 6.5 the chelators THP, DFO, NOTP and HBED performed well down to a concentration of 0.5 
µM, with THP and DFO both achieving over 95% radiolabelling. This suggests that these two 
chelators would be the most suitable for a one-step kit. However, as discussed above of these 
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two chelators only THP produces a single species upon radiolabelling with gallium-68 and so 
would be the most appropriate to incorporate into a bioconjugate for a one-step kit. 
 
FIGURE 2.21: Radiochemical yield as a function of ligand concentration for [68Ga]Ga-DOTA (pH 4.4, 30 min, 
100°C), [68Ga]Ga-NOTA (pH 3.6, 10 minutes, room temp), [68Ga]Ga-HBED (pH 4.6, 10 minutes, room temp) and 
[68Ga]Ga-THP (pH 6.5, 5 minutes). All experiments were conducted with the same batch of unprocessed gallium-
68 eluate. All radiolabelling buffers were made with 0.2 M acetic acid/sodium acetate. Figure modified with 
permission from (73). 
 
FIGURE 2.22: Radiochemical yields for the reaction of [68Ga]Ga3+ with DOTA, NOTA, NOTP, TRAP, HBED, DFO 
and THP under different concentrations of chelator (500 mM to 50 nM), different pH conditions (pH 3.5 or pH 




2.3 Applications for Gallium-68 One-Step Kits. 
The two major applications of gallium-68 tracers are for imaging somatostatin-expressing 
neuroendocrine tumours and GCP(II)/PSMA-expressing prostate cancer. In this section, the 
current radiolabelling practices are discussed alongside the steps that have been taken towards 
one-step kit-based radiolabelling. 
2.3.1 Gallium-68 Neuroendocrine Imaging 
The only FDA- (78) and EMA-approved (79) clinical applications for gallium-68 PET imaging 
agents are [68Ga]Ga-DOTA-TATE (in the US) and [68Ga]Ga-DOTA-TOC (in Europe) for detection 
and staging of somatostatin receptor–positive neuroendocrine tumours. This approval, which 
was granted in 2016, was expedited by the tracer receiving an orphan drug designation in 2014 
due to the rarity of neuroendocrine tumours (80). The structures of these bioconjugates are 
shown in figure 2.23. The FDA and EMA have granted the marketing approval to Advanced 
Accelerator Applications (Saint-Genis-Pouilly, France) who have commercialised [68Ga]Ga-DOTA-
TATE in the USA under the name NetSpot and [68Ga]Ga-DOTA-TOC in Europe as SomaKit-TOC. It 
is available in two forms. The first as a ready-to-use dose of [68Ga]Ga-DOTA-TATE delivered 
directly to hospitals, however, this is restricted to a select number of urban areas in the USA. 
Secondly, it is available as a two-vial kit for reconstitution in a radiopharmacy using the 
GalliaPharm generator (44).  
 




2.3.1.1 Radiolabelling with an Automated Synthesis Module  
Before the marketing approval of NetSpot or SomaKit-TOC kits, it was most common for 
radiolabelling of [68Ga]Ga-DOTA-TATE or [68Ga]Ga-DOTA-TOC to be carried out with an 
automated synthesis module and this will remain the favoured method for many sites. Such 
synthesis can be used to generate these tracers for use within research studies or under 
regulations for non-approved radiopharmaceuticals and so are worth discussing here. There are 
a number of different automated synthesis methods described in the literature (27)(82), and the 
most appropriate choice depends on the generator and automated synthesis module available 
and is therefore likely to be different at every site.  
An example methodology from Royal North Shore Hospital, Sydney, Australia is described below. 
This method has been used for 500 runs over 3 years and the radiochemical yields and purity 
obtained have been reported alongside synthesis failure rates (27). A Modular Lab 
PharmTracer® (Eckert & Ziegler, Berlin, Germany) automated synthesis system controlled by the 
Modular Lab PharmTracer® (Eckert & Ziegler) software was used along with single-use synthesis 
cassettes (C4-GA68-PP Eckert & Ziegler) and the Galliapharm germanium-68/gallium-68 
generator (Eckert & Ziegler). The setup for the automated synthesis model required the removal 
of the cassette from its sterile packaging and attachment to the module, followed by a 5 minute 
cassette pressure test. The high purity pharmaceutical grade reagents (0.9% saline, ethanol, pre-
processing eluent (0.02 M HCl in 98% acetone) and DOTA-TATE peptide in acetate buffer) and 
cartridges (one ion-exchange and one C18 reverse phase) were then added to the cassette and 
the generator attached. Once setup was complete the automated synthesis was initiated and 
took 33 minutes to run. The radiolabelling involved the following automated steps: 1) The 
generator was eluted with 0.1 M HCl and the eluate concentrated on an ion exchange cartridge; 
2) The ion exchange cartridge was then eluted with 0.02 M HCl in 98% acetone and transferred 
into the reaction vial which already contained 40 µg DOTA-TATE peptide in acetate buffer; 3) 
The reaction mixture was heated at 95°C for 400 seconds to form [68Ga]Ga-DOTA-TATE and 
evaporate the acetone; 4) The contents of the reaction vial were removed and passed through 
a C18 cartridge, trapping the [68Ga]Ga-DOTA-TATE; 5). The C18 cartridge was then eluted with 
ethanol through a sterile filter into the product vial followed by a saline wash. Once 
radiosynthesis was completed QC procedures were conducted before batch release. Each run 
produced [68Ga]Ga-DOTA-TATE with a RCP of over 95% by HPLC and iTLC and decay corrected 
radiochemical yields of at least 81.8 ± 0.4%. 
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Because of the complicated set-up of an automated synthesis rig and the number of moving 
parts, there is a broad range of issues that can cause the automated synthesis to fail. In 1.6% of 
synthesis over the 3 years of the study, the problems were so major that production had to be 
cancelled for that day and no patients could be scanned. Reasons for these failures included 
leaks within the cassette, the ion exchange cartridge failing to elute, the syringe driver breaking, 
and high retention of activity on the C18 cartridge. On top of this figure 2.24 summarises 
additional more minor failures that occurred over the same 3 year period and their frequency. 
 
FIGURE 2.24: Rate and type of radio-synthesis failures for an automated synthesis rig, used to produce [68Ga]Ga-
DOTA-TATE over three years. These failures were due to either cassettes or the automated synthesis rig not 
performing as required. Reproduced with permission from (27). 
2.3.1.2 Radiolabelling with Commercially Available Kits 
As discussed above, there are two commercially available kits for neuroendocrine imaging, 
NetSpot and Somakit-TOC, both from Advanced Accelerator Applications. The NetSpot kit 
contains DOTA-TATE and the Somakit-TOC kit contains DOTA-TOC as the active ingredients. All 
other aspects of the kits are the same and so the contents and reconstruction process described 
below are applicable to both kits (44). As the kits do not have a pre-processing step they must 
be used only with the GalliaPharm generator (32). The kits consist of two vials and a silica 
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cartridge. Both vials are septum-sealed and sterile. The first becomes the reaction vial and 
contains the following lyophilised components: 40 µg DOTA-TATE or DOTA-TOC, 5 µg 1,10-
phenanthroline, 6 µg gentisic acid and 20 mg mannitol (44). The second contains a buffer 
solution, consisting of 60 mg formic acid, 56.5 mg sodium hydroxide and 1 mL water for injection 
(44). The cartridge contains 660 mg porous silica, and is used to reduce the amount of 
germanium-68 in the generator eluate (although this should already be < 0.001%). The 
radiolabelling process using these kits proceed as follows (44). The generator is eluted with 5 mL 
of 0.1 M HCl which is passed through the silica cartridge (USA only) and into vial 1, which must 
be vented. Then 0.5 mL of the buffer within vial 2 is added to vial 1 which is then heated to 95°C 
for 7 minutes in a heating block. Then the vial is removed and allowed to cool to room 
temperature for 10 minutes. A sample is then removed for QC. This process is summarised in 
figure 2.25 and takes at least 20 minutes to perform. 
With these kits the process is shorter, requires much less equipment, is much simpler to set up, 
and is likely to be better controlled and give more consistent results than using the automated 
synthesis rig. However, the process still requires 2 vials and a heating step, and so needs to be 




FIGURE 2.25: Flowchart describing the radiolabelling process for [68Ga]Ga-DOTA-TATE or [68Ga]Ga-THP-TATE, 
compared to the ideal one-step kit. 
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2.3.1.3 Single Vial Kits for Neuroendocrine Tumours 
It has been demonstrated that a single rather than a two-vial kit can be used for radiolabelling 
of gallium-68-based tracers for neuroendocrine tumours with DOTA-TOC (83) DOTA-TATE (84), 
DOTAGA-TOC (81) and DOTAGA-TATE (81). The structures of these bioconjugates are shown in 
figure 2.23 and figure 2.26. These studies demonstrated that the correct pH for radiolabelling 
can be reached with a lyophilised single kit, but a heating step to 95°C is still required for 
radiolabelling to proceed. These studies used amounts of bioconjugate similar to that in the 
commercial kits (30-50 µg) and the radiolabelled product passed all QC tests.  
 
FIGURE 2.26: The structure of DOTAGA-TOC and DOTAGA-TATE (81). 
2.3.1.4 Alternative Bioconjugates for Imaging Neuroendocrine Tumours  
In order to avoid the heating step required for DOTA and DOTAGA, alternative chelators which 
bind gallium-68 quantitatively at room temperature in 10 minutes or less have been conjugated 
to TOC or TATE peptides. NODAGA-TATE (56), DATA-TOC (72) and THP-TATE (74) (figure 2.27) all 
show simple, room temperature radiolabelling, however, none have yet demonstrated they can 
be formulated into in a lyophilised one-step kit. Additionally, the pH required for such 
radiolabelling differs between the conjugates (NODAGA-TATE pH 3.5, DATA-TOC pH 4.2, THP-
TATE pH 6). Room temperature radiolabelling for [68Ga]Ga-NODAGA-TATE was performed in a 
two-step process (56). Firstly the gallium-68 from the generator (0.1 M HCl) was neutralised with 
sodium acetate buffer, and then NODAGA-TATE was added and the mixture incubated at room 
temperature for 10 minutes. The minimum final concentration of NODAGA-TATE required to 
obtain a RCP better than 95% as analysed by HPLC, was 10 µM. The simplest radiolabelling 
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procedure described for DATA-TOC (72) was conducted as follows: 13 nmol of DATA-TOC was 
dissolved 0.2 mL 1 M ammonium acetate and then 0.9 mL of fractionated gallium-68 eluate (0.1 
M HCI) was added to the reaction vial. The solution was briefly vortexed and left to stand at 
ambient temperature for 10 minutes giving a final pH of 4.2 and a DATA-TOC concentration of 
12 µM. [68Ga]Ga-DATA-TOC was produced in over 95% radiochemical yield as determined by 
iTLC. The simplest radiolabelling described for THP-TATE (74) was again very similar. 1 mL of 
fractionated gallium-68 eluate (0.1 M HCI) was added to a 50 µL solution of THP-TATE (50:50 
ethanol/water, 12 nmol) immediately followed by ammonium acetate buffer (2 M, 200 μL). The 
solution was left to stand at ambient temperature for 2-5 minutes which gave a final pH of 5-6 
and a THP-TATE concentration of 10 µM. [68Ga]Ga-THP-TATE was produced in over 95% 
radiochemical yield as determined by iTLC and HPLC. All three conjugates therefore 
demonstrate, simple, quantitative radiolabelling processes at similar concentrations (10-12 µM) 
close to those suitable for one-step kit preparation with adequate molar activity (<10 µM). 
 
FIGURE 2.27: The structures of NODAGA-TATE (56), DATA-TOC (85) and THP-TATE (74) 
The radiolabelling methods for DATA-TOC and THP-TATE relied on ammonium acetate as the 
neutralising and buffering agent, which is not an excipient approved for human use and is also 
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volatile and therefore unsuitable for lyophilisation, meaning reformulation of this buffer would 
be required before a true one-step kit can be developed. It would also be ideal for any kit 
developed to be able to cope with the full elution volume of a generator to remove the need for 
a fractionation process and creating a one-step radiolabelling procedure. 
In order to ensure that the change of chelator did not impact the somatostatin targeting of the 
tracers both [68Ga]Ga-DATA-TOC (85) and [68Ga]Ga-THP-TATE (74) have been evaluated in a 
mouse model of neuroendocrine cancer, but surprisingly [68Ga]Ga-NODAGA-TATE has not 
progressed to preclinical studies. Both [68Ga]Ga-DATA-TOC (85) and [68Ga]Ga-THP-TATE (74) 
demonstrated targeting to somatostatin-expressing tumours which could be specifically blocked 
by the co-injection of TATE peptide. However, when [68Ga]Ga-DATA-TOC and [68Ga]Ga-THP-TATE 
were compared to their DOTA analogues in a mouse model, the biodistributions observed were 
not identical, confirming the chelator portion of a bioconjugate can impact on the biological 
properties of a tracer. [68Ga]Ga-DATA-TOC is currently undergoing clinical evaluation (86) and it 
will be interesting to see if these differences in biodistribution or targeting ability occur in human 
studies as well. 
2.3.1.5 Conclusion on Neuroendocrine Labelling with Gallium 
The marketing approval of and commercialisation of two-vial kits for [68Ga]Ga-DOTA-TATE and 
[68Ga]Ga-DOTA-TOC production demonstrate the appeal of kit-based formulations. Alternative 
bioconjugates have shown that simplified radiolabelling can be achieved with the right chelator 
but that chelator choice can influence targeting efficiency. These results move the field towards 
the development of one-step kits for gallium-68-based radiopharmaceuticals. Now that DOTA-
TATE and DOTA-TOC have been approved by regulatory authorities it is unlikely that novel 
conjugates will replace them due to the time and costs involved. However, this idea could be 
applied to new gallium-68 tracers which show clinical promise but have not yet received 
regulatory approval, and may in fact, expedite their translation into the clinic. 
2.3.2 Gallium-68 PSMA Tracers  
As discussed in chapter 1 GCP(II)/PSMA targeted radiopharmaceuticals show great clinical 
promise for imaging prostate cancer, and have demonstrated utility in both initial staging and in 
cases of biochemical recurrence. Here the radiolabelling for the gallium-68 PSMA tracers that 
have already been developed will be reviewed in the context of one-step kit development to 
determine whether novel bioconjugates would be required to achieve this. The three most 
important gallium-based PSMA tracers are [68Ga]Ga-HBED-CC-PSMA, [68Ga]Ga-DOTA-
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PSMA(617) and [68Ga]Ga-DOTAGA-PSMA(I&T). Radiolabelling of DOTA-based PSMA tracers 
[68Ga]Ga-DOTA-PSMA(617) and [68Ga]Ga-DOTAGA-PSMA(I&T) has only been described using 
automated synthesis modules (87)(88)(89). The automated synthesis of [68Ga]Ga-DOTA-
PSMA(617) and [68Ga]Ga-DOTAGA-PSMA(I&T) is extremely similar to those used for [68Ga]Ga-
DOTA-TOC and [68Ga]Ga-DOTA-TATE discussed above because they all utilise the DOTA chelator. 
Therefore the individual protocols of these tracers will not be discussed here. Instead, this 
section will focus on the most widely used [68Ga]Ga-PSMA tracer, [68Ga]Ga-HBED-CC-PSMA, 
which utilises the HBED-CC chelator and therefore has its own unique considerations for 
radiolabelling. 
 
FIGURE 2.28: The structure of HBED-CC-PSMA (90). 
2.3.2.1 Explanation of Isomers of [68Ga]Ga-HBED-CC-PSMA 
As discussed above HBED is an acyclic chelator with optimal radiolabelling at room temperature 
and pH 4. However, its structure, consisting of 6 groups of 3 different donor types means that 
upon binding at least 3 HBED isomers can form, the RR, RS, and SS. Rather than the HBED 
chelator, [68Ga]Ga-HBED-CC-PSMA utilises the HBED-CC chelator which has an additional 
pendant carboxylic acid group attached to each of the phenol rings allowing the chelator to be 
functionalised. In HBED-CC-PSMA one of these additional carboxylic acid groups is attached to 
an aminohexanoic acid linker and which is in turn attached to the side chain of the lysine within 
the GCP(II)/PSMA targeting pharmacophore (Lys-C(O)-Glu) and the other remains free as shown 
in figure 2.28. The functionalisation of HBED-CC with PSMA makes the two phenol donor groups 
of the chelator inequivalent; one is attached to the GCP(II)/PSMA targeting moiety and the other 
has a pendant carboxylic acid. This means the RS and SR conformations also become 
inequivalent increasing the number of possible geometric isomers from 3 to 4 as shown in figure 
2.29. Each of these geometric isomers will be present as a racemic mixture of its two 




FIGURE 2.29: The possible geometric isomers for hexadentate Ga-HBED-CC-PSMA RR, SS, RS and SR. Note that 
SR and RS are not equivalent, unlike [Ga-HBED]. Each isomer depicted here is one of a pair of enantiomers. 
Despite the complexities described above, only two separable species were observed in the 
HPLC of [68Ga]Ga-HBED-CC-PSMA when radiolabelling was performed at room temperature 
(figure 2.30) (65). However, it is important to note that this could be due to the HPLC conditions 
used and does not prove there were only two species present. The two peaks observed occur in 
a ratio of 1:1 (area under the radio-peak). However, when radiolabelling was performed at 95°C 
the ratio changed to 9:1 as shown in figure 2.30. The major species is proposed from NMR 
studies (64) to be the RR conformation, which due to minimised steric hindrance should be the 
most thermodynamically favoured as the phenol donor groups are trans. When this mixture was 
left for 3 hours in the buffer used for patient injection, in order to mimic the maximum time 
between synthesis and patient injection, the ratio of these two peaks stayed at this 9:1 ratio 
(figure 2.31). This demonstrates that further interconversion does not occur and suggests that 
the major peak is the more thermodynamically stable. Conversion from the 1:1 ratio to the 9:1 
ratio can also be achieved by controlling the pH. If [68Ga]Ga-HBED-CC-PSMA is radiolabelled at 
room temperature producing the 1:1 ratio and then stored at pH 4 and pH 7 for 3 hours the 
sample stored at pH 7 remains at the 1:1 ratio but the one at pH 4 converts to the 9:1 ratio 
(figure 2.32). This finding is confirmed by earlier observations where interconversion of 
[67Ga]Ga-HBED-CC at pH 7 into the most stable geometric isomer took 7 days. However, this was 
at a concentration of >2 mM which appears to encourage the formation of the less 
thermodynamically stable species (91). 
These results suggest that there are at least two geometric isomers that are favoured by kinetics 
at room temperature with micromolar concentrations of HBED-CC-PSMA and therefore form 
rapidly (~2 minutes) (65). However, the thermodynamically favoured species can be 
preferentially formed by incubation at pH 3.5 or 95°C. Of these the much quicker method, and 
therefore the only one suitable for radiochemical synthesis with gallium-68 is heating to 95°C 
for 10 minutes. However, this only produces ~90% of the most favoured complex, rather than a 
single species. For comparison in clinical radiolabelling procedures for [68Ga]Ga-DOTA-TATE, the 
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minimum RCP required for administration is higher at 91% with the remaining activity known to 
be only unchelated gallium-68, rather than an alternative radiolabelled complex (24). In 
technetium-99m kits the RCP required is normally >95% but this is only measured by iTLC and it 
is known that in some cases many species are formed, as discussed earlier. 
The concerns surrounding the presence of multiple species is that these may have different 
GCP(II)/PSMA targeting abilities or biodistributions that would impact on detection rates, the 
quality of the image produced or other clinically-relevant parameters. The performance of 
[68Ga]Ga-HBED-CC-PSMA and [natGa]Ga-HBED-CC-PSMA, made at room temperature and those 
made at 95°C have only been compared in vitro (65). These results showed minimal differences 
between IC50 values of [natGa]Ga-HBED-CC-PSMA produced by these two methods (27.4 ± 1.3 
nM and 24.8 ± 1.2 nM) or between the uptake of [68Ga]Ga-HBED-CC-PSMA in GCP(II)/PSMA 
expressing cells as shown in figure 2.33. These results suggest there would be no difference in 
affinity between the tracers made by the two methods. However, no comparative studies have 
been done in animal models or clinical studies and geometric isomers could behave differently 
under these conditions to what is seen in vitro. In order to minimise concerns about having two 
major species present the majority of published clinical studies for [68Ga]Ga-HBED-CC-PSMA use 
a heating step of 95°C for 10 minutes to obtain ~90% of the major species (65)(92)(93).  
Presently it is unknown what stance the regulatory bodies will take on the presence of multiple 
isomers of [68Ga]Ga-HBED-CC-PSMA, and whether the heating step provides a high enough 
radiochemical purity to overcome any concerns. However, it is very likely that this issue would 
be raised during the approval process and that more extensive evidence into the complexes 
formed, and any differences in their performance will be required. These multiple species may 
therefore create a large barrier to gaining regulatory approval or marketing authorisation for 
[68Ga]Ga-HBED-CC-PSMA and any other tracers incorporating the HBED or HBED-CC chelator. 
This would mean that access to these tracers would remain restricted to larger research 
hospitals which can produce it within research studies or under regulations for non-approved 





FIGURE 2.30: Radio-HPLC traces of [68Ga]Ga-HBED-CC-PSMA radiolabelled (A) room temperature 
radiolabelling (B) 95 °C radiolabelling. The peaks correspond to (1), the thermodynamically more stable, and 
(2), the thermodynamically less stable geometric isomer. Modified with permission from (65). 
 
FIGURE 2.31: Radio-HPLC traces of [68Ga]Ga-HBED-CC-PSMA radiolabelled at 95 °C (A) just after radiolabelling 
is complete (B) and after subsequent storage in the injection buffer (2 mL ethanol, 8 mL phosphate buffered 
saline (PBS)) for 3 hours. The peaks correspond to (1), the thermodynamically more stable, and (2) the 
thermodynamically less stable geometric isomer. These graphs demonstrate that the ratio of the peaks remains 




FIGURE 2.32: Radio-HPLC traces of [68Ga]Ga-HBED-CC-PSMA radiolabelled at room temperature (A) 
radiolabelling just after radiolabelling is complete, (B) after subsequent storage at pH 4 for 3 hours (showing its 
conversion to the more thermodynamically stable geometric isomer and (C) after storage at pH 7 for 3 hours; 
under the latter conditions no conversion of the isomers is seen. The peaks correspond to (1), the 
thermodynamically more stable, and (2) the thermodynamically less stable geometric isomer. Modified with 
permission from (65). 
 
FIGURE 2.33: (A) LNCaP-cell binding and internalisation of [68Ga]Ga-PSMA-HBED-CC labelled at room 
temperature or 95 °C, respectively. 500 µM 2-PMPA was used for blocking studies. Data are expressed as mean 
± SD (n = 3); (B) IC50 determination for [natGa]Ga-PSMA-HBED-CC labelled at room temperature and at 95 °C. 
[68Ga]Ga-HBED-CC-PSMA was used as the probe. Reproduced with permission from (65). 
When considering the development of [68Ga]Ga-HBED-CC-PSMA into a one-step kit these 
questions around the different species formed also need to be addressed. If the multiple isomers 
are an issue then a heating step becomes mandatory and it is not possible to develop this 
bioconjugate into a one-step kit. As the majority of the clinical work has been done with this 
heating step, clinical studies would need to be repeated with a mixture of the two geometric 
isomers formed at room temperature. Therefore it would be ideal to have a one-step kit, without 
a heating step which did not produce multiple geometric isomers. For this, an alternative 
bioconjugate would be required. 
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2.3.2.2 Automated Synthesis of [68Ga]Ga-HBED-CC-PSMA (65) 
The most-referenced automated synthesis methodology for [68Ga]Ga-HBED-CC-PSMA (65) is 
summarised below but other variations exist and methods are likely to vary significantly from 
site to site due to the range of generators and synthesisers used. A Scintomics GRP 
(Fürstenfeldbruck, Germany) fully automated synthesis module with a control centre and GRP-
interface software were used along with disposable cassette kits (ABX advanced biochemical 
compounds) and the IDB-Holland BV generator (Baarle-Nassau, The Netherlands). The setup for 
the automated synthesis module required the removal of the cassette from its sterile packaging 
and attachment to the module, followed by a cassette pressure test. The high purity 
pharmaceutical grade reagents (5 M NaCl solution, ultrapure water, ethanol:water (1:1, v:v), and 
HBED-CC-PSMA peptide in acetate buffer containing ascorbic acid) and cartridges (one cation 
exchange and one C18 reverse phase) were then added to the cassette and the generator 
attached. Once setup was complete the automated synthesis was initiated and took 35 minutes 
to run. The radiolabelling involved the following automated steps: 1) The generator was eluted 
with 10 mL of 0.6 M HCl which was diluted with 9 mL of ultrapure water and passed through an 
ion exchange cartridge; 2) The ion exchange cartridge was then eluted with 5 M NaCl solution 
into the pre-heated reaction vial which contained HBED-CC-PSMA (1.9 µg, 2 nmol) in acetate 
buffer and ascorbic acid; 3) The reaction mixture was heated at 100°C for 10 minutes to form 
[68Ga]Ga-HBED-CC-PSMA; 4) The contents of the reaction vial were removed and passed through 
a C18 cartridge, trapping [68Ga]Ga-HBED-CC-PSMA; 5) 9 mL ultrapure water was used to rinse the 
reaction vessel and the C18 cartridge, and the C18 cartridge was washed with a further 5 mL of 
ultrapure water; 6) The C18 cartridge was then eluted with 2 mL of a 1:1 (v:v) ethanol:water mix 
through a sterile filter and then diluted in 8 mL phosphate buffered saline (PBS). Once this radio-
synthesis was completed QC procedures were conducted before batch release. Each run 
produced [68Ga]Ga-HBED-CC-PSMA with decay-corrected radiochemical yields of 80% ± 5% and 
RCP over 99% by HPLC and iTLC if the two diastereomers were combined and 89% if only the 
more thermodynamically stable isomer was included (the two isomers were distinguishable by 
HPLC but not iTLC). 
2.3.2.3 Single Vial Kits for [68Ga]Ga-HBED-CC-PSMA Imaging 
The need for an automated synthesis rig for [68Ga]Ga-HBED-CC-PSMA radiolabelling has been 
questioned in recent publications (94), especially when using generator eluate which has low 
germanium-68 breakthrough. Instead, formulations for single vial kits have been developed and 
shown to achieve suitable radiochemical yields (95)(96). Only some of these kits retained the 
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heating step. The radiolabelling procedure for a kit which included a heating step can be 
summarised as follows. Lyophilised vials containing 21 nmol (20 µg) HBED-CC-PSMA and 98 mg 
sodium acetate were prepared and then radiolabelling was performed by the addition of 2 mL 
of the fractionated eluate from an ITG germanium-68/gallium-68 generator (0.05 M HCl) to the 
vial followed by heating at 85 °C for 10 minutes (95) and QC. A published method without a 
heating step (96) used very similar lyophilised kits, containing 5 nmol (5 µg) HBED-CC-PSMA and 
98 mg sodium acetate trihydrate. These were radiolabelled by adding 1 mL of fractionated 
eluent from an iThemba germanium-68/gallium-68 generator (0.6 M HCl) and allowed to 
incubate at room temperature for 15 minutes before QC. 
2.3.2.4 Commercial Single Vial Kit Radiolabelling for [68Ga]Ga-HBED-CC-PSMA 
The manufacturer ANMI (Liege, Belgium) has developed a one-step kit for labelling of [68Ga]Ga-
HBED-CC-PSMA at room temperature (97)(98) which has now been tested in a clinical study (99) 
but does not have FDA or EMA approval. This lyophilised kit contains 25 µg (26 nmol) HBED-CC-
PSMA. The rest of the kit contents have not been disclosed for commercial reasons, but must 
contain a neutralising agent or buffer to modify the pH to 4-5. The kit was reconstructed with 
1.1 mL (the total eluate volume) of 0.1 M HCl eluted from an IRE-Elit germanium-68/gallium-68 
generator (Fleurus, Belgium) (99). After this addition, the kit was shaken and left to stand at 
room temperature for 5 minutes before a sample is removed for QC. The final concentration of 
HBED-CC-PSMA was 23 µM. RCP was over 98% when measured by iTLC. Some radio-HPLC 
validation was performed but this was not deemed necessary for every batch. [68Ga]Ga-HBED-
CC-PSMA made with the ANMI kits has been tested in a clinical study of fifty prostate cancer 
patients (25 for initial staging, and 25 with biochemical recurrence) and showed the ability to 
detect primary tumours, cancerous lymph nodes and bone metastases (99). As there is no 
heating step in this method the two major isomers of [68Ga]Ga-HBED-CC-PSMA would have been 
formed. This is not discussed in the clinical paper but was mentioned in previously published 
abstracts about these kits which stated the ratio of isomers was 1:1 (97)(98). The isomeric 
composition is therefore different from the majority of clinical studies where the heating step 
will have been used to ensure ~90% of one isomer. The two production methods were not 
compared in the same patients within the clinical study for the kit and so it is not possible to 




2.4 Concluding Remarks 
PSMA tracers show exceptional clinical promise for imaging prostate cancer, but to date, no 
PSMA tracers have been approved by the FDA or EMA. Because of the large number of prostate 
cancer patients that could benefit from a PSMA scan each year it would be ideal if the PSMA 
tracer that became established in routine clinical practice was accessible to a wide range of 
hospitals: a radiolabelling procedure based on a generator-produced radionuclide and a one-
step kit could enable this to happen, and the germanium-68/gallium-68 generator makes this 
possible for PET imaging. The [68Ga]Ga-PSMA tracers clinically assessed so far do not meet the 
ideal properties for a one-step kit and therefore there is an opportunity to develop novel 
bioconjugates that can achieve this. After reviewing the chelators available for gallium-68, THP 
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3 The Development of [68Ga]Ga-THP-PSMA and Its Use in Imaging 
Prostate Cancer 
The content of this chapter has been published in the form of an original research article in the 
Journal of Nuclear Medicine (1) 
3.1 Introduction 
As outlined in chapter 2, there is a desire and a need to have simple and robust radiolabelling 
procedures for all radiopharmaceuticals, and one-step, kit-based radiopharmaceuticals offer the 
greatest ease of GMP production. For years kit-based radiopharmaceuticals have dominated 
technetium-99m tracer production (2) but despite this history within nuclear medicine, the same 
approach has not been adopted for PET radiotracers, even though this concept has been 
proposed for over 20 years (3)(4). This was initially due to the prevalence of the fluorine-18 and 
carbon-11-based PET tracers which, as non-metals, are covalently incorporated into 
radiotracers, and so require complex multi-step synthetic chemistry, incompatible with a kit. 
However, interest has increased in the metal-based PET radionuclides, including copper-64, 
zirconium-89, gallium-68, scandium-44, and yttrium-96, where there is the opportunity to use 
chelating agents to incorporate the radiometal (5). If chelators with optimal properties can be 
designed, this opens the possibility for a one-step kit. Of these radiometals the most suitable for 
PET imaging of small molecules and peptides with fast pharmacokinetics is gallium-68, due to its 
well-matched 67.8 minute half-life, and the 89.14% positron decay which allows high-quality 
images to be obtained with acceptable patient dose (4)(6)(7)(8)(9). 
In addition to these advantages, gallium-68 is available from a generator, which means it is 
potentially accessible to a wider range of hospitals than cyclotron-produced radionuclides. The 
germanium-68/gallium-68 generator is based on the parent radioisotope germanium-68 (t1/2 = 
270.95 days (10)), which decays via electron capture to gallium-68. The elution of the 
Galliapharm pharmaceutical grade generator (Eckert and Ziegler, Radiopharma, GmbH) which 
has marketing authorisation across Europe (11), provides up to 1.85 GBq of gallium-68 in 5 mL 
of 0.1 M HCl. This is enough activity for between 1 and 4 patient doses depending on the age of 
the generator and the radiosynthesis method. Additionally, the generator can be eluted several 
times a day (up to every 2 hours), and only needs replacing once a year (8). The GMP-compatible 
eluate meets all the British and European Pharmacopeia monograph standards, including 
germanium-68 breakthrough (< 0.001%) and can be used clinically without any purification steps 
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(12) (although purification steps are typically needed to improve subsequent radiolabelling of 
conventional bifunctional chelator conjugates). 
The chemical properties of gallium also lend themselves to single step kit-based radiolabelling. 
In fact, one might expect that it should be simpler to design a kit for gallium-68 than technetium-
99m, due to its strongly preferred oxidation state of gallium(III), whereas technetium-99m is 
eluted from the generator as 99mTc-pertechnetate(VII) and has to be reduced to a lower 
oxidation state (Tc(VI), Tc (V), Tc(IV), Tc(III) or Tc(I)) before it can be chelated (2). This brings the 
disadvantage of requiring the inclusion of a reducing agent such as tin chloride, which in a 
gallium-68 kit, could be avoided. No-carrier-added gallium-68 is eluted from the generator in a 
solution of hydrochloric acid, in the form of [Ga(H2O)6]3+ which is stabilised by the low pH 
(13)(14). As the pH is increased ligands containing oxygen or nitrogen donors, can be used to 
chelate gallium-68. These properties demonstrate that, in theory, a gallium-68 
radiopharmaceutical kit could be extremely simple, containing just a pH modifier and the metal-
free pharmaceutical. 
To achieve such a kit, the chelator used to incorporate gallium into the bio-conjugate must meet 
several criteria (4): its labelling should reach completion (> 95% radiochemical yield) quickly (< 
5 minutes) at room temperature and be unaffected by common trace metals in the generator 
eluate, without additional steps to concentrate, heat, buffer, or purify. Its complex should resist 
in vivo transchelation (e.g. by transferrin or serum proteins), and conjugation and radiolabelling 
should not induce mixtures of diastereomers, enantiomers, or geometric isomers, nor adverse 
pharmacokinetics, (for example, delayed clearance or non-speciﬁc binding). The current 
generation of clinically assessed gallium-68 chelators, such as DOTA and HBED-CC, do not meet 
these criteria, as discussed in chapter 2. 
A class of chelator with the potential to meet the requirements for kit-based labelling outlined 
above and in chapter 2 is the tris(hydroxypyridinone) (THP) system, which has been shown to 
bind gallium-68 rapidly at room temperature and neutral pH, with high yield and purity, without 
the need to process the generator eluate (15)(16)(17)(18)(19). The structure of THP-Ac is shown 
in figure 2.19 alongside its functionalised derivatives. The THP (tris(hydroxypyridinone) chelator 
is an acyclic ligand and an O6 donor through its three hydroxyl groups and three carbonyl groups 
on its 1,6-dimethyl-3-hydroxypyridin-4-one arms, and forms a neutral complex with gallium(III). 
Such a complex would be predicted to have a (distorted) octahedral geometry. This tripodal 
design aimed to avoid the formation of geometric isomers upon binding but would allow the 
formation of delta and lambda enantiomers associated with all hexadentate tripodal chelators. 
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The performance of THP has been evaluated against a range of common chelators and 
demonstrated superior radiolabelling properties under milder conditions (15)(16). 
THP has also been functionalised and conjugated to peptides and proteins (THP-Tyr3-octreotate, 
THP-RDG and THP-αvβ3 integrin) and retains both its mild radiolabelling and in vivo targeting 
properties (16)(17)(20)(21). This provides an excellent starting point to develop one step 
radiopharmaceutical kits which utilise the THP technology. 
As the advantages of kit-based radiolabelling are only fully realised when applied to clinical 
production, efforts should be focused on developing such radiolabelling for radiotracers which 
serve a clinical need. Prostate cancer is the most prevalent type of cancer where [18F]FDG 
imaging is unsuitable for staging and detection of disease recurrence, and so alternative PET 
imaging agents are required (22). The over-expression of the prostate specific membrane 
antigen (GCP(II)/PSMA) on the majority of prostate cancers provides a way to specifically target 
radiotracers to disease sites (22)(23), and a small urea-based inhibitor can be used to target 
GCP(II)/PSMA. This is a versatile scaffold which is suitable for conjugation to chelators without 
dramatically changing its affinity (24)(25)(26). A [68Ga]Ga-labelled conjugate of this targeting 
moiety with HBED-CC as the chelator (figure 3.1) has shown outstanding clinical promise in 
several trials in patients with prostate cancer (27)(28) as described in chapter 1 and has 
established itself rapidly in routine use in research hospitals across the world. Studies have been 
carried out in Germany (27), UK (29), Australia (30), India (31), South Africa (32), mainly driven 
by demand from clinicians and patients, demonstrating that GCP(II)/PSMA imaging fulfils a 
clinical need (33). Recently published studies have also shown the impact of [68Ga]Ga-PSMA 
scans on patient management (29)(30) and further studies into the effect on patient outcomes 




FIGURE 3.1: Structures of (A) DOTA-PSMA (PSMA-617) (34); (B) HBED-CC-PSMA (DKFZ-PSMA-11) (25); (C) 
THP-PSMA 
The choice of HBED-CC as the chelator makes radiolabelling of [68Ga]Ga-HBED-CC-PSMA possible 
at room temperature, but the labelling produces an undesirable mixture of cis/trans geometric 
isomers distinguishable by HPLC (25)(31)(32)(35)(36). Thus, a heating step is still required, to 
reduce the number of isomers and increase the yield of one of these to approximately 90%, as 
it has been suggested that these isomers may have different in vivo properties (35). Clinical 
radiosynthesis of tracers based on these chelators is currently performed on cartridge-based 
synthesis modules, taking 35 minutes and typically affording 80 ± 5% decay-corrected 
radiochemical yield (35). Such production requires a high level of radiochemical expertise and 
infrastructure rarely available outside research hospitals. Switching from this to a one-step kit-
based process would ensure that tracer production is simple, robust, and a less labour-intensive 
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process which is quicker to validate. All these features should lead to faster and wider adoption 
across radiopharmacies and consequently better access for patients. 
In this study a THP bioconjugate targeting GCP(II)/PSMA, incorporating the (Lys-C(O)-Glu) 
pharmacophore has been evaluated (figure 3.1) (24)(25)(34). The aims of this work were to 
determine the potential of [68Ga]Ga-THP-PSMA to achieve one-step kit-based labelling and to 




3.2 Experimental Aims 
The experimental aims of this chapter are: 
 Synthesise a THP-PSMA conjugate 
 Assess radiolabelling of [68Ga]Ga-THP-PSMA without pre- or post-processing 
 Develop a one-step kit for [68Ga]Ga-THP-PSMA suitable for use with the Galliapharm 
germanium-68/gallium-68 generator (Eckert and Ziegler) 
 Evaluate the uptake of [68Ga]Ga-THP-PSMA in prostate cancer cells that over-express 
GCP(II)/PSMA, and compare its affinity for GCP(II)/PSMA to the established tracers 
[68Ga]Ga-HBED-CC-PSMA (DKFZ-11) and [68Ga]Ga-DOTA-PSMA (PSMA-617) 
 Evaluate the biodistribution and tumour uptake of [68Ga]Ga-THP-PSMA in a preclinical 
mouse model with a subcutaneous prostate cancer xenograft and compare to the 




3.3 Materials and Methods 
All reagents and consumables were purchased from Sigma Aldrich or Fischer Scientiﬁc, with the 
exception of Fmoc-Lys-Dde-COOH (Bachem AG, Bubendorf, Switzerland), 2-
(phosphonomethyl)pentane-1,5-dioic acid (PMPA) (Enzo Life Sciences, Exeter, UK), Anti-PSMA-
VioBright-FITC and REA-(control)-VioBright FITC (MACS Milenyi Biotec, Bisley, UK), DOTA-PSMA 
(PSMA 617), and HBED-CC-PSMA (DKFZ-11) (ABX, Radeberg, Germany). Severe combined 
immunodeﬁcient (SCID)/beige mice were purchased from Charles River (Margate, UK). DU145 
and DU145-PSMA cell lines were provided by Dr. Florian Kampmeier (37). 
3.3.1 Instrumentation 
NMR: Nuclear magnetic resonance (NMR) 1H- and 13C- spectra were acquired on a Bruker Avance 
III 700 spectrometer operating at 700 MHz (1H frequency), equipped with a quadruple-
resonance QCI cryoprobe.  
LC-ESIMS: High-resolution liquid chromatography electrospray ionisation mass spectrometry 
(LC-ESIMS) was performed in positive ion mode on an Agilent 6520 Accurate-Mass Q-TOF LC/MS 
connected to an Agilent 1200 HPLC. 
HPLC: All high-resolution liquid chromatography (HPLC) utilised an Agilent 1200 LC with in-line 
radio (sodium iodide gamma-detector) and ultraviolet detection (220 nm analytical, 280 nm 
preparative). Data were analysed using Laura software (version 4.0.2.75; LabLogic Systems Ltd.). 
HPLC methods: The chemical purity of THP-PSMA and radiolabelling of [68/67Ga]Ga-THP-PSMA 
were assessed using an Agilent Eclipse XDB C18 5 µm 4.6 × 150 mm column with an isocratic 
mobile phase (87.5% H2O, 12.5% acetonitrile (ACN), 0.075% triﬂuoroacetic acid (TFA), 0.05% 
triethylamine), with a ﬂow rate of 1 mL/minute. [68/67Ga]Ga radiolabelling of HBED-CC-PSMA and 
DOTA-PSMA(617) was assessed with the same HPLC equipment but an alternative mobile phase: 
A = H2O with 0.05% TFA, B = ACN with 0.05% TFA, gradient: 0-5 minutes = 90% A, 5-15 minutes 
= ramp to 50% B (4%/min), 15-20 minutes = 90% A, with a ﬂow rate of 1 mL/minute. Serum 
stability was assessed using size-exclusion chromatography with a Phenomenex BioSep 5 mm 
size-exclusion chromatography s2000 column (300 × 7.8 mm) with phosphate-buffered saline 
(PBS) as the mobile phase and a ﬂow rate of 1 mL/minute. 
iTLC: Instant thin-layer chromatography Radiolabelling for all [67/68Ga]Ga-PSMA radiotracers 
was assessed by iTLC utilising Varian ITLC SGI0001 strips (10 cm length) with a mobile phase of 
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1 M ammonium acetate in water/methanol (1:1). iTLC plates were scanned with a LabLogic 
miniScan TLC reader and analysed with Laura software. 
3.3.2 Synthesis of THP-PSMA  
Synthesis of H-Lys-(Dde)-2CT-resin (compound 3): 2-Chlorotrityl resin (350 mg equivalent to a 
loading of 0.35 mmol) was inserted in a fritted polypropylene syringe, and a solution of Fmoc-
Lys-DdeCOOH (600 mg, 1.1 mmol) (compound 1, reaction scheme 3.1) and excess N,N-
diisopropylethylamine (DIPEA) in dichloromethane (DCM) was added. After being stirred 
overnight to form compound 2, the resin was washed with DCM and subsequently treated with 
methanol for 10 minutes. Thereafter, the resin was washed with dimethylformamide (DMF) and 
DCM and ﬁnally dried under vacuum. Resuspension of the beads in a solution of piperidine/DMF 
(20:80) for 20 minutes followed by separation of the resin from the supernatant by suction 
ﬁltration and washing with DMF and DCM produced resin-bound compound 3.  
Synthesis of resin-bound THP-PSMA (compound 9): Bis(tert-butyl) ester L-glutamate 
hydrochloride (444 mg, 1.5 mmol) was dissolved in anhydrous DCM (100 mL) containing DIPEA 
(750 µL, 4.3 mmol). This solution was added dropwise to a 3-neck round bottom ﬂask containing 
a solution of triphosgene (150 mg, 0.5 mmol) in anhydrous DCM (5 mL) at 0°C under a nitrogen 
atmosphere. The reaction solution was then allowed to warm to room temperature and stirred 
for 1 hour. The previously prepared H-Lys-(Dde)-2CT-resin compound 3 (reaction scheme 3.1) 
(250 mg, equivalent to a loading of 0.25 mmol) was added and stirred overnight to form 
compound 6 (reaction scheme 3.1). The resin was separated from the supernatant by suction 
ﬁltration in a fritted polypropylene syringe, washed, and dried. The resin was suspended in a 
mixture of 2% (v/v) hydrazine hydrate in 2 mL of DMF and stirred for 15 minutes, and then 
washed with DMF. This step was repeated 4 times to produce compound 7 (reaction scheme 
3.1). Compound 7 (100 mg equivalent to a loading of 0.1 mmol) was added to a solution of 
glutaric anhydride (114 mg, 1 mmol) and DIPEA (358 µL, 2 mmol) dissolved in 2 mL of DMF, and 
the mixture was stirred for 3 hours to produce compound 8 (reaction scheme 3.1). Compound 
8 (50 mg, equivalent to a loading of 0.05 mmol) was suspended in a solution of HATU (20 mg, 
0.05 mmol) and DIPEA (18 µL, 0.1 mmol) in anhydrous DMF (0.5 mL), and in situ activation of 
the carboxylate was allowed to proceed for 10 minutes. A solution of THP-NH2 (70 mg, 0.09 
mmol), synthesised by a previously published method (38), in DMF/DMSO (2.5 mL/2 mL) 
containing DIPEA (18 µL, 0.1 mmol) was then added to this suspension and stirred for 36 hours, 





REACTION SCHEME 3.1: Reaction scheme for the synthesis of THP-PSMA. a. 2-chlorotrityl polymer-bound resin 
beads, DIPEA, DCM; b. Piperidine, DMF; c. Triphosgene, DIPEA, DCM, 0°C; d. Compound 3, Compound 5, DCM; e. 
Hydrazine hydrate, DMF; f. Glutaric anhydride, DIPEA, DMF; g. THP-NH2, HATU, DIPEA, DMF, DMSO; h. TFA, 
phenol, TIPS, H2O. 
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Cleavage of THP-PSMA (compound 10) from resin: Cleavage and removal of the side-chain 
protecting groups were performed by treating the resin-bound compound 9 with TFA for 3 hours 
at room temperature in the presence of phenol (5% w/v), water (5% v/v), and triisopropylsilane 
(2% v/v) as scavengers. The ﬁltrate was collected and the resin washed with TFA and DCM. The 
solution was concentrated to less than 0.5 mL at 40°C under a gentle stream of nitrogen. Ice-
cold diethyl ether was added to precipitate THP-PSMA (compound 10, reaction scheme 3.1). 
The suspension was centrifuged, the supernatant decanted off, the precipitate washed with 
diethyl ether, and then dissolved in aqueous ACN and lyophilised. Crude THP-PSMA was puriﬁed 
by semi-preparative reversed-phase HPLC to give a TFA salt (C54H77N11O19.(CF3COO)3) (molecular 
weight (MW), 1,526.33). Semi-preparative reversed-phase HPLC was conducted using an Agilent 
Eclipse XDB C18 5 µm 21.2 × 150 mm column with the concentration of mobile phase B increasing 
at a rate of 1 %/minute (A = H2O with 0.2% TFA, B = ACN with 0.2% TFA, starting from 100% A at 
time 0; ﬂow rate, 5 mL/minute). The yield of THP-PSMA(CF3COO)3 was 4 mg, 2.6 mmol, 5.2% 
yield from resin loading. The analytical HPLC retention time (Rt) was 13 minutes 23 seconds, and 
purity was greater than 98% assuming equal extinction coefficients for product and impurities. 
Analytical data can be found in the results section. 
3.3.3 [natGa]Ga-THP-PSMA NMR  
Varying the gallium to THP-PSMA ratio: Solutions of THP-PSMA (3 mg/mL, MW 1526.33, 2 mM), 
[natGa]Ga(NO3)3.X(H2O) (10 mg/mL, MW anhydrous basis 255.74, < 39 mM) and sodium 
bicarbonate (0.5 M) were prepared in deuterium oxide (D2O). [natGa]Ga-THP-PSMA was 
produced by the addition of the gallium nitrate solution to the THP-PSMA solution and 
neutralising to pH 7 with the sodium bicarbonate solution. 1D 1H NMR  spectra of three different 
samples were obtained: one without gallium (2 mM THP-PSMA, sample 1) one with THP-PSMA 
in excess (1.9 mM THP-PSMA, < 0.8 mM natGa, sample 2) and a third with gallium in excess (1.3 
mM THP-PSMA, < 5.2 mM natGa, sample 3). All concentrations of natural gallium here are a 
maximum level as they were calculated using the molecular mass of [natGa]Ga(NO3)3 rather than 
the hydrate. 
Stability over time: NMR sample 3 containing excess gallium was kept at 4° C for 3 weeks and 
monitored with 1D 1H NMR spectroscopy. 
Variable temperature NMR spectroscopy: This study was carried out with sample 3, [natGa]Ga-
THP-PSMA containing excess gallium, to observe the fluxionality of the system. The sample was 
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evaluated over a range of bore temperatures (5°C, 25°C, 50°C, and 70°C) and was acclimatised 
for 10 minutes prior to the acquisition of 1D 1H NMR spectra. 
3.3.4 Preparation of Lyophilised Kits  
One step kits were prepared either in-house, named here “type-A” or by ROTOP Pharmaka 
GmbH (Dresden-Rossendorf, Germany) named here “type-B”. Type A kits for one-step 
radiolabelling were made by lyophilising an aqueous solution (5.25 mL) containing sodium 
bicarbonate (44 μg), sodium phosphate monobasic (8.6 mg), sodium phosphate dibasic 
heptahydrate (8.9 mg), and THP-PSMA (40 mg, 26 nmol) in a plastic vial affording a white 
powder. Type-B lyophilised kits used with the clinical generator for one-step radiolabelling were 
The GMP compliant GalliProst™ kits by ROTOP Pharmaka GmbH (Dresden-Rossendorf, 
Germany) for Theragnostics Ltd. (Bracknell, UK) in radiopharmaceutical grade glass vials, with 
septum seals. The exact formulation of this kit is confidential, but they contained 40 µg of THP-
PSMA (39). 
3.3.5 Radiolabelling  
Radiolabelling and radioanalysis (HPLC and iTLC) of [67/68Ga]Ga-DOTA-PSMA (PSMA-617) (34), 
[67/68/natGa]Ga-HBED-CC-PSMA (DKFZPSMA-11) (25)(35), and [68/67/natGa]Ga-THP-PSMA were 
performed as follows. 
[68Ga]Ga-THP-PSMA radiolabelling: Initial gallium-68 radiolabelling optimisation was performed 
with a Galliapharm (Eckert and Ziegler) germanium-68/gallium-68 generator, producing 120–
400 MBq of gallium-68. Eluates (0.1 M HCl, 5 mL, Sigma Aldrich, high-performance capillary 
electrophoresis grade) were fractionated (10 × 0.5 mL) but not preconditioned to concentrate 
gallium-68 or remove trace metal contaminants. Typically, gallium-68 (5-75 MBq, 250 µL of the 
hottest fraction second mL) was added to a solution containing THP-PSMA at a range of 
concentrations (5-0.01 µg in 3 µL) in sodium bicarbonate solution (1 M, 26 µL), producing a 
solution with a pH of 6.5-7.5. Radiochemical yield was evaluated after 5 minutes at room 
temperature using HPLC and iTLC (HPLC: [68Ga]Ga-THP-PSMA retention time (Rt) = 10.9 minutes, 
unbound [68Ga]Ga3+ Rt = 2.32 minutes; iTLC: [68Ga]Ga-THP-PSMA retention factor (Rf) = 0.8–1, 
unbound [68Ga]Ga3+ Rf = 0). For in vivo studies, THP-PSMA (2 µg) was labelled with gallium-68 as 
described above; a greater than 95% radiochemical purity was consistently achieved. 
To evaluate labelling using the entire eluate without fractionation, Galliapharm (Eckert and 
Ziegler) germanium-68/gallium-68 generator eluate (5 mL 0.1 M HCl, 122–202 MBq) or Galli EO 
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(IRE ELiT) germanium-68/gallium-68 generator eluate (1.1 mL eluate diluted to 5 mL with 0.1 M 
HCl, 600–660 MBq) was added directly into a the vented, type-A, freeze-dried, kit vial. After 
being mixed, carbon dioxide evolution visibly ceased after 15 seconds, providing a transparent, 
colourless solution at pH 6-7 with a ﬁnal concentration of 5.25 µM THP-PSMA. ITLC was 
performed at 5 minutes and HPLC at 10 minutes after reconstitution. Decay-corrected 
radiochemical yield determined by each method were greater than 95% (n = 3 per generator). 
Labelling was also evaluated using type-B kits manufactured by ROTOP Pharmaka GmbH using a 
pharmaceutical grade Galliapharm (Eckert and Ziegler) germanium-68/gallium-68 generator 
within a radiopharmacy. The generator was less than 1 month old, produced 1100-1200 MBq of 
gallium-68, had been validated for clinical use and was pre-eluted 24 hours prior. The generator 
was eluted with 5 mL clinical grade 0.1 M HCl, directly into the kit vial, which was vented with a 
needle. The kit was then mixed until the generation of carbon dioxide ceased. 10 minutes after 
the addition of gallium-68 the activity was 1156 MBq, the pH 6, and the radiochemical purity 
97.3%, as assessed by iTLC. 
3.3.6 Preparation of PSMA Tracers for Biological Evaluation. 
Conversion of [67Ga]Ga-citrate to [67Ga]Ga-chloride: This step is required because the presence 
of citrate reduces the radiolabelling efﬁciency of gallium-67 with a number of chelators (40). 
[67Ga]Ga-citrate (6.49 mM citrate; Mallinckrodt) was passed over a Silica Light Sep-Pak cartridge 
(120 mg sorbent, 55-105 µm particle size) at 1 mL/minute to capture the radio-metal on the 
cartridge. This process was repeated 3 times whereupon approximately 90% of the activity 
remained on the cartridge. After being washed with 5 mL of H2O, the gallium-67 was eluted with 
400 µL of 0.1 M HCl and collected in 50 µL fractions. The 5th and 6th fractions which had the 
highest activity concentration (75 MBq/50 µL) were used for labelling (activity concentration, 
1.5 GBq/mL). 
[67Ga]Ga-THP-PSMA for in vitro studies: 10 µL of a 2 mg/mL solution (20 µg, 13.1 nmol THP-
PSMA, molecular weight 1,526.33) was added to 50 µL of [67Ga]Ga3+ in 0.1 M HCl (converted 
from [67Ga]Ga-citrate as described above) and the pH adjusted to 6.5–7.5 with 4.5 µL of 1 M 
sodium bicarbonate. Labelling was assessed after 5 minutes at room temperature by iTLC and 
HPLC. Before being added to cells, the tracer was diluted to 50 nM in PBS.  
[68/67Ga]Ga-DOTA-PSMA(617) for in vitro studies: 50 µL of [67Ga]Ga3+ or [68Ga]Ga3+ in 0.1 M HCl, 
5.25 µL of 1 M HCl, and 20 µL of 2.1 M 4-(2-hydroxyethyl)1-piperazineethanesulfonic acid 
(HEPES) were combined, producing a solution at pH 3.5. For gallium-67 labelling, 20 µg (13.3 
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nmol) of DOTA-PSMA(617) (ABX; molecular weight, 1,498.18) were added; for gallium-68 
labelling, 2 µg (1.3 nmol) of DOTA-PSMA(617) were added. The solution was heated to 95°C for 
30 minutes, and then labelling was assessed by iTLC and HPLC. Before being added to cells, the 
tracer was diluted to 50 nM total ligand concentration in PBS.  
[68/67Ga]Ga-HBED-CC-PSMA for in vitro studies: 50 µL of [67Ga]Ga3+ or [68Ga]Ga3+in 0.1 M HCl, 5 
µL of 1 M HCl, and 50 µL of 2.1 M HEPES were combined, producing a solution at pH 4.5. For 
gallium-67 labelling, 29 µg (20.6 nmol) of HBED-CC-PSMA (ABX; molecular weight, 1,403.09) 
were added; for gallium-68 labelling, 2 µg (1.4 nmol) of HBED-CC-PSMA were added. The 
solution was heated to 95°C for 10 minutes, and then labelling was assessed by iTLC and HPLC. 
Before being added to cells, the tracer was diluted to 50 nM total ligand concentration in PBS.  
[68Ga]Ga-HBED-CC-PSMA for in vivo studies: Gallium-68 eluate (200 µL, 35-50 MBq) was added 
to a pre-prepared solution of HBED-CC-PSMA (15 µL, 105 µM, 2.2 µg of HBED-CC-PSMA) and 
sodium bicarbonate (19 µL, 1 M) and heated at 90°C for 10 minutes (pH 3-4). A radiochemical 
yield of greater than 95% was achieved consistently.  
3.3.7 Preparation of Natural Gallium Chelated PSMA Complexes.  
[natGa]Ga-THP-PSMA: 124 µL of 0.93 mM THP-PSMA were added to 93 µL of 6.4 mg/mL 
[natGa]Ga(NO3)3.X(H2O) dissolved in 0.1 M HCl (a 20-fold excess of gallium over THP-PSMA). The 
pH was adjusted to 6.5–7.5 with 14 µL of 1 M sodium bicarbonate, and 231 µL of PBS was then 
added. The solution was sonicated for 15 minutes, producing a ﬁnal solution of 0.25 mM 
[natGa]Ga-THP-PSMA. This solution was diluted in PBS to produce the range of concentrations 
required for the inhibition assay (50% inhibition constant, IC50). This complex was characterised 
by LC-ESIMS as shown in table 3.2. 
[natGa]Ga-HBED-CC-PSMA: 124 µL of 0.93 mM HBED-CC-PSMA were added to 93 µL of 6.4 
mg/mL [natGa]Ga(NO3)3.X(H2O) dissolved in 0.1 M HCl (a 20-fold excess of gallium over HBED-CC-
PSMA). The pH was adjusted to 4 with 13 µL of 1 M sodium bicarbonate, and the solution was 
heated to 95°C for 10 minutes. The pH was adjusted to 6.5-7.5 with 1 M sodium bicarbonate 
followed by sonication for 15 minutes, producing a ﬁnal solution of 0.5 mM [natGa]Ga-HBED-CC-





3.3.8 Stability of [68Ga]Ga-THP-PSMA and [68Ga]Ga-DOTA-PSMA(617) in the 
presence of unchelated gallium 
[68Ga]Ga-THP-PSMA or [68Ga]Ga-DOTA-PSMA(617) (molar activity 30.81 and 4 MBq/nmol 
respectively) was added to a solution of [natGa]Ga(NO3)3.X(H2O) in PBS. Final radiotracer total 
ligand concentration was 1 nM, final concentration of [natGa]Ga(NO3)3.X(H2O) ranged from 0 
mg/mL to 0.5 mg/mL. Stability was monitored up to 2 hours by iTLC. 
3.3.9 Log D OCT/PBS measurement 
Each [67Ga]Ga-labelled radiotracer (50 µL, 10 µM; molar activity, 1.5 MBq/nmol) was added to a 
pre-equilibrated mixture of 500 µL of octanol (OCT) and 450 µL of PBS (pH 7.4). The mixture was 
mixed for 30 minutes with a shaker plate and the phases separated by centrifugation (10,000 
rpm, 10 minutes). Aliquots from each phase were analysed on a gamma counter. 
3.3.10 Serum Stability  
[68Ga]Ga-THP-PSMA was labelled at 5 MBq/nmol and 20 µL were added to 180 µL of human 
serum, giving a ﬁnal THP-PSMA concentration of 2.5 µM. Samples were incubated at 37°C and 
monitored over 6 hours by size-exclusion HPLC. [68Ga]Ga-THP-PSMA without serum and 
unchelated [68Ga]Ga3+ incubated with serum were analysed similarly. 
3.3.11 Cell Lines 
The GCP(II)/PSMA negative cell line chosen was DU145, a human carcinoma prostate cancer cell 
line derived from a brain metastatic site, which does not express GCP(II)/PSMA. The 
GCP(II)/PSMA-expressing cell line chosen was a genetically modified daughter cell line of DU145, 
DU145-PSMA. This cell line had previously been transduced to express full-length human 
GCP(II)/PSMA, following a published method (37). These cells were cultured in RPMI 1640 
medium supplemented with 10% foetal bovine serum, 2 mM L-glutamine, and 
penicillin/streptomycin. To prepare for experiments, cells were grown at 37°C in an incubator 
with humidiﬁed air equilibrated with 5% CO2. 
3.3.12 Flow Cytometry 
Expression of GCP(II)/PSMA in the DU145-PSMA cell line and the absence of this receptor in the 
DU145 cell line was assessed using flow cytometry. 1 × 106 cells were suspended in 100 µL PBS 
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containing 0.5% bovine serum albumin and then incubated with 10 µL of either Anti-PSMA-
VioBright-FITC antibody (MACS Milenyi Biotec CAT 130-106-612), REA-control-VioBright-FITC 
(MACS Milenyi Biotec CAT 130-113-455) or PBS, for 15 minutes on ice. After this time the cells 
were washed twice with PBS and then analysed on a FACS Calibur (FL1 channel, voltage 525). 
Gating and analysis were performed using Flowing Software (version 2.5.1, Turku Centre for 




3.3.13 Gamma Counting  
Radioactivity counting was performed with a gamma-counter (LKB Wallac; PerkinElmer) for log 
POCT/PBS measurement, cell studies and in vivo biodistribution. The emissions from gallium-67 and 
gallium-68 for each detection window of the LKB Wallac gamma-counter (PerkinElmer) were 
















FIGURE 3.2: Emissions from (top) gallium-68 and (bottom) gallium-67 across all energy windows detectable 
by the gamma-counter. The range of windows used to measure the presence of gallium-67 (101-117) in red and 




3.3.14 Cell Uptake and IC50 Assays 
Cell uptake: To determine the specificity of [68Ga]Ga-THP-PSMA for GCP(II)/PSMA-expressing 
cells, the cellular uptake was determined in GCP(II)/PSMA-expressing cells DU145-PSMA and 
non–GCP(II)/PSMA-expressing cells DU145 (37). The two cell lines were seeded in a 6 well plate 
(1 x 106 cells/well) 1 day before the assay. Prior to incubation, the medium was replaced with 
980 µL of fresh complete medium and then 20 µL of [68Ga]Ga-THP-PSMA was added 
(radiolabelling mixture diluted in PBS) to give a 1 nM total ligand concentration on cells. Plates 
were incubated at 37°C for 1 hour. Then the supernatant was removed and the cells were 
washed with 2 × 1 mL PBS to determine the unbound fraction, followed by an acid wash (0.5 M 
glycine, pH 2.5, at 4°C, 5 minutes) to determine cell surface-bound activity. Attached cells were 
lysed with 1 M NaOH to determine activity internalised by the cells. Fractions were then gamma-
counted. 
Cell uptake over time: To determine the cellular uptake of each tracer at 37°C and 4°C over time 
DU145-PSMA DU145 were seeded in a 24-well plate (0.25 × 106 cells/well), 1 day before the 
assay. Two minutes before incubation, the medium was replaced with 245 µL of fresh complete 
medium at 37°C or 4 °C, then 5 µL of one of the [67Ga]Ga-PSMA tracers (molar activity, 0.75–2.2 
MBq/nmol) were added, giving a ﬁnal total ligand concentration of 1 nM. Plates were incubated 
at 37°C or 4°C. At each time point, the supernatant was removed and cells were washed with 3 
× 250 µL of PBS to determine the unbound fraction, followed by an acid wash (0.5 M glycine, pH 
2.5, at 4°C, 5 minutes) to determine cell surface–bound activity. Cells were lysed with 1 M NaOH 
to determine activity internalised by the cells. Fractions were gamma-counted. 
IC50: To determine the IC50, competitive binding studies were performed with DU145-PSMA cells 
with 1 nM [68Ga]Ga-DOTA-PSMA(617) as the probe, blocked with [natGa]Ga-THP-PSMA or 
[natGa]Ga-HBED-CC-PSMA over a range of concentrations. Cells (0.25 × 106 per well) were seeded 
in a 24-well plate, 1 day before the assay. Before incubation, the medium was replaced with 240 
µL of fresh complete medium. Increasing concentrations of [natGa]Ga-THP-PSMA or [natGa]Ga-
HBED-CC-PSMA (5 µL) followed by 1 nM [68Ga]Ga-DOTA-PSMA(617) (5 µL, molar activity, 5–7.5 
MBq/nmol ligand, diluted in PBS) were added to the cells (total volume, 250 µL). After 30 
minutes incubation at 37°C, the cells were washed with PBS (3 × 250 µL), lysed with NaOH (1 M, 
250 µL), and the wells washed with PBS (250 µL). The activity present in supernatant and lysate 
was measured by gamma-counting. Data were analysed using GraphPad Prism (version 5.04, 
GraphPad Software) and a 1-site-ﬁt log IC50 algorithm.  
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3.3.15 Relative Affinity Measurements 
Due to the poor solubility of [natGa]Ga-THP-PSMA above 0.25 mM, an alternative measure of 
afﬁnity was developed, allowing the relative afﬁnity of 2 gallium PSMA tracers to be determined 
simultaneously without the need for the natural gallium complex, therefore mitigating any 
solubility difﬁculties. The assay was designed based on Clark’s theory of classical ligand-receptor 
interactions (41) and allowed the relative affinity of the 2 tracers to be determined. The 
assumptions and equations on which this assay was based on are detailed in section 3.8. In brief 
these equations show that in order to calculate the relative affinity (dissociation constant = Kd) 
of two tracers, they must be incubated at the same time with the same receptor and their 
specific binding determined once the uptake has reached equilibrium. The cell uptake over time 
assay described above was used to determine that equilibrium was reached after incubation at 
4°C for 2 hours (figure 3.17). The 2 isotopes of gallium, gallium-67 and gallium-68, with their 
different half-lives (3.2613 days and 67.83 minutes respectively (9)(42)) and different emission 
profiles make it possible for two radiotracers to be incubated at the same time with the same 
receptor and their individual emissions and therefore uptake to be determined. The tracers 
compared in this study were: [67/68Ga]Ga-DOTA-PSMA, [67/68Ga]Ga-HBED-CC-PSMA, and 
[67/68Ga]Ga-THP-PSMA. Each [67Ga]Ga-PSMA tracer was compared to each [68Ga]Ga-tracer (table 
3.1) and affinity ratios were obtained by measuring total and non-specific binding for each tracer 
(gamma counting) and calculating the ratio of their specific binding. 
The relative affinity measurements were carried out using the following methodology. DU145-
PSMA cells were seeded with 1.5 x 106 cells/well in a 6 well plate, one day before the assay. Two 
minutes prior to incubation with tracer, the cell medium was replaced by 1410 µL fresh complete 
medium at 4°C. 30 µL of [67Ga]Ga-PSMA tracer (50 nM, molar activity 0.75-2.2 MBq/nmol), and 
30 µL [68Ga]Ga-PSMA tracer (50 nM, molar activity 4-26 MBq/nmol, diluted in PBS) and 30 µL 
PBS were added, giving a total volume of 1.5 mL and final concentrations of 1 nM [67Ga]Ga-PSMA 
tracer and 1 nM [68Ga]Ga-PSMA tracer (total labelled and unlabelled PSMA conjugate 
concentration 2 nM). Additionally, non-specific uptake was determined by using non-
GCP(II)/PSMA-expressing cells (DU145) or by blocking GCP(II)/PSMA-expressing cells (DU145-
PSMA) with 750 µM PMPA (30 µL in place of the PBS added 2 minutes before the radiotracers). 
After 2 hours incubation at 4°C, the cells were washed with 3 × 250 µL 4°C PBS to determine the 
unbound fraction. They were then incubated with 0.5 M glycine pH 2.5 at 4°C for 5 minutes to 
determine the cell surface-bound fraction and then lysed with 1 M NaOH and the well washed 
with PBS to determine the fraction internalized by the cells. The activity from the [67Ga]Ga-PSMA 
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tracer and the [68Ga]Ga-PSMA tracer present in each fraction was measured by gamma counting 
(gallium-68 values were corrected for their gallium-67 component and gallium-67 was measured 
once the gallium-68 within the sample had decayed (> 10 half-lives) and all values were decay 
corrected). Specific binding was calculated by subtracting the non-specific binding (binding of 
the tracer to DU145 cells or to DU145-PSMA cells in the presence of PMPA) from the total 
binding percentage of activity associated with the DU145-PSMA cells when no blocking agent is 


















750 mM PMPA 












750 mM PMPA 
3  9 
[68Ga]Ga-THP-PSMA 
DU145-PSMA 
18 18  
[68Ga]Ga-THP-PSMA 
DU145 
9 9  
[68Ga]Ga-THP-PSMA 
DU145-PSMA + 
750 mM PMPA 
9 9  
 
TABLE 3.1: Number of wells incubated with each combination of tracers and blocking agents for the relative 
affinity measurements. 
3.3.16 Mouse Model of Prostate Cancer  
Animal studies complied with the guidelines on responsibility in the use of animals in bioscience 
research of the U.K. Research Councils and Medical Research Charities, under U.K. Home Ofﬁce 
project and personal licences. Subcutaneous prostate cancer xenografts were produced in 
SCID/beige mice (male, 5-12 weeks old) by injecting 4 × 106 DU145-PSMA or DU145 cells 
suspended in serum-free media the right ﬂank. Imaging was performed once a tumour had 
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reached 5-10 mm in diameter (1-4 weeks after injection). In order to provide a further control, 
one SCID beige mouse was injected with 4 × 106 DU145-PSMA into the right flank and an 
additional 4 × 106 DU145 cells into the left flank. Imaging was performed when the diameter of 
each tumour was 5 mm ensuring that the total tumour was below the 11 mm diameter project 
licence limit (3 weeks after inoculation). 
3.3.17 PET/CT scanning  
PET imaging was performed on mice under isoﬂurane anaesthesia with a BioScan nanoPET-CT 
PLUS (Mediso Medical Imaging Systems, Budapest, Hungary) 
Mice without prostate cancer xenografts: A SCID/beige male mouse without a prostate cancer 
xenograft, was anaesthetised, positioned on the scanner, and its tail vein cannulated. A CT scan 
was performed and then a PET scan was initiated as [68Ga]Ga-THP-PSMA (10.6 MBq, 114 µL, 0.5 
µg) was administered. This ensured that the first pass of the tracer was imaged. The PET scan 
was acquired for a total of 4 hours and was a terminal procedure. 
Mice with a single prostate cancer xenograft: PET/CT imaging was performed on 4 groups of 
mice (n = 3 each). Before radiotracer administration, CT was performed, the tracer was then 
injected through the cannulated tail vein and dynamic PET data was collected for the ﬁrst hour 
after injection. Mice were then euthanised by cervical dislocation and organs harvested, 
weighed, and gamma-counted. Mice bearing DU145-PSMA tumours were administered either 
[68Ga]Ga-THP-PSMA (5-15 MBq, 50-140 µL, 0.4-0.9 µg, group 1) or [68Ga]Ga-HBED-CC-PSMA (5-
15 MBq, 50-140 µL, 0.6-1.3 µg, group 2) by tail vein injection. A third group (group 3) was co-
administered [68Ga]Ga-THP-PSMA and the GCP(II)/PSMA-inhibitor, PMPA (50 µg) (43)(44) for 
blocking studies. Mice bearing DU145 tumours were administered [68Ga]Ga-THP-PSMA (group 
4). 
Mouse with two prostate cancer xenografts: A 1 hour PET scan was acquired after tail vein 
administration of [68Ga]Ga-THP-PSMA (104 µL, 8.7 MBq, 0.7 µg), a CT scan was then performed, 
and after completion, the mouse was culled by cervical dislocation. 
Imaging protocol: The PET/CT scans were obtained on a BioScan nanoPET-CT PLUS (Mediso 
Medical Imaging Systems, Budapest, Hungary) scanner using their proprietary acquisition 
software (Nucline, version 2.00). CT was performed with an X-ray tube voltage of 45 kVp, 600 
ms of exposure time, and 360° projections. This scan took 10 minutes to obtain. All dynamic PET 
scans were acquired within a 94.7 mm ﬁeld of view from 0 to 60 minutes after tail vein injection 
of the [68Ga]Ga-PSMA tracer, for the non-tumour bearing mouse that was imaged for 4 hours, 4 
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× 60 minute scans were performed. Acquisition took place in 1-5 coincidence mode with a 
coincidence window of 5 ns and a 400-600 keV energy window. The dynamic PET data were 
reconstructed using Nucline software (version 2.00). Data were allocated to both 20 and 2 
minute bins using 0.4 mm3 voxels for PET and 0.21 mm3 voxels for CT.  
Image processing: Image processing and analysis were performed using Vivoquant software 
(version 1.23). Before analysis, both CT and PET images were realigned and processed to a voxel 
size of 0.21 mm3 and the PET output calibrated to display MBq per voxel. Regions of interest 
(ROIs) for each data ﬁle were produced using 3 different techniques: ﬁxed-volume ROIs, Otsu 
thresholding, and freehand segmentation from the CT image. Fixed-volume ROIs were used for 
muscle (a 17.2 mm3 sphere within the thigh muscle) and blood pool (a 2.2 mm3 sphere in the 
left ventricle). These ROIs were positioned manually and drawn in triplicate within each organ. 
Otsu thresholding was used to determine the total activity deriving from the kidneys or the 
bladder. This method was not suitable for tumour uptake because of the close proximity of 
kidney signal. Total tumour volume was drawn manually from the CT image, deﬁned 3 times per 
animal, and the average value from these 3 ROIs determined. Percentage injected dose per cubic 
centimetre (%ID/cm3) values for each ROI were calculated using the activity and volume of the 
ROI and the injected dose (ID) as the total activity within the image, excluding activity within the 
tail. Time-activity curves were produced from the 2 minute bins, and total uptake was 
determined from the 20 minute binned data at the 40-60 minute time point. Static images were 
produced from dynamic data between 40 and 60 minutes and scaled between 0 and 25 %ID/cm3. 
The images of the mice without prostate cancer xenografts and the mouse with two prostate 
cancer xenografts were analysed in the same manner but the images were scaled between 0 
and 10 %ID/cm3. 
3.3.18 Biodistribution Studies  
Additional [68Ga]Ga-THP-PSMA biodistribution and blocking studies were performed in mice 
bearing DU145 or DU145-PSMA tumours without imaging or continuous anaesthesia. [68Ga]Ga-
THP-PSMA (3.5–12.7 MBq, 0.7–0.9 mg THP-PSMA) was administered via tail vein injection under 
isoﬂurane anaesthesia. After injection anaesthesia ceased and 1 hour after injection the animals 





3.3.19 Statistical Analysis  
Data were analysed in GraphPad Prism 5 (version 5.04 or version 7.04) and expressed as mean 
± standard deviation (SD). Student t tests were used to determine statistical significance; a P 




3.4.1 Synthesis of THP-PSMA  
Reaction Scheme 3.1 shows the route used to synthesise THP-PSMA. The resin-bound PSMA 
inhibitor (compound 7) was prepared by in situ formation of a bis(tert-butyl) glutamate 
isocyanate (compound 5) followed by coupling with resin-bound protected lysine (compound 
3). After deprotection and coupling with glutaric anhydride, the intermediate bearing a pendant 
carboxylate (compound 8) was activated with HATU and formed an amide bond with the free 
amine of a THP derivative (38). Cleavage from the solid support and glutamate deprotection 
using triﬂuoroacetic acid (TFA) formed THP-PSMA (figure 3.1 and reaction scheme 3.1). 
Puriﬁcation by semi-preparative HPLC afforded THP-PSMA as a TFA salt, yield 4 mg, 2.6 µmol, 
5.2% yield, (C54H77N11O19.(CF3COO)3) calculated molecular weight of TFA salt 1526.33, HPLC: Rt = 
13.4 minutes, greater than 98% purity. LC-ESIMS data are shown in figure 3.3, figure 3.4 and 
table 3.2. 1H NMR: (D2O, pH 3, 700 MHz): 1.37 (m, 2H), 1.50 (m, 2H), 1.7 (m, 1H), 1.78 (m, 2H), 
1.85 (m, 1H), 1.92 (t, J = 8.09, 6H), 1.96 (m, 1H), 2.14 (m, 1H), 2.18 (dd, J= 6.59, 4H), 2.22 (t, J = 
8.09, 6H), 2.35 (t, J =6.64, 2H), 2.49 (t, J = 7.49, 2H), 2.57 (s, 9H), 3.13 (t, J = 6.98, 2H), 3.36 (t, J = 
6.64, 2H), 3.91 (s, 9H), 4.15 (dd, J = 8.99, 5.59 1H), 4.23 (dd, J = 8.70, 4.97 1H), 4.67 (s, 9H), 7.00 
(s, 3H) 13C[1H] NMR: (D2O, pH 3, 175 MHz): 20.5, 21.9, 22.4, 26.5, 27.8, 29.3, 29.4, 30.1, 30.7, 
34.8, 35.5, 35.9, 36.1, 38.5, 39.0, 52.8, 113.6, 138.1, 143.2, 149.9, 159.4, 161.0, 173.2, 175.5, 
175.7, 176.2, 176.6, 177.4. Additional 1H, and 13C NMR data are shown in figure 3.5, table 3.3, 
table 3.4 and table 3.5. 
Ion Calculated monoisotopic peak 
(m/z values) 
Observed monoisotopic peak 
(m/z values) 
[C54H77N11O19 + 2H]+2 592.77714 592.77689 
[C54H77N11O19 + 3H]+3 395.52052 395.52027 
[C54H74N11O19Ga + H]+ 1250.44910 1250.45092 
[C54H74N11O19Ga + 2H]+2 625.72819 625.72846 
 








FIGURE 3.4: Mass spectrum of THP-PSMA (A) [C54H77N11O19 + 2H]+2 and (B) [C54H77N11O19 + 3H]+3 both obtained 




FIGURE 3.5: Structure of THP-PSMA with protons detectable in D2O labelled a- s (red) and additional carbon 

























m 2 4 1.36 2.23 m    
n 2 4 1.50 2.26 m l   
o2 1 4 1.70 1.10 m  n,m p 
j 2 4 1.78 2.53 m i+k i+k  
o1 1 4 1.85 0.75 m  n,m p 
f 6 2 1.93 6.53 t  e  
r2 1 4 1.96 0.94 m    
r1 1 4 2.14 1.04 m    
k+i 4 2 2.18 4.47 dd j j  
e 6 2 2.22 6.36 t  f  
g 2 2 2.35 2.23 t h h  
s 2 2 2.49 2.33 t r1, r2 r1, r2  
c 9 0 2.57 9.67 s    
l 2 2 3.13 2.16 t m m n 
h 2 2 3.36 2.12 t g g  
un-
known 
  3.71 1.60 s    




s    
p 1 2 4.14 1.01 dd o1, o2 o1, o2 n, m 
q 1 2 4.23 1.06 dd r1, r2 r1, r2 s 
d 6 0 4.67 2.62 s    
a 3 0 7.00 2.84 s    
 
TABLE 3.3: Assignment of 1H NMR (400 MHz, D2O) spectra, and summary of correlations detected in 2D 1H 
COSY and 2D 1H TOCSY spectra of THP-PSMA pH 3. Integration calibrated to the height of the peak 
corresponding to the 9 methyl hydrogens in position ‘b’. s = singlet, d = doublet, t = triplet, dd = doublet of 













1 3 177.40 2.91  
13 1 176.62 1.38  
5 3 176.15 3.13  
10 1 175.74 1.06  
12 1 175.45 0.91  
7 1 173.21 0.85  
8,9 2 161.02 2.87  





3 3 149.95 3.23  
2 2 143.17 2.85  
4 3 138.15 2.49  
a 3 113.61 5.91 A 




6 1 58.23 0.95  
p 1 53.54 1.34 p 
q 1 52.78 1.72 q 
l 1 39.02 1.67 l 
b 3 38.50 4.93 b 
g 1 36.07 1.26 g 
h 1 35.96 1.50 h 
d 3 35.53 4.90 d 
k + i 2 34.88 4.35 k + i 
o 1 30.72 1.79 o 
s 1 30.11 2.45 s 
e 3 29.43 4.32 e 
f 3 29.27 5.07 f 
m 1 27.78 2.12 m 
r 1 26.48 1.87 r1 + r2 
n 1 22.38 1.93 n 
j 1 21.91 1.85 j 
c 3 20.52 5.93 c 
 
TABLE 3.4: Assignment of signals within the 13C spectra of THP-PSMA (175 MHz, D2O) pH 3 and HSQC 









PPM Integration Splitting 
m 2 4 1.33 2.25 m 
n 2 4 1.48 2.08 m 
o2 1 4 1.61 1.07 m 
o1 1 4 1.71 0.97 m 
j 2 4 1.76 2.08 t 
r2 1 4 1.84 1.27 m 
f 6 2 1.94 5.70 t 
r1 1 4 1.99 1.34 m 
k+i 4 2 2.16 4.05 q 
e + g 6 2 2.22 8.05 t 
s 2 2 2.37 2.20 t 
c 9 0 2.39 8.73 s 
l 2 2 3.11 8.73 t 
h 2 2 3.37 3.12 t 
unknown   3.72 1.52 s 
b 9 0 3.66 9 
(calibrated to 9) 
s 
p+q 1 2 3.99 1.96 q 
d 6 0 4.54 3.73 s 
a 3 0 6.45 2.70 s 
 
TABLE 3.5: Assignment of 1H NMR spectra of THP-PSMA (400 MHz, D2O) pH 7. Integration calibrated to the 
height of the peak corresponding to the 9 methyl hydrogens in position b. 
3.4.2 [natGa]Ga-THP-PSMA NMR 
Varying gallium to ligand ratio: The change to the 1H spectrum of THP-PSMA upon adding 
gallium to form [natGa]Ga-THP-PSMA was studied using 3 different samples, all in D2O at pH 7 
(neutralised with sodium bicarbonate). Sample 1 contained THP-PSMA, sample 2 contained THP-
PSMA plus [natGa]Ga-THP-PSMA with THP-PSMA in excess and sample 3 contained [natGa]Ga-
THP-PSMA plus excess gallium. Changes in the 1H spectra were observed at both levels of 
gallium. In sample 2, the signal deriving from THP-PSMA remained stable, but a set of new peaks 
with lower intensity, corresponding to the signal from [natGa]Ga-THP-PSMA, were observed as 
shown in figure 3.6. In sample 3 when natGa was in excess, the peaks from THP-PSMA 
disappeared and the [natGa]Ga-THP-PSMA peaks increased in intensity (figure 3.6). Therefore 
there is only evidence of two species in solution, the free ligand and the complexed ligand. There 
was no change to the shape or shift of the [natGa]Ga-THP-PSMA signal with further addition of 
gallium, only the intensity increased, suggesting the structure of the [natGa]Ga-THP-PSMA 
complex formed does not change between the two concentrations, and it is assumed that this 








FIGURE 3.6: Change in 1H NMR spectrum as gallium is added to THP-PSMA. Sample 1, THP-PSMA; sample 2, 
THP-PSMA plus Ga-THP-PSMA with THP-PSMA in excess; sample 3, Ga-THP-PSMA excess Ga. (A) NMR spectrum 
between 6.3 and 6.7 ppm showing signal from Ha protons; (B) NMR spectrum between 4.2 and 4.75 ppm showing 
signal from Hd protons; (C) NMR spectrum between 1.2 and 3.8 ppm showing signal from Hb and Hc protons. 
As expected the signals from the THP portion of the molecule showed the most dramatic 
changes upon gallium binding (signals Ha–Hf), compared to signals from the urea-based inhibitor 
or the linker (Hg-Hs, see figure 3.5 for proton labelling scheme). In particular, the signal from the 
methyl groups on the pyridinone rings Hb and Hc (at 2.39 ppm and 3.66 ppm) were split into 3 
singlets, as shown in figure 3.6C. This suggests each ring was in a different environment after 
gallium binding and that the C3 symmetry that might have been expected intuitively (but 
superficially) was not present in the complex. Further confirmation of this comes from the 
singlet at 4.5 ppm (Hd) which arises from the CH2 of the 3 ligand arms, splits into 6 doublets in 
the region 4.0-5.2 ppm upon binding (5 doublets were observable at 25°C with 1 masked by the 
water suppression, but all 6 were revealed at 5°C, figure 3.7). These all have similar J values 
(14.7-16.1 Hz) typical of 2JH-H geminal coupling constants for -N-CH2-C= groups (45). This shows 
each proton in the three Hd CH2 groups are in a distinct environment, again suggesting the three 
arms of THP are not equivalent upon binding gallium. The aromatic proton on each pyridinone 
ring (Ha), which gave rise to a singlet at 6.45 ppm in the THP-PSMA spectrum, was also split into 
a number of smaller peaks in the region 6.5-6.7 ppm, upon binding gallium as shown in figure 
3.6A. There are 3 strong peaks and then 3 smaller more poorly defined peaks within this region. 
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These protons are in very close proximity (4 bonds) to the bound gallium, which is likely the 
cause of this more complicated splitting pattern. 
Stability over time: The only change in spectrum after storing sample C (excess gallium) at 4°C 
for 3 weeks was a new singlet that developed at 3.36 ppm, believed to be an impurity. No change 
in assigned peaks was observed. This suggests an equilibrium state was reached rapidly upon 
binding natGa and maintained over time. 
Variable temperature study: 1H NMR analysis was performed at 4 different temperatures on 
[natGa]Ga-THP-PSMA (sample 3, gallium in excess) and the spectra compared see figure 3.7. The 
variable temperature NMR spectra show that the relative intensity of peaks did not change with 
temperature suggesting the same species are present at all temperatures and that the system 
was at equilibrium, in agreement with the stability studies. Some spectral changes were 
observed upon varying the temperature; lower temperatures (5°C) caused peaks to sharpen and 
there was an increased detection of fine splitting. As the temperature increased, broadening 






FIGURE 3.7: NMR spectra of [natGa]Ga-THP-PSMA (sample 3, [natGa]Ga-THP-PSMA excess gallium) when bore 
temperature was set to 5°C, 25°C, 50°C and 70°C. (A) NMR spectrum between 6.3 and 6.7 ppm showing signal 
from He protons; (B) NMR spectrum between 4.1 and 5.2 ppm showing signal from Hd protons; (C) NMR 
spectrum between 1.2 and 3.8 ppm showing signal from Hb and Hc protons of the chelator as well as signal from 
the rest of the linker and GCP(II)/PSMA targeting motif. 
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3.4.3 Radiolabelling  
[68Ga]Ga-THP-PSMA initial optimisation: The THP chelator enabled radiolabelling with 
unmodiﬁed generator eluate, in a single step. [68Ga]Ga3+ (5-75 MBq) in aqueous HCl (0.1 M, 250 
µL) was added to pre-prepared THP-PSMA (5-0.01 µg in 3 µL of H2O) in sodium bicarbonate 
solution (1 M, 27 µL). After 5 minutes, pH was 6.5-7.5. Radiochemical purity (RCP), determined 
by HPLC and iTLC, as a function of THP-PSMA concentration is shown in figure 3.8. Molar 
activities between 15 and 45 MBq/nmol were consistently achieved with the labelling conditions 
used for in vivo work (2 µg, 1.3 nmol THP-PSMA, 250 µL 20–60 MBq of gallium-68 eluate, 95% 
radiochemical purity). 
 
FIGURE 3.8: Dependence of radiochemical purity of [68Ga]Ga-THP-PSMA on the mass of THP-PSMA in 280 μL, 
as measured by HPLC (red) and iTLC (black) after 5 minutes; n = 3, mean ± SD. 
One-step kit for radiolabelling: When kit vials containing lyophilised THP-PSMA (40 µg, 26 
nmol), sodium bicarbonate (44 mg), and sodium phosphate buffer (17.5 mg) were used (kit A), 
radiosynthesis of [68Ga]Ga-THP-PSMA was achieved in one-step by direct addition of 5 mL of 
generator eluate (0.1 M HCl, 122-202 MBq from the Galliapharm (Eckert and Ziegler) generator, 
or 600-660 MBq from the Galli EO (IRE ELiT) generator). After 5 minutes, the pH was 6–7 and iTLC 
conﬁrmed radiochemical purity above 95% with molar activities of up to 22 MBq/nmol using the 


















radioactive species (figure 3.10). ITLC analysis up to 3 hours after reconstitution showed no 
instability or autoradiolysis (figure 3.11). 


















FIGURE 3.9: Radio-iTLC of [68Ga]Ga-THP-PSMA labelled using one-step kit, analysed 5 minutes after 
reconstitution (Rf unchelated [68Ga]Ga3+ = 0, Rf [68Ga]Ga-THP-PSMA = 0.8–1). 
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FIGURE 3.10: HPLC (λ = 220 nm) of THP-PSMA (blue, Rt = 13.38 minutes) and [natGa]Ga-THP-PSMA (black, Rt = 
10.92 min, excess [natGa]Ga(NO3)3.X(H2O) was present with Rt = 1.47 minutes), and radio-HPLC of [68Ga]Ga-THP-
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FIGURE 3.11: Radiochemical purity as measured by iTLC of [68Ga]Ga-THP-PSMA labelled with 5 mL one-step 
kits as a function of incubation time at room temperature, with both the Galli EO (IRE ELiT) generator and 
Galliapharm (Eckert and Ziegler) generator. The broken red line represents quality control threshold of 95% (n 
= 3, mean ± SD). 
One-step kit radiolabelling with pharmaceutical grade germanium-68/gallium-68 generator: 
The radiolabelling of a 40 µg THP-PSMA kit (kit B) produced to radiopharmaceutical standards 
by ROTOP Pharmaka GmbH was performed in one-step using the eluate from a pharmaceutical 
grade Galliapharm (Eckert and Ziegler) generator. The full elution volume from the generator 
was added directly to the kit (5 mL, 0.1M HCl, 1156 MBq) and after 10 minutes the pH was 6. 
The radiochemical purity of [68Ga]Ga-THP-PSMA was confirmed above 97% with iTLC and a molar 
activity of 43 MBq/nmol was achieved. 
3.4.4 Radiochemical Stability in the Presence of Excess Gallium 
The stability in the presence of unchelated gallium was monitored for [68Ga]Ga-THP-PSMA and 
[68Ga]Ga-DOTA-PSMA(617) up to 2 hours. The presence of excess gallium had no effect on the 
radiochemical purity of [68Ga]Ga-DOTA-PSMA(617) (>99% RCP maintained for all concentrations 
tested) but [68Ga]Ga-THP-PSMA showed a drop to 76 ± 3.5% over 2 hours at 0.5 mg/mL 
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FIGURE 3.12: Effect of [natGa]Ga(NO3)3.X(H2O) concentration on the stability of (top) [68Ga]Ga-THP-PSMA and 
(bottom) [68Ga]Ga-DOTA-PSMA(617) over time. Black = 0 mg/mL, blue = 0.005 mg/mL, red = 0.5 mg/mL. (n = 3 
for each time point) 
3.4.5 Lipophilicity and Serum Stability  
The log DOCT/PBS values of the 3 [68Ga]Ga-PSMA complexes at pH 7.4 were similar: -5.35 ± 0.1 for 
[67Ga]Ga-THP-PSMA (n = 6), -5.40 ± 0.2 for [67Ga]Ga-HBED-CC-PSMA (n = 6), and -5.40 ± 0.1 for 
[67Ga]Ga-DOTA-PSMA(617) (n = 5), indicating that all tracers are hydrophilic and lipophilicity is 
unlikely to underlie differences in in vivo performance (figure 3.13). In serum, [68Ga]Ga-THP-
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FIGURE 3.13: Octanol:PBS log D values at pH 7.4 for [67Ga]Ga-THP-PSMA (black), [67Ga]Ga-HBED-CC-PSMA 
(grey) [67Ga]Ga-DOTA-PSMA(617) (hatched) [67Ga]Ga3+ (white). 
 
FIGURE 3.14: Size exclusion HPLC radiochromatograms of (A) [68Ga]Ga-THP-PSMA; (B) [68Ga]Ga-THP-PSMA 
after 6 hours incubation in human serum at 37°C; showing < 2% transchelation to serums; protein (C) [68Ga]Ga3+ 




FIGURE 3.15: Flow cytometry results for DU145 and DU145-PSMA cells without staining (top), after staining 
with recombinant engineered antibody (REA) conjugated to FITC as a control (middle) and after staining with 
Anti-PSMA-FITC (bottom). These results confirm that DU145 cells do not express GCP(II)/PSMA and that > 97% 




3.4.6 Flow Cytometry 
Incubation of DU145 and DU145-PSMA cells with Anti-PSMA-VioBright-FITC followed by analysis 
by flow cytometry showed no expression of GCP(II)/PSMA in DU145 cells and that over 97% of 
the population of DU145-PSMA cells expressed GCP(II)/PSMA (figure 3.15). 
3.4.7 In Vitro Cell Uptake and Binding Afﬁnity Assays  
The percentage uptake of [68Ga]Ga-THP-PSMA in GCP(II)/PSMA-expressing DU145-PSMA cells 
and non GCP(II)/PSMA-expressing DU145 cells after 1 hour at 37°C is shown in figure 3.16. These 
results confirm the uptake of [68Ga]Ga-THP-PSMA was GCP(II)/PSMA-mediated, and that this 
tracer has low non-specific uptake. They also demonstrate the tracer was not only bound to the 
surface of GCP(II)/PSMA-expressing cells but was also internalised. Uptake of [67Ga]Ga-DOTA-
PSMA(617), [67Ga]Ga-HBED-CC-PSMA, and [67Ga]Ga-THP-PSMA in DU145-PSMA and DU145 cells 
at 37°C and 4°C is shown in figure 3.17. All 3 tracers showed time-dependent accumulation in 
GCP(II)/PSMA-expressing cells, but low uptake in non GCP(II)/PSMA-expressing cells. At 37°C, 
uptake continued to increase with time, preventing measurement of equilibrium binding 
parameters such as the dissociation constant (Kd), but at 4°C, a plateau was reached for all 
tracers after approximately 2 hours. Relative afﬁnity was therefore measured after 2 hours at 
4°C. Results showed that the Kd of [67/68Ga]Ga-THP-PSMA was 10.4 ± 3.4 times higher than that 
of [67/68Ga]Ga-HBED-CC-PSMA and 8.6 ± 3.4 times higher than that of [67/68Ga]Ga-DOTA-
PSMA(617) (figure 3.18). This is in agreement with directly measured IC50 values of [natGa]Ga-
THP-PSMA (361 ± 60 nM) and [natGa]Ga-HBED-CC-PSMA (34.3 ± 4.1 nM) (figure 3.19) and 
validates this newly developed “relative affinity” method. 
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FIGURE 3.16: Percentage uptake of 1 nM [68Ga]Ga-THP-PSMA in DU145-PSMA and DU145 cells at 1×106 
cells/mL after 1 hour incubation at 37°C. Surface-bound activity (white) and internalised activity (grey) are 
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FIGURE 3.17: Uptake of 1 nM [67Ga]Ga-HBED-CC-PSMA (top), [67Ga]Ga-DOTA-PSMA(617) (middle) and 
[67Ga]Ga-THP-PSMA (bottom) over time at 4°C (right) and 37°C (left), 1×106 cells/mL. Combined internalised 
and cell surface-bound activity of DU145-PSMA cells (blue); internalised activity of DU145-PSMA cells (black); 
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FIGURE 3.18: Ratio of Kd of 2 tracers incubated at 1 nM with DU145-PSMA cells at 4°C for 2 hours. Ratios were 
calculated from speciﬁc binding obtained by incubating the gallium-67 labelled tracer in the same well as its 
gallium-68 labelled comparator, and vice versa. Total number of wells was n = 34 for comparison of [67/68Ga]Ga-
THP-PSMA with [67/68Ga]Ga-HBED-CCPSMA or [67/68Ga]Ga-DOTA-PSMA(617) and n = 18 for comparison of 
[67/68Ga]Ga-HBED-CC-PSMA with [67/68Ga]Ga-DOTA-PSMA(617); mean ± SD. 
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FIGURE 3.19: Representative IC50 experiments for (top) [natGa]Ga-THP-PSMA and (bottom) [natGa]Ga-HBED-CC-
PSMA with 1 nM [68Ga]Ga-DOTA-PSMA(617) as the probe (n = 4 for each concentration). IC50 values in the main 
text are the mean of at least 3 experiments.   
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3.4.8 PET Imaging and Biodistribution  
PET/CT scanning of [68Ga]Ga-THP-PSMA in a non-tumour bearing SCID/beige mouse for 4 hours, 
(figure 3.20) showed that excretion of [68Ga]Ga-THP-PSMA was rapid and exclusively renal, with 
very low spleen and liver uptake. This confirms the stability of [68Ga]Ga-THP-PSMA in vivo, as 
unchelated gallium-68 is known to be distributed throughout the body with uptake in the bone, 
liver, spleen, kidneys and intestine (13)(16). 
 
FIGURE 3.20: PET/CT images of SCID mouse without a prostate cancer xenograft administered with [68Ga]Ga-
THP-PSMA with PET images scaled from 0-10 %ID/cm3: (A) 0-1 hours; (B) 1-2 hours; (C) 2-3 hours; (D) 3-4 
hours. 
In SCID/beige mice bearing GCP(II)/PSMA-positive xenografts (DU145-PSMA, group 1) PET/CT 
showed that most of the activity was associated with bladder and kidneys by 60 minutes figure 
3.21 and figure 3.22. Blood clearance, represented by the blood pool in the left ventricle, was 
rapid, decreasing to 1 %ID/cm3 within 30 minutes (figure 3.23). With images scaled between 0 
and 25 %ID/cm3, tumours were clearly delineated (figure 3.21). Analysis of the 40 to 60 minute 
post-injection images gave a tumour uptake value of 5.6 ± 1.2 %ID/cm3 (figure 3.24). Speciﬁcity 
was conﬁrmed both by mice bearing a GCP(II)/PSMA-negative but otherwise similar tumour 
(DU145, group 4) with uptake of 1.5 ± 1.2 %ID/cm3 (P < 0.05 compared with group 1), and by 
blocking experiments in mice bearing a DU145-PSMA tumour where PMPA was co-administered 
with [68Ga]Ga-THP-PSMA (group 3), giving a tumour uptake of 1.0 ± 0.4 %ID/cm3 (P <0.05 
compared with group 1). A further control was performed by imaging a mouse bearing one 
DU145 and one DU145-PSMA tumour with [68Ga]Ga-THP-PSMA. This showed significant 
differences between tracer uptake in these two tumours (1.6 %ID/cm3 compared to 0.2 




FIGURE 3.21: Representative PET/CT images of mice bearing xenografts at 40–60 minutes after injection with 
PET images scaled from 0–25 %ID/cm3. White arrows indicate the location of tumour. (A) [68Ga]Ga-THP-PSMA 
in DU145-PSMA tumour (group 1). (B) [68Ga]Ga-THP-PSMA in DU145 tumour (group 4). (C) [68Ga]Ga-THP-PSMA 
in DU145-PSMA tumour blocked with PMPA (group 3). (D) [68Ga]Ga-HBED-CC-PSMA in DU145-PSMA tumour 
(group 2). 
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FIGURE 3.22: Time-activity curves of SCID/beige mice bearing DU145-PSMA tumours, derived from PET 
imaging data from mice imaged with [68Ga]Ga-THP-PSMA or [68Ga]Ga-HBED-CC-PSMA during the first hour 
post-injection. Plotted data are the mean and standard deviation of three mice calculated from the total %ID in 
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FIGURE 3.23: PET-derived time activity curves of tumour, muscle and blood pool of SCID/beige mice bearing 
DU145-PSMA tumours, imaged with (top) [68Ga]Ga -THP-PSMA or (bottom) [68Ga]Ga -HBED-CC-PSMA for 1 hour 




FIGURE 3.24: PET/CT-derived %ID/cm3 in tumour and tumour-to-blood and tumour-to-muscle ratio 40–60 
minutes after injection. [68Ga]Ga-THP-PSMA in DU145-PSMA tumour, (group 1, black), [68Ga]Ga-THP-PSMA in 
DU145-PSMA, [68Ga]Ga-THP-PSMA in DU145 tumour, (group 4, grey), tumour blocked with PMPA, (group 3, 




FIGURE 3.25: CT and PET/CT images of SCID mouse with two prostate cancer tumours imaged with [68Ga]Ga-
THP-PSMA: One xenograft of DU145 cells (left flank) and another of DU145-PSMA cells (right flank). PET images 
were acquired 40-60 minutes post-injection and scaled from 0-10 %ID/cm3. Both maximum intensity 
projections (1) and axial slices (2) slices are shown. (A) CT image showing ROIs of the DU145-tumour (red) and 
the DU145-PSMA tumour (green) (B) PET/CT image showing ROIs of the DU145-tumour (red) and the DU145-
PSMA tumour (green) (C) PET/CT image showing difference in uptake between the GCP(II)/PSMA-expressing 




For comparison with an established PET tracer, mice bearing DU145-PSMA tumours were 
imaged with [68Ga]Ga-HBED-CC-PSMA (group 2) (25)(27)(35). Time-activity curves for [68Ga]Ga-
HBED-CCPSMA (group 2) and [68Ga]Ga-THP-PSMA (group 1) showed similar blood clearance, 
tumour uptake, and renal excretion (figure 3.21, figure 3.22 and figure 3.23). Image analysis of 
40-60 minutes PET images revealed that tumour uptake of [68Ga]Ga-THP-PSMA (5.3 ± 0.1 
%ID/cm3) was not signiﬁcantly different from that of [68Ga]Ga-HBED-CC-PSMA (5.6 ± 1.2 
%ID/cm3). Ex vivo biodistribution data, summarised in figure 3.26 and table 3.6, were consistent 
with PET image analysis, conﬁrming renal excretion and excellent speciﬁcity of [68Ga]Ga-THP-
PSMA for GCP(II)/PSMA-expressing tumours. [68Ga]Ga-THP-PSMA showed ex vivo 
biodistribution similar to [68Ga]Ga-HBED-CC-PSMA, apart from markedly lower spleen uptake 
(3.7 ± 1.3 and 17.6 ± 6.1 %ID/g respectively) (table 3.6). Importantly, anaesthesia appeared to 
severely affect tracer uptake in the kidney and excretion to the bladder, with large variation in 


















FIGURE 3.26: Ex vivo biodistribution of [68Ga]Ga-THP-PSMA in mice with DU145-PSMA (white) or DU145 
tumour (grey), culled 1 hour after injection (n = 3, mean ± SD). Unlike PET-imaged animals, these were not 































  (n=3) (n=3) (n=3)  (n=3) 
Tumour  16.4 ± 7.4 0.69 ± 0.7 1.40 ± 0.2  19.5 ± 7.6 
Blood 
 
0.73 ± 0.4 1.23 ± 1.7 1.11 ± 0.7 
 
2.18 ± 1.2 
Intestines  0.35 ± 0.1 0.64 ± 0.6 0.71 ± 0.3  1.20 ± 0.5 
Kidney 
 
40.4 ± 34 52.3 ± 77 5.20 ± 5.0 
 
63.4 ± 23 
Liver  0.45 ± 0.2 0.59 ± 0.7 0.60 ± 0.2  0.69 ± 0.1 
Lungs 
 
0.50 ± 0.2 0.94 ± 1.3 0.72 ± 0.3 
 
1.29 ± 0.4 
Muscle  0.51 ± 0.4 0.31 ± 0.4 0.21 ± 0.1  0.26 ± 0.1 
Salivary glands 
 
0.28 ± 0.1 0.48 ± 0.7 0.33 ± 0.2 
 
0.76 ± 0.1 
Spleen  3.70 ± 1.3 3.61 ± 3.1 0.75 ± 0.1  17.6 ± 6.1 
Tumour to organ 
ratios      
 
Tumour to blood  30.8 ± 28 0.93 ± 0.4 1.64 ± 0.9  11.0  ± 6.0 
Tumour to muscle 
 
44.6  ± 28 3.16 ± 1.1 9.79 ± 6.8 
 
77.0  ± 34 
Tumour to spleen  4.38  ± 0.8 0.17 ± 0.1 1.87 ± 0.3  1.16 ± 0.42 
 
TABLE 3.6: Ex vivo biodistribution at 1 hour post-injection for PET-imaged mice. Mice bearing DU145-PSMA 
tumours were injected with [68Ga]Ga-THP-PSMA, [68Ga]Ga-THP-PSMA plus the blocking agent PMPA, or 





The aim of this study was to develop a gallium-68 radiotracer that targets GCP(II)/PSMA with 
radiolabelling procedures suitable for development into a single-step kit-formulated 
radiopharmaceutical, which required only the addition of unprocessed, unfractionated 
generator eluate to a single vial. The latter requirement was met by incorporating the THP 
chelator. A THP-PSMA conjugate has been synthesised and characterised and could be 
quantitatively radiolabelled with gallium-68 (and gallium-67). Radiolabelling yields of greater 
than 95% and molar activity of 15–45 MBq/nmol with unprocessed generator-produced gallium-
68 were achieved in one-step at pH 7 and room temperature within 5 minutes without further 
puriﬁcation. On the basis of this, a lyophilised kit was developed, which could be 
labelled/reconstituted simply by adding 5 mL of raw generator eluate. One-step kits can only be 
used with generators with less than 0.001% germanium-68 breakthrough, the limit for human 
injection as set within the European pharmacopoeia (12). Of such generators, the Galliapharm 
(Eckert and Ziegler) is the only one with marketing authorisation across Europe (11), and it 
incidentally has the largest elution volume (5 mL, 0.1 M HCl) and so the kit was designed to be 
compatible with this generator. Kits made in-house were proven to consistently produce 
[68Ga]Ga-THP-PSMA with radiochemical purity over 95% within 5 minutes, using both the 
Galliapharm (Eckert and Ziegler) and the Galli EO (IRE ELiT) generators, and the radiolabelled 
product was shown to be stable for 3 hours. Pharmaceutical grade kits were then produced by 
ROTOP Pharmaka GmbH which allowed them to be assessed within a radiopharmacy, with an 
entire (5 mL) elution from a pharmaceutical grade Galliapharm (Eckert and Ziegler) generator. 
In these conditions [68Ga]Ga-THP-PSMA was produced within 10 minutes with a radiochemical 
purity of 97% and molar activity of 43 MBq/nmol. These radiolabelling properties demonstrate 
that kit-based radiolabelling of gallium-68 tracers is entirely feasible with an appropriate 
chelator. Additionally, the kit was designed exclusively with excipients approved for human use 
and after labelling the solution was at near neutral pH and suitable osmolality for direct 
administration to patients. 
As well as rapid and simple radiolabelling, the coordination properties of THP endow its 
conjugates with other properties well suited to radiopharmaceutical application. It is highly 
selective for tripositive metal ions with an ionic radius similar to that of iron(III) and gallium(III) 
(19), potentially reducing the need to remove contaminating metal ions in raw generator eluate 
through purification steps. Unlike HBED-CC, the tripodal design of THP restricts the number of 
geometric isomers that form on Ga3+ coordination and on reversed-phase HPLC, [68Ga]Ga-THP-
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PSMA elutes as a single radioactive species (figure 3.10), shown by LC-MS to be a 1:1 complex 
with gallium (table 3.2). Initial NMR experiments also provide evidence of the formation of a 
single complex. However, it also suggests that upon binding gallium each arm of THP was in a 
different environment. This could be explained by hydrogen bonding between two adjacent 
arms of THP, which could occur between the C=O of one and the NH of the second, as shown in 
figure 3.27 and figure 3.28 and would make each arm inequivalent as the first would be a H-
bond donor, the second a H-bond acceptor and the third neither. If this hydrogen bond was 
present it may also provide an energy barrier for interconversion of the delta and lambda 
isomers. However, such isomerism is subject to equilibration that is rapid compared with the 
timescale of HPLC and in vivo processes, and is therefore unlikely to be biologically relevant. 
 
FIGURE 3.27: Structure showing possible hydrogen bonding interaction that could cause non-equivalence in 
the 3 ligand arms. 
 
FIGURE 3.28: Schematic showing how the presence of a hydrogen bond between 2 arms of THP could cause 
non-equivalence in the 3 ligand arms and give rise to 2 distinct left- and right-handed species. 
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The lipophilicity of [68Ga]Ga-THP-PSMA is low (log Doct/PBS = -5.35 ± 0.1) and comparable to that 
of established [68Ga]Ga-PSMA ligands. In vitro experiments demonstrate that [68Ga]Ga-THP-
PSMA binds speciﬁcally to GCP(II)/PSMA, although with approximately 10-fold weaker afﬁnity 
than [68Ga]Ga-HBED-CC-PSMA and [68Ga]Ga-DOTA-PSMA(617). The method developed to assess 
relative affinity for GCP(II)/PSMA allowed the radioactive versions of 2 gallium-tracers to be 
evaluated at low concentration (1 nM) without excess gallium, avoiding issues with solubility 
and the values obtained agreed with established IC50 methods. The relative affinity method is 
also a valuable new tool for screening gallium-68 ligands as it requires much less ligand than IC50 
measurements and can be performed quickly at a single ligand concentration. However, there 
may be an advantage in performing this method with an isolated NAALADase-based assay, as is 
typically used for measuring Ki values (25)(34)(46), rather than a cell-based assay, as this would 
avoid the complications caused by internalisation and retention of tracers within the cells. 
Although THP-PSMA was rationally designed on the basis of previous literature (25)(44)(47)(48), 
no optimisation was carried out on the speciﬁc target afﬁnity of THP-PSMA bioconjugates and 
so there remains an opportunity to develop higher affinity bioconjugates incorporating THP. This 
topic is explored fully in chapters 6 and 7. However, the simplicity of radiolabelling, excellent 
serum stability, and in vitro GCP(II)/PSMA binding justiﬁed further evaluation of the new tracer 
in vivo. Assessment in SCID/beige mice bearing prostate cancer xenografts showed that 
incorporation of THP into bio-conjugates confers no THP-speciﬁc adverse pharmacokinetics. The 
rapid renal excretion, low non-speciﬁc uptake of [68Ga]Ga-THP-PSMA in non-target tissues, and 
high radioactivity concentration in GCP(II)/PSMA-expressing tumours are clinically desirable 
features. In the preclinical model used here, tumour uptake and pharmacokinetic properties of 
[68Ga]Ga-THP-PSMA and [68Ga]Ga-HBED-CC-PSMA are indistinguishable except that spleen 
uptake of [68Ga]Ga-THP-PSMA was lower, by almost a factor of 5. Although GCP(II)/PSMA-
targeting radiopharmaceuticals generally appear to share high uptake in spleen in mice, murine 
spleen is not believed to express GCP(II)/PSMA (49). It seems likely therefore that some other 
target capable of binding the PSMA tracers is present in the spleen and that [68Ga]Ga-THP-PSMA 





Use of THP as the gallium-68 chelator facilitates rapid chelation under mild conditions and 
produces a GCP(II)/PSMA-targeted bioconjugate that can be labelled in one-step by 
reconstitution of a kit with unprocessed generator eluate. This is the first time that a one-step 
kit has been demonstrated for a [68Ga]Ga-bioconjugate. Labelling requires only a generator, a 
lyophilised kit, a syringe, quality control facilities, and PET shielding. Kit-based labelling can be 
performed in a few minutes, using the full volume of unprocessed generator eluate (5 mL), 
without post synthesis puriﬁcation and achieve a greater than 95% radiochemical purity. In vivo, 
[68Ga]Ga-THP-PSMA accumulates in GCP(II)/PSMA-expressing tumours, with good tumour-to-
background ratio and delineation of GCP(II)/PSMA-positive tumour lesions similar to [68Ga]Ga-
HBED-CC-PSMA. One-step kit-based radiolabelling of gallium-68 radiopharmaceuticals has been 
shown to be feasible with THP and would facilitate wider and more economical use of gallium-
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3.8 Theory to Support the Assay Design for Relative Affinity Measurements  
According to Clark’s theory (41) classical ligand-receptor interactions can be studied in systems 
where the following assumptions hold: 1) All the receptor molecules are equivalent and 
independent; 2) The response measured is proportional to the number of occupied receptor 
sites; 3) The interaction between ligand and receptor is reversible; 4) The ligand does not 
degrade or react during the experiment, and only exists as the free ligand or bound to the 
receptor; 5) The number of occupied ligand sites is determined at equilibrium. 
A method that satisfies these requirements has therefore been proposed. In this experiment the 
ligand will be the [67/68Ga]Ga-PSMA radiotracer ([67/68Ga]Ga-DOTA-PSMA(617), [67/68Ga]Ga-
HBED-CC-PSMA, or [67/68Ga]Ga-THP-PSMA) and the receptor will be GCP(II)/PSMA expressed on 
the surface of DU145-PSMA cells, all of these receptors should be identical as this cell line was 
genetically engineered to express this receptor (37). This satisfies assumption 1. The use of a 
radioactive tracer to measure the number of occupied sites is a well-established, direct and 
accurate method, in line with assumption 2. The interaction between the urea-based motif, used 
in all these tracers to target GCP(II)/PSMA, and the receptor is known to be reversible satisfying 
assumption 3, as the interaction does not involve the creation of covalent bonds between the 
substrate and the protein or the cleavage of the substrate: it is purely an inhibitor. Additionally, 
efflux from the protein/cells is seen when the concentration of tracer in the medium is reduced, 
further confirming the interaction is reversible. These tracers have been shown to be stable 
within the conditions proposed and in order to ensure any off-site reactions/interactions are 
taken into account, the experimental procedure proposed has 2 different controls for unspecific 
binding (blocking GCP(II)/PSMA sites with the known inhibitor PMPA, and the use of non 
GCP(II)/PSMA-expressing cells DU145). This should satisfy assumption 4. Importantly, 
assumption 5 states that the measurements must also be performed at equilibrium for the 
models to hold. In line with previously published studies, in this experiment it is assumed that 
an equilibrium state is reached once the uptake of tracer over time plateaus (41). Graphs 
displaying uptake over time for the three [67Ga]Ga-PSMA tracers show that a plateau is not 
reached within 4 hours at 37°C, but at 4°C, a temperature where internalisation of the tracer 
would be dampened (26)(50), the plateau is reached by 2 hours (figure 3.17). With all these 
constraints satisfied we can use the classical ligand-receptor interactions to determine relative 




Classical ligand-receptor interactions can be shown as: 
 
At equilibrium, the dissociation constant Kd can be defined as: 
 
If two different tracers are considered; tracer 1 and tracer 2, their individual dissociation 
constants (Kd) can be defined as: 
   
Which can be rearranged as: 
   
If these two tracers are incubated in the same experiment with the same receptor, then the 
total number of receptors, and the number of free receptors is controlled and becomes 








Therefore the relative affinity is equivalent to the ratio of the two tracers’ dissociation constants 
and this can be calculated from: 
 
This requires the specific binding of the two tracers to be determined, which can be calculated 
as shown below.  
 
 
From these equations, we have determined that in order to calculate the relative affinity (Kd) of 
two tracers, they must be incubated at the same time with the same receptor (and so in this 
experiment in the same well, containing DU145-PSMA cells) and their specific binding 
determined. This was achieved by utilising the 2 isotopes of gallium, gallium-67 and gallium-68, 
which have different half-lives (3.26 days (42) and 68 minutes (9) respectively) and different 
emission profiles as shown in figure 3.2. The [67Ga]Ga-PSMA tracer and the [68Ga]Ga-PSMA 
tracer were incubated in the same well, and then the cells were washed, lysed and prepared for 
gamma-counting. The gamma-emissions from the gallium-68 tracer were measured directly 
after the experiment using a pre-selected emission window and then the samples were left to 
decay for at least 12 hours (ten half-lives) to ensure only gallium-67 remained in the sample. The 
samples were then gamma-counted for with the optimal window for gallium-67, which was used 
to determine the uptake of the gallium-67 tracer. Then the sample was counted with the window 
as used for gallium-68 so that the contribution of the gallium-67 present in the sample to the 
values measured for gallium-68 could be determined and decay corrected. These were then 
subtracted from the [68Ga]Ga-PSMA uptake values obtained directly after the experiment 
providing the true [68Ga]Ga-PSMA uptake values. Each gallium-67 tracer was compared with 
176 
 
each gallium-68 tracer in the same well in order to compensate for any differences caused by 
the labelling procedures with the 2 gallium isotopes. 
The tracer concentration chosen was 1 nM with 1 million cells per mL as this was below the IC50 
of all three tracers (figure 3.19). This ensured that there was a large excess of receptors and the 
non-radioactive constituent of the tracer was at a low enough concentration not to block uptake 
of the radioactive tracer. The assessment of the non-specific uptake of the tracer was 
determined by 2 methods, the use of DU145 cells which do not express GCP(II)/PSMA but are 
the mother cell line of DU145-PSMA and so should be identical in other features, and by using 




4 Clinical studies with [68Ga]Ga-THP-PSMA 
Since the development of [68Ga]Ga-THP-PSMA, this tracer has been evaluated in a phase 1 
clinical trial at Peter MacCallum Cancer Centre, Melbourne, Australia (1)(2), two clinical research 
studies at Hannover Medical School, Hannover, Germany (3)(4), and a clinical research study at 
Guy’s and St Thomas’ Hospital, London, UK (5). In this chapter, the published work on the clinical 
translation of [68Ga]Ga-THP-PSMA will be summarised and discussed. 
4.1 Overview of Phase 1 Clinical Study, Peter MacCallum Cancer Centre, Melbourne 
Australia 
A phase 1 study which aimed to establish the safety profile of [68Ga]Ga-THP-PSMA and its ability 
to delineate GCP(II)/PSMA-expressing prostate cancer using PET/CT, was conducted at the Peter 
MacCallum Cancer Centre in 2016 (2) and the results published in 2017 (1). 
4.1.1 Radiochemistry 
The GMP compliant GalliProst™ radiopharmaceutical kits produced by ROTOP Pharmaka GmbH, 
were used for the radiolabelling [68Ga]Ga-THP-PSMA within this study. A Galliapharm generator 
(Eckert & Zeigler, Berlin, Germany), for which the one-step kits were designed for, was not 
available for these studies and instead two different generators were used: the iThemba (IDB 
Holland BV, Netherlands) which elutes with 5 mL of 0.5 M HCl and the Galli Eo (IRE-Elit, Fleurus, 
Belgium) which elutes with eluted with 1.1 mL 0.1 M HCl. Therefore these kits could not be 
reconstructed in a one-step process, as is possible with the GalliaPharm generator. However, 
the radiolabelling was still extremely simple and rapid when compared to the automated 
synthesis required for [68Ga]Ga-HBED-CC-PSMA and over >99% RCP was consistently achieved.  
4.1.2 Patient Selection and Imaging Protocols 
Overall 14 patients were included in the phase 1 study and were grouped into 2 cohorts. Cohort 
A contained 8 patients with prior multi-parametric MRI and biopsy-proven prostate cancer, and 
were scheduled for prostatectomy but had not received any other treatment. These patients 
were administered 228-270 MBq [68Ga]Ga-THP-PSMA (35 µg cold compound) and imaged with 
CT and a dynamic PET up to 90 minutes, then with static scans at 2 and 3 hours. Histological 
samples from these patients’ prostatectomies and lymph node dissections were stained for 
GCP(II)/PSMA (Dako (Agilent) clone 3E6) which allowed the uptake of the tracer to be correlated 
with GCP(II)/PSMA-expression. Cohort B contained 6 patients who were selected because they 
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had metastatic prostate cancer which had previously shown [68Ga]Ga-HBED-CC-PSMA uptake. 
These patients were also imaged with [68Ga]Ga-THP-PSMA within 22 days of their original scan 
allowing  the biodistribution and lesion uptake of the two tracers to be compared. These patients 
were administered 172-275MBq [68Ga]Ga-THP-PSMA and imaged at 15 minutes, 1 and 2 hours. 
4.1.3 Safety 
No adverse events were seen in any of the patients administered with [68Ga]Ga-THP-PSMA.  
4.1.4 Biodistribution and Dosimetry 
[68Ga]Ga-THP-PSMA showed rapid renal excretion and very low background uptake in non-
target tissues as demonstrated in figure 4.1. The majority of the activity was associated with the 
kidneys and the bladder within 15 minutes. The dosimetry results reflect this distribution with 
the highest absorbed dose to the urinary bladder and kidneys. The mean effective dose 
determined for [68Ga]Ga-THP-PSMA was 0.021 mSv/MBq, a very similar value to those found for 
[68Ga]Ga-HBED-CC-PSMA (0.024 mSv/MBq (6)), [68Ga]Ga-DOTA-PSMA 617 (0.021 mSv/MBq (7)) 
[18F]F-PSMA-1007 (0.022 mSv/MBq (8)) and [18F]DCFPyL (0.0139 mSv/MBq (9)). When the two 
tracers were compared in the same patient there were clear differences in background uptake 
as shown in figure 4.2. In particular, lower uptake was seen for [68Ga]Ga-THP-PSMA in the 
salivary glands (parotid), spleen, and liver, which was quantified using SUVmax values (table 4.1). 
In the [68Ga]Ga-THP-PSMA images there was notable uptake in the urinary tract between 
kidneys and the bladder which may have been difficult to distinguish from pelvic lymph nodes if 
only PET was performed, but the two could clearly be differentiated on PET/CT axial slices. 








Patient Parotid Liver Spleen 
Blood 
Pool 
Parotid Liver Spleen 
Blood 
Pool 
9 5.0 2.6 2.7 1.8 20.0 8.2 9.3 1.8 
10 3.5 4.8 4.8 1.6 18.3 72 9.8 1.2 
11 4.4 2.1 2.1 1.7 16.7 4.8 8.8 1.4 
12 3.9 2.2 3.2 1.9 18.7 6.3 15.9 1.7 
13 2.9 2.4 3.2 2.3 14.2 6.2 14.5 1.9 
14 4.2 1.9 1.6 1.9 27.0 5.1 4.4 0.6 
Mean 4.0 2.7 2.9 1.9 19.2 17.1 10.5 1.4 
 
TABLE 4.1: Physiologic uptake (SUVmax) of [68Ga]Ga-THP-PSMA compared to [68Ga]Ga-HBED-CC-PSMA for 




4.1.5 Performance of [68Ga]Ga-THP-PSMA in Initial Staging 
The results from cohort A showed the ability of [68Ga]Ga-THP-PSMA to specifically delineate 
primary tumours with had high levels of GCP(II)/PSMA-expression (defined as 
immunohistochemistry ranking of +3) as shown in figure 4.1. Patients without high levels of 
expression of GCP(II)/PSMA in their primary tumour (n = 2) did not show [68Ga]Ga-THP-PSMA 
uptake, demonstrating the selectivity of this tracer. In this set of patients, lymph node 
involvement was only detected by [68Ga]Ga-THP-PSMA in one patient, but histological analysis 
of dissected lymph nodes showed the presence of cancer in the lymph nodes of two further 
patients. However, these lymph nodes were 0.6 mm and 0.1 mm in size; much smaller than the 
8 mm detection limit of conventional imaging (10). [68Ga]Ga-HBED-CC-PSMA imaging is also 
known to miss a proportion of lesions of a similar size when correlated with histology prior to 
prostatectomy (11). 
 
Figure 4.1: A prostate adenocarcinoma patient with a Gleason score of 4 + 4 = 8. (A) [68Ga]Ga-THP-PSMA PET 
multi-time point PET images from 0 to 120 minutes demonstrating rapid blood pool clearance and low 
background activity. (B) 120 minute PET image after voiding fused to multi- parametric MRI T2 sequence 
demonstrating focal uptake in the left posterior mid-zone lesion. (C) Histopathologic correlation following 
prostatectomy with area of adenocarcinoma shaded in black, and zoomed-in area demonstrating 3+ staining 
with GCP(II)/PSMA immunohistochemistry. Reproduced with permission from (1). 
4.1.6 Comparison of [68Ga]Ga-THP-PSMA with [68Ga]Ga-HBED-CC-PSMA in 
Metastatic Prostate Cancer 
[68Ga]Ga-THP-PSMA was able to successfully identify metastatic sites in all patients, including 
those within the prostate bed, pelvic and distant lymph nodes and bone. Statistically significant 
differences in SUVmax were seen between the same metastases imaged with [68Ga]Ga-THP-PSMA 
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and with [68Ga]Ga-HBED-CC-PSMA with mean values of 10.7 and 30.3 respectively (P <0.01). 
Example patient scans can be seen in figure 4.2. Although the tumour to background ratio was 
maintained, the lower intensity within cancerous lesions may mean that smaller areas of disease 
do not reach the threshold for detection and are consequently missed. This problem could 
explain why within this study, although the majority of scans showed a concordant number of 
disease sites, in one patient only 2 lesions were detected on the [68Ga]Ga-THP-PSMA scan 
compared to 4 with the [68Ga]Ga-HBED-CC-PSMA scan. However, these differences were not 
followed up with histology and so conclusions about which tracer gave a more accurate 
distribution of prostate cancer sites cannot be drawn. An optimal PSMA tracer would combine 
the low background uptake of [68Ga]Ga-THP-PSMA with the high SUVmax values in GCP(II)/PSMA-
expressing prostate cancer seen for [68Ga]Ga-HBED-CC-PSMA. 
 
FIGURE 4.2: Comparison of (A) [68Ga]Ga-HBED-PSMA PET/CT (177MBq, 56 minute uptake period) to (B) 
[68Ga]Ga-THP-PSMA PET/CT (232 MBq, 60 minute uptake period) in the same patient. A solitary focal bone 
metastasis in the vertebra is well-visualised on both images. Image reproduced with permission from (1). 
4.1.7 Conclusions from Phase 1 Study 
The phase 1 study showed [68Ga]Ga-THP-PSMA is safe and can be used to identify GCP(II)/PSMA-
expressing prostate cancer in both initial staging and metastatic cancer. When imaging was 
performed in the same patient with both [68Ga]Ga-THP-PSMA and [68Ga]Ga-HBED-CC-PSMA the 
uptake in both the background tissues and prostate cancer was lower for [68Ga]Ga-THP-PSMA, 
however, interpretation of either scan provided the same staging information, showing similar 
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clinical utility. Further studies in larger patient populations would be required to evaluate 
whether the differences in the images produced by the two tracers would impact on patient 
management. 
4.2 Studies from Hannover Medical School, Hannover, Germany 
Both studies from Hannover Medical School looked at the performance of [68Ga]Ga-THP-PSMA 
in patients with biochemical recurrence after radical prostatectomy. The first looked at 25 
patients and focused on comparing [68Ga]Ga-THP-PSMA to [68Ga]Ga-DOTAGA-PSMA(I&T) in 
similar patient populations (but not the same patients) (3), and the second was a larger study of 
99 patients where the detection rate across a range of blood PSA levels was determined (4). 
4.2.1 Radiochemistry 
The radiolabelling for both studies was performed with GalliProst™ kits. These were 
reconstituted by the elution of an ITG gallium-68 generator (Isotope Technologies Garching 
GmbH, Garching, Germany) directly into the radiopharmaceutical kit in a one-step process. The 
eluate from these ITG generators was 5 mL of 0.05 M HCl. As the kits were designed for 5 mL 0.1 
M HCl the pH is likely to have been higher than 7 with the ITG eluate, but this was not 
commented on in the papers (3)(4). Over 95% radiochemical purity was achieved and each 40 
µg kit (THP-PSMA content) was used for two patients. This process was carried out in around 5 
minutes, much faster than the 37 minutes required for the synthesis module production of 
[68Ga]Ga-DOTAGA-PSMA(I&T) at the same radiopharmacy. This gave the advantage that more 
activity was available for patient imaging (3). 
4.2.2 Patient Selection and Imaging Protocols 
All patients recruited in the two studies had biochemical recurrence defined as a PSA of 0.01 
ng/mL or more after radical prostatectomy (range in study 1: 0.05–19.0 ng/mL, range study 2: 
0.01 – 8400 ng/mL). However, this is a very low PSA level at which to define biochemical 
recurrence. The European Association of Urology (EAU) guidelines on prostate cancer 
management define recurrence 0.2 ng/mL or above (12) over 4 times that used in this study. 
Additionally, the European Association of Nuclear Medicine (EANM) and Society of Nuclear 
Medicine and Molecular Imaging (SNMMI) procedure guidelines for prostate cancer imaging 
also recommend [68Ga]Ga-PSMA imaging only in patients with PSA levels over the 0.2 ng/mL 
threshold (13) so most published studies use this value (14)(15). Patients were administered 
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with 150 MBq [68Ga]Ga-THP-PSMA using one GalliProst™ kit for two patients (~20 µg THP-PSMA 
per patient) and then imaged at 1 hour post-injection after voiding the bladder. 
4.2.3 Biodistribution 
The biodistribution of [68Ga]Ga-THP-PSMA in these studies matched that observed in the phase 
1 trial. When the distribution was compared to [68Ga]Ga-DOTAGA-PSMA(I&T) in a similar patient 
population (but not the same patients) [68Ga]Ga-DOTAGA-PSMA(I&T) showed higher non-target 
uptake and higher uptake in prostate cancer metastases as shown in figure 4.3. SUVmax uptake 
values in different prostate cancer lesions cannot be fairly used to compare tracers and neither 
can the number of lesions detected. This is because the true number of metastases in each 
patient and the extent of GCP(II)/PSMA-expression in those metastases is not known. Therefore, 
limited conclusions can be drawn from these result as two small populations of patients where 
used and each group was only imaged with one tracer. 
 
FIGURE 4.3: Images of two different patients with metastatic prostate cancer imaged at 1 hour post-injection 
with (A) [68Ga]Ga-THP-PSMA and (B) [68Ga]Ga-DOTAGA-PSMA(I&T). Reproduced with permission from (3). 
4.2.4 Performance of [68Ga]Ga-THP-PSMA in Biochemical Recurrence 
These two studies show that [68Ga]Ga-THP-PSMA is suitable for the detection of local 
recurrence, lymph node and bone metastasis in cases of rising PSA after radical prostatectomy. 
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In the smaller study, prostate cancer lesions were detected in 12 out of 25 patients and in the 
larger study, it was 52 out of 99 patients. A strong correlation was seen between detection rates 
and PSA blood levels as summarised in figure 4.4 with higher detection rates seen above 1 
ng/mL. 
 
FIGURE 4.4: The number of patients with biochemical relapse scanned with [68Ga]Ga-THP-PSMA PET/CT where 
the site of reoccurrence could be detected on the scan (A) Histogram of absolute numbers of positive and 
negative patients at 1 hour post-injection (B) Percentage detection. Error bars show 95% confidence intervals. 
Reproduced with permission from (4). 
4.2.5 Conclusions from Studies at Hannover Medical School 
These two studies showed [68Ga]Ga-THP-PSMA can be used to identify GCP(II)/PSMA-expressing 
prostate cancer in biochemical recurrence. The detection rate correlated with the level of blood 
PSA, a proven biomarker for disease burden in biochemical recurrence (16). The tracer is able to 
distinguish lesions at much lower PSA levels than those where anatomical imaging and bone 
scans become clinically useful (20 ng/mL) (12). 
4.3 Studies at Guy’s and St Thomas’ Hospital, London, UK 
The work conducted at Guy’s and St Thomas’ hospital has been presented at the British Nuclear 
Medicine Society conference in April 2018 by Professor Gary Cook and the abstract published in 
Nuclear Medicine Communications (5). The results described here reference both the slide pack 
from this presentation and the published abstract. 
4.3.1 Radiochemistry 
[68Ga]Ga-THP-PSMA was radiolabelled using the GalliProst™ kits. These were reconstructed by 
the elution of a Galliapharm gallium-68 generator (Eckert and Zeigler, Berlin, Germany, 5 mL, 
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0.1 M HCl) directly into the radiopharmaceutical kit in a one-step process and radiolabelling was 
assessed using two iTLC methods, with 95% radiochemical purity in both required to pass QC. 
This was the first [68Ga]Ga-PSMA tracer to be produced within Guy’s and St Thomas’ 
radiopharmacy. 
4.3.2 Patient Selection and Imaging Protocols 
118 patients were included in this study and were analysed as two groups depending on whether 
the scan was conducted for primary staging (50 patients) or biochemical recurrence (68 
patients). In this study biochemical recurrence was defined as a PSA >0.1 ng/mL. The study’s aim 
was to determine the frequency of a clinical management change as a result of a [68Ga]Ga-THP-
PSMA PET/CT scan for these two populations. All patients had documented management plans 
before being included in the study, and information on PSA levels, Gleason scores, and PSA 
doubling times were available. Patients were administered 102-182 MBq of [68Ga]Ga-THP-PSMA, 
and a dynamic PET scan was performed for the first 10 minutes post-injection followed by a 
static half body scan at 60 minutes. 
4.3.3 Results in Initial Staging 
[68Ga]Ga-THP-PSMA PET/CT scans for all patients in the cohort undergoing initial staging, 
showed uptake of the tracer in the primary tumour, as expected. Some patients showed 
additional nodal and/or metastatic sites. As a result of having the scan, additional information 
was obtained for 24% of the patients and 24% of the patients had a change of management. 
4.3.4 Results for Biochemical Recurrence 
When [68Ga]Ga-THP-PSMA PET/CT was used to image patients with biochemical recurrence, the 
site of recurrence was detected in 59% of scans. The distribution of these patients across the 
PSA range is shown in figure 4.5. No disease sites were detected for patients with a PSA of less 
than 0.5 ng/mL and the detection rate was between 80 and 90% in patients with PSA levels of 2 
ng/mL or above. As a result of the scan, 34% of patients presenting with biochemical recurrence 
had a change to their management. The number of patients with a change in management 
within each PSA level is shown in figure 4.6. No patients with a PSA below 0.5 ng/mL had a 
change in management as the site of reoccurrence was not detected in any patient. However, a 




4.3.5 Conclusions from Studies at Guy’s and St Thomas’ 
[68Ga]Ga-THP-PSMA was able to detect the site of prostate cancer in all patients imaged for 
primary staging and 59% of patients with biochemical recurrence. The data from the scan 
influenced patient management in both cohorts, however, the number of patients with a change 
in management was 24% in primary staging but 34% in patients with biochemical recurrence. 
 
FIGURE 4.5: The number of patients where the site of recurrence was detectable on the [68Ga]Ga-THP-PSMA 
PET/CT scan, at each PSA level (ng/mL). The numbers on top of the bars indicate the number of patients with 
detectable recurrence and the total number of patients scanned within this PSA range. Figure courtesy of 




FIGURE 4.6: The number of patients with a change in management due to the results of the [68Ga]Ga-THP-PSMA 
PET/CT scan, at each PSA level (ng/mL). The numbers on top of the bars indicate the number of patients with 
detectable recurrence and the total number of patients scanned within this PSA range. Figure courtesy of 




[68Ga]Ga-THP-PSMA, has been found to be safe and to effectively detect prostate cancer in both 
initial staging and biochemical recurrence. However, differences in biodistribution are seen 
between [68Ga]Ga-THP-PSMA, [68Ga]Ga-HBED-CC-PSMA and [68Ga]Ga-DOTAGA-PSMA(I&T). 
These include lower background uptake in non-target tissue for [68Ga]Ga-THP-PSMA, as well as 
a higher rate of renal excretion, which produces some pooling of tracer in the urinary tract. This 
is combined with lower average SUVmax values in GCP(II)/PSMA positive prostate cancer. 
However, overall these tracers all give comparable tumour to background (liver) ratios.  
The differences seen in the biodistribution of the tracers could be caused by a number of factors. 
These include: the affinity of the tracer for GCP(II)/PSMA (found in chapter 3 to be 361 ± 60 nM 
for Ga-THP-PSMA and 34.3 ± 4.1 nM for Ga-HBED-CC-PSMA); the ability of the tracers to 
differentiate between GCP(II)/PSMA and other similar receptors; the blood circulation time and 
excretion pathways (controlled by the hydrophilicity, charge, and size of the tracer); and the 
stability of the tracers in vivo. There are limited quantitative data available in the literature about 
the normal expression levels of GCP(II)/PSMA throughout the body and so it is difficult to know 
how accurately the uptake of a PSMA tracer reflects the distribution of GCP(II)/PSMA-
expression. Immunohistochemistry studies have shown GCP(II)/PSMA-expression in the kidney, 
intestinal tract and the prostate but no expression in the liver, spleen and salivary glands 
(17)(18). This fits more closely with the biodistribution seen for [68Ga]Ga-THP-PSMA than that of 
[68Ga]Ga-HBED-CC-PSMA and [68Ga]Ga-DOTAGA-PSMA(I&T). However, there are also mRNA 
studies which show expression of the GCP(II)/PSMA gene in the salivary glands, spleen and liver 
but protein expression was not confirmed (19). Further insight comes from the biodistribution 
of the zirconium-89 labelled GCP(II)/PSMA targeting humanised antibody J591 which does not 
show tracer uptake in the salivary and lacrimal glands of prostate cancer patients (20). See figure 
4.7 for example [89Zr]Zr-huJ591 PET scans up to 8 days post-injection. 
Although it is interesting to consider which tracer’s biodistribution most accurately correlates 
with GCP(II)/PSMA-expression, the scans purpose is to meet a clinical need: the identification of 
metastatic prostate cancer. Prostate cancer typically progresses from the primary tumour to 
lymph nodes within the pelvis (pelvic, hypogastric, iliac, sacral), then distant lymph nodes (aortic, 
common iliac, inguinal, supraclavicular, cervical) and to the skeleton, with other organs such as 
the lung and liver only involved at a very late stage (21). Therefore, it is most important that the 
tumour to background ratio is sufficient around these lymph nodes. The physiological uptake 
seen for [68Ga]Ga-HBED-CC-PSMA and [68Ga]Ga-DOTAGA-PSMA(I&T) in the liver, spleen and 
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salivary glands does not affect the ability to detect prostate cancer metastasis in either the pelvic 
or distant lymph nodes, and so this physiological uptake has little negative effect on the clinical 
utility of the scan. This in turn, means that the lack of the uptake with [68Ga]Ga-THP-PSMA in 
these organs also brings little benefit. This is not true however, when molecular radiotherapy is 
being considered. Here uptake in salivary and lacrimal glands becomes very important to 
consider as these organs are particularly radiosensitive (22). In studies with [177Lu]Lu-DOTA-
PSMA(617) damage to these tissues due to the uptake of this tracer has caused xerostomia (dry 
mouth) and keratoconjunctivitis sicca (dry eyes) in a significant proportion of patients (87% 
experienced dry mouth and 17% dry eyes in a recent phase 2 study (23)). Therefore the lower 
uptake seen for [68Ga]Ga-THP-PSMA in these glands may offer an advantage if the same 
bioconjugate could be radiolabelled with a therapeutic isotope and used for molecular 
radiotherapy. This idea will be explored further in chapter 5, where [67Ga]Ga-THP-PSMA will be 
evaluated for molecular radiotherapy. 
 
FIGURE 4.7: MIP images of a patient administered [89Zr]Zr-huJ591 Images show physiological distribution in 
the cardiac and vascular blood pool, decreasing with time, in liver, spleen, kidneys, and gastrointestinal tract, 
but not in the salivary and lacrimal glands. Images show increased accumulation in bone lesions over time. (20) 
In the studies conducted at Hannover Medical School and Guy’s and St Thomas’ Hospitals where 
[68Ga]Ga-THP-PSMA was used in cases of biochemical recurrence, the detection rate was shown 
to be correlated with PSA level, and appears most effective when PSA is above 1 ng/mL. The 
definition of biochemical recurrence after prostatectomy is a PSA level greater than 0.2 ng/mL 
(12). However, imaging with bone scintigraphy or CT has only been shown effective in 
determining the site of relapse when patients have a PSA over 20 ng/mL (12). Therefore, patients 
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presenting with a PSA level in the range of 0.2 ng/mL – 20 ng/mL have biochemical recurrence 
but conventional imaging is not effective for them. All [68Ga]Ga-PSMA tracers including [68Ga]Ga-
THP-PSMA allow detection in this vital range of PSA levels, however, it appears that [68Ga]Ga-
THP-PSMA may not have as good detection rate in patients presenting with a 0.2-1 ng/mL PSA 
as the alternative tracers, although a large comparative study in the same patients would be 
required to confirm this. 
The study conducted at Guy’s and St Thomas’ Hospital showed that the results of a [68Ga]Ga-
THP-PSMA scan can affect patient management. In primary staging with [68Ga]Ga-THP-PSMA 
24% of patients showed a change in management, a very similar rate to the 21% determined for 
a multicentre prospective study conducted in Australia for [68Ga]Ga-HBED-CC-PSMA (24). In 
patients with biochemical recurrence, 34% of patients imaged with [68Ga]Ga-THP-PSMA had a 
change in treatment. This is lower than that value obtained for [68Ga]Ga-HBED-CC-PSMA in an 
Australian prospective multicenter study, where management was changed in 62% of patients 
(24), but similar to the 39% of patients with biochemical recurrence that had there management 
changed in a retrospective study at University College London Hospital (25). With such variation 
between the results obtained in two different studies with [68Ga]Ga-HBED-CC-PSMA, it is difficult 
to determine if the lower number of changes to patient management for [68Ga]Ga-THP-PSMA in 
cases of biochemical recurrence is significant, and even a reflection on the [68Ga]Ga-PSMA tracer 
used or instead due to differences in study design, the planned management before the scan 
which could vary between hospitals or clinicians, and how treatment changes are made at 
different hospitals.  
As well as demonstrating the clinical utility of [68Ga]Ga-THP-PSMA these studies have also 
demonstrated that its kit-based radiosynthesis offers advantages to the radiopharmacies 
producing the tracer and leads to a drop in synthesis time, from around 40 to less than 10 
minutes. It was also the first [68Ga]Ga-PSMA tracer to be produced at Guy’s and St Thomas’ 





4.5 Concluding Remarks 
In conclusion, the one-step kit-based formation of [68Ga]Ga-THP-PSMA provides advantages in 
the production of the tracer, while the use of the THP as the chelator does not affect the 
information derived from scans in patients. Effective detection of prostate cancer is possible 
with [68Ga]Ga-THP-PSMA for both initial staging and in biochemical recurrence and the results 
of the scan have been shown to impact management of prostate cancer patients. To be able to 
accurately assess the performance of the tracers and the clinical impact of the tracer choice, 
more extensive comparative studies would be required. However, [68Ga]Ga-THP-PSMA certainly 
provides advantages over conventional imaging and has the simplest radiolabelling procedure 
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5 Targeting Gallium-67 to Prostate Cancer with [67Ga]Ga-THP-PSMA 
5.1 Introduction 
The clinical need to image metastatic prostate cancer more accurately, especially in hormone-
resistant prostate cancer, is being met by small molecule GCP(II)/PSMA imaging. Unfortunately 
once the diagnosis has been confirmed, there are often limited therapeutic options available for 
these patients and so targeted molecular radiotherapy options are currently being investigated. 
This has been encouraged by the success of alpha-based therapy using radium-223 chloride 
([223Ra]RaCl2) in men with castrate-resistant prostate cancer and bone metastases, which is now 
FDA-approved (1). A phase III study where patients received six injections of radium-223 chloride 
at a dose of 50 kBq per kilogram of body weight once every 4 weeks, showed improved overall 
survival compared to placebo, with the median survival increasing by 3.6 months (2). Cationic 
radium is naturally bone-seeking due to its ability to mimic calcium and gets incorporated into 
the newly forming inorganic matter of bone in areas of increased osteoblastic activity, such as 
bone metastases (3). The delivery mechanism of [223Ra]RaCl2 is therefore specific to bone-based 
metastases, meaning that soft tissue metastases do not receive radium-223 or its associated 
dose, and consequently do not respond. However, due to the targeting mechanism, there is also 
a lot of off-target uptake, as shown in figure 5.1 (4), and so it would be ideal if the targeting of 
therapeutic isotopes to prostate cancer metastases could be improved. As well as the possibility 
of imaging metastatic disease, GCP(II)/PSMA-expression provides a mechanism to specifically 
deliver radiotherapeutic isotopes to both bone and soft tissue metastases. Such targeting can 
be done using similar urea-based scaffolds, as utilised in the imaging agents, but replacing the 





FIGURE 5.1: Gamma scintigraphy images of [99mTc]Tc-MDP(top) and [223Ra]RaCl2 (bottom) in a patient with 
skeletal metastases Note the non-specific uptake in the [223Ra]RaCl2 images including significant off-target gut 
uptake. Reproduced with permission from (4). 
As reviewed in chapter 1, the most investigated options for GCP(II)/PSMA targeted molecular 
radiotherapy have been β--based therapy using [131I]I-MIP-1095 (5)(6), [177Lu]Lu-DOTA-
PSMA(617) (7)(8) or [177Lu]Lu-DOTAGA-PSMA (I&T) (9). As shown in figure 5.2, all of these tracers 
use the same urea-based GCP(II)/PSMA targeting motif. [131I]I-MIP-1095 was the first PSMA-
based β- therapy to be evaluated used this targeting structure and was administered to 28 men 
with metastatic resistant prostate cancer. It caused a significant reduction in PSA levels and bone 
pain (5). Studies investigating multiple doses of [131I]I-MIP-1095 therapy have also been 
conducted, but show that although the first dose reduces tumour burden, there is little 
advantage in repeating doses, and doing so increases the likelihood and intensity of side effects 
(6). Compared to [131I]I-MIP-1095, the lutetium-177-based GCP(II)/PSMA targeted therapies 
[177Lu]Lu-DOTA-PSMA(617) (10)(11) and [177Lu]Lu-DOTAGA-PSMA(I&T) (12)(13) have been 
performed in much higher patient numbers across a range of different sites. Like the iodine-131-
based therapy, these have shown a reduction in tumour burden and blood PSA levels. Seven of 
these studies were included in a recent meta-analysis and which concluded that across the 
studies, 51% of patients administered [177Lu]Lu-PSMA molecular radiotherapy had a reduction 





FIGURE 5.2: Structures of [131I]I-MIP-1095 (5)(15), [125I]I-DCIBzL (16), [125I]I-variant 8 (17), DOTA-PSMA(617) 
(18), DOTAGA-PSMA(I&T) (19), YC-36 (16), THP-PSMA (20). 
Tracers for GCP(II)/PSMA-targeted molecular radiotherapy, must possess favourable 
pharmacokinetics if they are to be translated into the clinic. It is paramount that the radiotracer 
accumulates rapidly in GCP(II)/PSMA-expressing tumours, where it should be retained for as 
long as possible, in order to deposit the maximum dose. In addition, it should have low uptake 
in non-target organs, preventing radiation damage. In non-cancerous tissues. where uptake is 
due to renal excretion (bladder, kidney) or mediated by GCP(II)/PSMA-expression (kidneys (21)), 
it would be ideal if the tracer washed out of these organs faster than from the tumour. Such 
properties have been shown in a preclinical model of prostate cancer for [177Lu]Lu-DOTA-
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PSMA(617) (18). In BALB/c nu/nu mice with LNCaP tumours, the uptake of [177Lu]Lu-DOTA-
PSMA(617) was 11.2 ± 4.17 %ID/g at 1 hour, and remained stable until 24 hours, when it was 
found to be 10.58 ± 4.5 %ID/g. Conversely, the washout from the kidneys was significant, 
changing from 137.5 ± 77.8 %ID/g at 1 hour, to 2.13 ± 1.36 %ID/g at 24 hours (18). Additionally, 
very high tumour to blood (1,058) and tumour to muscle values (529) were seen at 24 hours 
after injection. These observations held when the distribution of [177Lu]Lu-DOTA-PSMA(617) was 
studied in prostate cancer patients (8), with the concentration of tracer in the tumour sustained 
for much longer than in the kidney, as shown in figure 5.3. 
 
FIGURE 5.3: Time activity concentration curves in a representative patient. Tumour metastasis (red), kidneys 
(cyan and dashed blue), spleen (orange) and liver (green). This figure was reproduced with permission from 
(8). 
However, these properties are not shared by all PSMA tracers that use the urea-based targeting 
motif. In fact, very small changes in the structure can affect the pharmacokinetics significantly. 
This has been demonstrated in a preclinical model (athymic nude mice with PC3-PIP tumours) 
with the iodine-based tracers [125I]I-DCIBzL (17)(22) and [125I]I-variant 8 (17), which had very 
similar structures (figure 5.4) and initial tumour uptake values (13.5 ± 2.1 %ID/g and 12.1 ± 4.9 
%ID/g respectively at 1 hour). [125I]I-DCIBzL was retained in both the tumour and the kidney for 
48 hours whereas [125I]I-variant 8 was washed out of both within 24 hours as shown in figure 
5.4. The differences between [177Lu]Lu-DOTA-PSMA(617), [125I]I-DCIBzL and [125I]I- variant 8 are 
stark, even though they all had the same targeting motif and subnanomolar Ki or IC50 values 
when measured with a NAALADase fluorescence-based assay (0.8 ± 0.3 nM (metal-free 
compound) (23), 0.010 ± 0.004 nM (17) and 0.557 ± 0.265 nM (17) respectively). This 
demonstrates there are more factors at play than the affinity for the target, and highlights the 




FIGURE 5.4: The tumour and kidney uptake of [125I]I-DCIBzL, and [125I]I-variant 8 at 1 hour and 48 hours and 
24 hours. Data from reference (17). 
When considering molecular radiotherapy it is important that the size of a tumour being treated 
is matched by the range over which a therapeutic radionuclide deposits its dose. Beta emitters 
have a range of 2-10 mm with a linear energy transfer (LET) of 0.1-1.0 keV/µm (24), and so are 
suitable for delivering a considerable dose to macroscopic tumours that are over 2 mm in 
diameter, without substantial “crossfire” to surrounding tissue. However, they are unlikely to 
be effective therapy for micro-metastases (0.2-2 mm in size (25)), isolated tumour cell clusters 
(< 0.2 mm in size or < 200 cancer cells (25)) or circulating individual tumour cells, as the majority 
of the energy from each decay would be deposited in non-target tissue rather than the cancer 
cell itself (24)(26). These smaller targets are of high importance as they are responsible for 
relapse in many patients and are very difficult to locate and treat (27)(28). Targeting them with 
molecular radiotherapy requires the radioactive decay to be deposited within a much shorter 
range, ideally within the cell itself or even just within the nucleus. This necessitates the use of 
therapeutic radionuclides with a short range but high enough LET to cause DNA damage. Auger 
electrons meet these criteria as they typically travel less than 0.5 µm and have a LET of 4-26 
keV/µm (26). It is not only the emission of Auger electrons that causes therapeutic effects, 
additionally, a high positive charge is generated on the atom, due to the ejection of negatively 
charged electrons. This unstable positive charge has high potential energy and will be rapidly 
neutralised by stripping electrons from the surroundings (29). This effect is known as “the 



































has been shown to contribute to irreparable double-strand breaks (30). Such double-strand 
breaks are hazardous to the cell and can trigger apoptosis (31). 
The possibility of Auger electron-based PSMA therapy has been demonstrated with [125I]I-
DCIBzL, which uses the urea-based GCP(II)/PSMA targeting motif (figure 5.2)(16). This work 
showed that Auger-emitting [125I]I-DCIBzL causes DNA damage in vitro as assessed by clonogenic 
assays and monitoring double-strand breaks using γH2AX staining. The study went on to show a 
significant reduction in tumour doubling time in a subcutaneous xenograft model in mice. Future 
work with more realistic models of micrometastases are ongoing, to validate its use for this type 
of disease, and any possible side effects before translation into the clinic (32). Particular issues 
are likely to be kidney toxicity, due to their natural GCP(II)/PSMA-expression (21)(33), and 
thyroid toxicity, as iodine naturally accumulates in the thyroid and therefore metabolites or 
autoradiolysis products of the tracer could build up in the thyroid, leading to a significant dose 
to this organ (34)(35). The 59.4 day half-life of iodine-125 (26) may also lead to challenges when 
attempting to block uptake to radiosensitive organs, due to the time over which it would need 
to be maintained. The long half-life also has an environmental impact, with any radioactive 
waste produced requiring long-term containment. 
Gallium-67 has been proposed as an alternative Auger electron emitting radionuclide for 
molecular radiotherapy (24)(36)(37)(38)(39). Gallium-67 has a half-life of 78 hours (26) and 
decays by electron capture, producing a number gamma emissions (91-888 keV (40)) that can 
be used for SPECT studies, and an average of 4.7 Auger electrons per decay with a total energy 
of 6.3 keV (26). Recent evaluation of gallium-67 in vitro using viability and clonogenic assays has 
shown that it is able to induce cell death when cell surface-bound or internalised and that 1 Bq 
of gallium-67 per cancer cell is required to achieve 90% cell killing (38). In the study, gallium-67 
was delivered to cells as a lipophilic gallium-8-hydroxyquinoline complex which entered cells by 
passive diffusion through the cell membrane. However, this makes it unspecific and therefore 
unsuitable for targeted molecular radiotherapy, as uptake needs to be receptor-mediated to 
ensure the therapy is targeted only to cancer cells. To date, gallium-67 has only been shown to 
have a targeting therapeutic effect in lymphoma cells (39)(41), myeloid leukemic blasts (42) and 
lymphoma xenograft mouse models (43). In those studies, targeting was achieved with gallium-
67 citrate (36)(42) or anti-CD74 (41)(43) or anti-CD20 antibodies (39). Gallium-67-based 
molecular radiotherapy has not previously been considered for prostate cancer, nor utilised a 
peptide targeting motif. The work in this chapter aims to lay the groundwork for such 
therapeutic studies by determining the quantity of gallium-67 that can be delivered to 
GCP(II)/PSMA-expressing cells and tumours in a targeted manner, using [67Ga]Ga-THP-PSMA. 
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A further advantage of using gallium-67 is that its isotope gallium-68 is suitable for PET imaging. 
Since gallium-67 and gallium-68 versions of the same complex will be chemically identical, they 
will have exactly the same behaviour in vivo (44). This means that gallium-68 PET imaging could 
be accurately used to assess patient suitability for therapy with gallium-67. It also means that 
any radiotracers or chelators that have been designed for imaging with gallium-68 can be 
labelled with gallium-67 through similar procedures. In particular, this means the specificity of 
the THP chelator for gallium, which underpins its excellent radiolabelling properties, should be 
suitable for radiolabelling of THP-PSMA with both radioisotopes of gallium. 
This piece of work aims to assess the potential of [67Ga]Ga-THP-PSMA to specifically deliver 
gallium-67 to prostate cancer. Radiolabelling of THP-PSMA tracer with gallium-67 will be 
optimised for high molar activity and stability over time. [67Ga]Ga-THP-PSMA will then be 
assessed both in vitro and pre-clinically to determine uptake and retention over time. These 





5.2 Experimental Aims 
The above aims will be addressed through the following experimental objectives: 
 Radiolabel [67Ga]Ga-THP-PSMA at high molar activity 
 Evaluate the serum stability of [67Ga]Ga-THP-PSMA 
 Evaluate the uptake and efflux of [67Ga]Ga-THP-PSMA in GCP(II)/PSMA-expressing cells 
 Evaluate the biodistribution and tumour uptake of [67Ga]Ga-THP-PSMA over 7 days in a 




5.3 Materials and Methods 
All reagents and consumables were purchased from Sigma Aldrich or Fischer Scientiﬁc, with the 
following exceptions: DOTA-PSMA (PSMA 617) was purchased from ABX (Radeberg, Germany). 
THP-PSMA was synthesised as described in chapter 3 or purchased from Chematech-mdt (Dijon, 
France). Severe combined immunodeﬁcient (SCID)/beige mice were purchased from Charles 
River (Margate, UK). DU145 and DU145-PSMA cell lines were provided by Dr Florian Kampmeier 
(45). 
5.3.1 Gallium-67 Source 
Gallium-67 was purchased from Nordion Inc. (Ottawa, ON, Canada), where it was produced by 
proton irradiation of enriched zinc-68, according to the nuclear reaction 68Zn(p, 2n)67Ga. This 
gallium-67 was provided in 0.1 ± 0.05 M HCl. The levels of the trace metals  Zn2+, Cu2+, and Fe3+ 
were all below 0.27 µg/GBq at batch release, and the molar activity was ≥ 37 TBq/g with a 
radionuclidic purity of over 99.9% (maximum level of Ga-66 detected at 0.04%). The activity 
concentration was 65.6 – 57.5 GBq/mL at the time of batch release. 2.5-2.8 GBq [67Ga]Ga3+ 
arrived in the lab in 70-79 µL of 0.1 M HCl, an activity concentration of 35-38 GBq/mL. 
5.3.2 Instrumentation 
HPLC and radio-HPLC: All high-performance liquid chromatography (HPLC) utilised an Agilent 
1200 LC with in-line radio (sodium iodide gamma detector) and UV detection (254 nm). Data 
were analysed using Laura software (V.4.0.2.75 LabLogic Systems Ltd.). Radiolabelling of 
[67Ga]Ga-THP-PSMA was assessed using an Agilent Eclipse XDB C18 5 m 4.6 x 150 mm column 
with an isocratic mobile phase (90% H2O, 10% ACN, 0.05% TFA) and a flow rate of 1 mL/minute. 
Radiolabelling of [67Ga]Ga-DOTA-PSMA(617) was assessed with the same HPLC equipment but 
an alternative mobile phase: A = H2O with 0.05% TFA, B = ACN with 0.05% TFA, gradient: 0-5 
minutes = 90% A, 5-15 minutes = ramp to 50% B (4%/min), 15-20 minutes = 90% A, with a flow 
rate of 1 mL/minute. Serum stability was assessed using size exclusion chromatography using a 
Phenomenex BioSep 5 µm SECs 2000 column (300 × 7.8 mm) with PBS and 2 mM EDTA as the 
mobile phase and a flow rate of 1 mL/minute. 
iTLC methods: Radiolabelling of [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-PSMA(617) was 
assessed by iTLC utilising Varian ITLC SGI0001 strips (10 cm length) with a mobile phase of 1 M 
ammonium acetate in water/methanol (1:1). ITLC plates were scanned with a Lab-Logic mini-
Scan TLC reader and analysed with Laura software. 
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Gamma counting: Radioactivity counting was performed with a γ-counter (LKB Wallac; 
PerkinElmer) for cell studies and in vivo biodistribution. 
5.3.3 Radiolabelling 
Initial radiolabelling [67Ga]Ga-THP-PSMA: [67Ga]Ga3+ in 0.1 M HCl (5-10 µL, 32-158 MBq) was 
added to THP-PSMA (0.25-5 µg, 1-10 µL) and neutralised with sodium bicarbonate solution to 
pH 6.5-7.5 (1 µL, 0.5-1 M) producing a range of THP-PSMA concentrations between 5 and 156 
µM. Labelling was assessed after 5 minutes by HPLC and iTLC. 
Highest molar activity radiolabelling [67Ga]Ga-THP-PSMA: 1 µL THP-PSMA (0.5 mg/mL, 0.5 µg, 
0.33 nmol) solution was added to 5 µL of [67Ga]Ga3+ in 0.1 M HCl (115 MBq) and then neutralised 
to pH 7 by the addition of 5.5 µL 0.1 M sodium bicarbonate solution. After 5 minutes, 
radiolabelling was assessed by iTLC, and at 10 minutes by HPLC. 93% radiochemical purity (RCP) 
was achieved with a maximum molar activity of 326 MBq/nmol (213.9 MBq/µg). 
5.3.4 Stability to Autoradiolysis [67Ga]Ga-THP-PSMA 
1 µL THP-PSMA (2 mg/mL, 2 µg, 1.3nmol) was added to 50 µL [67Ga]Ga3+ (141 MBq) and 
neutralised to pH 6.5-7.5 with 6 µL 1 M sodium bicarbonate solution. ITLC was completed after 
5 minutes (molar activity 108 MBq/nmol, >95% RCP, final concentration 2.5 MBq/µL, THP-PSMA 
23 µM). The stability over time was monitored by iTLC. To assess the effect of ascorbic acid and 
dilution on the stability, this radiolabelling was repeated and then [67Ga]Ga-THP-PSMA was 
diluted to 1 MBq/µL in PBS containing 12 µg ascorbic acid. Final concentrations were THP-PSMA 
8 µM, ascorbic acid 488 µM. The stability over time was monitored by iTLC up to 18 hours.  
5.3.5 Preparation of [67Ga]Ga-PSMA Tracers for Biological Evaluation. 
THP-PSMA for in vitro studies: 1 µL THP-PSMA (2 mg/mL, 2 µg, 1.3 nmol) was added to 50 µL 
[67Ga]Ga3+ (180 MBq) in 0.1 M HCl, followed by neutralisation to pH 7 with 6 µL 1 M sodium 
bicarbonate solution (final concentration 3.2 MBq/µL, THP-PSMA 23 µM). Radiolabelling was 
assessed by HPLC and iTLC after 5 minutes. Over 99% RCP was achieved with a molar activity of 
138.5 MBq/nmol. The solution was then diluted in PBS containing 12 µg ascorbic acid to a tracer 
concentration of 6.4 µM to produce solution A. Solution A was diluted 1 in 10 to give solution B 
(640 nM), and 1 in 100 to give solution C (64 nM). 
DOTA-PSMA(617) for in vitro studies: 50 µL [67Ga]Ga3+ in 0.1M HCl (145 MBq) was combined 
with 5 µL 1 M HCl and 20 µL 2.1 M HEPES buffer. After the pH was checked (pH 3.2, 2 µL reaction 
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solution), DOTA-PSMA(617) was added (1 µL, 1 mM, 1.5 µg, 1 nmol) followed by heating at 95 
°C for 30 minutes. Radiolabelling was assessed by iTLC and HPLC. The resulting RCP was 98 %, 
and the molar activity was 120 MBq/nmol. On the day of the cell experiments, the molar activity 
had dropped to 76 MBq/nmol but the RCP was still 96%. This solution was diluted to a tracer 
concentration of 6.4 µM in PBS, to produce solution D. Solution D was diluted 1 in 10 to give 
solution E (640 nM) and 1 in 100 to give solution F (64 nM). 
THP-PSMA for in vivo studies: 6 µL THP-PSMA (3 µg, 2 nmol) was added to 15 µL of [67Ga]Ga3+ 
in 0.1M HCl (360 MBq) followed by 3 µL of 0.5 M sodium bicarbonate to adjust the pH to 6.5-7.5 
(final concentration 82 µM THP-PSMA). Radiolabelling was assessed by HPLC after 5 minutes. 
Over 95% RCP was achieved with a molar activity of 180 MBq/nmol. The solution was diluted in 
PBS to the concentration required for injection and monitored over time to ensure the 
administered radiotracer had a RCP of >90% at the point of injection. 
5.3.6 Serum Stability 
20 µL of [67Ga]Ga-THP-PSMA with a molar activity of 25 MBq/nmol (7 MBq, 0.3 nmol) was added 
to 200 µL human serum. The following controls were also produced: [67Ga]Ga-THP-PSMA 
without serum (20 µL [67Ga]Ga-THP-PSMA diluted in 200 µL PBS, 7 MBq, 0.3 nmol) and 
unchelated [67Ga]Ga3+ incubated with serum (1.5 µL [67Ga]Ga3+ in 0.1M HCl, diluted in 18.5 µL 
PBS and then added to 200 µL human serum, 1.7-2.5 MBq). Samples were incubated at 37°C and 
monitored over 8 days by size exclusion HLPC. Chromatograms were decay-corrected and 
normalised to account for the activity used.  
5.3.7 Cell Lines 
The GCP(II)/PSMA-negative cell line chosen was DU145, a human carcinoma prostate cancer cell 
line derived from a brain metastatic site. The GCP(II)/PSMA-expressing cell line chosen was a 
genetically modified daughter cell line of DU145, DU145-PSMA. This cell line had previously been 
transduced to express full-length human GCP(II)/PSMA, with a published method (45) and has 
been shown to have 2.4 times higher expression levels than the naturally GCP(II)/PSMA 
expressing cell line LNCaP by saturation binding studies (45). These cells were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 
penicillin/streptomycin (full RPMI 1640 medium). To prepare for experiments, cells were grown 




5.3.8 Cell Uptake and Efflux Studies 
Cell uptake over time: To determine the cellular uptake of [67Ga]Ga-THP-PSMA and [67Ga]Ga-
DOTA-PSMA(617) over time DU145 and DU145-PSMA cells were seeded in a 24 well plate (0.25 
x 106 cells/well) 24 hours before the assay. Just before the assay, cell medium was replaced with 
250 µL fresh full RPMI 1640 medium. 5 µL of [67Ga]Ga-THP-PSMA or [67Ga]Ga-DOTA-PSMA(617) 
diluted in PBS was added to the cells to give a final concentration of 12.5 nM. Cells were returned 
to the incubator (37 °C, 5% CO2) and monitored up to 4 hours. At each time point, the medium 
was removed from the cells and cells were washed with PBS (0.25 mL x 3). The supernatant and 
washes were combined to determine the unbound fraction, followed by an acid wash (0.25 mL, 
0.5 M glycine, pH 2.5, 5 minutes) to determine cell surface-bound activity. Finally, the cells were 
lysed with 1 M NaOH (0.25 mL) and the plates washed with PBS (0.25 mL) to determine the 
activity internalised by the cells. Fractions were gamma-counted and the percentage of activity 
in each environment at each time point was determined.  
Cell efflux assay: To determine the cellular efflux of [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-
PSMA(617) over time, DU145 and DU145-PSMA cells were seeded in a 24 well plate (0.25 x 106 
cells/well) 24 hours before the assay. Just before the assay, the cell medium was replaced with 
250 µL fresh RPMI 1640 medium. 5 µL of [67Ga]Ga-THP-PSMA or [67Ga]Ga-DOTA-PSMA(617) 
diluted in PBS was added to the cells to give a final concentration of 12.5 nM. Cells were returned 
to the incubator (37 °C, 5% CO2) for 1 hour. After 1 hour the supernatant was removed from all 
wells and replaced with new RPMI 1640 medium (250 µL). Efflux was then measured for up to 4 
hours. At each time point, the unbound, cell surface-bound and internalised fractions were 
determined using the same method as for cell uptake described above. 
Cell uptake study with high molar activity [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-
PSMA(617): DU145-PSMA cells, DU145 cells and medium-only controls were used for this 
experiment. Cells were prepared at 1 million cells/mL and 250 µL medium containing 0.25 
million cells were added to sterile 1.5 mL centrifuge tubes. 5 µL of [67Ga]Ga-THP-PSMA or 
[67Ga]Ga-DOTA-PSMA(617) with molar activities of 138.5 MBq/nmol and 76 MBq/nmol 
respectively were added to each tube (final concentration and total activity added to cells: 
[67Ga]Ga-THP-PSMA C: 1.25nM, 43 kBq; B: 12.5 nM, 430 kBq; A: 125 nM = 4300 kBq; [67Ga]Ga-
DOTA-PSMA(617) F: 1.25 nM = 24 kBq; E: 12.5 nM = 240 kBq). The cells were incubated with the 
tracer for 1 hour at 37°C, 5% CO2. At each time point the unbound, cell surface-bound and 




5.3.9 Mouse Model of Prostate Cancer 
Animal studies complied with UK Research Councils and Medical Research Charities guidelines 
on responsibility in the use of animals in bioscience research, under UK Home Office project and 
personal licences. Subcutaneous prostate cancer xenografts were produced in SCID/beige mice 
(male, 6-7 weeks) by injecting 4 × 106 DU145-PSMA cells in 50 µL non-supplemented RPMI 
medium into the flank. Injection of [67Ga]Ga-THP-PSMA for imaging or biodistribution was 
undertaken once the tumour was palpable and had reached 5-10 mm in diameter (3-4 weeks 
after inoculation). 
5.3.10 SPECT/CT Scanning 
Mice bearing DU145-PSMA tumours (n = 3) were administered [67Ga]Ga-THP-PSMA (40 MBq, 
100 μL, 0.33 µg, 0.22 nmol) by tail vein injection. At each time-point, CT/SPECT imaging was 
performed under isoflurane anaesthesia with a BioScan nanoSPECT-CT®PLUS (Mediso, 
Hungary). 
The SPECT/CT scans were performed on a BioScan nanoSPECT-CT®PLUS (Mediso, Hungary) 
machine and the acquisition software (Nucline 1.07). CT acquisition was performed using 65 kVp 
tube voltage, with an exposure time of 500 ms with 180○ projections at a pitch of 1. One field of 
view was scanned, covering the whole body of the mouse apart from the tail, which required 12 
minutes for completion. These settings had a CT dose index volume of 0.9 cGy and a dose length 
product of 79.8 cGy.mm and were chosen to minimise CT dose to the mouse. 
The SPECT scanner has 4 heads which could be fitted with either a 1 mm or 2.5 mm multi-pinhole 
collimator. The collimator with 1 mm apertures (recommended for mouse imaging) was used 
for time-points 3 hours, 1 day and 4 days. However, the collimator with 2.5 mm apertures 
(recommended for rat imaging) was used for the 7 day scan due to the lower activity within the 
mice. The machine was calibrated with gallium-67 for each collimator used. The energy windows 
used were: primary 93.20 ± 20% keV, secondary 184.60 ± 20% keV and tertiary 300.00 ± 20% 
keV, as shown in figure 5.5. The SPECT scanning parameters were optimised depending on the 
activity remaining within the mouse to ensure at least 30,000 counts were detected per scan 
that could be used for image reconstruction. This meant varying the seconds per frame between 
40 and 240 and the total number of projections between 30 and 45, resulting in the scan times 












3 hour 1 40 30 45 
1 day 1 80 53 40 
4 day 1 120 80 40 
7 day 2.5 240 120 30 
 
TABLE 5.1: SPECT/CT acquisition parameters for each time point after [67Ga]Ga-THP-PSMA injection. 
 
FIGURE 5.5: Energy windows used for SPECT imaging with gallium-67. Primary 93.20 ± 20% keV (red), 
secondary 184.60 ± 20% keV (green), and tertiary 300.00 ± 20% keV (blue). 
5.3.11 Image Processing 
The SPECT/CT data from each scan was reconstructed using Nucline software (v 2.00). The CT 
scans were reconstructed with a Ran Lak filter to produce a voxel size of 146 x 146 x 146 µm. 
SPECT data collected with each collimator type (1 mm or 2.5 mm aperture) were reconstructed 
using the gallium-67 calibration data acquired with the same collimator type. Images acquired 
with different collimators are therefore not directly comparable. Image processing and analysis 
were performed using Vivoquant software (v 1.23). Before analysis, both CT and PET images 
were realigned, processed to a voxel size of 0.16 mm3 and the SPECT output calibrated to display 
MBq per voxel. Regions of interest (ROIs) for each data file were produced using freehand 
segmentation from the CT image. %ID/cm3 values for each ROI were calculated using the activity 
and volume of the ROI and the injected dose as the decay corrected value administered at t = 0. 
During analysis, backscatter was accounted for by defining a background area within the field of 
view but outside of the mouse, and subtracting this value in MBq/mm3 from values obtained for 
the ROIs. 
5.3.12 Ex vivo Biodistribution Studies 
Ex vivo biodistribution of [67Ga]Ga-THP-PSMA was performed in mice bearing DU145-PSMA 
tumours without imaging. Three mice were used to assess radiotracer biodistribution at each 
time point post-injection: 1 hour, 3 hours, 1 day and 7 days. [67Ga]Ga-THP-PSMA (100 µL, 1.5-
10.9 MBq, 0.33 µg, 0.22 nmol THP-PSMA) was administered via tail vein injection under 
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isoflurane anaesthesia. After injection, anaesthesia ceased and the mice were returned to the 
animal house until the specified time-point, when they were culled by cervical dislocation and 
their organs harvested, weighed and counted. 
5.3.13 Statistical Analysis   
Data were analysed in GraphPad Prism 5 (version 5.04 or version 7.04) and expressed as mean 
± standard deviation. Student t tests were used to determine statistical significance; a P value of 






Radiochemical purity achieved after [67Ga]Ga-THP-PSMA labelling over a range of 
concentrations is shown in figure 5.6. Radiochemical purity was consistently over 90% at 
concentrations of 23 µM or above. The highest molar activity achieved with 93% labelling was 
326 MBq/nmol. In these conditions, the occupancy of gallium-67 in the THP chelator is 22.1%. 
This shows that there is potential for much higher occupancy levels than routinely achieved for 
gallium-68 (5 mL, 40 µg, THP-PSMA kits labelled with 1500 MBq would only have 0.005% 
occupancy). The highest molar activity achieved with [67Ga]Ga-DOTA-PSMA was 120 MBq/nmol 
with 98% radiochemical purity. This is an occupancy of gallium-67 in the DOTA chelator of 8.1%. 
This was the highest molar activity attempted experimentally with DOTA-PSMA(617), so does 
not represent its upper limit. 
 
FIGURE 5.6: Dependence of radiochemical purity of [67Ga]Ga-THP-PSMA on the concentration of THP-PSMA as 
measured by iTLC after 5 minutes pH 6.5-7.5. 
5.4.2 Stability to Autoradiolysis 
Radiolabelled [67Ga]Ga-THP-PSMA (108 MBq/nmol, 2.5 MBq/µL, THP-PSMA 23 µM) was 
observed to undergo autoradiolysis with a drop to under 90% radiochemical purity in 2 hours. 
However, stability at this molar activity was extended to 18 hours by the addition of ascorbic 
acid accompanied by dilution in PBS to 1 MBq/µL (THP-PSMA 8 µM, ascorbic acid 488 µM) (figure 
5.7). 

































FIGURE 5.7: Stability over time of [67Ga]Ga-THP-PSMA with (red) and without (black) the addition of ascorbic 
acid and dilution in PBS as monitored by iTLC. 
5.4.3 Serum Stability 
Human serum stability studies of [67Ga]Ga-THP-PSMA (figure 5.8) showed minimal (< 5%) 
transchelation to serum proteins after 8 days incubation at 37°C. 
5.4.4 Cell Uptake Over Time and Efflux Assays 
Uptake over time of [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-PSMA(617), in DU145-PSMA and 
DU145 cells at 37°C are shown in figure 5.9. Both tracers showed time-dependent accumulation 
in GCP(II)/PSMA-expressing cells, but very low uptake (< 0.5 %) in non-GCP(II)/PSMA-expressing 
cells, confirming uptake is GCP(II)/PSMA-mediated. The uptake was higher at each time point 
for [67Ga]Ga-DOTA-PSMA(617) compared to [67Ga]Ga-THP-PSMA. Efflux studies (figure 5.10) 
show that both tracers are released from cells to the supernatant over time, but that the 
percentage of [67Ga]Ga-THP-PSMA retained in the cell is half that of [67Ga]Ga-DOTA-PSMA(617) 
across the time points studied. Therefore not only is less [67Ga]Ga-THP-PSMA delivered to the 




FIGURE 5.8: Size exclusion HPLC radiochromatograms of (A) [67Ga]Ga-THP-PSMA; (B) [67Ga]Ga-THP-PSMA 
after 1 hour incubation in human serum at 37°C, showing 0% transchelation to serum proteins; (C) [67Ga]Ga-
THP-PSMA after 8 days incubation in human serum at 37°C, showing < 5% transchelation to serum; (D) 
[67Ga]Ga3+ incubated in human serum for 8 days showing [67Ga]Ga3+ bound to serum protein and EDTA . All 





FIGURE 5.9: Uptake of 12.5 nM [67Ga]Ga-THP-PSMA (A) and [67Ga]Ga-DOTA-PSMA (B) over time at 37°C, 1×106 
cells/mL. Combined internalised and cell surface-bound activity DU145-PSMA cells (blue); internalised activity 
DU145-PSMA cells (black); internalised and cell surface-bound activity DU145 cells (red). Data points show 





FIGURE 5.10: Efflux of [67Ga]Ga-THP-PSMA (A) and [67Ga]Ga-DOTA-PSMA (B) at 37°C, 1×106 cells/mL. Prior to 
assay cells had been incubated for 1 hour at 37°C with of 12.5 nM tracer and then the supernatant was replaced. 
Combined internalised and cell surface-bound activity in DU145-PSMA cells (blue); internalised activity in 
DU145-PSMA cells (black); internalised and cell surface-bound activity in DU145 cells (red). Data points show 
mean ± SD (n = 4 for [67Ga]Ga-THP-PSMA, n = 3 for [67Ga]Ga-DOTA-PSMA). 
5.4.5 Cell Uptake with High Molar Activity [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-
PSMA(617) 
The proportion of tracer bound to the cell surface and internalised into the cell after 1 hour 
incubation with a range of tracer concentrations are shown in figure 5.11. Both tracers showed 
low non-receptor-mediated uptake in non-GCP(II)/PSMA-expressing DU145 cells. The total 
activity associated with the cell surface and internalised after incubation (1 hour, 37°C) with 
[67Ga]Ga-THP-PSMA (1.25 nM, 12.5 nM, or 125 nM) or [67Ga]Ga-DOTA-PSMA(617) (1.25 nM, or 
12.5 nM) is shown in figure 5.12. For both tracers the maximum value achieved was ~ 0.1 Bq/cell, 
however, for [67Ga]Ga-DOTA-PSMA(617) this was achieved at a 10 fold lower concentration of 
tracer and at a lower molar activity (molar activity 76 MBq/nmol compared to a molar activity 




FIGURE 5.11: (A) Percentage uptake in DU145-PSMA cells of [67Ga]Ga-THP-PSMA (molar activity 138.5 
MBq/nmol) and (B) [67Ga]Ga-DOTA-PSMA(617) (molar activity 76 MBq/nmol) after 1 hour at 37°C, 1×106 
cells/mL over a range of concentrations. Surface-bound activity (white) and internalised activity (grey) are 
shown (mean ± SD, n = 2). 
 
FIGURE 5.12: (A) Activity per cell of [67Ga]Ga-THP-PSMA (molar activity 138.5 MBq/nmol) and (B) [67Ga]Ga-
DOTA-PSMA(617) (molar activity 76 MBq/nmol) after 1 hour at 37°C, 1×106 cells/mL over a range of 
concentrations. Bars show surface-bound activity DU145-PSMA cells (white); internalised activity DU145-PSMA 
cells (grey) (mean ± SD, n = 2). 
5.4.6 Ex vivo Biodistribution of [67Ga]Ga-THP-PSMA 
Biodistribution of [67Ga]Ga-THP-PSMA at 1 hour showed that the majority of the tracer was no 
longer in circulation and that excretion was exclusively renal with the majority of the activity 
associated with the kidneys. Uptake in the GCP(II)/PSMA-expressing tumour was seen (3.5 ± 1.2 
%ID/g). Over time, the activity in the whole body, including that associated with both the kidney 
and the tumour, decreased. The largest change occurred over the first 24 hour period, but 
activity was still detectable in the kidney and tumour 7 days post-injection. Tumour uptake of 
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[67Ga]Ga-THP-PSMA was highest at 1 hour post-injection (3.47 ± 1.15 %ID/g), but then decreased 
over time, with a reduction to 1.12 ± 0.4 %ID/g in 3 hours, 0.2 ± 0.07 %ID/g in 24 hours and 0.16 
± 0.07 %ID/g in 7 days. The highest tumour to background ratios (tumour to muscle = 215, 
tumour to blood = 132) were observed at the 3 hour time-point. Table 5.2 and figure 5.13 












Time point 1 hour 3 hours 24 hours 7 days  
(n = 3) (n = 3) (n = 3) (n = 3) 
 %ID/g %ID/g %ID/g %ID/g 
Tumour 3.47 ± 1.15 1.12 ± 0.40 0.20 ± 0.07 0.16 ± 0.07 
Blood 0.12 ± 0.04 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 
Small Intestines 0.06 ± 0.01 0.1 ± 0.12 0.02 ± 0.01 0.01 ± 0.00 
Kidney 8.02 ± 3.22 1.83 ± 0.41 0.40 ± 0.10 0.20 ± 0.02 
Liver 0.07 ± 0.02 0.09 ± 0.00 0.08 ± 0.01 0.07 ± 0.01 
Lungs 0.20 ± 0.04 0.07 ± 0.04 0.03 ± 0.00 0.04 ± 0.02 
Muscle 0.03 ± 0.01 0.01 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
Pancreas 0.06 ± 0.02 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.00 
Spleen 1.54 ± 0.75 0.18 ± 0.04 0.05 ± 0.02 0.06 ± 0.05 
Tumour to organ ratios     
Tumour to blood 28.6 ± 4 132 ± 95 107 ± 46 83 ± 81 
Tumour to muscle 134 ± 18 215 ± 100 58 ± 34 49 ± 21 
Tumour to spleen 2.6 ± 1.3 6.4 ± 1.9 4.1 ± 2.3 7.1 ± 9.7 
Tumour to kidney 0.4 ± 0.0 0.6 ± 0.1 0.6 ± 0.3 0.7 ± 0.3 
 





FIGURE 5.13: Ex vivo biodistribution-derived time-activity curves (%ID/g) of [67Ga]Ga-THP-PSMA in mice 
bearing DU145-PSMA tumours: (A) shows first 24 hours; (B) shows up to 7 days. Kidney (green), tumour (red), 
spleen (blue), muscle (black) (mean ± SD, n = 3). 
5.4.7 SPECT/CT Imaging Data 
Gallium-67 imaging had not been performed previously on the nanoSPECT/CT system within the 
department and so the achievable image quality was unknown. The images produced were 
prone to high background scatter but the organs of interest (kidney, bladder and tumour) could 
still be delineated in the SPECT image (figure 5.14). The image analysis showed good alignment 
with the ex vivo biodistribution, with tracer distribution reflecting renal excretion and tumour 
uptake. In agreement with the biodistribution results, the total activity within the whole animal 




FIGURE 5.14: Representative SPECT/CT images of a SCID/beige mouse with DU145-PSMA tumours imaged 
with [67Ga]Ga-THP-PSMA without scatter correction. The white arrows indicate the position of the tumour. For 
all images, the maximum intensity projection (1) and an axial slice (2) are shown. (A) 3 hour images scaled to 





FIGURE 5.15: SPECT/CT derived time-activity curves of [67Ga]Ga-THP-PSMA in mice bearing DU145-PSMA 
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The aim of this study was to radiolabel [67Ga]Ga-THP-PSMA at high molar activity and assess its 
ability to deliver gallium-67 to GCP(II)/PSMA-expressing cells. In vitro experiments were also 
completed with [67Ga]Ga-DOTA-PSMA(617) for comparison as this radiotracer is known to have 
a higher affinity for GCP(II)/PSMA (18)(20)(23) (chapter 3) and its lutetium-177 analogue has 
been used for [177Lu]Lu-DOTA-PSMA(617) therapy. It is not only the affinity for GCP(II)/PSMA 
that governs the activity delivered to each cell by a radiotracer and consequently the dose which 
that cell receives; molar activity is potentially just as critical, and should be as high as possible 
for therapeutic applications so that the highest possible target to background ratios can be 
obtained, without saturation of receptors. Therefore it was important to maximise the molar 
activity of the [67Ga]Ga-PSMA tracers within this study. To achieve this, gallium-67 at a high 
activity concentration (35 GBq/mL) in 0.1 M HCl was used without the presence of any weakly 
coordinating ligands such as citrate. [67Ga]Ga-THP-PSMA was labelled in one step at room 
temperature, with a radiochemical purity over 90%, within 10 minutes at pH 6-7 achieving a 
maximum molar activity of 326 MBq/nmol. In these conditions the occupancy of gallium-67 in 
the THP chelator was 22.1%. This is an extremely high value compared to most radiolabelled 
tracers and was achieved at room temperature within 10 minutes. This occupancy level for THP-
PSMA is much higher than had previously been achieved with gallium-67 converted from citrate 
(0.4% occupancy (20)) or routinely achieved with gallium-68 (5 mL, 40 µg THP-PSMA kits labelled 
with 1500 MBq would only have 0.005% occupancy (20)). One factor allowing this increased 
occupancy is the higher activity concentration of the gallium-67 supplied/used (35 GBq/mL, 24 
µM gallium-67) compared to gallium-67 in HCl converted from gallium-67 citrate (1.5 GBq/mL, 
1 µM gallium-67 (20)) or gallium-68 from an Galliapharm (Eckert and Ziegler) generator (0.3 
GBq/mL, 2.9 nM gallium-68 (20)). Another factor is likely to be the levels of contaminating trace-
metals, and so it would have been interesting to have carried out ICP-MS on these samples to 
identify the all trace-metals in these different sources of gallium-67. However, it is known that 
iron and titanium are the trace metal contaminants that have the greatest impact on 
radiolabelling of THP (chapter 2, figure 2.20). The gallium-67 supplied by Nordion is likely to have 
had a lower concentration of these metal contaminants than, the gallium-67 converted from 
citrate or the gallium-68 from a generator. This is because, in the case of gallium-67, citrate 
buffers have been introduced (sodium citrate di-hydrate, sodium chloride) which are likely to 
contain trace-metals, and for gallium-68 the titanium-dioxide column of the generator is a major 
source of titanium in its eluate (46). 
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The occupancy level achieved for gallium-68 is therefore not limited by the chelator choice, the 
ability of THP to achieve excellent occupancy under the right conditions has been demonstrated 
here, but instead, it is most likely limited by the activity concentration of radioactive gallium-68 
available and the levels of contaminating trace metals within it. Therefore further investigations 
into how these parameters could be improved for gallium-68 could be very valuable to the field.  
After increasing the stability of [67Ga]Ga-THP-PSMA by the addition of ascorbic acid in 
combination with dilution in PBS, to protect against autoradiolysis, in vitro experiments were 
performed to assess the tracer uptake and efflux over time. When compared to [67Ga]Ga-DOTA-
PSMA(617), [67Ga]Ga-THP-PSMA showed almost 10 fold lower uptake and double the efflux rate; 
attributes that are unfavourable for a therapeutic radiotracer. It would be ideal to deliver a large 
amount of gallium-67 specifically to cells that express GCP(II)/PSMA, and for that gallium-67 to 
remain in that cell, even when the concentration drops in surrounding tissue/blood (as 
mimicked by the efflux assay), to deliver the maximum activity and consequently dose to the 
cell. The fate of [67/68Ga]Ga-PSMA tracers after they enter the cell is unknown and this could 
greatly affect the rate of efflux. Of particular interest would be where the tracers localise, 
whether they are broken down intracellularly, and whether they release gallium. Current 
information about the intracellular location of PSMA compounds using the same urea-based 
scaffold can only be gleaned from fluorescent GCP(II)/PSMA imaging agents such as YC-36 (figure 
5.2), which do show perinuclear accumulation (16). However, these results should be 
interpreted with caution as fluorescent agents require large, often lipophilic, substituents to be 
added to the GCP(II)/PSMA targeting moiety and so could have very different intracellular 
distribution to radiometal versions. Microautoradiography methods could provide insight into 
the location of the radiometal (within the resolution of this technique) and therefore could be 
used to help design tracers that not only have high affinity for GCP(II)/PSMA but also localise 
close to the nucleus, which is believed to induce the highest therapeutic effect (20)(26). 
However, the technique is limited as it is only possible to visualise the radiometal rather than 
specifically the radiometal complex, as it is not possible to differentiate between chelated and 
un-chelated radio-gallium within the cell. 
With both [67Ga]Ga-THP-PSMA and [67Ga]Ga-DOTA-PSMA(617), with molar activities of 138.5 
MBq/nmol and 76 MBq/nmol respectively, specific delivery of gallium-67 to GCP(II)/PSMA-
expressing cells was possible. However, a maximum of only 0.1 Bq/cell was experimentally 
achieved within 1 hour. This is 10 times lower than the level of 1 Bq per cell shown to be required 
to achieve 90% cell killing with [67Ga]Ga-8-hydroxyquinoline (38). Cell-associated activity of 0.1 
Bq/cell was achieved at 125 nM for [67Ga]Ga-THP-PSMA (138.5 MBq/nmol) and 12.5 nM for 
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[67Ga]Ga-DOTA-PSMA(617) (76 MBq/nmol). [67Ga]Ga-DOTA-PSMA(617) was not tested at 125 
nM due to the limited quantity of gallium-67 available for radiolabelling at the time of this 
experiment. It is likely that the activity per cell would have increased further at this 
concentration, but as the IC50 of [67Ga]Ga-DOTA-PSMA(617) is known to be in the range of 10-
40 nM (20)(23) it is likely that blocking from unlabelled DOTA-PSMA(617) would occur and so it 
would be unrealistic to extrapolate this data to 125 nM. It would have been interesting to extend 
this work and establish whether 0.1 Bq per cell was high enough to see a therapeutic effect, as 
the [67Ga]Ga-PSMA tracers may have different cellular distribution compared to that achieved 
by treatment with [67Ga]Ga-8-hydroxyquinoline and so its dose could have been deposited in 
different cell areas. Also, it is important to consider that 0.1 Bq per cell is a mean value across 
0.25 million cells. Studies looking into direct labelling of cells with [111In]In-8-hydroxyquinoline 
have shown with microautoradiography that there are large differences in how heavily cells are 
labelled within the same population (47). Similarly, in this study, it is unlikely that each cell had 
the same uptake of gallium-67 and therefore received the same dose. Therefore a portion of the 
GCP(II)PSMA-expressing cells could have taken up enough gallium-67 for it to have a toxic effect 
which may have been detectable. The therapeutic effects of [67Ga]Ga-THP-PSMA and [67Ga]Ga-
DOTA-PSMA(617) could have been monitored in vitro through, γ-H2AX staining for double-
strand DNA breaks (48), and clonogenic assays which assess the level of cell reproductive death 
(38)(49). This was not possible within this project as the supplier of gallium-67 at high activity 
concentration (required to achieve these high molar activities) ceased its production and a 
suitable alternative could not be found. Additionally, these results suggested the affinity of 
[67Ga]Ga-THP-PSMA was the factor limiting the uptake in vitro, rather than the molar activity, so 
this became the focus of future work. Chapter 6 provides a review of the GCP(II)/PSMA receptor 
which was used to propose higher affinity ligands and chapter 7 outlines the synthesis and 
evaluation of a new zinc ion binding motif designed to improve affinity for GCP(II)/PSMA. 
Although these results suggest the affinity of [67Ga]Ga-THP-PSMA is not ideal to continue in vitro 
studies, it was clear that the in vitro performance of the gallium-68 imaging agent [68Ga]Ga-THP-
PSMA had not limited its ability to delineate GCP(II)/PSMA-expressing tumours in vivo (chapter 
3 & 4 (20)). As explored in the introduction, uptake and retention of radiotracers in tumours and 
other GCP(II)/PSMA-expressing organs are not well predicted by in vitro affinity values (IC50 or 
Kd), and so it was important to assess these parameters experimentally. Therefore in vivo studies 
were performed to monitor the uptake and retention of [67Ga]Ga-THP-PSMA in GCP(II)/PSMA-
expressing tumours. These results showed the biodistribution was similar to that seen for 
[68Ga]Ga-THP-PSMA, with rapid renal excretion, low background uptake and specific uptake in 
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tumour (chapter 3 (20)). Biodistribution results showed decay-corrected tumour uptake of 
[67Ga]Ga-THP-PSMA was highest at 1 hour post-injection (3.47 ± 1.15 %ID/g), but then fell over 
time, with a reduction to 1.12 ± 0.4 %ID/g in 3 hours, 0.2 ± 0.07 %ID/g in 24 hours and 0.16 ± 
0.07 %ID/g in 7 days. These values can be extrapolated to gain an approximation of the amount 
of activity that could be delivered to the cells if [67Ga]Ga-THP-PSMA at 326 MBq/nmol (maximum 
molar activity) had been administered. With this molar activity injecting 0.22 nmol of THP-PSMA 
per mouse (the level used in this study) would result in an injected activity of 72 MBq. As the 
average tumour mass in this study was 0.05 g and assuming this tumour contained 108 cells per 
gram (50), this tumour contained 5 million cells. Therefore using the experimentally derived 
%ID/g at 1 hour (3.47 %ID/g = 2.5 MBq/g), it could be assumed that 0.124 MBq would have been 
delivered to the tumour at this time-point, providing an average of 0.025 Bq/cell. This low value 
suggests that again improvements to affinity would be required to deliver an adequate 
therapeutic dose to tumours. There was also little difference between the rate of washout of 
[67Ga]Ga-THP-PSMA from the tumour and the kidneys of the mice. This differs from published 
results for [177Lu]Lu-DOTA-PSMA(617) which showed, a more favourable biodistribution for 
molecular radiotherapy, with high retention in the tumour but washout from the kidney (18). 
SPECT/CT data showed trends consistent with the biodistribution. However, the SPECT images 
had high background scatter, and so these were difficult to interpret without the CT to provide 
structural information. This also meant that the scatter had to be corrected for before 
quantitative data could be obtained from the scan. However, the quality of the images obtained 






[67Ga]Ga-THP-PSMA can be labelled at high molar activity and specifically accumulates within 
GCP(II)/PSMA-expressing cells and tumours. However, this uptake is lower than for [67Ga]Ga-
DOTA-PSMA(617) and [67Ga]Ga-THP-PSMA is seen to have significant efflux from both cells and 
tumours over time, suggesting it is less suitable for therapeutic applications than other 
GCP(II)/PSMA tracers. High affinity [67Ga]Ga-PSMA tracers, labelled at high molar activity would 
be required to deliver a therapeutic cellular activity in vitro. Currently [67Ga]Ga-THP-PSMA does 
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23.  Wüstemann T, Bauder-Wüst U, Schäfer M, Eder M, Benesova M, Leotta K, Kratochwil C, 
Haberkorn U, Kopka K, Mier W. Design of Internalizing PSMA-Specific Glu-Ureido-Based 
Radiotherapeuticals. Theranostics. 2016;6:1085-1095. 
24.  Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of Cancer with High Linear Energy 
Transfer (LET) Radiation Delivered by Radionuclides Emitting α-Particles or Auger 
Electrons. Adv Drug Deliv Rev. 2017;109:102-118. 
25.  Naidoo K, Pinder SE. Micro- and Macro-Metastasis in the Axillary Lymph Node: A Review. 
Surgeon. 2017;15:76-82. 
26.  Buchegger F, Perillo-Adamer F, Dupertuis YM, Bischof Delaloye A. Auger Radiation 
Targeted into DNA: A Therapy Perspective. Eur J Nucl Med Mol Imaging. 2006;33:1352-
1363. 
27.  Pantel K, Alix-Panabières C, Riethdorf S. Cancer Micrometastases. Nat Rev Clin Oncol. 
2009;6:339-351. 
28.  Miller MC, Doyle G V, Terstappen LWMM. Significance of Circulating Tumor Cells 
Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and 
Prostate Cancer. J Oncol. 2010;2010:1-8. 




30.  Pomplun E, Sutmann G. Is Coulomb Explosion a Damaging Mechanism for 125IUdR? Int J 
Radiat Biol. 2004;80:855-860. 
31.  Khanna KK, Jackson SP. DNA Double-Strand Breaks: Signaling, Repair and the Cancer 
Connection. Nat Genet. 2001;27:247-254. 
32.  Shen C, Minn I, Chen Y, Mease RC, Brummet ME, Pomper MG, Kiess AP. Auger 
Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen in a 
Micrometastatic Model of Prostate Cancer. Int J Radiat Oncol. 2016;96:S110. 
33.  Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich 
JW, Haberkorn U. PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy 
of Prostate Cancer. J Nucl Med. 2015;56:293-298. 
34.  Nayak TK, Brechbiel MW. Radioimmunoimaging with Longer-Lived Positron-Emitting 
Radionuclides: Potentials and Challenges. Bioconjug Chem. 2009;20:825-841. 
35.  Riesco-Eizaguirre G, Santisteban P. A Perspective View of Sodium Iodide Symporter 
Research and Its Clinical Implications. Eur J Endocrinol. 2006;155:495-512. 
36.  Jonkhoff AR, Huijgens PC, Versteegh RT, Martens HJM, Teule GJJ, Ossenkoppelel GJ. 
Gallium-67 Radiotoxicity in Human U937 Lymphoma Cells. Br J Cancer. 1993;67:693-700. 
37.  Jonkhoff AR, Plaizier MABD, Ossenkoppele GJ, Teule GJJ, Huijgens PC. High-Dose Gallium-
67 Therapy in Patients with Relapsed Acute Leukaemia: A Feasibility Study. Br J Cancer. 
1995;72:1541-1546. 
38.  Othman MF bin, Mitry NR, Lewington VJ, Blower PJ, Terry SYA. Re-Assessing Gallium-67 
as a Therapeutic Radionuclide. Nucl Med Biol. 2017;46:12-18. 
39.  Michel RB, Brechbiel MW, Mattes MJ. A Comparison of 4 Radionuclides Conjugated to 
Antibodies for Single-Cell Kill. J Nucl Med. 2003;44:632-640. 
40.  Howell RW. Radiation Spectra for Auger-Electron Emitting Radionuclides: Report No 2 of 
AAPM Nuclear Medicine Task Group No.6. Med Phys. 1992:1371-1383. 
41.  Govindan S V, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, 
Sgouros G, Mattes MJ. Radionuclides Linked to a CD74 Antibody as Therapeutic Agents 
for B-Cell Lymphoma: Comparison of Auger Electron Emitters with Beta-Particle Emitters. 
J Nucl Med. 2000;41:2089-97. 
42.  Jonkhoff AR, Huijgens PC, Versteegh RT, van Lingen A, Ossenkoppele GJ, Dräger AM, 
Teule GJJ. Radiotoxicity of 67-Gallium on Myeloid Leukemic Blasts. Leuk Res. 
1995;19:169-174. 
43.  Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Advances in Brief Therapy of 
Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice 
with an Anti-CD74 Antibody Conjugated with 111 Indium, 67 Gallium, or 90 Yttrium. Clin 
Cancer Res. 2001;7:1505-1510. 
44.  Price EW, Orvig C. Matching Chelators to Radiometals for Radiopharmaceuticals. Chem 
Soc Rev. 2014;43:260-90. 
45.  Kampmeier F, Williams JD, Maher J, Mullen GE, Blower PJ. Design and Preclinical 
Evaluation of a 99mTc-Labelled Diabody of MAb J591 for SPECT Imaging of Prostate-
Specific Membrane Antigen (PSMA). EJNMMI Res. 2014;4:13. 
46.  Tsionou MI, Knapp CE, Foley CA, Munteanu CR, Cakebread A, Imberti C, Eykyn TR, Young 
JD, Paterson BM, Blower PJ, Ma MT. Comparison of Macrocyclic and Acyclic Chelators for 
Gallium-68 Radiolabelling. RSC Adv. 2017;7:49586-49599. 
47.  Puncher MR, Blower PJ. Frozen Section Microautoradiography in the Study of 
Radionuclide Targeting: Application to Indium-111-Oxine-Labeled Leukocytes. J Nucl 
Med. 1995;36:499-505. 
48.  Kuo LJ, Yang L-X. Gamma-H2AX - a Novel Biomarker for DNA Double-Strand Breaks. In 
Vivo (Brooklyn). 2008;22:305-9. 
49.  Franken NAP, Rodermond HM, Stap J, Haveman J, Bree C Van. Clonogenic Assay of Cells 
226 
 
in Vitro. Nat Protoc. 2006;1:2315-2319. 






6 The Prostate Specific Membrane Antigen: Structure, Active Site and 
Interaction with Natural Substrates 
The results in chapters 3, 4 and 5 indicate that there is an opportunity to re-design the THP-
PSMA bioconjugate to have higher affinity for GCP(II)/PSMA. The following literature survey was 
conducted to inform this process and at the end of this chapter, my hypotheses for higher 
affinity variants of THP-PSMA will be presented. In this chapter, the major structural 
components of GCP(II)/PSMA will be described from the latest high-resolution crystal structures 
as well as the important interactions between GCP(II)/PSMA and its natural substrates. The 
interactions of inhibitors are also discussed, especially those used to determine the mechanism 
of enzymatic hydrolysis for GCP(II)/PSMA. The interactions that will be discussed govern the 
substrate’s affinity and specificity. Of the two natural substrates N-acetyl-L-aspartyl-L-glutamate 
(NAAG) and poly-γ-glutamated folate, the latter has the most similar structure to the THP-PSMA 
bioconjugate that is the subject of optimisation. Therefore the interactions between 
GCP(II)/PSMA and poly-γ-glutamated folate will be focused on in this chapter. 
6.1 Overview of GCP(II)/PSMA 
The prostate specific membrane antigen (PSMA) is a transmembrane zinc-dependent metallo-
enzyme formed of 750 residues, with a molecular weight of 110,000 daltons (1). The human 
PSMA gene was first cloned from the LNCaP prostate cancer cell line and is located in 
chromosome 11p11-12 (2). PSMA is known and referred to in the literature by multiple names: 
N-acetylated-α-linked acidic dipeptidase (NAALADase), folate hydrolase 1 (FOLH1), and 
glutamate carboxypeptidase II (GCP(II), EC 3.4.17.21) (3). This occurred due to the antigen being 
discovered independently in both prostate cancer, where it was named PSMA, and in the brain, 
where it was thought only to hydrolyse N-acetyl-L-aspartyl-L-glutamate (NAAG) and therefore 
named N-acetylated-α-linked acidic dipeptidase (NAALADase) (4). Separate names for this 
receptor prevailed until it was determined that these peptidases were in fact identical; found in 
multiple locations and had multiple functions. At this point, it was given the more general name 
glutamate carboxypeptidase II (GCP(II)) (1)(3). 
Healthy human tissues that express GCP(II)/PSMA include the prostate gland (the cytoplasm and 
apical side of the epithelium surrounding prostatic ducts), the nervous system (astrocytes and 
Schwann cells), the kidney (proximal tubules) and the small intestine (jejunal brush border 
membranes) (3)(5)(6). The enzymatic activity of GCP(II)/PSMA is the cleavage of the terminal 
glutamate through the hydrolysis of a peptide bond; if a glutamate chain is present the 
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glutamates can be cleaved sequentially. GCP(II)/PSMA has two known natural substrates; N-
acetyl-L-aspartyl-L-glutamate (NAAG) and poly-γ-glutamated folate. The structures of these 
compounds and their cleavage products are shown in figure 6.1. Note that in poly-γ-glutamated 
folate the glutamic acid chain is formed by a peptide bond between the side chain of one 
glutamic acid and the amino group of the next glutamic acid, rather than a traditional peptide 
backbone. GCP(II)/PSMA hydrolyses NAAG into glutamate and N-acetyl-aspartate (NAA) (7) and 
hydrolyses poly-γ-glutamated(n) folate into glutamate and poly-γ-glutamated(n-1) folate or folic 
acid (8). Kinetic studies have been used to determine the rate at which GCP(II)/PSMA can 
hydrolyse these compounds. The Michaelis constant (KM) of NAAG was found to be 250 nM (8) 
(Michaelis constant (KM) is equal to the concentration of the substrate when the rate is half of 
the maximum velocity). For poly-γ-glutamated folate the KM was dependent on the number of 
glutamates in the poly-γ-glutamate chain. When only one cleavable glutamate was present the 
KM was found to be 400-500 nM (8). The KM value dropped to 50-100 nM with two cleavable 
glutamates and remained at this value for longer chain lengths (KM was assessed with up to six 
cleavable glutamates) (8).  
 
FIGURE 6.1: The structure of the natural substrates of GCP(II)/PSMA and their hydrolysis products. The cleaved 




6.1.1 GCP(II)/PSMA in the Brain  
NAAG is one of the three most prevalent neurotransmitters in the mammalian brain (9). The 
function of GCP(II)/PSMA in the brain in the glutamate signalling pathway has been well 
described and reviewed (9)(10), and so will not be discussed further here.  
6.1.2 GCP(II)/PSMA in the Small Intestine 
The cleavage of terminal glutamates from poly-γ-glutamated folate occurs in the small intestine, 
within the jejunal brush border. This is because poly-γ-glutamated folates present in food need 
to be hydrolysed to produce glutamate and folic acid before they can be transported in the blood 
and utilised by the body. Folic acid is integral to many metabolic processes in the body including 
DNA synthesis, DNA methylation and the formation of methionine (2). All of these processes are 
known to be important for cell proliferation. Glutamate, on the other hand, is a non-essential 
amino acid that can be synthesised by the body. It is an excitatory neurotransmitter in the 
central nervous system, and is also a precursor for the synthesis of many metabolites including 
δ-1-pyrroline-5-carboxylate, β-citrylglutamate, L-γ-glutamyl-L-cysteine, γ-aminobutyrate and 
glutathione (11). 
6.1.3 GCP(II)/PSMA in the Prostate and Kidney 
The role of GCP(II)/PSMA in the prostate and kidney is not fully understood, especially as neither 
NAAG, nor poly-γ-glutamated folate are present in the bloodstream under normal conditions. 
However, GCP(II)/PSMA does have receptor-like features, suggesting that GCP(II)/PSMA may be 
involved in transmembrane signalling or receptor-ligand interactions (1). These include its ability 
to undergo endocytic internalisation and the presence of a polyproline type II helix on its surface, 
which in other cells, is known to mediate protein-protein interactions (1). These functions, if 
confirmed, would give an explanation for the localisation of GCP(II)/PSMA at these sites and also 
further insight into its prevalence in prostate cancer (1)(3). 
6.1.4 GCP(II)/PSMA in Prostate Cancer 
GCP(II)/PSMA-expression levels are over one thousand times higher in malignant prostate 
cancer tissues than in normal/healthy tissues (2). GCP(II)/PSMA has also been detected in the 
neovasculature of a number of tumours including those of the kidney, bladder, thyroid, breast 
and colon (12)(13). In prostate cancer, GCP(II)/PSMA-expression level increases with cancer 
grade and the highest levels of expression are found in androgen-resistant prostate cancer (14). 
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This relationship suggests that GCP(II)/PSMA plays a role in cancer progression. However, 
biological mechanisms by which GCP(II)/PSMA aids malignant transformation or metastatic 
behaviour have not yet been determined (15). The expression of GCP(II)/PSMA is known to be 
negatively regulated by androgens, but its expression is increased by fibroblast, transforming, 
and epidermal growth factors (16). Increased GCP(II)/PSMA-expression has been shown in vitro 
to increase the metabolism of poly-γ-glutamated folates and folate uptake, and consequently 
proliferation in both physiological and low folate environments (17)(18). Blood typically contains 
folate but not poly-γ-glutamated folate, as this form is used for intracellular folate storage. 
However, in areas of necrosis poly-γ-glutamated folates could be released from dying cells. 
Therefore upregulation of GCP(II)/PSMA in prostate cancer and the neovasculature of other 
tumours may occur so that poly-γ-glutamated folates released from necrotic cells can be utilised. 
This additional folate could, in turn, increase the proliferation of the tumour (2). However, this 
is just a hypothesis; the physiological function of GCP(II)/PSMA in prostate cancer has not yet 
been determined and, as discussed above, it could also be upregulated on the cell surface 
because it provides a mechanism for transmembrane signalling. 
6.1.5 GCP(II)/PSMA Internalisation 
Membrane-bound GCP(II)/PSMA undergoes spontaneous internalisation, with 60% of the 
GCP(II)/PSMA internalised every hour (19). However, the internalisation rate can be increased 
by binding the monoclonal antibody J591 which increases the internalisation rate in a dose-
dependent manner, to a maximum of three times the rate of spontaneous internalisation (19). 
Confocal microscopy and electron microscopy have been used to show that GCP(II)/PSMA-
[mAb] complexes are endocytosed through clathrin-coated pits (2). The protein is then recycled 
to the cell membrane by the recycling endosomal compartment (REC) or transported to the 
lysosomes where it is degraded (2). The bound ligands may also be retained in the lysosomal 
compartments or may be released within the cell, where they could redistribute within the cell, 
or diffuse out of it (15). Conversely, small molecule substrates and inhibitors of the active site of 
GCP(II)/PSMA do not alter the rate of internalisation, showing that internalisation and enzymatic 
function are independent processes (2). 
6.1.6 Structure of GCP(II)/PSMA 
GCP(II)/PSMA is a typical type II transmembrane protein with three main parts: a short N-
terminal cytoplasmic tail; a single helix that spans the membrane; and a large extracellular 
region. The N-terminal of the protein is important for internalisation and recycling of 
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GCP(II)/PSMA, through clathrin-coated pits (2). The membrane-spanning helix fixes the protein 
in the membrane and connects the intracellular and extracellular parts. It has been shown that 
GCP(II)/PSMA dimerises through interlinking the extracellular regions of two GCP(II)/PSMA 
enzymes and that it only has hydrolytic activity in this form (1). The extracellular region of 
GCP(II)/PSMA resembles the transferrin receptor and has 54% homology with it (2). Like 
transferrin, GCP(II)/PSMA is heavily glycosylated on nitrogen and oxygen sites. Its ten nitrogen 
glycosylation sites have been shown to be vital for: enzymatic activity, targeting GCP(II)/PSMA 
to the membrane and ensuring correct protein folding and stability (20)(21). Interestingly, the 
glycosylation profile varies between prostate cancer cell lines suggesting that different sugar 
epitopes may affect the metastatic potential of GCP(II)/PSMA-expressing prostate cancer (2). 
The extracellular domain of GCP(II)/PSMA produces the enzymatic function of the protein and 
is comprised of three individual domains: the protease domain (domain I); the apical domain 
(domain II); and the C-terminal (domain III). All three are required for substrate binding and 
processing as residues from each domain contribute to the binding cavity and active site. An 
overview of the structure of GCP(II)/PSMA is shown in figure 6.2.  
 
FIGURE 6.2: The overall structure of GCP(II)/PSMA dimer showing the short N-terminal cytoplasmic tail, a 
single membrane-spanning helix and a large extracellular region which is divided into 3 domains: domain (I) is 
shown in green, domain (II) is shown in dark blue and, domain (III) is shown in yellow. The zinc ions in the active 
site are represented as red spheres and the N-linked sugar moieties are coloured cyan. Reproduced with 
permission from (3). 
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6.2 Overview of the Active Site of GCP(II)/PSMA 
GCP(II)/PSMA is a protease which cleaves terminal glutamates from its natural substrates NAAG 
and poly-γ-glutamated folate. The nomenclature used for the amino acid residues in protease 
substrates is P1 for the residue N-terminal to the cleavage site and P1’ for the residue C-terminal 
to the cleavage site (22). The values of P then increase towards the N terminus and the values 
of P’ increase towards the C terminus, as shown in figure 6.3. The protease binding pockets, 
which accommodate each residue, are named S1 and S1’ at each side of the cleaved bond and 
increase in the same manner as the values for P or P’. For the natural substrates of GCP(II)/PSMA, 
NAAG and poly-γ-glutamated folate, the P1’ residue is always the terminal glutamate and 
interacts with the S1’ pocket. The other side of the cleavable peptide bond is the P1 residue 
which interacts with the S1 pocket (1). Figure 6.4 identifies the P1 and P1’ regions of 
GCP(II)/PSMA’s natural substrates and a number of its known inhibitors.  
 





FIGURE 6.4: The structures of the natural substrates and inhibitors of GCP(II)/PSMA and their P1 and P1’ 
regions. The red line denotes the bond that is broken through hydrolysis. (A) N-acetyl-L-aspartyl-L-glutamate 
(NAAG), (B) Poly-γ-glutamated folate, (C) Phosphinate-based inhibitor SPE ((2S)-2-{[(2-carboxy-ethyl)-
hydroxy-phosphinoyl]methyl}-pentanedioic acid), (D) Urea-based inhibitor DCIBzL ((S)-2-(3-((S)-1-carboxy-
(4-iodobenzamido)pentyl)ureido)pentanedioic acid), (E) Phosphonate-based inhibitor without a P1 region 2-




The binding pocket for GCP(II)/PSMA consists of a 20 Å entrance tunnel leading to the active site 
of the enzyme at the base of the cavity. The key active site components are: two zinc ions; an 
activated water molecule (or OH-) which bridges the zinc ions; and a catalytic glutamic acid 
residue Glu424 which acts as a proton shuttle during hydrolysis. The importance of Glu424 has 
been evaluated with mutagenesis studies (23) where Glu424 was replaced with an alanine 
residue. This caused complete loss of hydrolytic activity, demonstrating that Glu424 is vital for 
the enzymatic mechanism (23). Deeper into the cavity, past the active site, is the S1’ pocket 
which is specific for terminal glutamate residues. An overview of the structure is shown in figure 
6.5. There is evidence that the hydrolysis of peptide bonds by GCP(II)/PSMA proceeds through 
an induced-fit mechanism. This requires that the substrate induces changes in the conformation 
of the enzyme upon binding and that this rearrangement stabilises a transition state with a lower 
activation energy for bond cleavage, allowing hydrolysis to occur. Evidence supporting an 
induced-fit mechanism will be discussed throughout this chapter. 
 
FIGURE 6.5: An overview of the substrate binding site of GCP(II)/PSMA showing the S1’ site, S1 site, zinc ions, 
arginine patch, internal funnel and entrance lid. The inhibitor inside the enzyme is JRB-4-73. Modified with 




6.2.1 Crystallographic Studies of the Active Site 
High-resolution X-ray crystal structures (1.65-2.4 Å) of GCP(II)/PSMA are available and provide 
detailed information about the active site, S1, and S1’ pockets of this enzyme. However, it should 
be noted that before these high-resolution crystal structures were obtained, the best available 
models suggested different substrate-pocket binding, and therefore a different mechanism of 
action (25)(26). Alongside this a number of different hydrolysis mechanisms have been proposed 
for GCP(II)/PSMA (1)(27) and consequently there continues to be some confusion in the 
literature. Here only the latest high-resolution structures will be discussed alongside the 
quantum and molecular mechanics (QM/MM) modelling that was used to propose a hydrolysis 
mechanism.  
High-resolution crystal structures of GCP(II)/PSMA have been obtained ligand-free (28), and in 
complex with a number of substrates and inhibitors (29)(30)(31). Combining these findings with 
mutagenesis studies (23) has provided insight into how natural substrates and inhibitors sit 
within the enzyme and the mechanism of hydrolysis itself. There are four key crystal structures 
of GCP(II)/PSMA which have provided this insight: 1) the unbound state of GCP(II)/PSMA (28); 
2) GCP(II)/PSMA in complex with a urea-based inhibitor DCIBzL (((S)-2-(3-((S)-1-carboxy-(4-
iodobenzamido)pentyl)ureido)pentanedioic acid), which acts as a mimic of the cleavable 
peptide bond (30); 3) GCP(II)/PSMA in complex with SPE ((2S)-2-{[(2-carboxy-ethyl)-hydroxy-
phosphinoyl]methyl}-pentanedioic acid), a phosphinate analogue of NAAG. The phosphinate 
group maintains its tetrahedral conformation when it binds the zinc ions of the active site 
mimicking the substrate transition state (23)(31); 4) a mutant of GCP(II)/PSMA where the 
catalytic residue Glu424 (E424) was replaced with an alanine (completely inhibiting its catalytic 
activity), in complex with the natural substrate NAAG. The chemical structures of these 
substrates and inhibitors are shown in figure 6.4. 
These crystal structures all confirm the presence of the two zinc ions in the active site. Zn1 is 
coordinated by His377 and Asp453. Zn2 is coordinated by Glu425 and His553. The two zinc ions 
are bridged by Asp387 (23)(28)(30)(31)(32). Interestingly, the Asp387-Pro388 peptide bond is in 
the less common cis conformation, a feature often found in other zinc metalloenzymes (1). 
Mutagenesis studies have shown that if any of these five residues that bind the two zinc ions 
are substituted for alternative residues, loss of enzymatic activity occurs (His377 for Ala, Asp387 
for Glu, Asp453 for Asn, Glu425 for Gln and His553 for Ala) (32). When no substrate is bound, 
the zinc ions are 3.3 Å apart and tetrahedrally coordinated to these residues plus a hydroxyl 
group (OH-) which bridges the two zinc ions symmetrically (28). There has been some debate as 
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to whether a hydroxyl group or an activated water molecule bridges the two zinc ions; however, 
the shortened Zn-O bond lengths (2.01-2.03 Å (28)) compared to standard Zn-OH2 distances (2.2-
2.4 Å (23)) indicate it is a hydroxyl group. This has been confirmed through QM/MM calculations 
which revealed that as soon as a water molecule bridges the two zinc ions, one of its protons 
would be abstracted by the Glu424 residue (23). As the enzyme performs bond cleavage through 
hydrolysis, which is typically acid- or base-catalysed, it is logical that this hydroxyl molecule plays 
a key part in the mechanism. 
In the mutant GCP(II)/PSMA(E424A) with NAAG in the active site, the hydroxyl molecule (OH-) 
remains bound symmetrically between the two zinc ions, and the oxygen of the carbonyl group 
of the cleavable peptide bond interacts with Zn1 (23). This same carbonyl group is both 
orientated and polarised by a hydrogen bond between it and a hydroxyl group on the side chain 
of the Try552 residue, which itself is polarised by the nearby positively charged Arg210 residue. 
At the other end of the cleavable peptide bond, the amide is shown to form a hydrogen bond to 
the backbone carbonyl oxygen between Gly518 and Asn519. In order to study the interactions 
of the Glu424 residue GCP(II)/PSMA, the urea inhibitor of DCIBzL can be used as a substrate 
mimic (30). These inhibitors utilise a urea bond in place of the peptide bond which makes them 
unsusceptible to cleavage by the enzyme. This allows them to be crystallised with the fully active 
enzyme forming GCP(II)/PSMA-[DCIBzL]. When the urea inhibitor sits within the active site of 
GCP(II)/PSMA, all of the interactions seen for GCP(II)/PSMA(E424A)-[NAAG] are conserved but 
in addition the N-H of the urea, which sits in the same place as the N-H of the peptide bond in 
the natural substrate, forms a hydrogen bond to Glu424. This provides further evidence that 
Glu424 acts as a proton shuttle, delivering a proton from the water molecule to this amine 
during hydrolysis.  
In the crystal structure of GCP(II)/PSMA(E424A)-[NAAG], the cleavable peptide bond remained 
planar, because without the Glu424 residue, it could not pass into the transition state required 
to break the bond. This would not be the case if NAAG entered the fully functional GCP(II)/PSMA; 
instead of remaining planar, a tetrahedral intermediate will form. It is well known that 
acid/base-catalysed hydrolysis of peptide bonds proceeds through sp3 hybridisation at the 
carbonyl carbon and therefore the active site of GCP(II)/PSMA must allow for a tetrahedral 
transition state. An understanding of how the active site changes when a tetrahedral 
intermediate is formed can be obtained from studying how inhibitors that mimic this transition 
state sit within the active site. A phosphonate group is a good mimic, as it will maintain its 
tetrahedral geometry upon binding and has two oxygens, one that can mimic the carbonyl 
oxygen of the peptide bond and one that can mimic the hydroxyl (OH-) as it attacks the carbon 
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of the carbonyl. The crystal structure of GCP(II)/PSMA complexed with SPE (figure 6.4) shows 
that the phosphonate group displaces the bound water molecule and that it binds the two zinc 
ions using both oxygen groups. Another important observation is that that these two oxygen 
atoms sit in very similar positions to the carboxyl oxygen of the natural substrate and the oxygen 
of the hydroxyl (OH-). By superimposing the GCP(II)/PSMA-[SPE] crystal structure with the 
GCP(II)/PSMA(E424A)-[NAAG] crystal structure as shown in figure 6.6, the key differences 
between the initial binding mode (Michaelis complex) and the phosphonate mimic of the 
transition state can be seen (23). The key differences observed are: in the GCP(II)/PSMA-[SPE] 
crystal structure the carbonyl carbon centre (mimicked by the phosphorus atom in SPE) is moved 
1 Å towards Zn2 and the nitrogen atom (mimicked by a carbon atom in SPE) is moved 0.7 Å 
towards the catalytic Glu424 residue (23). Such changes could not occur if the peptide bond 
remained planar and so it must be stabilised in a resonance form which allows the bonds to 
lengthen and twist. Such stabilisation comes from the hydrogen bond between the oxygen of 
the carbonyl and the Try552 residue (which itself is polarised by adjacent residues). The change 
in the substrate’s conformation is complemented by changes in the active site itself with the 
zinc ions moving away from each other (the distance increases from 3.3 Å to 3.7 Å) and the 
histidine residues His377 and His533 moving with them (23). The changes to the active site 
stabilise the transition state and consequently catalyse hydrolysis. These are therefore one 




FIGURE 6.6: The structures of the GCP(II)/PSMA(E424A)-[NAAG] complex superimposed on the GCP(II)/PSMA-
[SPE] complex on corresponding Cα atoms. Atoms are shown as: carbon (green, GCP(II)/PSMA(E424A)-[NAAG] 
complex; grey, GCP(II)/PSMA-[SPE] complex), nitrogen (blue), oxygen (red), and phosphate (orange). The Zn 
ions are shown as blue (GCP(II)/PSMA(E424A)-[NAAG] complex) and grey (GCP(II)/PSMA-[SPE] complex) 
crosses; the hydroxyl molecule (OH-) is shown as a red cross. The direction of movement of GCP(II)/PSMA side 
chains and the substrate reaction intermediate is indicated by arrows with distances shown in Å. The P1 portion 
of the substrate/reaction intermediate (or transition state) was omitted for clarity. This figure is reproduced 




6.2.2 Enzymatic Mechanism 
The inferences that can be made about the enzymatic mechanism of GCP(II)/PSMA, from the 
four crystal structures discussed, have been further combined with QM/MM calculations to 
characterise the transition states (23). There are four equilibrium structures revealed by these 
models: the Michaelis complex (substrate bound in the active site); the first transition state; the 
reaction intermediate; and the second transition state (determined to be the rate-limiting step 
from calculated energy barriers). Each of these intermediates are shown in figure 6.7. All of these 
equilibrium structures confirm the important role of the two zinc ions, the hydroxyl molecule 
and the glutamic acid residue Glu424. 
 
 
FIGURE 6.7: The QM/MM equilibrium structures of (A) the Michaelis complex (substrate bound in the active 
site), (B) the first transition state, (C) the reaction intermediate, (D) the second transition state, leading to the 




The Michaelis complex shown in figure 6.7A has the same interactions as seen for GCP(II)/PSMA-
[DCIBzL] and GCP(II)/PSMA(E424A)-[NAAG]. The key interactions can be summarised as follows: 
1) a weak interaction between the carbonyl oxygen and Zn(1); 2) the same carbonyl oxygen, 
hydrogen bonding to the Try552 which controls its orientation; 3) the formation of a hydrogen 
bond between the N-H group of the peptide bond and the carbonyl oxygen between Gly518 and 
Asn519; 4) the Glu424 aligning itself so that its deprotonated oxygen is stabilizing the OH- 
bridging the zinc ions.  
In the first transition state (figure 6.7B) the key difference is that the carbonyl carbon adopts a 
tetrahedral geometry as it undergoes nucleophilic attack by the hydroxyl molecule (OH-). This 
tetrahedral conformation at the carbonyl carbon creates increased negative charge on the 
carbonyl oxygen which is stabilised by the zinc ions and the catalytic glutamic acid. At the other 
end of the peptide bond, the conformation also shifts; the nitrogen atom moves towards the 
proton on the Glu424 residue. The reactive intermediate is shown in figure 6.7C and was 
identified by calculating the local energy minima between the two transitions states. Here the 
other end of the peptide bond moves into tetrahedral conformation as the lone pair on the 
nitrogen points towards the proton on the Glu424, ready for a subsequent N-H bond to form. 
This tetrahedral conformation at the nitrogen, is stabilised by the carbonyl between Gly518 and 
Asn519. In the second and final transition state, shown in figure 6.7D, a bond forms between 
the proton of Glu424 and the nitrogen atom. This bond formation will cause the subsequent 
cleavage of the peptide bond, which in this second transition state is no longer planar and has 
increased in length from 1.4  to 1.6 Å. 
These transition states have provided enough evidence for a detailed reaction mechanism to be 
proposed for the hydrolysis of NAAG. This is shown in figure 6.8. Once NAA and glutamate have 
been formed, the NAA is pulled out of the active site by the positive charge of the arginine 
residues lining the S1 pocket, and the glutamate can exit the active site via a small hole at the 
back of the S1’ pocket (1)(15)(33). This mechanism can also be applied to the serial removal of 
glutamate from poly-γ-glutamated folates as shown in figure 6.9 and figure 6.10. 
It is not only the interaction described here that contributes to the induced-fit mechanism; the 
S1’ pocket and to a lesser extent the S1 pocket also change conformation to aid binding, stabilise 
the transition state and consequently increase the rate of hydrolysis (1)(31). The structure of the 
S1 and S1’ pockets, and their substrate recognition properties through the “glutarate sensor” 







FIGURE 6.8: The GCP(II)/PSMA reaction cycle with NAAG. This cycle depicts important steps/structures 






FIGURE 6.9: The GCP(II)/PSMA reaction cycle with poly-γ-glutamated(n=2) folate. This cycle depicts important 





FIGURE 6.10: The GCP(II)/PSMA reaction cycle with poly-γ-glutamated(n=1) folate. This cycle depicts important 





6.3 Detail of S1’ Pocket 
The S1’ pocket has been fully characterised through crystallographic studies (1). The important 
residues that interact with the P1’ glutamate are Arg210, Tyr552, Tyr700, Lys699, and Asn257. 
Glutamate bound to the active site is shown in figure 6.11. Arg210, Tyr552 and Tyr700 all interact 
with the C-terminal carboxylate group of the glutamate rather than its side chain. Arg210 forms 
a strong ion pair between its positive charge on its guanidinium moiety and the negative charge 
on the substrate’s carboxylate. The two tyrosine residues, Tyr552 and Try700, form hydrogen 
bonds to the substrate from their hydroxyl groups. Lys699 and Asn257 interact with the side 
chain of the glutamate, with Lys699 forming a salt bridge (a hydrogen bond and an electrostatic 
interaction between two ionised sites) and Asn257 forming a hydrogen bond. The majority of 
these residues are part of domain (II) but residues Lys699 and Try700 are an exception (34). 
These are part of domain (III) and also a series of residues (692-704) which have a different 
structure when the S1’ pocket is substrate-free compared to when glutamate or a glutaric acid 
is bound in the pocket. For this reason, this series of residues (692-704) has been termed the 
“glutarate sensor”. The choice of the name “glutarate” sensor rather than glutamate sensor was 
chosen by the original paper’s author because this interaction does not require the presence of 
the amine group of a glutamic acid (glutamate) and so it was named accordingly (1). However, 
it is important to remember that for cleavage to occur there must be a glutamate in the S1’ 
position. 
When the S1’ pocket is unoccupied the 692-704 chain forms flexible loops with multiple 
conformations, characterised by weak electron density in the crystal structure (1)(28). When 
this happens, a space is created between the active site and the main cup of the GCP(II)/PSMA 
dimer. When a substrate is bound this region forms a hairpin structure (strand 692-695, turn, 
strand 699-704) named the β15/β16 hairpin, which closes this gap, and Lys699 and Try700 bind 
directly to the glutamate/glutarate substrate as described above. There are significant structural 
changes between the bound and unbound state with the position of Tyr700 moving 4.7 Å and 
other residues in the chain moving as much as 7.6 Å. The two different positions of the sensor 
can be seen in figure 6.12. This hairpin region is directly involved in the specific binding of 





FIGURE 6.11: The binding mode of cleaved glutamate in the S1’ portion of the GCP(II)/PSMA binding pocket. 
Reproduced with permission from (34). 
 
FIGURE 6.12: The two positions of the “glutarate sensor”, the first when phosphate is within the active site and 
the second when glutamate is docked in S1’. Reproduced with permission from (1). 
The “glutarate sensor” is also likely to play a role in the release of glutamate from the active site, 
via a small hole in the back of the S1’ pocket. Such an exit route is of particular importance for 
the natural substrate poly-γ-glutamated folates. In this structure, there are multiple glutamates 
that could be cleaved sequentially from the substrate, and it would be inefficient to require the 
release of the cleaved poly-γ-glutamated(n-1) folate followed by the glutamate through the 
entrance tunnel before the poly-γ-glutamated(n-1) folate could re-bind the active site. Instead it 
has been proposed that the hole formed when the “glutarate sensor” (692-704 residue series) 
is disengaged from the S1’ pocket would allow the cleaved terminal glutamate to pass out of the 
enzyme, and thus the poly-γ-glutamated(n-1) folate can move into the active site directly after 
cleavage and the next glutamate in the chain can be cleaved. This release mechanism would 
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require the hairpin to be able to discriminate between the binding of the natural substrates and 
the hydrolysis products, engaging this loop with the substrate and releasing it with the product. 
Evidence supporting the hypothesis that the enzyme can differentiate between the natural 
substrates and their hydrolysis products can be found by looking at differences in inhibition and 
enzymatic rate. The IC50 inhibition value for glutamate is in the micromolar range (30 µM (35)) 
whereas the KM values for the natural inhibitors are in the nanomolar range (NAAG 250 nM, 
poly-γ-glutamated folates 50- 500 nM (7)(8)) showing that glutamate alone does not bind the 
active site as strongly as the natural substrates. This implies that although the interaction of the 
“glutarate sensor” with cleaved glutamate is observed in the crystal structure, it is not as strong 
as when the substrate also binds the zinc ions in the active site, probably due to the conditions 
required for crystallisation. Additional evidence to support this comes from the difference in IC50 
values between 2-PMPA and glutamate. PMPA has a very similar structure to glutamate, but 
with an additional zinc ion binding phosphonate moiety (figure 6.4). This causes a dramatic 
improvement in affinity with the IC50 value dropping to just 0.3 nM (35). This implies that the 
GCP(II)/PSMA can discriminate between 2-PMPA and glutamate and that this is governed by the 
interaction with the zinc ion. 
The important residues in the structure of the S1’ pocket have been corroborated by a site-
directed mutagenesis study (34). This showed that the S1’ pocket is vital for high affinity 
substrate or inhibitor binding and that Arg210 is the most important residue within this pocket 
(figure 6.11). This is because it interacts directly with the carboxylate of the C-terminal of the 
glutamate and maintains the S1’ pocket’s conformation by controlling the positioning of the 
Tyr552 side chain. The importance of the S1’ pocket in controlling affinity was also confirmed by 
studies where the P1’ part of the inhibitor was changed, which caused 100-1000 fold decreases 
in binding affinity (36). From these studies it can be concluded that the P1′ moiety is very 
sensitive to structural changes and it is the feature primarily responsible for tight GCP(II)/PSMA 
binding (31). Further studies have shown that the chirality of the glutamate residue is also crucial 




6.4 Detail of S1 Pocket 
6.4.1 The Arginine Patch and the ‘Binding’ and ‘Stacking’ Conformations of the 
Arg536 Residue 
The residues of the S1 pocket that interact with the substrate are Asn519, Arg534, Arg463 and 
Arg536 (1)(31)(34). The arginine residues form a positively charged area within the S1 pocket 
named “the arginine patch” which is responsible for the preference of GCP(II)/PSMA for acidic 
residues in the P1 position (28). A chloride ion is found within this arginine patch, and crystal 
structures show that it fixes the position of the Arg534 and Arg463 residues through ionic 
interactions (28) as shown in figure 6.13. Experiments where hydrolytic activity was measured 
under different chloride concentrations, showed activity was Cl- dependent (4), and so it is 
believed that this chloride ion is also essential for enzymatic activity. When a natural substrate 
is present within the S1 pocket, the Asn519 and Arg534 form hydrogen bonds to the carboxylate 
oxygen of the substrate. This is the key interaction that determines affinity for the S1 pocket. 
However, there is also the potential for an additional hydrogen bonding interaction between 
Arg536 and the carboxylate oxygen to occur, which increases affinity further. This happens when 
the orientation of Arg536 changes from the “stacking” to the “binding” position (31). The change 
of preference from the stacking to the binding position requires the adjacent Arg463 to be 
repositioned by 2 Å, through interaction with a suitably positioned carboxyl oxygen on the 
substrate, which in turn prevents Arg536 from adopting the “stacking” conformation through 
steric hindrance. The “binding” position requires a 4.5 Å shift of the Arg536 residue’s 
guanidinium group, which is stabilised by the S1 bound chloride atom. When in this “binding” 
position the Arg536 is able to form two hydrogen bonds to the γ-carboxylate of the P1 substrate. 
Substrates that promote the “binding” position of Arg536 by interacting with the Arg463 residue 
have significantly higher affinity than those which do not. It is claimed that this rearrangement 
is responsible for the 100-fold difference in IC50 between MPE (a phosphonate transition-state 
analogue of poly-γ-glutamated folate) and EPE (a phosphonate transition-state analogue of γ-
glutamyl-glutamate) (0.12 ± 0.03 nM and 14.0 ± 4.2 nM respectively) (31). The structures of 
these two compounds are shown in figure 6.14.  
The S1 pocket has been shown to accommodate more substrate diversity than the S1’ pocket 
using both substrate inhibitor binding and mutagenesis studies (34). This includes variation in 
stereochemistry. However, it is favourable to have an acidic residue (either aspartic acid or 
glutamic acid) in the P1 position due to their interactions with the arginine patch (34). These 
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same studies also suggest that S1 interactions do not affect the affinity as strongly as S1’ but 
instead are more important in controlling specificity and substrate turn-over (34). 
 
FIGURE 6.13: The residues of the arginine patch within the S1 pocket. The side chain of Arg536 can adopt two 
alternate conformations. (A) Arginine 536 can adopt two distinct conformations referred to as the “stacking” 
(R536s) and “binding” (R536b) conformation, respectively. A transition between the two conformations is 
associated with a 4.5 Å shift of the guanidinium group. The atoms are coloured blue (nitrogen), red (oxygen), 
grey (carbon), and yellow (chloride ion). Polar interactions stabilizing individual conformations of Arg536 are 
shown as broken lines. Figure reproduced with permission from (31). 
 
FIGURE 6.14: The structures of the inhibitors MPE and EPE phosphonate, which are transition state analogues 
of poly-γ-glutamated folate and γ-glutamyl-glutamate, respectively (31). 
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6.4.2 The Entrance Lid and the Arene-Binding Pocket 
Crystallographic studies of GCP(II)/PSMA have revealed that the entrance tunnel to the active 
site has a lid, that can exist in an open or closed conformation, depending on the bound 
substrate (8)(31)(39). These two positions are shown in figure 6.15. This lid is made from the 
residues Trp541 to Gly548 and moves a distance of 9 Å between the open and closed states. In 
general, the lid is only open when larger substrates such as poly-γ-glutamated folate or its 
analogues are present. It is not possible for these substrates to bind with the lid closed due to 
steric hindrance. The motion of this lid is controlled by the peptide bond between Asn540 and 
Trp541 which acts as a hinge and flips between two conformations (31). The open conformation 
allows the enzyme to accommodate larger substrates and reveals an additional binding cleft 
named the “arene binding pocket”. This site is formed of the indole group of Trp541 (the first 
residue of the entrance lid) and the guanidinium groups of Arg511 and Arg463 which allow for 
π-cation and π-stacking interactions with ligands containing aromatic groups (39). An increase 
in substrate affinity is observed if binding at the enzyme active site and also at the arene-binding 
cleft occurs (8)(39). However, it is important to note that, for poly-γ-glutamated folates, the 
interaction with the arene-binding cleft varies depending on the number of glutamate moieties 
in the structure, and that the molecule must contain at least two glutamates to allow it to reach 
the arene binding pocket at all (8). This same effect was seen for poly-γ-glutamated folate 
analogues, where there was a clear demonstration of an optimal linker length between the zinc 
ion binding moiety and the arene-binding region (39). Studies have also found that the 
properties of the aromatic group, which interacts with the arene-binding pocket, affect its 
affinity. The aromatic groups with the lowest LUMO (lowest unoccupied molecular orbital) 
energies had the strongest interactions with the arene binding pocket (a substrate with 
dinitrophenol had a higher affinity than ones with nitrophenol or phenol) (39). Mutagenic 
studies where the arene-binding site was altered showed a large impact on the crystallographic 
binding modes of poly-γ-glutamated folate but a much smaller effect on the hydrolysis rate of 
poly-γ-glutamated folates (8).  This suggests that the substrate is likely to dock at the active site 
through the glutamate terminal first and then secondary interactions occur between the 
substrate and the arene-binding site (8). Therefore these interactions are more likely to be 




FIGURE 6.15: The open (left) and closed (right) conformations of the entrance lid to the active site of 
GCP(II)/PSMA. This lid is formed by the amino acids Trp541–Gly548 (highlighted red in the open conformation 
and blue in the closed). Reproduced with permission from (31). 
6.5 Summary of All Interactions of GCP(II)/PSMA with its Natural Substrates 
The previous sections revealed the features of the substrate binding pockets and active site 
which allow recognition and tight binding of the natural substrates and are involved in the 
induced-fit hydrolysis mechanism. These interactions can be summarised as follows: 1) the 
glutamate moiety binds within the S1’ pocket, ensuring a tight fit and moves the “glutarate 
sensor” into its binding mode; 2) the coordination of the oxygen of the cleavable peptide bond, 
to the zinc ions in the active site; 3) the presence of a carboxylic acid residue in the P1 position, 
that is able to hydrogen bond to the positively charged arginine patch; 4) a carbonyl oxygen, 
that is able to interact with the Arg463 residue and causes the conformational change required 
for the Arg536 residue to move from its “stacking” to its “binding” mode; 5) larger substrates 
can cause the entrance lid to open, revealing the arene-binding region, that can form π-stacking 
interactions with substrates containing suitably aligned aromatic groups. 
Figure 6.16 highlights the areas of the structure of the natural substrates poly-γ-glutamated 
folate and NAAG that interact with GCP(II)/PSMA. Figure 6.17 is a schematic highlighting the 
regions of the enzyme that interact with the substrate. The interactions within the S1’ binding 
pocket, active site and S1 binding pocket are similar between the two substrates but the larger 








FIGURE 6.16: Summary of interactions of NAAG and poly-γ-glutamated folates with GCP(II)/PSMA active site. 





FIGURE 6.17: The internal cavity of human GCP(II)/PSMA. The schematic representation of GCP(II)/PSMA is in 
the centre of the figure. Flexible segments (the entrance lid, the arginine patch and the “glutarate sensor”) are 
depicted in two conformations by solid and dashed lines, respectively. Residues lining the internal cavity are 
shown as one-letter codes and the zinc ions are depicted as circles. The coloured areas on this schematic show 
the location for each of the following binding interactions (A-yellow) the position of the “glutarate sensor”, when 
the pharmacophore pocket is empty (yellow) or occupied by an inhibitor/substrate (red); (B-orange) the details 
of the arene-binding site occupied by the dinitrophenyl group of ARM-P2. The arene-binding site is coloured 
orange; (C-blue) the surface representation of the arginine patch (cyan) in the “stacking conformation”; (D-blue) 
the S1 accessory hydrophobic pocket is opened by simultaneous repositioning of the side chains of Arg463 and 
Arg536; (E-grey) hydrogen-bonding interactions between the S1’ (pharmacophore) pocket-bound substrate 
and interacting GCP(II)/PSMA residues; (F-green) interactions in the vicinity of the active-site zinc ions. 
Phosphinate (top) and urea (middle) zinc ion binding groups. The peptide bond of NAAG (bottom) is shown for 
comparison. In all figures, zinc ions and water molecules are shown as purple and red spheres, respectively. 




6.6 Design of Novel THP-PSMA Ligands for Higher Affinity 
By reviewing the substrate inhibitor interactions for GCP(II)/PSMA with poly-γ-glutamated folate 
and NAAG, the features of the substrate that are likely to lead to higher affinity have been 
identified. This has formed the basis for my proposals for novel higher affinity variants of THP-
PSMA which will be described below.  
6.6.1 S1’ Pocket 
It is clear from the literature reviewed that conserving the terminal glutamate in any 
GCP(II)/PSMA targeting group is essential. This group is responsible for tight binding within the 
active site and so should not be altered in the design of a high-affinity tracer. 
6.6.2 Zinc Ion Binding Group 
The zinc ion binding group is the second most important feature of an inhibitor for GCP(II)/PSMA 
and it is resilient to more diversity than the S1’ pocket. In the natural substrates, the zinc ion 
binding group is the carboxyl oxygen of the cleavable peptide bond. As reviewed above, this is 
replaceable by a urea group, which mimics the initial binding mode of the peptide bond, and 
with a phosphonate, phosphinate or phosphoramidate, all of which mimic the tetrahedral 
transition state through which the complex passes during bond cleavage. In these the zinc ion 
binds directly to the oxygen of the urea or two of the oxygens of the 
phosphonate/phosphinate/phosphoramidate, one mimicking the position of the carboxyl 
oxygen of the peptide bond and the other the position of the hydroxyl molecule (OH-) which 
bridges the two zinc ions. The binding between the zinc ions and the substrate is very important 
and improving its strength could increase the affinity of the substrate for GCP(II)/PSMA. One 
way that this could be achieved is through replacing these oxygen atoms with sulfur atoms, as 
sulfur groups bind more strongly to zinc ions. The phosphonamidothionate, and 
phosphonamidodithionate zinc ion binding groups have previously been investigated (40) but 
no work has been published on thiourea-based zinc ion binding groups. This hypothesis will be 
explored in chapter 7 which describes the development and evaluation of a novel thiourea-
PSMA inhibitor. Figure 6.18 shows the known zinc ion binding groups for GCP(II)/PSMA and 




FIGURE 6.18: Structures of known and proposed zinc ion binding groups for GCP(II)/PSMA substrates and 
inhibitors. All except the thiourea have been synthesised previously (24)(40).  
6.6.3 S1 Pocket 
It is known that the S1 pocket can withstand much more structural diversity than the S1’ pocket 
and that interactions in this region tend to have more effect on specificity than the affinity of 
inhibitors (34). Most enzymes have evolved to be very specific for their natural substrates and 
so it is logical to try to understand the interactions that the natural substrate has with this pocket 
and replicate these as closely as possible when designing a high-affinity inhibitor or tracer. In 
this discussion, poly-γ-glutamated folate will be the natural substrate focused on, due to its 
greater structural similarities with THP-PSMA. As described above poly-γ-glutamated folate has 
a carboxylic acid group in the P1 position which interacts with the positively charged arginine 
patch, and so we hypothesise this will be important to conserve. It also has a carbonyl oxygen 
which hydrogen bonds to Arg463 causing Arg536 to move into its “binding” mode. The position 
of this carboxyl group in the substrate is vital to ensure this interaction can occur, and so we 
hypothesise this should also be conserved. If the aim is to maintain the position of the carboxylic 
acid and carbonyl groups in the structure, then the most common GCP(II)/PSMA targeting motif 
used in PSMA radiotracers (Lys-C(O)-Glu) is unsuitable. This design places the carboxylic acid of 
the lysine in a slightly different position to the carboxylic acid in the natural substrate, while the 
lysine side chain extends the molecule past the position of the carboxyl group in the natural 
substrate, removing the opportunity for that interaction to occur. These differences are 
demonstrated in figure 6.19. However, the position of the carboxylic acid and the carboxyl group 
255 
 
could be conserved at the same time as introducing a urea group, in order to make the tracer 
resistant to enzymatic cleavage, if the Dap-C(O)-Glu motif was used instead. This structure is 
shown in figure 6.19. Dap or L-diaminopropanoic acid, is a non-proteinogenic amino acid, which 
can be made synthetically and is commercially available. Obtaining the structure shown in figure 
6.19 would require the amine group at the end of the Dap side chain to form one half of the 
urea group rather than its α-amine. The concept of linking amino acids together using their side 
chains, came from studying the natural substrate poly-γ-glutamated folate. In this structure, the 
terminal carboxylic acids of the side chains are bound to the α-amine group of the next glutamic 
acid in the chain.  
 
FIGURE 6.19: Modifications that could be used to make the urea-based mimic align more closely to the structure 
of the natural substrate. For poly-γ-glutamated folate the position of the carboxylic acid required to bind with 
the arginine patch is highlighted in blue and the position of the carbonyl which hydrogen bonds to Arg463 is 
shown in red. These features are preserved in the Dap-C(O)-Glu motif and highlighted in the same colours. The 
amine groups highlighted in green in the L-lysine is the amine that reacts to form the urea bond in the Lys-C(O)-
Glu motif. The amine group highlighted in purple in the L-diaminopropanoic acid is the amine that reacts to form 
the urea bond in the Dap-C(O)-Glu motif. 
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It may also be beneficial to use the poly-γ-glutamate structure in the natural substrate as the 
linker between the motif that binds the active site and the THP chelator. The optimal length of 
the chain can also be determined from studies with poly-γ-glutamated folate. These suggest that 
there should be at least 3 glutamates in the chain before the aromatic groups of the folate; more 
may be beneficial (8). The final interaction that should be conserved occurs between the 
aromatic groups of the folate and the arene binding pocket. It is unlikely that the THP chelator 
itself would align correctly to interact with this arene binding pocket and so it would be 
beneficial to introduce an aromatic group before the chelator itself. There is already a 
bifunctional version of THP available which could be used to incorporate an aromatic group; 
THP-Ph-NCS (41) (figure 6.20). The phenol group could also be exchanged for a dinitrophenol 
which was found to have the strongest interaction with this region in inhibitor studies (39), 
although that would require developing a new synthetic pathway. 
By combining all of the interactions present between poly-γ-glutamated folate and 
GCP(II))/PSMA with a non-cleavable zinc ion binding group and the THP-chelator, a hypothetical 
higher-affinity THP-PSMA tracer has been designed. The structure of a THP-PSMA bioconjugate 
which could form the basis of a family of ligands is shown in figure 6.21, with the features 





FIGURE 6.20: The structures of the bifunctional chelator THP-Ph-NCS, poly-γ-glutamated folate, and a proposed 
high-affinity THP-PSMA variant. The parts of the molecule highlighted in blue are the aromatic groups that will 










6.7 Concluding Remarks 
In this chapter, the important high-resolution crystal structures of GCP(II)/PSMA have been 
reviewed. This has provided insights into the important interactions between GCP(II)/PSMA and 
its natural substrates, including the hydrolysis mechanism. These learnings have been used to 
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7 Development of a Thiourea-Based Inhibitor of PSMA 
7.1 Introduction 
Results from chapters 3 and 4 have shown that [68Ga]Ga-THP-PSMA is a successful imaging agent 
for GCP(II)/PSMA-expressing prostate cancer. This has been demonstrated in vitro, in a mouse 
model of prostate cancer (1), and in clinical studies, in which primary tumours, cancerous lymph 
nodes and bone metastases could be detected (2)(3)(4). The results of these scans also had an 
impact on patient management (2)(4). However, as discussed in chapter 5, the current tracer is 
not ideal for molecular radiotherapy with the Auger emitting isotope gallium-67, despite the 
exceptionally high molar activity that can be achieved (326 MBq/nmol, 22% occupancy of THP-
PSMA). The in vitro results show that even with high molar activity the amount of gallium-67 
that can be delivered to cells is limited by the uptake of the tracer into GCP(II)/PSMA-expressing 
cells. Additionally, in a xenograft mouse model of GCP(II)/PSMA-expressing prostate cancer the 
tracer has been shown to washout of solid tumours over the first 24 hours: a much faster rate 
than seen for the clinically tested therapeutic PSMA-tracers [177Lu]Lu-DOTA-PSMA(617) (5) and 
[125I]I-DCIBzL (6). One factor contributing to these in vitro and in vivo properties is likely to be 
the affinity of Ga-THP-PSMA for GCP(II)/PSMA. This was shown to be 10.4 ± 3.4 and 8.6 ± 3.4 
fold lower than for Ga-HBED-CC-PSMA and Ga-DOTA-PSMA(617) respectively (data from 
chapter 3 (1)). Affinity is related to the targeting and uptake in GCP(II)/PSMA-expressing cells as 
well as contributing to internalisation of tracers (7). Therefore improving the affinity for 
GCP(II)/PSMA is one strategy that could have a big impact on the uptake and retention of this 
tracer in prostate cancer. 
As explored in chapter 6, there are at least 5 important interactions between GCP(II)/PSMA and 
its natural substrates. Conservation of these features in inhibitor and radiotracer design could 
lead to higher affinity. Both the conservation of the terminal glutamic acid, and having a suitable 
binding group for the zinc ion within the active site, are known to be the most vital features of 
an inhibitor (8). Of these two, the only one amenable to change is the zinc ion binding group, 
and small changes to this group are known to have a large impact on the affinity of inhibitors 
(9)(10)(11)(12). When the natural substrates (NAAG and poly-γ-glutamated folate) bind to 
GCP(II)/PSMA, the group that interacts with the zinc ions is the carbonyl oxygen of the cleaved 
peptide bond, between the terminal glutamate and the remainder of the molecule (13). In 
designing an inhibitor or tracer, this peptide bond needs to be replaced with a peptide bond 
mimic (8) that is resistant to enzymatic cleavage but binds the active site tightly including 
maintaining this interaction with the zinc ion. Figure 7.1 shows the structures of previously 
264 
 
investigated zinc ion binding groups. All have the conserved glutamic acid or pentanedioic acid 
for binding the S1’ pocket. The most utilised peptide bond mimic for GCP(II)/PSMA tracers is a 
urea bond. Replacing a peptide bond with a urea reduces the electrophilicity of the carbonyl 
carbon and so this bond is no longer cleavable by the enzyme. This urea motif, in which oxygen 
is the zinc ion binding ligand, is used in [68Ga]Ga-THP-PSMA but also in all of the other PSMA-
based tracers discussed in chapter 1 ([11C]MCG, [123I]I-MIP-1095, [99mTc]Tc-MIP-1404, 
[18F]DCFPyL, [18F]F-PSMA-1007, [68Ga]Ga-HBED-CC-PSMA, [68Ga]Ga-DOTA-PSMA(617) and 
[68Ga]Ga-DOTAGA-PSMA (I&T)). Thiols and a range of phosphoryl-based groups have also been 
investigated (9)(10)(11). These included phosphonates (10), phosphinates (10), 
phosphoramidates (11). In these structures, the phosphoryl group mimics the tetrahedral 
transition state/intermediate (with an sp3 hybridised carbon) through which the substrate 
passes during enzymatic cleavage (13), and the oxygens of the phosphoryl groups bind to the 
zinc ion (14). There are no crystal structures available for the thiol-based inhibitors in the active 
site of GCP(II)/PSMA and so the exact positioning of this group is unknown. However, the 
number of methylene units between the thiol group and pentanedioic acid (figure 7.1) affects 
the binding to GCP(II)/PSMA and is optimal when there are three methylene groups present, 
suggesting this length allows for the greatest interaction between the thiol and the zinc ions (9). 
Crystal structures are available for urea, phosphonate, phosphinate, and phosphoramidate 
inhibitors within GCP(II)/PSMA and their binding modes are shown in figure 7.2 and figure 7.3. 
Additionally, phosphonamidothionate and phosphonamidodithionate analogues have been 
synthesised where one or two oxygens are replaced with a sulfur atom as shown in figure 7.1 
(15). Unfortunately, these have only been assessed as inhibitors for the enzyme 
carboxypeptidase-G and not with GCP(II)/PSMA. This enzyme is closely related to GCP(II)/PSMA 
and is also a zinc metalloenzyme which cleaves terminal glutamates. This study found that the 
affinity of phosphoramidate-, phosphonamidothionate-, or phosphonamidodithionate-based 
inhibitors was greatly affected by the group in the P1 position, but that in some cases the 
presence of sulfur improved the Ki value measured. The results of this study are shown in table 
7.1.  
The rationale for replacing oxygen with sulfur in an inhibitor for a zinc-based metalloenzyme is 
that zinc and sulfur are a better matched Lewis acid/Lewis base pair (as they are both borderline 
soft/hard) than zinc and oxygen (a hard Lewis base) (16). Zinc ions and sulfur-based ligands have 
a strong affinity for each other and typically form highly stable complexes (17)(18). This stronger 
interaction could improve the affinity of an inhibitor and may also increase the residence time 
within the active site, in turn affecting internalisation. Internalisation is a key feature when 
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designing radiotracers for molecular radiotherapy (particularly with Auger electron emissions) 
as this maximises the quantity of therapeutic isotope that accumulates in GCP(II)/PSMA-
expressing cells. 
Although the concept of exchanging an oxygen within a zinc ion binding group for a sulfur has 
been explored for phosphonyl derivatives, (albeit not tested with GCP(II)/PSMA itself), this has 
not been studied for the urea-based inhibitors. Therefore this study was designed to investigate 
the impact of using thiourea-based inhibitors in place of the successful urea-based inhibitors 
currently employed in PSMA radiotracers. The only change required in the structure is the 
replacement of the urea group in the existing inhibitor with its thiourea analogue. This should 
be synthetically achievable through the generation of an isothiocyanate intermediate, with 
existing well-characterised chemistry (19)(20)(21). Thiourea variants would be expected to act 
as inhibitors for GCP(II)/PSMA as all of the interactions present in the urea version should be 
conserved and the interaction with the zinc ion should be enhanced by the presence of the sulfur 
group. In addition, like the urea bond, the less electrophilic carbonyl of the thiourea (compared 
to that of a peptide bond) should make it resistant to cleavage by GCP(II)/PSMA. In order to 
investigate the consequences of this change, a simple model was used as a starting point: the 
symmetrical inhibitor Glu-C(O)-Glu, named urea-PSMA. This inhibitor has been reported to have 
a Ki value for GCP(II)/PSMA of 8 nM, and can be made by a simple solution-based synthetic route 
(22). The novel thiourea analogue of this inhibitor thiourea-PSMA (Glu-C(S)-Glu) will be 
synthesised and characterised and the IC50 values of these inhibitors will be compared alongside 
the widely used inhibitor PMPA (with a phosphonate zinc ion binding group) as a control. The 
structures of these three compounds are shown in figure 7.4. The names urea-PSMA/thiourea-
PSMA and Glu-C(O)-Glu/Glu-C(S)-Glu will be used interchangeably, depending on whether 




FIGURE 7.1: The structures of a range of zinc ion binding moieties that have been investigated as inhibitors for 
GCP(II)/PSMA or carboxy-peptidase-G. Note the conserved terminal glutamate or pentanedioic acid. These 
structures have been shown with their charge at physiological pH. 
 
FIGURE 7.2: Electron density map of the active site of GCP(II)/PSMA (blue contours) with the PMPA inhibitor 




FIGURE 7.3: Interactions of phosphorus- and urea-based zinc ion binding moieties of inhibitors within the active 
site of GCP(II)/PSMA. Individual atoms are coloured red (oxygen), blue (nitrogen), orange (phosphorus), and 










Et O O - 63 ± 1.1 
Et S O R 2.2 ± 0.13 
Et S O S 20 ± 1.6 
Et S S - 25 ± 1.3 
n-Bu O O - 0.63 ± 0.15 
n-Bu S O R 1.2 ± 0.11 
n-Bu S O S 3.7 ± 0.17 
n-Bu S S - 22 ± 1.4 
Ph O O - 24 ± 1.2 
Ph S O R 13 ± 0.65 
Ph S O S 46 ± 2.0 
Ph S S - 530 ± 71 
 
TABLE 7.1: A range of inhibitors and their experimentally obtained Ki values with carboxy-peptidase G (15). 
 
 
FIGURE 7.4: The structures of PMPA, urea-PSMA (Glu-C(O)-Glu) and thiourea-PSMA (Glu-C(S)-Glu), the 
inhibitors to be compared in this study.  
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7.2 Experimental Aims 
The above aims will be addressed through the following experimental objectives: 
 Synthesis and characterisation of urea-PSMA (Glu-C(O)-Glu) (synthesised previously 
(22)) and the novel inhibitor thiourea-PSMA (Glu-C(S)-Glu) 
 Stability studies under the conditions required for cell-based inhibition assays 




7.3 Materials and Methods 
All reagents and consumables were purchased from Sigma Aldrich (Gillingham, UK) or Fischer 
Scientiﬁc (Loughborough, UK), with the exception of DOTA-PSMA (PSMA 617) which was 
purchased from ABX (Radeberg, Germany). DU145 and DU145-PSMA cells were grown from 
stocks provided by Dr Florian Kampmeier (1). 
7.3.1 Instrumentation 
NMR: 1H- and 13C-NMR spectra were acquired on either a Bruker Avance III 400 spectrometer 
operating at 400 MHz (1H frequency) equipped with a QNP probe, or a Bruker Ascend 800 
spectrometer operating at 800 MHz (1H frequency) equipped with a TCI cyroprobe. 
Infrared spectroscopy: IR was conducted with solid sample on a Perkin Elmer Spectrum 100 FT-
IR Spectrometer using a universal ATR sampling accessory.  
Mass spectrometry: Routine direct injection mass spectrometry was conducted on a Waters 
Quadruple MS in positive ion mode. LC-MS results were produced with an Agilent ion-trap LC-
MS in positive ion mode, with an in-line photodiode array. The high-resolution mass 
spectrometry results were produced on a Thermo Scientific Exactive in positive ion mode. 
HPLC: Analytical and semi-preparative HPLC utilised an Agilent 1200 LC with in-line ultraviolet 
detection (220 nm, 240 nm or 254 nm). Two HPLC methods were used to monitor reactions, 
both with an Agilent Eclipse XDB C18 5 µm 4.6 × 150 mm column and the same mobile phases (A 
= H2O 0.1% TFA, B = acetonitrile 0.1% TFA). Method 1: 1 mL/minute with the following gradient: 
0-5 minutes 100% A, 5-15 minutes 0-50% B, 15-20 minutes 100% A. Method 2: 1 mL/minute with 
the following gradient: 0-5 minutes 98% A, 5-20 minutes 2-98% B, 20-25 minutes 98% B, 25-30 
minutes 98% A. Semi-preparative reversed-phase HPLC was conducted using an Agilent Eclipse 
XDB C18 5 µm 21.2 × 150 mm column with the concentration of mobile phase B increasing at a 
rate of 1%/minute (A = H2O with 0.2% TFA, B = acetonitrile with 0.2% TFA, starting from 100% A 




7.3.2 Synthesis of Tertiary Butyl Protected Urea-PSMA; Glu(tBu)2-C(O)-Glu(tBu)2 
 
REACTION SCHEME 7.1: Synthesis route for the production of tertiary butyl protected urea-PSMA – Glu(tBu)2-
C(O)-Glu(tBu)2. 
An oven dried three-necked round-bottomed flask with a dropping funnel, was attached to a 
Schlenk line and cycled with vacuum and nitrogen gas three times. Triphosgene (0.53 mmol, 156 
mg, MW 296.75) was added to the flask which was then cooled to 0°C in an ice bath. L-glutamic 
acid di-tert-butyl ester (1.6 mmol, 459 mg, HCl salt, MW 295.8) was dissolved in 20 mL anhydrous 
DCM containing two equivalents of DIPEA (550 µL, 3.2 mmol, MW 129.2, density 0.742 g/mL). 
This solution was added dropwise to the reaction flask over 45 minutes using the dropping 
funnel whilst the flask remained under nitrogen. The solution was stirred throughout addition 
and some fuming occurred. The ice bath was then removed and the reaction mixture left to 
warm to room temperature for 1 hour. Then a further 600 mg L-glutamic acid di-tert-butyl ester 
(2 mmol, HCl salt, MW 295.8) dissolved in 20 mL of DCM and 600 µL DIPEA (3.5 mmol, MW 
129.2, density 0.742 g/mL) was added to the dropping funnel and added slowly to the flask over 
45 minutes. The flask remained under nitrogen for 30 minutes post-addition and was then 
sealed and left to stir overnight. The next day the reaction mixture was washed with water (50 
mL x 3) and brine (50 mL x 1), dried over magnesium sulfate and the solvent removed by rotary 
evaporation. The product was identified using TLC with 80:20 DCM:ethyl acetate (starting 
material RF = 0, product RF = 0.65). The crude product was purified using flash chromatography 
(Biotage Isolaera™ Four) using a 10 g KP SNAP silica column with a DCM and ethyl acetate 
gradient (100% DCM to 60% DCM, 40% ethyl acetate) and then dried under vacuum to produce 
Glu(tBu)2-C(O)-Glu(tBu)2 as a white solid (562 mg, 1.03 mmol (MW = 544.69), yield 64%). 1H 
NMR: (CDCl3, 400 MHz, normalised to chloroform solvent peak (23)): δ 1.39 (s, 18H), 1.42 (s, 
18H), 1.83 (m, 2H), 2.02 (m, 2H), 2.27 (m, 4H), 4.30 (dd, J= 6.8, 12, 2H), 5.25 (broad s, 2H). 13C 
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NMR: (CDCl3, 100 MHz, normalised to chloroform solvent peak (23)): δ 28.07 (s, 6C), 28.14 (s, 
6C), 28.52 (s, 2C), 31.64 (s, 2C), 53.13 (s, 2C), 80.53 (s, 2C), 82.03 (s, 2C) 156.94 (s, 1C) 172.13 (s, 
2C), 172.50 (s, 2C). High-resolution mass spectrometry: [C27H48N2O9+H]+: observed m/z 
545.3426, theoretical m/z 545.3433,[C27H48N2O9+Na]+: observed m/z 567.3241, theoretical m/z 
567.3252. 
7.3.3 Synthesis of Urea-PSMA; Glu-C(O)-Glu. 
 
REACTION SCHEME 7.2: Synthesis route for the production of urea-PSMA – Glu-C(O)-Glu. 
A solution containing 75 mg phenol (0.8 mmol, MW 94.11), 75 µL H2O, 35.5 µL TIPS (0.17 mmol, 
MW 158.36, density 0.773 g/mL) and 1.5 mL TFA (19.6 mmol, MW 114.02, density 1.489 g/mL) 
was added to 66 mg of Glu(tBu)2-C(O)-Glu(tBu)2 (0.12 mmol, MW = 544.69) and the mixture 
stirred at room temperature for 6 hours. After this time 5 mL DCM was added and then the 
solution was evaporated to ~0.5 mL under a stream of nitrogen gas, and 15 mL of ice-cold 
diethylether was added, whereupon a white solid precipitated. The solid was separated from 
the diethyl ether by centrifugation, dried overnight at room temperature, dissolved in 7 mL 
water containing 0.1% TFA and then purified by semi-preparative HPLC. The purified sample was 
freeze-dried, forming a white solid. 18.6 mg (48% yield) of Glu-C(O)-Glu (50 µmol, MW 320.25) 
was produced. 1H NMR: (D2O plus drop of MeOD, 400 MHz, normalised to methanol solvent 
peak (23)) δ 1.97 (m, 2H), 2.16 (m, 2H), 2.50 (t, J = 7.6, 4H), 4.26 (dd, J = 5.2, 9.2, 2H). 13C NMR: 
(D2O plus drop of MeOD, 100 MHz, normalised to methanol solvent peak (23)) δ 27.82 (s, 2C), 
31.50 (s, 2C), 160.65 (s, 1C), 177.60 (s, 2C), 178.57 (s, 2C). High-resolution mass spectrometry: 
[C11H16N2O9+H]+: observed m/z 321.0924, theoretical m/z 321.0929, [C11H16N2O9+Na]+: observed 




7.3.4 Synthesis of Tertiary Butyl Protected Thiourea PSMA; Glu(tBu)2-C(O)-Glu(tBu)2 
 
REACTION SCHEME 7.3: Synthesis route for the production of tertiary butyl protected thiourea-PSMA – 
Glu(tBu)2-C(S)-Glu(tBu)2. 
An oven-dried three-necked round-bottomed flask with a dropping funnel was attached to a 
Schlenk line and cycled with vacuum and nitrogen gas three times. 5 mL DCM was added to the 
round-bottomed flask, followed by 260 µL of thiophosgene (3.4 mmol, MW 114.98, density 1.5, 
bright orange liquid). The flask was then cooled to 0°C in an ice bath. L-glutamic acid di-tert-
butly ester (1 g, 3.4 mmol, HCl salt, MW 295.8) was dissolved in 20 mL anhydrous DCM and 1.1 
mL DIPEA (6.3 mmol, MW 129.2, density 0.742 g/mL) was added dropwise to the flask over 45 
minutes using the dropping funnel whilst the flask remained under nitrogen. The solution was 
stirred throughout the addition and some fuming occurred. The ice bath was then removed and 
the reaction mixture was left to warm to room temperature for 1 hour. Then a further 1.1 g L-
glutamic acid di-tert-butyl ester (3.7 mmol, HCl salt, MW 295.8) dissolved in 20 mL of DCM and 
1.1 mL DIPEA (6.3 mmol, MW 129.2, density 0.742 g/mL) was added dropwise to the flask over 
45 minutes using the dropping funnel. The flask was left under nitrogen for a further 30 minutes, 
then sealed and left to stir overnight. The next day the reaction mixture was washed with water 
(50 mL x 3) and brine (50 mL x 1), dried over magnesium sulfate and then the solvent removed 
by rotary evaporation. The product was identified using silica TLC with 95:5 DCM:ethyl acetate 
(starting material RF = 0, product RF = 0.4). The crude product was purified using flash 
chromatography (Biotage Isolaera™ Four) using a 25 g SNAP KP silica column with a DCM and 
ethyl acetate gradient (100% DCM to 90% DCM, 10% ethyl acetate) and then dried under 
vacuum to produce Glu(tBu)2-C(S)-Glu(tBu)2 as a light yellow oil which solidified upon standing. 
260 mg, 0.46 mmol, a 14% yield (MW 560.75). 1H NMR: (CDCl3, 400 MHz, normalised to 
chloroform solvent peak (23)): δ 1.41 (s, 18H), 1.43 (s, 18H), 1.98 (m, 2H), 2.09 (m, 2H), 2.31 (m, 
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4H), 4.84 (broad s, 2H), 6.79 (broad s, 2H). 13C NMR: (CDCl3, 100 MHz, normalised to chloroform 
solvent peak (23)): δ 27.75 (s, 2C), 28.06 (s, 6C), 28.13 (s, 6C), 31.39 (s, 2C), 56.93 (s, 2C), 80.84 
(s, 2C), 82.53 (s, 2C) 171.38 (s, 2C) 172.51 (s, 2C), 182.50 (s, 1C). High-resolution mass 
spectrometry: [C27H48N2O8S+H]+: observed m/z 561.3195, theoretical m/z 561.3204, 
[C27H48N2O8S+Na]+: observed m/z 583.3010, theoretical m/z 583.3024 
7.3.5 Synthesis of Thiourea-PSMA; Glu-C(S)-Glu 
A number of different deprotection strategies were employed to obtain Glu-C(S)-Glu. The details 
of each will be described here. The method used to produce the Glu-C(S)-Glu used for 
characterisation, stability and cell studies was method C2. 
7.3.5.1 Deprotection Method A – Trifluoroacetic Acid  
 
REACTION SCHEME 7.4: Synthesis routes for the production of thiourea-PSMA – Glu(tBu)2-C(S)-Glu(tBu)2. 
Method A1 - 20 hour deprotection: A solution containing, 150 mg phenol (1.6 mmol MW 94.11), 
150 µL H2O, 75 µL TIPS (0.35 mmol, MW 158.36, density 0.773 g/mL) and 3 mL TFA (39 mmol, 
MW 114.02, density 1.489 g/mL) was added to 300 mg of Glu(tBu)2-C(S)-Glu(tBu)2 (0.53 mmol, 
MW = 560.75) and the mixture stirred at room temperature for 20 hours. After this time 2 mL 
DCM was added and then the solution was evaporated down under a stream of nitrogen gas. 
Once only ~0.5 mL remained 15 mL of ice-cold diethyl ether was added, and the resulting white 
solid was separated from the diethyl ether by centrifugation, dissolved in water and dried 
overnight in the freeze drier. Analysis of this crude mixture was carried out by analytical HPLC 
method 1. Purification was carried out with a 2 g C18 cartridge preconditioned with 
acetonitrile/0.1% TFA followed by water/0.1% TFA. The reaction mixture was loaded in 
water/0.1% TFA and the reaction products eluted with increasing concentrations of acetonitrile. 
Each fraction was analysed by MS with direct injection in positive ion mode, data are provided 




Method A2 - 6 hour deprotection: A solution containing 150 mg phenol (1.6 mmol, MW 94.11), 
150 µL H2O, 75 µL TIPS (0.35 mmol, MW 158.36, density 0.773 g/mL) and 4 mL TFA (52 mmol, 
MW 114.02, density 1.489 g/mL) was added to 200 mg of Glu(tBu)2-C(S)-Glu(tBu)2 (0.35 mmol, 
MW = 560.75) and the mixture stirred at room temperature for 6 hours. After this time 2 mL 
DCM was added and then the solution was evaporated down under a stream of nitrogen gas. 
Once only ~0.5 mL remained 15 mL of ice-cold diethyl ether was added, and the resulting white 
solid separated from the diethyl ether by centrifugation, dissolved in water and dried overnight 
in the freeze drier. Analysis of this crude mixture was carried out by analytical HPLC method 1. 
Purification was carried out with a 2 g C18 cartridge preconditioned with acetonitrile/0.1% TFA 
followed by water/0.1% TFA. The reaction mixture was loaded in water/0.1% TFA and the 
reaction products eluted with increasing concentrations of acetonitrile. Each fraction was 
analysed by direct injection low-resolution MS. Purification on the other half of the solid mixture 
was also carried out with semi-preparative HPLC, the desired fractions were freeze-dried and 
then analysed by MS, direct injection in positive ion mode, data are provided in the results 
section along with the identity of the compounds produced.  
7.3.5.2 Deprotection Method B – Sodium Hydroxide and Tetrahydrofuran 
Glu(tBu)2-C(S)-Glu(tBu)2 (100 mg, 178 µmol, MW 560.75) was dissolved in 7.5 mL of 
tetrahydrofuran and 7.5 mL of a 0.24 M NaOH solution. This solution was refluxed overnight at 
85°C. The next day the solution had turned orange-yellow. The reaction mixture was cooled to 
room temperature and neutralised to pH 5 with 4 M HCl. The colour faded upon neutralisation. 
The solvents were removed by rotary evaporation and then the product was separated from the 
salt of neutralisation and purified using a 2 g C18 cartridge preconditioned with acetonitrile 0.1% 
TFA followed by water 0.1% TFA. The reaction mixture was loaded in water/0.1% TFA and the 
reaction products eluted with increasing concentrations of acetonitrile. The crude product and 
each fraction from this purification method was analysed by MS, direct injection in positive ion 
mode, data are provided in the results section along with the identity of the compounds 
produced.  
7.3.5.3 Deprotection Method C – Hydrochloric Acid and Acetonitrile 
Deprotection method C1: Glu(tBu)2-C(S)-Glu(tBu)2 (5 mg, 9 µmol, MW 560.75) was dissolved in 
1 mL acetonitrile and 0.5 mL 4 M HCl. The reaction was stirred at room temperature and samples 
were taken for HPLC and LC-MS analysis at 18 hours, 90 hours and 138 hours. After this time the 
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reaction solution was reduced to less than 0.5 mL on the rotary evaporator and then diluted to 
5 mL in H2O. This solution was purified using semi-preparative HPLC and the desired fraction 
freeze-dried and dissolved in D2O and analysed by NMR. Data are provided in the results section 
along with the identity of the compounds produced. 
Deprotection method C2: Glu(tBu)2-C(S)-Glu(tBu)2 (30 mg, 53.5 µmol, MW 560.75) was 
dissolved in 4 mL acetonitrile and 2 mL 6 M HCl (final concentration 5 mg/mL) and stirred at 
room temperature for 8 hours. The reaction was monitored by HPLC. Figure 7.23 shows the HPLC 
results at the point that the reaction was quenched. After 8 hours the solution was neutralised 
to pH 3-7 with NaOH (4 M ~3330 µL), frozen and then freeze-dried to form a white powder. The 
solid was dissolved in 6 mL H2O containing 0.1% TFA and then purified by semi-preparative HPLC 
and freeze-dried forming a white solid. 7.7 mg (43%) of (Glu-C(S)-Glu) (22.8 µmol, MW 336.32). 
1H NMR: ((CD3)2SO, 400 MHz, normalised to DMSO solvent peak (23)): δ 1.85 (m, 2H), 2.01 (m, 
2H), 2.25 (m, 4H), 4.79 (dd, J=7.2, 12.8, 2H), 7.82 (d, J=8, 2H), 12.45 (broad s, 4H). 1H NMR: ((D2O 
PBS, 400 MHz, normalised to H2O solvent peak (23)) δ 2.10 (m, 2H), 2.24 (m, 2H), 2.48 (t, J=8 
4H). It is assumed that the additional expected CH peak resides under the H2O solvent peak. 
High-resolution mass spectrometry: [C11H16N2O8S+H]+: observed m/z 337.0697, theoretical m/z 
337.0700, [C11H16N2O8S+Na]+ observed m/z 359.0515, theoretical m/z 359.0520. 
7.3.6 Alternative Protection Strategy: Synthesis of Benzyl-Ester Protected Thiourea-
PSMA; Glu(Bn)2-C(S)-Glu(Bn)2 
 
REACTION SCHEME 7.5: Synthesis route for the production of benzyl-ester protected thiourea-PSMA – 
Glu(Bn)2-C(S)-Glu(Bn)2. 
As well as different deprotection strategies, different protection methods were investigated. 
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Method 1 – standard DIPEA levels: An oven-dried 3-necked round-bottomed flask with a 
dropping funnel was attached to a Schlenk line and cycled with vacuum and nitrogen gas three 
times. 5 mL DCM was added to the round-bottomed flask, followed by 250 µL of thiophosgene 
(3 mmol, MW 114.98, density 1.5, bright orange liquid) the flask was then cooled to 0°C in an 
ice bath. L-glutamic acid di-benzyl-ester (1 g, 2.75 mmol, HCl salt, MW 363.8) was dissolved in 
20 mL anhydrous DCM and 1 mL DIPEA (5.7 mmol, MW 129.2, density 0.742 g/mL) was added 
dropwise to the flask over 45 minutes using the dropping funnel whilst the flask remained under 
nitrogen. The yellow solution was stirred throughout the addition and some fuming occurred. 
The ice bath was then removed and the reaction mixture left to warm to room temperature for 
1 hour. Then a further 1.1 g L-glutamic acid di-benzyl-ester (3.0 mmol, HCl salt, MW 363.8) 
dissolved in 20 mL of DCM and 1 mL DIPEA (5.7 mmol, MW 129.2, density 0.742 g/mL) was added 
dropwise to the flask over 1 hour using the dropping funnel and the solution turned yellow. The 
flask was left under nitrogen for a further 30 minutes, then sealed and left to stir overnight. The 
reaction mixture was washed with water (50 mL x 3) and brine (50 mL x 1), dried over magnesium 
sulfate and then the solvent removed by rotary evaporation. The product was identified using 
silica TLC with 50:50 hexane:ethyl acetate (starting material RF = 0, product RF=0.9). The crude 
product was purified using flash chromatography (Biotage Isolaera™ Four) using a 25 g SNAP KP 
silica column with a hexane and ethyl acetate gradient (100% hexane to 20% ethyl acetate). The 
collected fractions were dried under vacuum and analysed by MS, direct injection in positive ion 
mode. Data are provided in the results section along with the identity of the compounds 
produced. 
Method 2- increased DIPEA levels: An oven-dried 3-necked round-bottomed flask, with a 
dropping funnel was attached to a Schlenk line and cycled with vacuum and nitrogen gas three 
times. 5 mL DCM was added to the round-bottomed flask, followed by 240 µL of thiophosgene 
(2.75 mmol, MW 114.98, density 1.5, bright orange liquid). The flask was then cooled to 0°C in 
an ice bath. L-glutamic acid di-benzyl-ester (1 g, 2.75 mmol, HCl salt, MW 363.8) was dissolved 
in 20 mL anhydrous DCM and 1.1 mL DIPEA (6.3 mmol, MW 129.2, density 0.742 g/mL) was 
added dropwise to the flask over 30 minutes using the dropping funnel whilst the flask remained 
under nitrogen. The yellow solution was stirred throughout the addition and some fuming 
occurred. The ice bath was then removed and the reaction mixture left to warm to room 
temperature for 1 hour. Then a further 1 g L-glutamic acid di-benzyl-ester (2.75 mmol, HCl salt, 
MW 363.8) dissolved in 20 mL of DCM and 2 mL DIPEA (11.4 mmol, MW 129.2, density 0.742 
g/mL) was added dropwise to the flask over 1 hour using the dropping funnel and the solution 
turned red-brown. The flask was left under nitrogen for a further 30 minutes, then sealed and 
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left to stir overnight at room temperature. The reaction mixture was washed with water (50 mL 
x 3) and brine (50 mL x 1), dried over magnesium sulfate and then the solvent removed by rotary 
evaporation. The product was identified using silica TLC with 95:5 DCM:ethyl acetate (starting 
material RF =  0, product RF  =  0.2, side-product RF = 0.6). 500mg of the crude product was purified 
using flash chromatography (Biotage Isolaera™ Four) using a 10 g SNAP KP silica column with a 
hexane and ethyl acetate gradient (100% DCM to 100% ethyl acetate) which produced 3 
different peaks, although peaks 2 and 3 were not well-separated by the gradient. The collected 
fractions were dried under vacuum and analysed by LC-MS in positive ion mode. Data are 
provided in the results section along with the identity of the compounds produced. 
7.3.7 Stability Studies 
These studies have shown that the cyclisation of Glu-C(S)-Glu to Glu-C(S)-pyroGlu occurs at both 
high and low pH, and that this cyclisation is detectable by NMR. Therefore it was important to 
ensure that the product was stable at pH 7, the pH at which cell studies would be carried out. In 
order to ensure that Glu-C(S)-Glu was stable at near neutral pH the compound was dissolved in 
D2O containing ten times the standard concentration of PBS (NaCl 1.37M, KCl 27 mM, Na2HPO4 
100 mM, KH2PO4 18 mM). This only brought the pH to 4 and so ammonium acetate was used to 
raise the pH to at least 6.5 (final concentration 1 M ammonium acetate). This mixture was then 
monitored by 1H NMR (400 MHz) at time points up to 48 hours to look for any evidence of 
cyclisation. The same experiment was also carried out with Glu-C(O)-Glu over 48 hours. 
7.3.8 Concentration Determination by NMR 
In order to determine the relative concentration of the two inhibitors urea-PSMA (Glu-C(O)-Glu) 
and thiourea-PSMA (Glu-C(S)-Glu), quantitative NMR studies were performed. Here, equal 
volumes (200 µL) of the two stability samples (~25 mM) containing Glu-C(O)-Glu and Glu-C(S)-
Glu were mixed and then a further 200 µL of a 125 mM NMR standard, maleic acid, was added. 
This sample was analysed in a shaped NMR tube with an oval rather than a circular cross-section 
(Bruker Z106898). This shaped tube reduces the negative impact that the conductivity of high 
salt solutions (< 60 mM) has on the signal-to-noise ratio by reducing the resistance of the sample 
to radio frequency penetration (24). Analysis was conducted on an 800 MHz NMR with a 
relaxation time (D1) of 20 seconds, long enough to ensure that the spectrum was quantitative. 
The 800 MHz machine gave improved resolution and separation between the peaks of interest 
compared to the 400 MHz. The integration of these peaks was used to confirm the concentration 
279 
 
of each solution that had been mixed to produce this NMR sample. These solutions of known 
concentrations were used to prepare the inhibitor solutions for future cell assays. 
7.3.9 Cell Studies 
The GCP(II)/PSMA-negative cell line chosen was DU145, a human carcinoma prostate cancer cell 
line derived from a brain metastatic site, which does not express GCP(II)/PSMA. The 
GCP(II)/PSMA-expressing cell line chosen was a genetically modified daughter cell line of DU145, 
DU145-PSMA. This cell line had previously been transduced to express full-length human 
GCP(II)/PSMA, with a published method (25). These cells were cultured in RMPI 1640 medium 
supplemented with 10% foetal bovine serum, 2 mM L-glutamine, and penicillin/streptomycin. 
To prepare for experiments, cells were grown at 37°C in an incubator equilibrated with 
humidiﬁed air and 5% CO2. 
IC50: To determine the IC50, competitive binding studies were performed with DU145-PSMA cells 
with 1 nM [68Ga]Ga-DOTA-PSMA as the probe and blocking with Glu-C(O)-Glu, Glu-C(S)-Glu and 
PMPA over a range of concentrations (1 nM - 400 µM). As both Glu-C(O)-Glu and Glu-C(S)-Glu 
had been dissolved in 10 x PBS and 1 M ammonium acetate to maintain pH at 7 for the stability 
and quantification NMR studies, care was taken to ensure that the same amount of these 
reagents were added into every well used in this assay. Cells (0.25 × 106 per well) were seeded 
in a 24-well plate, 1 day before the assay. At the time of the assay, the medium was removed 
and replaced with 240 µL of complete RMPI medium at 37°C. Increasing concentrations of Glu-
C(O)-Glu, Glu-C(S)-Glu or PMPA (5 µL dissolved in 1 M ammonium acetate and 10 x PBS) followed 
by 1 nM [67Ga]Ga-DOTA-PSMA (5 µL, molar activity 5–10 MBq/nmol, diluted in PBS) were added 
to the cells (total volume, 250 µL). A control was also included to account for non-specific binding 
where non-GCP(II)/PSMA-expressing cells (DU145) prepared in the same way were also 
incubated with 1 nM [67Ga]Ga-DOTA-PSMA. After 1 hour incubation at 37°C, the supernatant 
was removed and the cells were washed with PBS (2 × 0.25 mL), lysed with NaOH (1 M, 0.25 mL), 
and the wells washed with PBS (0.25 mL). The activity present in supernatant and lysate was 
measured by γ-counting. Data were analysed using GraphPad Prism (version 7.04 GraphPad 
Software) and a 1-site–ﬁt log IC50 algorithm. 
Stability of Glu-C(S)-Glu in the presence of cells: NMR spectroscopy was used to determine if 
cyclisation of Glu-C(S)-Glu to Glu-C(S)-pyroGlu occurred whilst the blocking agent was incubated 
with cells. DU145-PSMA cells (1 × 106 per well) were seeded in a 6-well plate, 1 day before the 
assay. At the time of the assay, the medium was removed and replaced with 980 µL of PBS at 
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37°C. Then 20 µL of Glu-C(S)-Glu was added (dissolved in 1 M ammonium acetate and 10 x PBS) 
to give a final concentration of 400 µM on the cells. The cells were then incubated at 37°C for 1 
hour. As a control, wells without any cells were incubated with Glu-C(S)-Glu in the same way. 
After 1 hour the supernatant was removed from the wells (containing cells or with no cells), 
centrifuged to remove any cell debris or particulates, then analysed by 1H NMR spectroscopy at 
400 MHz. 
7.3.10 Statistical Analysis   
Data were analysed in GraphPad Prism 5 (version 5.04 or version 7.04) and expressed as mean 
± standard deviation. Student t tests were used to determine statistical significance; a P value of 





7.4.1 Synthesis of Urea-PSMA; Glu-C(O)-Glu 
Urea-PSMA (Glu-C(O)-Glu) was successfully synthesised in two steps. In the first, the tertiary 
butyl-protected form (Glu(tBu)2-C(O)-Glu(tBu)2) was produced by the reaction of tertiary butyl-
protected glutamic acid with triphosgene in the presence of DIPEA base to form an isocyanate 
intermediate. This was then reacted with a further protected glutamic acid in the presence of 
excess DIPEA base. This formed a urea bond between these two amino acids producing the 
symmetrical product Glu(tBu)2-C(O)-Glu(tBu)2. After purification with flash column 
chromatography, this product was deprotected using trifluoroacetic acid in the presence of 
phenol and TIPS as scavengers. The final product was then purified by semi-preparative HPLC 
and characterised. The NMR spectroscopy and high-resolution mass spectrometry results are 
detailed in the methods section and the IR spectra of the two compounds are shown in figure 
7.5 and figure 7.6. 
 
FIGURE 7.5: IR spectrum for tertiary butyl-protected urea-PSMA Glu(tBu)2-C(O)-Glu(tBu)2 : a characteristic 




FIGURE 7.6: IR spectrum for Glu-C(O)-Glu: a characteristic urea C=O stretch is seen at 1637 cm-1 (26). 
7.4.2 Synthesis of Tertiary Butyl Protected Thiourea-PSMA; Glu(tBu)2-C(S)-Glu(tBu)2 
The t-butyl-protected thiourea-PSMA (Glu(tBu)2-C(S)-Glu(tBu)2) was produced by the reaction of 
t-butyl protected glutamic acid with thiophosgene in the presence of DIPEA base to form an 
isothiocyanate intermediate which was then reacted with t-butyl-protected glutamic acid in the 
presence of excess DIPEA base. This formed a thiourea bond between these two amino acids 
producing the symmetrical product Glu(tBu)2-C(S)-Glu(tBu)2. The protected thiourea 
intermediate was purified by flash column chromatography and characterised. The NMR 
spectroscopy and high-resolution mass spectrometry results are detailed in the methods section 




FIGURE 7.7: IR spectrum for tertiary butyl-protected thiourea-PSMA Glu(tBu)2-C(S)-Glu(tBu)2 : a characteristic 
thiourea C=S stretch is seen at 1326 cm-1 (26). 
7.4.3 Synthesis of Thiourea-PSMA; Glu-C(S)-Glu 
A number of different strategies were investigated for the deprotection of the t-butyl protected 
thiourea-PSMA in order to produce thiourea-PSMA (Glu-C(S)-Glu). This was required due to the 
formation of side-products when deprotection was carried out with the same method as used 
for the preparation of urea-PSMA. After optimisation experiments, method C2, which used 
acetonitrile and 6 M HCl for deprotection, was used to isolate enough thiourea-PSMA (Glu-C(S)-
Glu) for thorough characterisation and cell studies. 
7.4.3.1 Deprotection Method A1 – TFA 20 hours 
When deprotection of thiourea-PSMA with TFA was carried out for 20 hours, the crude product 
contained a mixture of products, as determined by analytical HPLC (method 1 figure 7.8). This 
was then purified using a C18 cartridge eluted with increasing concentrations of acetonitrile. The 
mass spectra were determined for these fractions and the 9:1 water: acetonitrile fraction 
showed a major peak with of 319 m/z (figure 7.9). This mass corresponds to the desired product 
([Glu-C(S)-Glu+H]+ m/z = 337.06) minus 18 mass units, which is likely to correspond to the loss 
of a water molecule (exact mass = 18.01), suggesting a dehydration reaction had occurred. 
Further investigation was required to determine whether this dehydration was occurring in the 




FIGURE 7.8: HPLC analysis of the crude deprotection mixture, after Glu(tBu)2-C(S)-Glu(tBu)2 was reacted with 
TFA for 20 hours, method A1. HPLC method 1. 
 
FIGURE 7.9: MS analysis of C18 purified product, after Glu(tBu)2-C(S)-Glu(tBu)2 was reacted with TFA for 20 
hours. The major signal at 319.08 m/z corresponds to the mass of Glu-C(S)-Glu minus 18 mass units, suggesting 
the loss of water.  
7.4.3.2 Deprotection Method A2 – TFA 6 hours 
When the deprotection time was reduced from 20 hours to 6 hours, the analytical HPLC (method 
1) of the crude product still showed multiple peaks, but a larger peak was observed at a retention 
time of 13.5 minutes as shown in figure 7.10. This crude mixture was purified by two different 
methods, C18 cartridge and semi-preparative HPLC. The MS analysis of the fractions from the C18 
cartridge showed major peaks with an m/z of 301, 319 and 337 in the 5% and 10% acetonitrile 
washes as shown in figure 7.11 and figure 7.12. The peak at m/z 337 corresponds to the value 
of the desired product [Glu-C(S)-Glu+H]+ demonstrating it was detectable in the MS and 
therefore the peak at 319 is unlikely to be a MS artefact or product of a gas phase reaction. The 
signal at 319 has 18 fewer mass units than [Glu-C(S)-Glu+H]+, and the signal at 301 has a further 
loss of 18 mass units suggesting the sequential loss of water from the molecule. Semi-
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preparative HPLC was used to isolate the major peaks produced upon deprotection and 
determine their identity. The MS of the first peak isolated by preparative HPLC showed a major 
peak at 337 m/z corresponding to the desired product, and a small peak at 319 m/z (figure 7.13). 
The second isolated peak showed a major product at 337 m/z but also a peak at 319 m/z (figure 
7.14). This suggests that semi-preparative HPLC could separate these two products, but of 
course, it would be ideal to only produce Glu-C(S)-Glu during deprotection by avoiding 
production of this dehydrated side product. 
 
FIGURE 7.10: HPLC analysis of the crude deprotection mixture, after Glu(tBu)2-C(S)-Glu(tBu)2 was reacted with 
TFA for 6 hours, method A2. HPLC method 1.  
 
FIGURE 7.11: MS analysis of the C18 purified product, after Glu(tBu)2-C(S)-Glu(tBu)2 was reacted with TFA for 
6 hours method A2 . The major peak at 337 m/z corresponds to the mass of Glu-C(S)-Glu, and the signal at m/z 




FIGURE 7.12: MS analysis of C18 purified product, after Glu(tBu)2-C(S)-Glu(tBu)2 was reacted with TFA for 6 
hours method A2. The major signal at 337 m/z corresponds to the mass of Glu-C(S)-Glu. The signal at 319 m/z 
=319.08 corresponds to the mass of Glu-C(S)-Glu minus 18 mass units, suggesting the loss of water. 
 
FIGURE 7.13: MS analysis of reaction products purified by semi-preparative HPLC, after Glu(tBu)2-C(S)-
Glu(tBu)2 was reacted with TFA for 6 hours method A2. The major signal at 337 m/z corresponds to the mass of 
Glu-C(S)-Glu.  
 
FIGURE 7.14: MS analysis of reaction products purified by semi-preparative HPLC, after Glu(tBu)2-C(S)-
Glu(tBu)2 was reacted with TFA for 6 hours, method A2. The major signal at 337 m/z corresponds to the mass 
of Glu-C(S)-Glu. The signal at 319.08 m/z corresponds to the mass of Glu-C(S)-Glu minus 18 mass units, 
suggesting the loss of water. 
7.4.3.3 Deprotection Method B.  
As the undesired side product in methods A1 and A2 appeared to be a dehydration product that 
was formed under low water but highly acidic conditions, an alternative method was tested in 
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which an aqueous base was used to deprotect the tertiary butyl groups. A disadvantage of this 
method was that at the end of the reaction the sodium hydroxide was neutralised to pH 5 with 
hydrochloric acid, which produced a large excess of salt. This had to be removed from the 
solution before the product could be isolated and impeded analysis of the crude mixture by MS. 
However, MS signals were observed in a highly diluted sample of the crude mixture as shown in 
figure 7.15. The signals differ by a mass of 22 and were therefore most likely sodium adducts. It 
was therefore assumed that the same side product, a dehydrated form of Glu-C(S)-Glu, had 
formed (336 – 18 (H2O) + 23 (Na) = 341). This was confirmed by removing the salt and purifying 
the crude mixture with a C18 cartridge. The 9:1 water:acetonitrile/0.1% TFA fraction was 
analysed by MS and showed a signal at m/z = 319 corresponding to the same dehydrated side-
product observed for previous deprotections (figure 7.16). This suggests that the highly basic 
conditions of this reaction caused this dehydration to occur, even in the presence of water. 
Heating of the reaction mixture is also likely to have accelerated the formation of this undesired 
dehydrated product. 
 
FIGURE 7.15: MS analysis of the crude reaction mixture, after Glu(tBu)2-C(S)-Glu(tBu)2 was deprotected by 
method B. The major signal at 341 m/z corresponds to the mass of the dehydrated Glu-C(S)-Glu plus sodium. 
 
FIGURE 7.16: MS analysis of the crude reaction mixture, after Glu(tBu)2-C(S)-Glu(tBu)2 was deprotected by 




7.4.3.4 Deprotection Method C1 
In an attempt to avoid the dehydration of Glu-C(S)-Glu, reaction conditions C1 were chosen to 
slow down the deprotection and allow the formation of the different species in solution to be 
observed over time. The conditions chosen were 1 mL acetonitrile to ensure the Glu(tBu)2-C(S)-
Glu(tBu)2 was fully dissolved, and 0.5 mL 4 M HCl to provide the acidic conditions for 
deprotection but also enough water to reduce dehydration. The reaction was then monitored 
by analytical HPLC method 2 and LC-MS. The combined analytical HPLC and LC-MS results after 
18 hours of reaction can be seen in figure 7.17A. The fully protected Glu(tBu)2-C(S)-Glu(tBu)2 
was still observed, plus each of the partially deprotected species (Glu(tBu)-C(S)-Glu(tBu)2, Glu-
C(S)-Glu(tBu)2/Glu(tBu)-C(S)-Glu(tBu), Glu-C(S)-Glu(tBu)), and the desired final product Glu-C(S)-
Glu. This demonstrates that deprotection happens sequentially and that under these conditions 
the desired product Glu-C(S)-Glu was produced before the dehydrated side-product. Note also 
that there are 2 signals with masses corresponding to Glu-C(S)-Glu(tBu)2, suggesting a mixture 
of constitutive isomers gives rise to different retention behaviours on the C18 column. After 90 
hours the majority of the deprotection reaction was completed with only a small peak observed 
corresponding to Glu-C(S)-Glu(tBu) at a retention time of 16 minutes as shown in figure 7.17B. 
The LC-MS of this sample confirmed that the major peak was Glu-C(S)-Glu and that the second 
peak was the dehydrated side product with an m/z of 319. After 138 hours, the sample was fully 
deprotected and the major species had become the dehydrated side-product (figure 7.17C). In 
order to understand more about this side-product and to isolate as much Glu-C(S)-Glu as 
possible. This sample was purified by semi-preparative HPLC, the fractions containing the 2 
peaks were freeze-dried and then analysed by HPLC and NMR. Figure 7.18 shows the analytical 
HPLC (method 2) for each peak isolated by semi-preparative HPLC, demonstrating there is no 
interconversion during this separation/purification.  
The 1H NMR spectra of the dehydrated side-product is shown in figure 7.19 and the 
corresponding COSY is shown in figure 7.20. These results suggest that Glu-C(S)-Glu has been 
dehydrated under the reaction conditions and has cyclised to form Glu-C(S)-pyroGlu. The 
integration of each peak matches this cyclised structure as does the evidence from the COSY 
spectrum, as the peak at 5.28 ppm is only coupled to the peak at 2.47 ppm. The NMR spectra 
for the isolated Glu-C(S)-Glu peak (figure 7.21) shows that the major product is the desired 
compound but there is also some cyclised material present. This cyclisation could have occurred 
after purification as the product was stored in acidic conditions (HPLC buffer containing 0.1% 
TFA) and suggests that this product is sensitive to low pH and should only be stored as a solid or 
at near-neutral pH. This investigation has revealed that the deprotection is sequential, and that 
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the cyclised product is only produced after the desired product. The different species produced 





FIGURE 7.17: HPLC chromatograms of deprotection reaction method C1 over time. (A) HPLC of the reaction 
mixture after 18 hours, with peaks identified from LC-MS data. (B) HPLC of the reaction mixture after 90 hours, 
with peaks identified from LC-MS data. (C) HPLC of the reaction mixture after 138 hours. 
 
FIGURE 7.18: (A) HPLC of the reaction solution after 138 hours of deprotection though method C1. The two 
major product peaks were separated by semi-preparative HPLC. These isolated fractions, corresponding to (B) 
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peak 1; (C) peak 2; were then reinjected on the HPLC. This shows the peaks do not interconvert on this time 
frame and demonstrates the purity of products used for NMR analysis.  
 
FIGURE 7.19: 400 MHz 1H NMR spectra of cyclised side-product Glu-C(S)-pyroGlu. 1H NMR: (D2O, 400 MHz, 




FIGURE 7.20: 400 MHz 1H COSY NMR spectra of cyclised side-product Glu-C(S)-pyroGlu. This demonstrates the 
coupling between the proton in position H1 and those in positions H2-5. 
 
FIGURE 7.21: 400 MHz 1H NMR spectra of Glu-C(S)-Glu, purified after 138 hour deprotection by method C1 by 
semi-preparative HPLC.  
 
FIGURE 7.22: Species detected during the deprotection of Glu(tBu)2-C(S)-Glu(tBu)2 over 138 hours and the 
order in which they are produced. Note that it is not clear in which order the carboxylic acids are deprotected, 
only that this happens sequentially, and so the specific structures shown are only illustrative.  
7.4.3.5 Deprotection Method C2 
This method was used to isolate the final product in sufficient quantities to characterise and 
carry out cell studies. Method C2 was very similar to method C1 except that the acid 
concentration was increased to 6 M to accelerate the reaction so the deprotection could be 
carried out in 8 hours. The reaction was monitored by analytical HPLC method 2 until the 
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production of Glu-C(S)-pyroGlu was just detectable as shown in figure 7.23. Then the reaction 
was neutralised, frozen, freeze-dried and purified by semi-preparative HPLC. When the fractions 
were collected from the semi-prep system they were immediately frozen in liquid nitrogen and 
freeze-dried to avoid unnecessary exposure of the product to the acidic HPLC solvent. The solid 
produced was analysed by 1H NMR in both DMSO-d6 and D2O and showed a pure product. The 
compound was further characterised by IR and high-resolution MS. See results section and figure 
7.24, figure 7.25 and figure 7.26. 
 
FIGURE 7.23: HPLC of deprotection mixture C2 after 8 hours. At this time-point, the reaction was neutralised 
and freeze-dried ready for purification. HPLC method 2. 
 
FIGURE 7.24: 400 MHz 1H NMR (D2O pH ~3) spectra of Glu-C(S)-Glu, purified after 8 hour deprotection with 




FIGURE 7.25: 400 MHz 1H NMR ((CD3)2SO) spectra of Glu-C(S)-Glu, purified after 8 hour deprotection with 
method C2 followed by purification by semi-preparative HPLC. 
 
FIGURE 7.26: IR spectra for thiourea-PSMA Glu-C(S)-Glu. Characteristic thiourea C=S stretch seen at 1350 cm-1 
(26). 
7.4.4 Alternative Protection Strategy: Synthesis of Benzyl-Ester Protected Thiourea-
PSMA; Glu(Bn)2-C(S)-Glu(Bn)2 
As the deprotection strategies described above all had low yield due to the formation of Glu-
C(S)-pyroGlu, or the requirement to stop the reaction before the deprotection was complete to 
avoid its formation, alternative protection strategies were considered to avoid this. The benzyl 
protecting group was chosen as a viable alternative as it can be removed by hydrogenation in 
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the presence of a palladium catalyst (22), avoiding the need for the highly acidic or basic 
conditions. Therefore the reaction was carried out by the same method as used for tertiary butyl 
protected glutamic acid but replacing this with benzyl-ester protected glutamic acid. This 
strategy caused the formation of the isothiocyanate intermediate (Bn)2Glu-NCS ([(Bn)2Glu-
NCS+H]+ m/z-= 370) but not the formation of the desired product Glu-C(S)-Glu(Bn)4. The mass 
spectrum of this reaction mixture is shown in figure 7.27. This suggests there was insufficient 
base present to deprotonate the primary amine of the glutamic acid and therefore it could not 
react with the isothiocyanate to form the thiourea. The reaction was therefore repeated with 
higher levels of DIPEA. Although this overcame the original issue and the thiourea formed, a side 
reaction also occurred; the cyclisation of the desired product to form (Bn)2Glu-C(S)-pyroGlu(Bn) 
with an m/z of 589 ( 
figure 7.28). The LC-MS data for this reaction is shown in figure 7.29. As this protection strategy 
caused the cyclisation to occur in the protected state, rather than at the later deprotection step, 
this avenue was not pursued further. 
 
FIGURE 7.27: MS analysis of the crude reaction mixture for the synthesis of benzyl-ester protected thiourea-
PSMA method 1, showing the desired product 370 m/z [(Bn)2Glu-NCS+H]+ and the unreacted isothiocyanate 
intermediate 392 m/z [(Bn)2Glu-NCS+Na]+. 
 
FIGURE 7.28: Structures of the products formed after reacting benzyl-ester protected glutamic acid with 




FIGURE 7.29: LC-MS data for the reaction products of the synthesis of benzyl-ester protected thiourea-PSMA 
method 2. This spectrum shows the presence of two species [(Bn)2Glu-C(S)-pyroGlu(Bn)+H]+ (m/z = 589) and 
[(Bn)2Glu-C(S)-Glu(Bn)2+H]+ (m/z = 697). The delay between detectors was 0.3 minutes. 
7.4.5 Stability Studies 
In order to ensure that thiourea-PSMA (Glu-C(S)-Glu) did not cyclise over time at pH 7, NMR 
studies were conducted for 48 hours after solution preparation to assess stability. From the NMR 
spectra obtain previously for both (Glu-C(S)-Glu) and the cyclised side product (Glu-C(S)-
pyroGlu) (figure 7.19 and figure 7.24) it was evident that the best signal to monitor was the 
triplet at 2.3 ppm from the 4 Hc protons. Upon cyclisation this triplet decreases in intensity and 
a mutliplet signal at lower chemical shift appears as shown in figure 7.21. It was not possible to 
also monitor the signals from the 4 Hb1/2 protons due to the signal from the ammonium acetate 
used to neutralise the solution overlapping with them. Figure 7.30 shows the 1H NMR spectra 
for each of the time-points monitored and demonstrates that the molecule is stable under these 
conditions. The same study was conducted for urea-PSMA (Glu-C(O)-Glu), and showed that the 




FIGURE 7.30: Stability study for Glu-C(S)-Glu monitored by 1H NMR spectroscopy (400 MHz). No change in the 
spectra over the time-course confirms the compound is stable under these conditions for up to 48 hours. 
7.4.6 Confirming Concentration of Inhibitors through Quantitative NMR 
In order to prepare for future cell studies, it was important to quantify the concentration of the 
inhibitor compounds present in solution. NMR spectroscopy was chosen as the most 
appropriate quantification method. Equal volumes of a solution containing ~24 mM thiourea-
PSMA (Glu-C(S)-Glu), a solution containing ~25 mM urea-PSMA (Glu-C(O)-Glu) and a 125 nM 
standard of maleic acid were mixed together and the NMR spectrum of the resulting solution 
measured at 800 MHz. This spectrum is shown in figure 7.31. The peak at 2.30 ppm was 
confirmed to be from urea-PSMA as the integration of this peak matched the signal at 4.00 ppm 
known from earlier NMR studies to derive from the protons highlighted in green, and gave the 
expected 2:4 ratio. Therefore the peak at 2.33 ppm was identified as deriving from the Glu-C(S)-
Glu and so the ratio of this triplet and the triplet at 2.30 ppm was used to obtain the ratio of 
these two components in solution. As the two signals slightly overlapped, the central peak of 
each triplet was integrated rather than the whole triplet. This gave a ratio of 1:1.4 (thiourea-
PSMA:urea-PSMA). The quantity of these two compounds relative to the maleic acid present 
was calculated using the peak at 6.10 ppm and the combined integration of the triplets from the 
thiourea-PSMA and urea-PSMA. This gave a ratio of 1:0.92 (maleic acid: thiourea-PSMA + urea-
PSMA). As the signal at 6.10 ppm from the maleic acid only came from 2 protons per molecule, 
but the signal at 2.30 and 2.33 came from 4 protons per molecule this needed to be accounted 
for when calculating the concentration. Therefore the total concentration of thiourea-PSMA 
plus urea-PSMA was 125 mM / 2 x 0.92 = 57.5 mM. The ratio of the thiourea and urea peaks is 
1:1.4 and so the final concentrations were determined as 24 mM for thiourea-PSMA and 33.5 
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mM for urea-PSMA. The remaining solutions from this study were then diluted to 20 mM in the 
same ammonium acetate PBS buffer for use in cell studies. 
 
FIGURE 7.31: 1H NMR spectrum (800 MHz) of a mixture of thiourea-PSMA (Glu-C(S)-Glu), urea-PSMA (Glu-
C(O)-Glu) and maleic acid. Each integration used to identify the peaks or to calculate the concentration of each 
compound present in the solution is highlighted. The identity of the protons producing each signal has been 




7.4.7 Cell Studies  
IC50 assays were carried out in triplicate for each inhibitor (PMPA, urea-PSMA, thiourea-PSMA) 
over a range of 1 nM to 400000 nM (final concentration in the cell suspensions). For all assays 
the probe used was [67Ga]Ga-DOTA-PSMA at a concentration of 1 nM DOTA-PSMA. Good 
agreement was seen between repeats of this assay conducted with the same inhibitor, which 
allowed differences in the performance of the inhibitors to be clearly established. The results 
are shown in figure 7.32. Of the three inhibitors used PMPA had the best IC50 value of 94 ± 4.3 
nM. Urea-PSMA had a ten-fold higher IC50 value than PMPA, (1340 ± 70 nM), however, the 
thiourea-PSMA showed a further hundred-fold higher IC50 value than the urea-PSMA (135000 ± 
6600 nM). In order to validate these results and ascertain whether or not the thiourea-PSMA 
was cyclising during incubation with the cells, a further NMR stability study was conducted. Here 
the thiourea-PSMA was incubated with 1 million cells for 1 hour in 1 mL of PBS at 37°C and the 
supernatant analysed by NMR (figure 7.33). This study showed that there is no detectable 
change in the thiourea-PSMA NMR signal after incubation under these conditions. Lactate, 
pyruvate and alanine excreted by the cells were also detected in the NMR spectrum. This result 
shows that thiourea-PSMA is stable when incubated with cells, and that the IC50 results were not 





FIGURE 7.32: Inhibition curves for (A) PMPA, (B) urea-PSMA (Glu-C(O)-Glu) and (C) thiourea-PSMA (Glu-C(S)-
Glu). Each assay repeat is represented by a different coloured curve. For each assay n = 4 wells at each 
concentration and error bars show SD values. (D) Average values across triplicate assays for each blocking agent. 
Note that non-specific binding of [67Ga]Ga-DOTA-PSMA with non-GCP(II)PSMA-expressing cells (DU145) was 




FIGURE 7.33: 1H NMR (400 MHz) spectrum of: (A) a sample of the thiourea-PSMA compound solution added to 
the cells for the IC50 assay. The signal at 2.2 ppm looks identical to that of the stability study. (B) thiourea-PSMA 
after incubation at 400 µM in an empty 6 well plate in 1 mL PBS for 1 hour. (C) thiourea-PSMA after incubation 
at 400 µM with 1 million cells in a 6 well plate in 1 mL PBS for 1 hour. Peaks corresponding to the release of 
lactic acid, pyruvate and alanine from the cell can be detected, but the signal coming from the thiourea-PSMA at 





The synthesis and characterisation of both urea-PSMA (Glu-C(O)-Glu) (synthesised previously 
(22)) and the novel inhibitor thiourea-PSMA (Glu-C(S)-Glu) have been successfully completed. 
However, thiourea-PSMA posed synthetic challenges due to its propensity to undergo 
intramolecular dehydration. The evidence available from the 1H and COSY NMR spectra suggests 
that the product formed is the γ-lactam, 5-oxopyrrolidine-2-carboxylic acid or pyroglutamic acid 
(figure 7.19). This has a five-membered ring closure between the nitrogen of the thiourea and 
the carbonyl carbon at the end of the glutamic acid side chain, with the loss of water. Similar 
cyclisation reactions are well-known with the formation of a pyroglutamic acid by dehydration 
of glutamic acid first discovered in 1882 when glutamic acid was heated to 180°C (27). 
Additionally, many peptides and proteins have pyroglutamic acid at their N-terminus, as shown 
in table 7.1. This has been shown to protect proteins from degradation, particularly by 
aminopeptidases (28)(29)(30). These pyroglutamic acids can form from either an N-terminal 
glutamic acid or glutamine residue, and this is catalysed in vivo by the enzyme glutaminyl cyclase 
as shown in figure 7.34 (28)(30)(31). Such cyclisation has also been shown to occur in the 
absence of this enzyme (30)(32) and it is known that pH affects the formation rate as shown in 
figure 7.35. In these literature examples the carbonyl carbon reacts with a primary amine, but 
in this study it reacted with one of the secondary amines of a thiourea. These amines therefore 
have different characteristics, and although the reactions are related, they are not identical. Like 
the formation of pyroglutamic acid from N-terminal glutamic acids, the cyclisation seen in this 
study is pH dependent, with cyclisation occurring at low and high pH but not when the pH was 
maintained between 6.5 and 7.5. Evidence for this was obtained by conducting 1H NMR 
spectroscopy stability studies (figure 7.30). A mechanism for such cyclisation at both high and 
low pH has been proposed in figure 7.36. Low pH would encourage cyclisation by promoting the 
protonation of the carboxylic acid so that water becomes the leaving group. At high pH the 
conditions will reach the pKa of the thiourea amine proton, with its loss facilitating cyclisation. It 
is interesting that cyclisation occurred to a greater extent in the thiourea-PSMA synthesis than 
in the urea-PSMA synthesis and shows that the presence of this sulfur greatly alters the 
behaviour of the system, in particular lowering the pKa of the amine protons. This observation 
can be explained by considering the resonance structures of urea and thiourea as shown in 
figure 7.37. It is likely that the enol resonance form would be more preferred for the thiourea 
than the urea due to its better stabilisation of the negative charge. Therefore it would have been 
ideal to have a deprotection strategy for thiourea-PSMA that avoided the use of either high or 
low pH. An existing method that may have been able to avoid extremes of pH is the removal of 
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t-butyl groups by reacting the protected compound with zinc bromide (500 mol% ZnBr2) in DCM 
at room temperature for 24 hours (33). However, this was not attempted, as an acceptable 
separation technique of deprotected thiourea-PSMA (Glu-C(S)-Glu) from ZnBr2 could not be 
conceived. Instead, an alternative strategy was attempted using benzyl-esters as the protecting 
group known to be removable by hydrogenation in the presence of a palladium catalyst (22). 
When t-butyl groups were used, no cyclisation was observed under the conditions required to 
form the protected thiourea. However, when this was conducted with benzyl protecting groups 
cyclisation occurred whilst the protecting groups were still intact. This can be explained by 
considering the electronic properties of these two protecting groups. A benzyl-ester is more 
electron withdrawing than a t-butyl ester and so it causes the carbon of the carboxyl group to 
become more electronegative, and therefore more prone to cyclisation under the basic reaction 
conditions (excess DIPEA). Additionally, the benzyl-ester is a good leaving group and forms 
toluene upon deprotection. There are alternative protection strategies possible for carboxylic 
acids, yet to be explored in this system, which could avoid high or low pH. An example is the 
“supersilyl” group which can be removed with just UV light (254 nm) (34).  
Instead of these alternatives methods, a method which could produce sufficient product for the 
required studies was adopted. By understanding that the processes of deprotection and then 
cyclisation were sequential, a deprotection method that slowed down the formation of Glu-C(S)-
pyroGlu was developed. This involved deprotecting (tBu)2Glu-C-(S)-Glu(tBu)2 in 6 M HCl and 
acetonitrile, over 8 hours and then neutralising the reaction to halt both the deprotection and 
cyclisation, followed by purification by semi-preparative HPLC. These are mild conditions which 
avoid the use of concentrated acid or a heating step, which are both likely to accelerate 
dehydration to pyroglutamic acid. However, this is not a suitable strategy for larger scale 
production and would be further complicated if the thiourea-PSMA motif was to be 
functionalised with a chelator in order to develop a radiotracer or other bioconjugate. In such 
cases, alternative synthetic strategies would need to be developed. Although the use of this 
motif for targeting GCP(II)/PSMA is unlikely in light of the IC50 results, this information is useful 
for others in this area, particularly as thioureas are routinely used in bioconjugate chemistry.  
PMPA, urea-PSMA and thiourea-PSMA were assessed in an IC50 cell assay to assess their ability 
to bind GCP(II)/PSMA. PMPA has been reported to have a Ki value of 0.3 nM (10) and urea-PSMA 
(Glu-C(O)-Glu) a Ki value of 8 nM (22). The IC50 studies conducted here were not designed to give 
the same values but instead to obtain the relative affinities for the inhibitors in this study and 
ascertain the size of affinity change upon substituting a urea with a thiourea. The IC50 values 
obtained in this study were 94 ± 4.3 nM for PMPA and 1340 ± 70 nM for urea-PSMA. Although 
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the absolute values are much higher for this assay than in previous literature, the difference 
between the two inhibitors is of the same order of magnitude as seen for the literature values. 
At the outset of this study, it was postulated that thiourea-PSMA would have higher affinity than 
its urea-PSMA analogue due to the importance of zinc binding within the GCP(II)/PSMA active 
site and the strong interaction between zinc ions and sulfur ligands. However, this was not seen 
in the experimental results. Instead, the opposite was observed: the thiourea-PSMA was a much 
weaker inhibitor, producing a high IC50 value of 135000 ± 6600 nM, 100 fold higher than that of 
the urea-PSMA derivative. The quantification and stability tests performed confirmed that 
thiourea-PSMA was at a known concentration during the assay and that it was stable for its 
duration. Therefore, this value is a true reflection of the difference in affinity caused by the 
replacement of a urea with a thiourea. This unexpected difference could be due to the larger 
radius of sulfur and the longer bond length of the C=S bond of thiourea groups compared to the 
C=O bond of urea groups (1.71 Å (35) and 1.26 Å (36) respectively). Such changes could cause 
the rest of the molecule to fit more poorly within the active site, reducing those interactions and 
counteracting any gain in affinity caused by the strength of the bond between the zinc ion and 
the sulfur ligand. This is not inconsistent with previous findings that suggest that the success of 
a zinc ion binding group is dependent on maintaining the interactions of the glutamate with the 
S1’ pocket.  
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Protein or peptide Sequence 




Anorexigenic peptide pGlu-His-Gly-OH 
Eisenine pGlu-Glu-Ala-OH 
Colon mitosis-inhibitory peptide pGlu-Glu-His-Gly-OH 
Peptide-inhibiting epidermal mitosis pGlu-Glu-asp-Cys-Lys-OH 
























TABLE 7.2: Naturally occurring peptides and proteins which have pyro-glutamic acid at their N-terminus (28). 
 
FIGURE 7.34: N-terminal cyclization of peptides with terminal glutamine and glutamic acid residues by the 




FIGURE 7.35: The formation of pyroglutamic acid after 12 weeks over a range of pH. An antibody with the 
terminal sequence EIVMTQSPATLSVSPGER (light chain) was incubated at pH 4.1, 4.6, 5.2, 5.7, 6.2, 7.0, and 8.0 
at 37 and 45 °C for 12 weeks. The percentage of pyroglutamic acid was calculated based on the peak areas of the 
light chain and the post light chain from the reversed-phase chromatogram. The minimum was found to be at 
pH 6.2. Reproduced with permission from (32). 
 
FIGURE 7.36: Proposed mechanisms for the formation of pyroglutamic acid 
 





Thiourea-PSMA (Glu-C(S)-Glu) has been successfully synthesised in quantities sufficient for 
inhibitor studies to be performed. Despite its propensity to cyclise in low or high pH its stability 
at pH 6.5-7.5 has been confirmed and cell studies have been performed to determine its 
inhibition constant (IC50). This was found, unexpectedly, to be much higher for thiourea-PSMA 
than urea-PSMA and PMPA. This suggests that this functional group is not suitable for making 
higher affinity tracers and therefore other interactions must govern the affinity more than the 
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8 Future Works 
In this section opportunities for future work will be discussed. Some of these are natural 
extensions of the work presented in this thesis, others are challenges that exist in the field as a 
whole that would be valuable to explore 
8.1 The Gallium-THP Complex 
THP displays outstanding radiolabelling properties with gallium isotopes and so it would be 
advantageous to understand what properties of THP confer these properties. Information about 
how THP coordinates gallium has been obtained from the NMR studies carried out in chapter 3. 
This work suggested that only a 1:1 complex was formed upon the coordination of gallium ions, 
and this complex remained the same when the THP-PSMA was at a higher concentration than 
the gallium ions and when gallium ions were in excess. It also showed that the complex was 
stable over time (3 weeks), and resistant to heating (70°C). Upon binding gallium, the proton 
signals from the THP section of the molecule split into 3 equal intensity signals, suggesting just 
one complex is formed, but that it does not have C3 symmetry and each arm of this tripodal 
chelator is in a different environment. This could be caused by hydrogen bonding between 2 of 
the arms of coordinated THP. More conclusive and extensive investigations were impeded by 
the poor solubility of Ga-THP-PSMA and the overlap of signals from the rest of the molecule (the 
linker and PSMA motif). It would be advantageous to develop more soluble variants of THP, 
functionalised with hydrophilic groups, which could be used for further NMR studies. X-ray 
crystallography studies would also be extremely informative, but again are likely to require a 
more soluble derivative of THP to facilitate crystal growth. In the absence of a crystal structure, 
it would be interesting to study this complex with X-ray absorption fine structure spectroscopy, 
which is able to provide information on the coordination environment and three-dimensional 
geometry around the metal centre (1). These results could all be combined with molecular 
modelling to gain a better understanding of the gallium binding properties of THP, allowing 
further improvements to be made to the THP ligand, which in turn could result in better 
tolerance to contaminating metals and high molar activity radiolabelling. 
8.2 Modifications to the THP Chelator 
The choice of chelator is known to influence the in vivo properties of radiotracers including 
biodistribution, circulation time, affinity, and targeting (2). These observations have also been 
reported for [68Ga]Ga-PSMA tracers (3)(4). Therefore it would be ideal to develop a library of 
THP chelators with different properties, such as lipophilicity, solubility and charge. This would 
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allow the most appropriate THP variant to be selected during radiotracer design, according to 
the in vivo properties required. Work towards this aim has already begun in this group, which 
has focused on ways of modifying the nitrogen substituent of the 3,4-hydroxypyridinone groups 
of THP. Additionally, as the THP chelator was originally designed as an iron scavenger it may also 
be fruitful and informative to screen a wide range of existing of iron chelators for their ability to 
chelate gallium under radiolabelling conditions, compared to THP. Studies of this nature have 
already begun (5), and there is particular interest in the potential of siderophores, which 
naturally occur as iron transporters in bacteria, fungi, and some plants (6)(7)(8). 
8.3 Modifications to THP-PSMA 
Hypotheses about how THP-PSMA could be modified to make higher affinity variants, after 
studying the interactions between poly-γ-glutamated folate and GCP(II)/PSMA, have already 
been discussed in chapter 6. These can be split into modifications to the GCP(II)/PSMA-binding 
motif and changes to linker design. The first modification proposed to the GCP(II)/PSMA-binding 
motif, a thiourea zinc binding group, was studied in chapter 7 but was found to result in 100-
fold weaker affinity than its urea analogue. This result is of interest to the scientific community 
as it suggests that if the zinc binding group is too large this will impede binding in other areas, 
reducing affinity. From this, it can be inferred that other bulky peptide bond mimics are also 
unlikely to be successful GCP(II)/PSMA inhibitors, for example, triazol-, squarate- or 
phosphonamido-dithionate-based inhibitors. The other proposal was the use of a Dap-C(O)-Glu 
motif instead of Lys-C(O)-Glu to target GCP(II)/PSMA as hopefully, this would conserve the 
interactions with arginine patch in the S1 pocket of the receptor,  present when the natural 
substrate, poly-γ-glutamated folate, binds the active site. Further ideas for modifications to the 
linker include the use of a poly-γ-glutamate chain of optimal length (greater than 2 glutamates), 
and the introduction of an aromatic group at the end of the linker before the chelator is 
attached, which could pi-stack with the arene-binding group of the entrance lid. Therefore the 
synthesis of a library of novel THP-PSMA variants incorporating these features, followed by 
evaluation in vitro and in vivo for their specific targeting of GCP(II)/PSMA would be valuable 
future work. Many of these insights have been obtained by studying the high-resolution X-ray 
crystal structures of GCP(II)/PSMA and the interactions observed between it and its natural 
substrates, therefore this approach should be encouraged when designing any future 
GCP(II)/PSMA targeted tracers or tracers for alternative receptors.  
8.4 Opportunities for Gallium-67 
The selectivity of THP for gallium, and the development of the THP-PSMA conjugate provided 
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the opportunity for gallium-67 to be explored as a targeted therapeutic radionuclide. The 
interest in Auger electron-emitting radionuclides is due to their high linear energy transfer and 
the very short range (< 2 m) of Auger electrons in tissue (9)(10). It has been hypothesised that 
Auger electrons would be effective in treating micro-metastases or circulating tumour cells, 
therefore slowing disease progression (11)(12). The work in chapter 3 showed that despite the 
exceptionally high molar activity of the labelled complex, [67Ga]Ga-THP-PSMA did not deliver a 
sufficient quantity of gallium to cells or tumours, and the activity that was delivered had poor 
retention, suggesting that [67Ga]Ga-THP-PSMA is not ideal for a therapeutic application. 
Therefore higher affinity bioconjugates with better retention need to be developed before the 
radiobiological effects of these tracers are investigated. There are still many questions that 
remain unanswered about the potential of gallium-67 itself as a therapeutic radionuclide. In 
order to provide more concrete evidence for the use of gallium-67 as a therapeutic radionuclide, 
the biological effects of its Auger electrons and the coinciding “coulomb explosion” effect should 
be explored more deeply along with their mechanism for cellular toxicity. This would be 
bolstered by a better understanding of how the subcellular distribution of gallium-67 impacts 
on its therapeutic effect, and whether cell membrane-bound gallium-67 can also lead to cell 
death. Such information would make it easier to design experiments to evaluate and screen 
radiotracers in vitro but also to design tracers that are able to deliver the radionuclide in the 
right form, to the right (subcellular) location, for the right duration. A consistent and affordable 
source of gallium-67 chloride, that facilitates the radiolabelling at high molar activity, will be 
essential for such studies to be carried out. Unfortunately, such commercial sources are 
becoming rarer and this is likely to limit the study of gallium-67 going forward. 
8.5 Opportunities for Gallium-68    
The recent popularity of gallium-68 has been driven by both the marketing authorisation in 
Europe of the Galliapharm (Eckert & Ziegler) generator (13), as well as its clinical application in 
PET imaging for both neuroendocrine tumours (14) and prostate cancer (15) becoming 
established. Now that the majority of research hospitals have access to a germanium-
68/gallium-68 generator, gallium-68 is likely to continue to be the PET radiometal utilised for 
translational studies, encouraged by its availability from generators, at modest cost, and the 
ease by which it can be incorporated into a radiotracer. Now that the advantages of THP have 
been proven in a clinical setting, THP may even become the chelator of choice for gallium-68 
radiolabelling with novel targeting vectors. Utilising THP would allow extremely simple labelling 
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for peptides and small molecules, but also for heat- and pH-sensitive proteins because of the 
mild chelation conditions of THP. 
8.6 One-Step Kits 
The THP chelator has made one-step kits possible for gallium-68 tracers, and this has been 
demonstrated for the first time through one-step kit labelling of [68Ga]Ga-THP-PSMA. Simple 
radiolabelling has also been demonstrated for other THP bio-conjugates including [68Ga]Ga-THP-
mal-J591c-scFv (16),  [68Ga]Ga-THP-TATE (17), and [68Ga]Ga-THP-RDG (18). The next challenge 
will be for the THP technology to be leveraged further and come into widespread use, either as 
a translational tool or in commercial radiopharmaceutical kits. The concept of developing one-
step kits for gallium-68 was inspired by the prevalence of technetium-99m kit-based 
radiolabelling. However, the radiolabelling now demonstrated for [68Ga]Ga-THP-PSMA is much 
simpler than the methods being used for [99mTc]Tc-PSMA and other technetium-99m-based 
bioconjugates. As described in chapter 2 these are still multistep processes, which typically 
involve heating to 100°C and take over 1 hour to perform (19)(20). Therefore it would be 
advantageous to develop ways to turn radiolabelling for these technetium-99m radiotracers into 
one-step kits. In fact, the desire for simple, rapid, single-step radiolabelling exists for all clinically 
relevant radiometals, not just those produced by a generator. The demonstration that such 
radiolabelling is achievable for gallium-68 should inspire the design novel chelators for all 
clinically relevant radiometals, with properties amenable to single-step radiolabelling. Of course, 
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